<SEC-DOCUMENT>0001493152-22-022063.txt : 20220811
<SEC-HEADER>0001493152-22-022063.hdr.sgml : 20220811
<ACCEPTANCE-DATETIME>20220811160112
ACCESSION NUMBER:		0001493152-22-022063
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220811
DATE AS OF CHANGE:		20220811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Processa Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001533743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				451539785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39531
		FILM NUMBER:		221155522

	BUSINESS ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076
		BUSINESS PHONE:		443-776-3133

	MAIL ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heatwurx, Inc.
		DATE OF NAME CHANGE:	20111028
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:PCSA="http://processapharmaceuticals.com/20220630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_PCSA_processapharmaceuticals.com_20220630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20220101_20220630 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001533743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_form10%2Dq.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityCentralIndexKey">0001533743</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonFraction name="PCSA:DueFromTaxAgencies" contextRef="AsOf2022-06-30" id="xdx2ixbrl0059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-06-30" id="xdx2ixbrl0068" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0069" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2022-06-30" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-06-30" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0149" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0194" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0240" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0272" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0304" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0314" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:NoncashMilestoneExpenseInConnectionWithLicenseAgreement" contextRef="From2021-01-012021-06-30" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:NonCashAcquisitionOfInprocessResearchAndDevelopment" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2021-01-012021-06-30" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRepurchaseOfEquity" contextRef="From2021-01-012021-06-30" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="From2022-01-01to2022-06-30" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-012021-06-30" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pcsa-20220630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-182021-08-20_custom_EquityDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:EquityDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-18</xbrli:startDate>
        <xbrli:endDate>2021-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-21</xbrli:startDate>
        <xbrli:endDate>2022-03-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-21</xbrli:startDate>
        <xbrli:endDate>2022-03-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-272022-03-29_custom_AposenseLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:AposenseLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-27</xbrli:startDate>
        <xbrli:endDate>2022-03-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_TwoThousandAndNineteenPlanMember_custom_OriginalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:OriginalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-11_us-gaap_SubsequentEventMember_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-032022-01-04_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-03</xbrli:startDate>
        <xbrli:endDate>2022-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-032022-01-04_us-gaap_RestrictedStockMember_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-03</xbrli:startDate>
        <xbrli:endDate>2022-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-04_us-gaap_RestrictedStockMember_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-202022-03-31_us-gaap_RestrictedStockMember_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-20</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockMember_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-292022-05-31_us-gaap_RestrictedStockMember_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-29</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_TwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_TwoThousandTwentyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_BaseCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:BaseCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_AprilOneTwoThousandTwentyTwo2022GrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PCSA:AprilOneTwoThousandTwentyTwo2022GrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-102022-07-11_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-10</xbrli:startDate>
        <xbrli:endDate>2022-07-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-03_us-gaap_WarrantMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_FacilityLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_EquipmentLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">PCSA:EquipmentLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-162022-05-17_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-16</xbrli:startDate>
        <xbrli:endDate>2022-05-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_AgreementsMember_custom_ContractResearchOrganizationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:AgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:ContractResearchOrganizationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>United
States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>Securities
and Exchange Commission</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; text-transform: uppercase"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20220101__20220630_zyXdKVrw5BO6"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--DocumentQuarterlyReport_c20220101__20220630_zlaixbiHz7Rb"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20220101__20220630_zY1CNIdqzypc"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, <span id="xdx_90A_edei--DocumentFiscalYearFocus_c20220101__20220630" title="Document Fiscal Year Focus"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--DocumentTransitionReport_c20220101__20220630_zXXbzF3rtX3g"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ____ to ____</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number <span id="xdx_90C_edei--EntityFileNumber_c20220101__20220630_zHlbkgn69Mw5"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityFileNumber">001-39531</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityRegistrantName_c20220101__20220630_zaSxuH2SyIig"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityRegistrantName">Processa
Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20220101__20220630_zGtJTdY5YlEb"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20220101__20220630_zmj26u281UK7"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityTaxIdentificationNumber">45-1539785</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20220101__20220630" title="Entity Address, Address Line One"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressAddressLine1">7380
Coca Cola Drive</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20220101__20220630" title="Entity Address, Address Line Two"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressAddressLine2">Suite 106</ix:nonNumeric></span>,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityAddressCityOrTown_c20220101__20220630" title="Entity Address, City or Town"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressCityOrTown">Hanover</ix:nonNumeric></span>,
<span id="xdx_905_edei--EntityAddressStateOrProvince_c20220101__20220630" title="Entity Address, State or Province"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20220101__20220630" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityAddressPostalZipCode">21076</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">(<span id="xdx_900_edei--CityAreaCode_c20220101__20220630" title="City Area Code"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:CityAreaCode">443</ix:nonNumeric></span>)
<span id="xdx_90C_edei--LocalPhoneNumber_c20220101__20220630" title="Local Phone Number"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:LocalPhoneNumber">776-3133</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20220101__20220630_zyf534m35YTj"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20220101__20220630_zyi2tKjYMVL7"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:TradingSymbol">PCSA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90D_edei--SecurityExchangeName_c20220101__20220630_zRY12FF9lFOk"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20220101__20220630_zJUf0QDdPFKe"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20220101__20220630_zqgFbWUZUE3k"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20220101__20220630" title="Entity Filer Category"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntitySmallBusiness_c20220101__20220630_z47lZ2Q0b6Wj"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20220101__20220630_zajwf50Wjf96"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_906_edei--EntityShellCompany_c20220101__20220630_zw6F0sbX848h"><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of outstanding shares of the registrant&#8217;s common stock as of August 4, 2022 was <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20220804_zKKyTsGWxuD9" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-08-04" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,856,205</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCESSA
PHARMACEUTICALS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART 1: FINANCIAL INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">ITEM 1: FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">ITEM 4. CONTROLS AND PROCEDURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">PART II. OTHER INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">ITEM 1. LEGAL PROCEEDINGS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">ITEM 1A. RISK FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">ITEM 4. MINE SAFETY DISCLOSURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">ITEM 5. OTHER INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">ITEM 6. EXHIBITS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_001"></span><b>PART
1: FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
1: FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_111_z1AnkjVAXnke" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20220630" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20211231" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zlFVfrqOtkL9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_zuMe9d4E6IQ5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzn4A_zgcsjvmP82K4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,064,142</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,497,581</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--DueFromTaxAgencies_i02I_maCzn4A_zzJBGJDG6Zcg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due from tax agencies</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0059">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DueFromTaxAgencies" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,274</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzn4A_zqlXciGxqMX2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,896,633</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,759,296</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i02TI_mtCzn4A_maCzYr4_zQkUVmPJyUng" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,960,775</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,327,151</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzYr4_z9OnrY7lmwNf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and Equipment,
    net</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0068">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0069">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsNoncurrentAbstract_i01B_zoXbran075m1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzX2P_z2sxhhDuLhs1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease right-of-use
    assets, net of accumulated amortization</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,890</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,181</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzX2P_zo6SBpiD6gIe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net
    of accumulated amortization</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,662,390</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,056,638</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--SecurityDeposit_i02I_maCzX2P_zN1ylxKv4Hv3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Security
    deposit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,535</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,535</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_i02TI_mtCzX2P_maCzYr4_zyvXm60kDKjd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Other Assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,696,815</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,136,354</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--Assets_i01TI_mtCzYr4_zI5ZnInn8oBa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,657,590</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,463,505</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zxl9MebbYC18" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzii6_zZS1rqLBlPK6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current maturities of operating
    lease liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,552</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,078</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_i02I_maCzii6_z0IjZhNDuMs8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">648,104</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,905</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--DueToLicensor_i02I_maCzii6_z9uEqOFG8LH4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due to licensor</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DueToLicensor" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">589,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:DueToLicensor" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DueToRelatedPartiesCurrent_i02I_maCzii6_zmyYBt5RFuT5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due to related parties</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0104">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,772</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzii6_zi53UeOb865a" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,412</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,265</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i01TI_mtCzii6_maCzI8M_zzQmjorC4XEg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,571,068</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">971,020</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_z22idwOglbn6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzI8M_zK3rWE1dPGDd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current operating lease
    liability</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,655</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,385</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_i01TI_mtCzI8M_maCz5Sb_zioEIkLK8Fsl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,575,723</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">978,405</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_i01I_maCz5Sb_z01SPUdSN39i" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commitments and Contingencies</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0122">-</span>&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; Equity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_maCzTwg_za9y00LLqOsd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock, par value
    $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_c20220630_pdd" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20220630_zEakK4PNLiTb" title="Common stock, shares authorized"><span title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span></span> shares authorized: <span id="xdx_904_eus-gaap--CommonStockSharesIssued_c20220630_pdd" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,919,317</ix:nonFraction></span> issued and <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_c20220630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,819,317</ix:nonFraction></span> outstanding at June 30, 2022, and <span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,710,246</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding
    at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,592</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,571</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzTwg_zxvCcpJCGaEc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in capital</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,595,106</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,306,861</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--TreasuryStockValue_i02NI_pp0p0_di_msCzTwg_z3T4dioSiZXb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Treasury stock at cost
    &#8212; <span id="xdx_905_eus-gaap--TreasuryStockShares_c20220630_pdd" title="Treasury stock shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares at June 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0149">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzTwg_zqxIb8ohH1D5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,214,831</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,823,332</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtCzTwg_maCz5Sb_zeeL8wGU6xW1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Stockholders&#8217; Equity</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,081,867</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,485,100</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtCz5Sb_zDa2VJqGjRXe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities and Stockholders&#8217; Equity</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,657,590</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,463,505</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_zGIcH88Qd501" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20220401__20220630_zgqWkCGVrqsh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20210401__20210630_zUDO6sbkAth" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20220101_20220630" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20210101_20210630" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three
                                            Months Ended</span></p>
                                                                                 <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">June
                                            30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Six
                                            Months Ended</span></p>
                                                                                <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">June
                                            30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpensesAbstract_iB_z0t0qXAxld4h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_i01_msCzrLp_z2Z0k40u7Aw4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and
    development expenses</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,137,292</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,614,954</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,181,912</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,086,401</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentInProcess_i01_msCzrLp_zLaQjP8gvQ66" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Acquisition of in-process
    research and development</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0172">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">515,630</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0174">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">515,630</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i01_msCzrLp_zpCN6Oiq5mua" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,034,456</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,329,213</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,218,550</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,051,073</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_iT_mtCzrLp_maCzDqg_zKVN3WV5PsRg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,171,748</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,459,797</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,400,462</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,653,104</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherIncomeAndExpensesAbstract_iB_zrhmZT6vzt78" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest_maCzDqg_zPkgGeQsXfyf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Forgiveness of PPP loan
    and related accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0192">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,771</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0194">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,771</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--InterestExpense_i01N_di_msCzDqg_zz4JsanmF3Td" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0197">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0198">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0199">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--InvestmentIncomeInterest_i01_maCzDqg_zZvhCVjxClg7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,380</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,814</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,963</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,755</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzDqg_maCzgg2_zcI0BV0JRzMe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Operating Loss Before
    Income Tax Benefit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,164,368</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,294,212</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,391,499</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,482,940</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msCzgg2_z22eDUsqBpJa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income Tax Benefit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0212">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">137,169</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0214">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">226,417</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_mtCzgg2_zlJgxjETftu7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Loss</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,164,368</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,157,043</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,391,499</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,256,523</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_zETKHuQuydfg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Loss per Common
    Share - Basic and Diluted</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.32</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.20</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.53</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.35</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Common
    Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,940,510</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,406,363</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,886,116</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,997,303</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statement of Changes in Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
and Six Months Ended June 30, 2021 and 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_114_zgMRMS7ejFS3" summary="xdx: Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zdI4J8NK2SUj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zEAiZRIhKCCk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zx0SddMuXql1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zMIr7n6tYUel" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_z7GglEyO6UQd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid-In</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43E_c20210101__20210331_eus-gaap--StockholdersEquity_iS_zzvjR4EuOmf5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance at January 1, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrW6jRshErf" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,187,984</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,419</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,333,857</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_z2PQ1e1nLOvk" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0240">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0234">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,395,798</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,939,478</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zG35NrkAx648" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlryIc7yzjj3" title="Stock-based compensation, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">620,590</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0244">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">620,591</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z53KpDHg8N98" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued in private placement, net of
    transaction costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo9boKRrdSm4" title="Shares issued in private placement, net of transaction costs, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,321,132</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,875,418</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,875,550</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zhxV6ar31Jhj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0258">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,099,480</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,099,480</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_435_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zbFrgRKP8zT2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance, March 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZWj1mpVomi7" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,521,616</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,552</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,829,865</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zlkduDPhgRw2" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,495,278</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,336,139</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zouHYyjQKoBf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3G939u6omVe" title="Stock-based compensation, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,300</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,592</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,596</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_z6X073eCEGo1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued in connection with license agreement</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2maWn2GfDVg" title="Shares issued in connection with license agreement, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,689</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,996</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zDBfJjG7x6w8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0291">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,157,043</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,157,043</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43C_c20210401__20210630_eus-gaap--StockholdersEquity_iE_zWuuNND0lJCc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, June 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXCZbn4HRTse" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,604,605</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,560</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,892,453</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zc81jzxMFW67" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,652,321</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,241,692</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zlDMPuAo4vxa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zMJiB8FHrU8l" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zNgLbgQfQi77" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zGGCS6TfJMpg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_zJcldY56Z5el" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid-In</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43A_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zbKMqO0eVF9l" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance at January 1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhSjtPKQtrnj" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,710,246</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,571</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,306,861</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zb8FgM3Tmiaf" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,823,332</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,485,100</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zhT5oJ64XxWl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpyvrgE8EVGe" title="Stock-based compensation, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,670</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">828,887</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">828,897</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_zUMS97f1l4vc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Acquisition of treasury
    stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--StockRepurchasedDuringPeriodShares_iN_di_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zpJXyxaqb8n" title="Acquisition of treasury stock, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_ecustom--SharesIssuedInConnectionWithPurchaseAgreementValue_zGf9Gu8de8xf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued in connection with the Purchase
    Agreement with Lincoln Park</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--SharesIssuedInConnectionWithPurchaseAgreementShares_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zELkOr05kH7k" title="Shares issued in connection with the Purchase Agreement with Lincoln Park, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">123,609</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,988</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zVJ4CGEej947" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,227,131</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,227,131</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43E_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zXWlRLivXTxk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance, March 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOVBGUKVElq9" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,937,525</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,593</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,585,736</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zLDFrI2u8NY5" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">100,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,050,463</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,236,866</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zruvebsuROUb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAGVd9bpUjfd" title="Stock-based compensation, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">18,208</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,009,370</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,009,369</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_zHPLDt55rToj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0364">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,164,368</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,164,368</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_433_c20220401__20220630_eus-gaap--StockholdersEquity_iE_zP1SJSXYC0f8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance, June 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuyO4hFaqql6" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,919,317</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,592</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,595,106</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zFQ97CsrTTj6" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">100,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,214,831</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,081,867</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_zzilsaB43Mf8" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20220101__20220630_zejiGfI3TjUh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20210101__20210630_zzwsxqR2DdV1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_ze2ErXVPeIGd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash Flows From Operating
    Activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_maCzKAQ_zDOHQq6MoMWe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,391,499</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,256,523</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zCBbe5EkWhh5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash used in operating activities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--Depreciation_i02_maCzKAQ_zWDSQXMxQMPl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">484</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseExpense_i02_maCzKAQ_z4rx1bBcLuP7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash lease expense
    for right-of-use assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,291</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,322</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--NoncashMilestoneExpenseInConnectionWithLicenseAgreement_i02_maCzKAQ_zGG3iuV3ptt4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash milestone expense
    in connection with license agreement</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:NoncashMilestoneExpenseInConnectionWithLicenseAgreement" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--NonCashAcquisitionOfInprocessResearchAndDevelopment_i02_maCzKAQ_zqjDTMFOKz6e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash acquisition of
    in-process research and development</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:NonCashAcquisitionOfInprocessResearchAndDevelopment" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maCzKAQ_zYElCo5rj3xc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of issuance
    costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,613</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i02_maCzKAQ_zkuQntNBZQ45" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of intangible
    asset</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,248</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">397,664</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_i02_maCzKAQ_z4sxEKQsbY18" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax benefit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">226,417</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_maCzKAQ_zuNdCLxu0eM8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,838,266</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,173,622</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest_i02N_di_msCzKAQ_zguVSX7fseC1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Forgiveness of PPP loan
    and related accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,771</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z3lcATZGOvdf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net changes in operating
    assets and liabilities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzKAQ_zx1oFP0FZrx8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">272,050</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">876,899</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maCzKAQ_zxvObiAxH9ae" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,256</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,320</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInInterestPayableNet_i03_maCzKAQ_zzgrWhPWxBN8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzKAQ_zh6qPe5OHT5c" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,199</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,816</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInDueToRelatedParties_i03_maCzKAQ_zMqf5vpLX9Q1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due (from) to related parties</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,772</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,614</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOtherReceivables_i03N_di_msCzKAQ_zCoBnu6hlKOe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other receivables</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">70,274</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,750</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maCzKAQ_z9VDdKbo4Iok" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,147</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,434</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzKAQ_maCzKGx_zAbt2k6Jllcg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,133,439</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,437,494</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zGSaUOmt0J43" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash Flows From Financing
    Activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maCzfYg_z1jX815gGoM" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from private
    placement</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,875,550</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromRepurchaseOfEquity_i01_maCzfYg_zHywUnlrcs3h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Acquisition of treasury
    stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProceedsFromRepurchaseOfEquity" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0450">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromPaymentsForOtherFinancingActivities_i01_maCzfYg_zkMzPmXXDgG3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,085</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzfYg_maCzKGx_zBXzax7mN5B2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    cash (used in) provided by financing activities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,852,465</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzKGx_zFHWBDj2lpa6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Increase (Decrease)
    in Cash</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,433,439</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,414,971</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    and Cash Equivalents &#8211; Beginning of Period</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,497,581</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,416,224</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    and Cash Equivalents &#8211; End of Period</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,064,142</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,831,195</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zlb82ljQskpc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Cash Financing Activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssued1_zouhjv91frqf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">123,609</ix:nonFraction></span> shares of common stock in connection with the Purchase Agreement with Lincoln Park</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zXzowtam2pMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82B_zmamq9bf2mG8">Organization and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock"><p id="xdx_847_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zMWUacrsjTU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_864_zCJHWuIXcEg4">Business
Activities and Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for
patients who have a high unmet medical need condition that affects survival or the patient&#8217;s quality of life and for which few
or no treatment options currently exist. We currently have five drugs: four in various stages of clinical development (PCS499, PCS12852,
PCS6422 and PCS3117) and one in nonclinical development (PCS11T). We group our drugs into non-oncology (PCS499 and PCS12852) and oncology
(PCS3117, PCS6422 and PCS11T). A summary of each drug is provided below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    most advanced product candidate, PCS499, is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline
    (PTX or Trental&#174;). We completed a Phase 2A trial for PCS499 in patients with ulcerative and non-ulcerative necrobiosis lipoidica
    (NL) in late 2020, and in May 2021 we enrolled the first patient in our Phase 2B trial for the treatment of ulcerative NL. We expect
    to complete our interim analysis and complete enrollment of the Phase 2B trial during the first half of 2023; and, depending on the
    results, begin a pivotal Phase 3 trial in 2023. We have experienced delays in the enrollment of patients for this trial due in part
    to COVID-19 and the rare nature of this disease. We have initiated a number of recruitment programs to increase the enrollment of
    patients in this study and continue to evaluate additional options to meet our enrollment goals.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
    is a highly specific and potent 5HT4 agonist which has already been evaluated in clinical studies in South Korea for gastric emptying
    and gastrointestinal motility. In October 2021, the FDA cleared our IND application to proceed with a Phase 2A trial for the treatment
    of gastroparesis. We enrolled our first patient on April 5, 2022, anticipate completing enrollment in the second half of 2022 with
    top-line results by the end of 2022, and should complete our final analysis in the first half of 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS6422
    is an orally administered irreversible enzyme inhibitor administered in combination with capecitabine. When combining capecitabine
    with PCS6422 (the &#8220;Next Generation Capecitabine&#8221;), capecitabine becomes a more potent cancer chemotherapy agent than
    current FDA approved capecitabine. On August 2, 2021, we enrolled the first patient in our Phase 1B dose-escalation maximum tolerated
    dose trial in patients with advanced refractory gastrointestinal (GI) tract tumors. Our interim analysis of Cohorts 1 and 2 found
    no dose-limiting toxicities (DLTs), no drug related adverse events greater than Grade 1, and no hand-foot syndrome. In addition,
    the interim analysis revealed when PCS6422 inhibits the DPD enzyme, 5-FU metabolism can be significantly decreased (&lt;10% metabolized
    to F-Bal compared to typically 80%) and the potency of capecitabine significantly increased compared to the present regimens of capecitabine
    (at least 50 times greater 5-FU potency based on systemic exposure per mg of capecitabine administered). The single dose of PCS6422,
    however, did not sustain the DPD inhibition throughout 7 days of capecitabine dosing which was needed to maintain the improved potency
    of capecitabine. Therefore, in an effort to define 6422 regimens that will maintain DPD inhibition throughout capecitabine dosing,
    we modified the protocol for the Phase 1B trial to not only determine the MTD of capecitabine, but to also further evaluate the timeline
    of DPD inhibition and de novo formation. We began enrolling patients in the amended Phase 1B trial in April 2022 and expect to complete
    enrollment while defining the Next Generation Capecitabine regimen (i.e., the PCS6422 regimens and the corresponding capecitabine
    regimens) by the end of 2022. We expect that our overall timeline has not changed with a Phase 2B or 3 trial starting in 2023-2024
    and NDA submission in 2027-2028.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117
    is a cytosine analog that is similar to gemcitabine (Gemzar&#174;), but different enough in chemical structure that some patients
    are more likely to respond to PCS3117 than gemcitabine. We continue to evaluate the potential use of PCS3117 in patients with pancreatic
    cancer and to evaluate ways to identify patients who are more likely to respond to PCS3117 than gemcitabine. We anticipate initiating
    a Phase 2B trial or adaptive designed Phase 3 trial in 2023 subject to meeting with FDA and obtaining additional funding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    only nonclinical drug candidate is PCS11T, an analog of SN38 (SN38 being the active metabolite of irinotecan) and a next generation
    irinotecan drug for multiple types of cancers. The manufacturing process and sites for drug substance and drug product are presently
    being evaluated. In addition, we are defining the potential paths to approval, which include defining the targeted patient population
    and the type of cancer. We hope to submit an IND in the first half of 2024, followed by a Phase 1B maximum tolerated dose trial.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="PCSA:ImpactOfCovidNineteenPolicyTextBlock"><p id="xdx_840_ecustom--ImpactOfCovidNineteenPolicyTextBlock_zcdJIDH53Fod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_868_zaFIwlDyvJTk">Impact
of COVID-19</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
COVID-19 pandemic continues to create uncertainties in expected timelines by causing delays in clinical trials and disruptions in
the supply chain for raw materials used in clinical trial work.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced delays in the enrollment of patients in our PCS499 Phase 2B trial due to COVID-19. Some potential patients have
died from COVID-19 prior to screening and others continue to be reluctant to travel to our testing sites for fear of contracting
COVID-19. Delays in enrollment lengthen the time of studies and increase their costs, which <span style="background-color: white">could
materially impact our business in future periods. Furthermore, the spread of COVID-19, which has caused a broad impact globally, may
materially affect us economically. </span>While we are hopeful the infection rate of COVID-19 will continue to decline, we cannot
predict the future impact COVID-19 will have on our current and future clinical trials. Continued delays could materially impact our business in future periods
and further extend our timelines. <span style="background-color: white">For
more information on the risks associated with COVID-19, refer to Part I, Item 1A, &#8220;Risk Factors&#8221; included in our Annual
Report on Form 10-K for the year ended December 31, 2021.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZnbC26CFdXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_zMWxLCSR8en8">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2021, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="PCSA:LiquidityPolicyTextBlock"><p id="xdx_843_ecustom--LiquidityPolicyTextBlock_zHWpnKAKdawk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zMTOusaVyIpi">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception, devoting substantially all of our efforts toward moving the drugs in our pipeline through the
regulatory process and other research and development activities, and have an accumulated deficit of approximately $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220630_zVhIVPBP50Y1" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">45.2</ix:nonFraction></span>
million as of June 30, 2022. During the six months ended June 30, 2022, we generated a net loss of approximately $<span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220630_zaSsid8WhRua" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">8.4</ix:nonFraction></span>
million, of which $<span id="xdx_90E_eus-gaap--OtherNoncashExpense_pn5n6_c20220101__20220630_zsxPy5JPfXhf" title="Non cash expenditures"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span>
million represented non-cash expenditures. Net cash used in our operating activities during the six months ended June 30, 2022 was
approximately $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220630_zClKBTC41KGl" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">4.1</ix:nonFraction></span>
million. We expect to continue to generate operating losses and negative cash flow from operations for the foreseeable future. Based on our
current plans, we believe our current cash balances are adequate for at least the next twelve months without considering amounts
available from the Purchase Agreement with Lincoln Park (see below and Note 3) or potential sales under our ATM Offering (see
below). Our ability to execute our longer-term operating plans, including unplanned future clinical trials for our portfolio of
drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or
other funding transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we
will obtain the necessary funding in the future when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had <span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20220101__20220630_zDJabtiVwReg" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-06-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> revenue during the six months ended June 30, 2022 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and operating expenses. Cash
used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2021, we entered into an equity distribution agreement (the &#8220;Sales Agreement&#8221;) with Oppenheimer &amp; Co. Inc.
under which we may issue and sell in a registered &#8220;at-the-market&#8221; offering shares of our common stock having an aggregate
offering price of up to $<span id="xdx_900_ecustom--MaximumNumberOfSharesToBeSoldAtMarketOffering_pn6n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3z7EJdaZN94" title="Maximum number of shares to be sold at the market offering"><ix:nonFraction name="PCSA:MaximumNumberOfSharesToBeSoldAtMarketOffering" contextRef="From2021-08-182021-08-20_custom_EquityDistributionAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">30.0</ix:nonFraction></span> million from time to time through or to our Sales Agent (the &#8220;ATM Offering&#8221;). We expect to
use net proceeds from the ATM Offering over time as a source for working capital and general corporate purposes. The shares under the
ATM Offering will be sold and issued pursuant to our S-3 shelf registration statement (Registration No. 333-257588) filed on July 30,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2022, we entered into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;) under which we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase
up to $<span id="xdx_900_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zzjDFAExIyvl" title="Commitment to purchase common stock"><ix:nonFraction name="PCSA:MaximumCommitmenttoPurchaseCommonStockValue" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span> of our shares of common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, subject to the terms and conditions in the Purchase Agreement,
during the term of the Purchase Agreement. See Note 3 for additional details concerning the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_zRBk2jRRQwn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zeTPnvxMEa34">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and
regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements
and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zwEDbNApiuN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zjzbQWC9g9Nk">Income
Taxes</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of June 30, 2022 and December 31, 2021, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets related to deferred start-up costs, federal orphan drug tax credit and certain other minor temporary differences
since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained
until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, we recognized the
tax benefit from our projected ordinary tax loss, which was used to offset the deferred tax liabilities related to the intangible asset
and resulted in the recognition of a deferred tax benefit shown in the condensed consolidated statements of operations for six months
ended June 30, 2021 and the remainder of 2021. No current income tax benefit or expense was recorded or is expected for 2022 or in the
foreseeable future since the deferred tax liability has been offset completely as of December 31, 2021 and we expect to generate future
taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zaQecVRfIK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_865_zlU3Z9kcO4Dh">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2022 exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSuMBt3ZNdFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zcDX0pnUpr0b">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>

</ix:nonNumeric><p id="xdx_852_zhpGSOtIXb14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zkhVwNUtVMFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82B_zVNYBLTGuTG9">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zaSHc5ft7Xul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets at June 30, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zIoYM0uGKiV7" style="display: none">Summary of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20220630_z54gRZ5GHxp1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20211231_zcVpqQnWfmF1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANz27j_zDn42NPjVvD2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross intangible assets</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,059,429</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,059,429</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANz27j_z4tugYEL164e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated amortization</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,397,039</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,002,791</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANz27j_zx3xyiJkeKNd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total intangible assets,
    net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,662,390</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,056,638</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zmsgYKTj69Pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
intangible assets consist primarily of costs we capitalized when we acquired the license rights to PCS499 in 2018. Amortization expense
was $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20220630_pp0p0" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">394,248</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20210630_zSbiHnFLgeCc" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">397,664</ix:nonFraction></span> for the six months ended June 30, 2022 and 2021, respectively, and is included within research and development
expense in the accompanying condensed consolidated statements of operations. As of June 30, 2022, our estimated amortization expense
for the year ended December 31, 2022 and for annual periods thereafter until the asset is fully amortized is approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20220630_zVlHmcVNjhId" title="Future amortization expenses, annual periods thereafter"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">788,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWgnKNqUNlNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82E_zhg7TJuti5Yd">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20220630_zOU1wwkaD26f" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220630_zvFjlcwrOUOd" title="Preferred stock, shares outstanding"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_zkQu1uKEC4lf" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zMrPgrgSQMod" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued or outstanding shares of preferred stock at either June 30, 2022 or December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Increase
in Our Authorized Number of Shares</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2022, we amended our Certificate of Incorporation to increase the number of authorized shares of our common stock from <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_z0g57LEKZpYe" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000,000</ix:nonFraction></span>
to <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20220101_zMMgI2LTe1dg" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-01-01" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span>. We believe <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20220630_zdi5m4HUqIf6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></span> authorized shares of common stock better aligns our capital structure with our future needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">ATM
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2021, we entered into the Sales Agreement with the Sales Agent under which we may issue and sell up to $<span id="xdx_901_ecustom--MaximumNumberOfSharesToBeSoldAtMarketOffering_pn6n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zCMm2Sn0mWKj" title="Maximum number of shares to be sold at the market offering"><ix:nonFraction name="PCSA:MaximumNumberOfSharesToBeSoldAtMarketOffering" contextRef="From2021-08-182021-08-20_custom_EquityDistributionAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">30.0</ix:nonFraction></span>
million of our common stock from time to time under the ATM Offering. We expect to use net proceeds from the ATM Offering over time
as a source for working capital and general corporate purposes. We did not sell any shares during the six months ended June 30,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Lincoln
Park Capital Fund, LLC Purchase Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 23, 2022, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up
to $<span id="xdx_90B_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_pn6n6_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zPNxcNoCPIV5" title="Commitment to purchase common stock"><ix:nonFraction name="PCSA:MaximumCommitmenttoPurchaseCommonStockValue" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15.0</ix:nonFraction></span> million of shares (the &#8220;Purchase Shares&#8221;) of our common stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUJv2yld8u8h" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share, subject to the terms
and conditions in the Purchase Agreement. We issued <span id="xdx_905_ecustom--SharesIssuedInConnectionWithPurchaseAgreementShares_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgpmkgcm7Hsa" title="Number of common stock issued on commitment fees, shares"><ix:nonFraction name="PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">123,609</ix:nonFraction></span> shares of common stock (valued at $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssuedInCommitmentFee_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_ziIkTXUy1lt8" title="Number of common stock issued on commitment fees, value"><ix:nonFraction name="PCSA:StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span>) to Lincoln Park as a commitment
fee in connection with entering into the Purchase Agreement and agreed to reimburse Lincoln Park $<span id="xdx_905_ecustom--ReimbursementFees_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIMuBOCSaCjf" title="Reimbursement fee"><ix:nonFraction name="PCSA:ReimbursementFees" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> for fees incurred in connection
with the Purchase Agreement. Concurrent with entering into the Purchase Agreement, we also entered into a registration rights agreement
with Lincoln Park (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we agreed to take certain actions relating to
the registration under the Securities Act of 1933, as amended, of the offer and sale of the shares of common stock available for issuance
under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Beginning
on March 23, 2022, we have the right to present Lincoln Park with a purchase notice (a &#8220;Regular Purchase Notice&#8221;), directing
Lincoln Park to purchase up to <span id="xdx_904_ecustom--NumberOfCommonStockSharesinRegularPurchase_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Number of common stock shares in regular purchase"><ix:nonFraction name="PCSA:NumberOfCommonStockSharesinRegularPurchase" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> Purchase Shares (the &#8220;Regular Purchase Amount&#8221;) provided that the closing sale price
of the common stock on the purchase date is not below a threshold price set forth in the Purchase Agreement (a &#8220;Regular Purchase&#8221;).
The Regular Purchase Amount may be increased to up to <span id="xdx_907_ecustom--NumberOfCommonStockSharesExceedingRegularPurchase_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Number of common stock shares exceeding regular purchase"><ix:nonFraction name="PCSA:NumberOfCommonStockSharesExceedingRegularPurchase" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares if the closing sale price of our common stock on the applicable purchase
date equals or exceeds certain higher threshold prices set forth in the Purchase Agreement. We and Lincoln Park may mutually agree to
increase the Regular Purchase Amount with respect to any Regular Purchase under the Purchase Agreement, provided that Lincoln Park&#8217;s
maximum committed purchase obligation under any single Regular Purchase shall not exceed $<span id="xdx_901_ecustom--DailyMaximumCommittedPurchaseObligationsValue_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zBeQtTHwO741" title="Daily maximum committed purchase obligations, value"><ix:nonFraction name="PCSA:DailyMaximumCommittedPurchaseObligationsValue" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,000</ix:nonFraction></span>. The above-referenced share amount
limitations and closing sale price thresholds are subject to adjustment for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement. The purchase price per share for
each Regular Purchase will be based on prevailing market prices of the common stock immediately preceding the time of sale as computed
in accordance with the terms set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park
must pay for shares of common stock under the Purchase Agreement. Lincoln Park may not assign or transfer its rights and obligations
under the Purchase Agreement.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
aggregate number of shares that we can issue to Lincoln Park under the Purchase Agreement may not exceed <span id="xdx_90F_ecustom--MaximumNumberOfSharesSoldInTransaction_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Maximum number of shares issued sold"><ix:nonFraction name="PCSA:MaximumNumberOfSharesSoldInTransaction" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,142,430</ix:nonFraction></span> shares (subject to
proportional adjustments for stock splits, reverse stock splits and similar events as described above), which is equal to <span id="xdx_905_ecustom--PercentageOfExchangeCapitalization_pid_dp_uPure_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zGUgQFBi9hfk" title="Nasdaq&apos;s exchange cap percent"><ix:nonFraction name="PCSA:PercentageOfExchangeCapitalization" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>% of the
outstanding shares of common stock immediately prior to the execution of the Purchase Agreement (the &#8220;Exchange Cap&#8221;), unless
(i) stockholder approval is obtained to issue shares of common stock in excess of the Exchange Cap, in which case the Exchange Cap will
no longer apply, or (ii) the average price of all sales of Purchase Shares to Lincoln Park under the Purchase Agreement equals or exceeds
the lower of (i) the Nasdaq official closing price immediately preceding the execution of the Purchase Agreement or (ii) the arithmetic
average of the five Nasdaq official closing prices for the common stock immediately preceding the execution of the Purchase Agreement,
plus an incremental amount to take into account the issuance of the commitment shares to Lincoln Park under the Purchase Agreement, such
that the transactions contemplated by the Purchase Agreement are exempt from the Exchange Cap limitation under applicable Nasdaq rules.
In all instances, we may not sell shares of our common stock to Lincoln Park under the Purchase Agreement if it would result in Lincoln
Park beneficially owning more than <span id="xdx_901_ecustom--BeneficialOwnershipLimitationPercentage_pid_dp_uPure_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zEdNwYslR3a4" title="Beneficial ownership limitation percentage"><ix:nonFraction name="PCSA:BeneficialOwnershipLimitationPercentage" contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the outstanding shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
may terminate the Purchase Agreement at any time, at our sole discretion, without any cost or penalty, by giving one business day notice
to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any
direct or indirect short selling or hedging of the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">There
are no limitations on use of proceeds, financial or business covenants, restrictions on future financings (other than restrictions on
our ability to enter into variable rate transactions described in the Purchase Agreement), rights of first refusal, participation rights,
penalties or liquidated damages in the Purchase Agreement. We may deliver Purchase Notices under the Purchase Agreement, subject to market
conditions, and in light of our capital needs from time to time and under the limitations contained in the Purchase Agreement. Any proceeds
that we receive under the Purchase Agreement are expected to be used for working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Repurchase
of Shares from Aposense, Ltd.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 29, 2022, we purchased <span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20220327__20220329__dei--LegalEntityAxis__custom--AposenseLtdMember_zCAQ2NSIwDHh" title="Number of repurchase of common stock, shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-03-272022-03-29_custom_AposenseLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of our common stock from Aposense Ltd. for $<span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodValue_c20220327__20220329__dei--LegalEntityAxis__custom--AposenseLtdMember_z0SP8I9Wa62b" title="Repurchase of common stock value"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-03-272022-03-29_custom_AposenseLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span> in a private transaction</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
are holding these shares as treasury stock until they are reissued or retired at the discretion of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z8JtaEh7JkH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Note
4 - <span id="xdx_820_zcodFvqfEepe">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 19, 2019, our stockholders approved, and we adopted the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019
Plan&#8221;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan <span style="background-color: white">originally provided</span> for the aggregate issuance of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember__us-gaap--AwardTypeAxis__custom--OriginalMember_zPLUoL0p8H1l" title="Maximum equity available for issuance under the plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-06-30_custom_TwoThousandAndNineteenPlanMember_custom_OriginalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> shares of our common stock, with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zzBjr0Z4Z2Z9" title="Shares available for future grants"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-06-30_custom_TwoThousandAndNineteenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">627,086</ix:nonFraction></span>
<span style="background-color: white">shares available for future grants at June 30, 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
July 11, 2022, our shareholders approved an increase in the aggregate number of shares of our common stock available for issuance under
our 2019 plan by 3,000,000 shares to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220711__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zIvB9HTYmFVb" title="Maximum equity available for issuance under the plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-07-11_us-gaap_SubsequentEventMember_custom_TwoThousandAndNineteenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> shares in total.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Compensation Expense</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7ClB0UYcF0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six month periods ended June 30, 2022 and 2021 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_z5I4ignx7VS2" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three
                                            Months Ended</span></p>
                                                                                <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">June
                                            30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Six
                                            Months Ended</span></p>
                                                                                <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">June
                                            30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxd3g4OmvjTi" title="Total" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">685,624</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdPAS0onR9R1" title="Total" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">191,594</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3BGzipHAmE5" title="Total" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">877,500</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVSSqQb6Zdsl" title="Total" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">245,385</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYUiMYF3lsyb" title="Total" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,323,745</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxL6dtq5NF0k" title="Total" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">673,729</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWZhN4qivM24" title="Total" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,960,766</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuOBCXBQstQb" title="Total" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">928,237</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630_zumQss4QUm9e" title="Total" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,009,369</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630_zKmuV1SQigKb" title="Total" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">865,323</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630_zYSqQzlJrZXc" title="Total" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,838,266</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_z42VtXLe2e08" title="Total" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,173,622</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zKydv2SBxYPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No
tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred
tax assets relating to this expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zANKSZJgIGHc" title="Stock option granted"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_do_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFajQdW0bOX5" title="Stock option cancelled or forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></span></span>
stock options were granted, cancelled or forfeited during the six months ended June 30, 2022. At June 30, 2022, we had outstanding options
for the purchase of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Outstanding options for the purchase shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">178,496</ix:nonFraction></span> shares with a weighted average exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted average exercise price of stock option outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.07</ix:nonFraction></span> and a weighted average remaining contractual life
of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXfX60nIth6g" title="Stock options outstanding, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.1</ix:nonNumeric></span> years. Options </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercisable at June 30, 2022 <span style="background-color: white">for
the purchase of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of option exercisable during period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">176,315</ix:nonFraction></span> shares of our common stock had a weighted average exercise price $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of options exercisable, weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.02</ix:nonFraction></span> and a weighted average remaining contractual
life of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1TmoAx9Hzt" title="Stock options exercisable, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.0</ix:nonNumeric></span> years. We had, a</span>s of June 30, 2022, total unrecognized stock-based compensation expense for these stock options of
approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" title="Unrecognized stock option expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,000</ix:nonFraction></span>, which is expected to be fully recognized by the end of the third quarter of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Awards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 4, 2022, we granted and issued Restricted Stock Awards (&#8220;RSAs&#8221;) for <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220103__20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zv6a2kr27iPg" title="Stock granted during period restricted stock, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-032022-01-04_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,766</ix:nonFraction></span> shares of our common stock to a consultant
for services to be provided in 2022. These RSAs had a fair market value of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdp0" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> on the date of grant and were expensed as stock-based
compensation during the six months ended June 30, 2022. Effective January 1, 2022, we also granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220103__20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zs5tsmjgjFje" title="Stock granted during period restricted stock, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-032022-01-04_us-gaap_RestrictedStockMember_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,832</ix:nonFraction></span> RSAs to our directors for their
2022 service which had a fair market value of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pp0p0_c20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zGAt2x1foFdg" title="Restricted stock fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-01-04_us-gaap_RestrictedStockMember_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">252,000</ix:nonFraction></span> on the date of grant and will cliff vest on December 31, 2022. Additionally, on
March 31, 2022, we issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220320__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zjuqygceQcte" title="Number of restricted shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-03-202022-03-31_us-gaap_RestrictedStockMember_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,572</ix:nonFraction></span> RSAs to our directors in satisfaction of the $<span id="xdx_90B_ecustom--AccruedDirectorsFees_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_pp0p0" title="Directors&apos; fees"><ix:nonFraction name="PCSA:AccruedDirectorsFees" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockMember_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></span> of directors&#8217; fees we had accrued at December
31, 2021. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2022, a director did not seek reelection
and forfeited the <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pp0p0_c20220529__20220531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zqNjQVcX4BG5" title="Restricted stock units forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-05-292022-05-31_us-gaap_RestrictedStockMember_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">18,208</ix:nonFraction></span> RSAs related to their 2022 service. <span style="background-color: white">We did not cancel any RSAs during
the six months ended June 30, 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
June 30, 2022, we had unvested RSAs for </span><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEUH56MJ2p51" title="Number of unvested restricted stock award" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,733</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares with a weighted average
grant date fair value of $</span><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z37CbNwR5w58" title="Weighted average grant date fair value" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.13</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
Unvested RSAs representing <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_c20220101__20220630__us-gaap--VestingAxis__custom--TwoThousandTwentyTwoMember_z1Y1uf8BZ5e6" title="Number of restricted stock expected to vest, shares"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" contextRef="From2022-01-012022-06-30_custom_TwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,733</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares are expected
to vest at various dates in 2022, <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_c20220101__20220630__us-gaap--VestingAxis__custom--TwoThousandTwentyThreeMember_z0R7GjGrcc8a" title="Number of restricted stock expected to vest, shares"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" contextRef="From2022-01-012022-06-30_custom_TwoThousandTwentyThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares are expected
to vest in 2023, and the remainder are expected to vest in 2024. As of June 30, 2022, the total unrecognized stock-based compensation
expense related to the outstanding RSAs was approximately $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1xfV1PTzb23" title="Unrecognized share based compensation expense"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">310,000</ix:nonFraction></span> which is expected to be recognized over a weighted average period
of approximately <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEoAOQqh3IAk" title="Weighted average period"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockMember" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">0.8</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Units</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z8d5T3Ki4Ot9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2022 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zjf0Q6rBUrB7" style="display: none">Schedule of Information About RSU Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Number
                                            of</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">shares</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Weighted-</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">average</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">grant-date
                    fair</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">value
                    per share</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsnTJ8vUfM6k" title="Number of shares, Beginning balance" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">439,593</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Awarded</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Number of shares, awarded" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,363,917</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted-average grant-date fair value per share, awarded" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09vNXbV5Ka9" title="Number of shares, forfeited" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,088</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted-average grant-date fair value per share, forfeited" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.81</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyHTyRw8XB09" title="Number of shares, shares issued" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted-average grant-date fair value per share, shares issued" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.65</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at June 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z04qac9KvjA6" title="Number of shares, ending balance" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,777,922</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zykyPXnb3Pmj" title="Weighted-average grant-date fair value per share, ending balance" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.12</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and unissued</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Number of shares, vested and unissued" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">440,374</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted-average grant-date fair value per share, vested and unissued" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at June 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Number of shares, unvested" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,337,548</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted-average grant-date fair value per share, unvested" style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.83</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zmqsT1P0r5F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, unrecognized stock-based compensation expense of approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn6n6_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkLtwdKbPSuk" title="Unrecognized share based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million for RSUs is expected to be fully recognized
over a weighted average period of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVnPTLJki7b5" title="Weighted average period, restricted stock units"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.8</ix:nonNumeric></span> years. The unrecognized expense excludes approximately $<span id="xdx_909_ecustom--UnrecognizedShareBasedCompensationExpense_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Unrecognized restricted stock expense"><ix:nonFraction name="PCSA:UnrecognizedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">349,000</ix:nonFraction></span> of expense related to certain RSUs
with a performance milestone that is not probable of occurring at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2022, we grant<span style="background-color: white">ed</span> RSUs related to the future issuance of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__custom--BaseCompensationMember_zexw2rKte1sj" title="Restricted stock units awarded"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_BaseCompensationMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,131</ix:nonFraction></span>
<span style="background-color: white">shares of our common stock p</span>ursuant to agreements with our Executive team and certain other
employees where a portion of their base compensation is paid in RSUs<span style="background-color: white">. The value of an RSU award
is based on the average share price of the month services were provided. </span>These RSUs are vested but must meet distribution requirements
before any shares of common stock are issued. Effective July 1, 2022, we established a $<span id="xdx_908_ecustom--MinimumPricePerShareOfEquityCompensation_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zICUThFSRYra" title="Minimum price per share of equity compensation"><ix:nonFraction name="PCSA:MinimumPricePerShareOfEquityCompensation" contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span> per share floor for the computation of the
number of shares our Executive team members could earn under this program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Included
in RSUs awarded during the six months ended June 30, 2022 are RSUs awarded on April 1, 2022 for <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zEX0L8T1Xui5" title="Restricted stock units awarded"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_AprilOneTwoThousandTwentyTwo2022GrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,979,818</ix:nonFraction></span>
shares of our common stock, of which RSUs related to the future issuance of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztmn0BWRNbE7" title="Common stock available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-07-102022-07-11_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">879,819</ix:nonFraction></span>
shares were subject to shareholder approval, which was received on July 11, 2022. These RSUs vest on January 1, 2023 and are subject
to distribution requirements before any shares of common stock are issued. The RSUs that were not subject to shareholder approval
ha<span style="background-color: white">d</span> a fair value on April 1, 2022 of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn5n6_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zk59jOiyljcb" title="Restricted stock fair value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_AprilOneTwoThousandTwentyTwo2022GrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span>
million while the RSUs that were approved by the shareholders on July 11, 2022 have a fair value, as of the approval date, of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pn5n6_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zknx6KVREl7" title="Fair value amount"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-102022-07-11_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USDPShares">2.9</ix:nonFraction></span>
million. <span style="background-color: white">The $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn5n6_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zRX2toEn2kW2" title="Restricted stock fair value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_AprilOneTwoThousandTwentyTwo2022GrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million is being recognized ratably over the period April 1, 2022 through
December 31, 2022, while the $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pn5n6_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5jT5L5VY8Me" title="Fair value amount"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-102022-07-11_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USDPShares">2.9</ix:nonFraction></span> million will be recognized </span> ratably over the remainder
of 2022</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning in the third quarter of 2022<span style="background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs <span style="background-color: white">will be </span> issue<span style="background-color: white">d</span> shares of our common stock upon the <span style="background-color: white">satisfaction </span> of the distribution restrictions contained
in their Restricted Stock Unit Award Agreement. The distribution restrictions are typically different (longer) than the vesting schedule,
imposing an additional restriction on the holder. Unlike RSAs, while employees may hold fully vested RSUs, the individual does not hold
any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU
converts into one share of our common stock. The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_do_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzLc42kaaYeg" title="Warrant cancelled or forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock purchase warrants were <span style="background-color: white">granted,
cancelled </span>or forfeited during the six months ended June 30, 2022. At June 30, 2022, we had outstanding and vested stock purchase
warrants for the purchase of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303,725</ix:nonFraction></span> <span style="background-color: white">shares with a weighted average exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants, weighted average exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.66</ix:nonFraction></span> and
a weighted average remaining contractual life of <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zV9lLDVAgu61" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember" format="ixt-sec:duryear" name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1">1.3</ix:nonNumeric></span> years.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective
May 3, 2022, we extended the expiration date of a warrant held by a consultant by one year in connection with the extension of their
service agreement. No other terms of the warrant, including the exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220503__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zOjmhbIxK9u5"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-03_us-gaap_WarrantMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.18</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">,
were changed. We will recognize expense of approximately $<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220503__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zN1LYkVhjkr9"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-05-03_us-gaap_WarrantMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">related to this warrant
modification over a one-year period beginning May 2022.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zDF0u2yO1cW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_820_zHjiZb7GB7Va">Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
and six month periods ended June 30, 2022 and 2021 excludes the impact of potentially dilutive common shares since those shares would
have an anti-dilutive effect on net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkOIJnlxehlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six month periods ended June 30, 2022 and 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zvhqEF0fMs0f" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20220401__20220630_za3vl8QvOkGg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20210401__20210630_z4cGDc2c6kI5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220101__20220630_zKB8vE2ktCra" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20210630_zLQu56bq0xP4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss
    per share:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zhV6ROILpGcj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss available to common stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,164,368</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,157,043</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,391,499</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,256,523</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zcCqDBb6YXbe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of common shares-basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,940,510</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,406,363</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,886,116</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,997,303</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_z6yzRSdmFfK2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net
    loss per share</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.32</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.20</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.53</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.35</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zwkZqaCPibTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the three and six month periods ended June 30, 2022 and 2021 excluded <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630_zINBxLXBCiAi" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,965,502</ix:nonFraction></span> and <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">709,954</ix:nonFraction></span> of potentially
dilutive common shares, respectively, related to outstanding stock options, stock purchase warrants and unvested restricted stock since
those shares would have had an anti-dilutive effect on net loss per share during the periods then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zPx7jmldjMie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82B_zo8oVMn90yXj">Operating Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220630_zpE5BH8pWdT6" title="Operating lease borrowing rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% to determine the present value of the lease payments based
on the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our condensed consolidated statements of operations totaled $<span id="xdx_904_eus-gaap--LeaseCost_pp0p0_c20220401__20220630_zYGHmnKkTkba" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,137</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--LeaseCost_pp0p0_c20210401__20210630_zMIPf1X54VF" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,801</ix:nonFraction></span> for the three months ended June 30
and 2021, respectively, and $<span id="xdx_906_eus-gaap--LeaseCost_c20220101__20220630_pp0p0" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,528</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--LeaseCost_c20210101__20210630_pp0p0" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2021-01-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,831</ix:nonFraction></span> for the six months ended June 30, 2022 and 2021, respectively. The weighted average remaining
lease terms and discount rate for our operating leases were as follows at June 30, 2022:</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zuCRzYZinoD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z0C2VaxiisOb" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remaining lease term (years) for
    our facility lease</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--FacilityLeaseMember_zvLor31lWt9b" title="Operating lease, weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-06-30_custom_FacilityLeaseMember" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.3</ix:nonNumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remaining lease term (years) for our equipment
    lease</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--EquipmentLeaseMember_zhcGBsJnb3b" title="Operating lease, weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-06-30_custom_EquipmentLeaseMember" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.8</ix:nonNumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining lease term (years)
    for our facility and equipment leases</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630_zRQthivWEHP7" title="Operating lease, weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-06-30" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.7</ix:nonNumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average discount rate for our facility
    and equipment leases</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220630_zpEBInSr38r" title="Weighted average discount rate for our facility and equipment leases" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zgZ8r5AqpuJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zkPy1Uev7nlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for all operating leases were as follows as of June 30, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zTnvStVTQxq4" style="display: none">Schedule of Maturities of Lease Liabilities for all Operating Leases</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20220630_z7iZtEbovtTa" style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzqtT_zxmLcTtIplP4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,457</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzqtT_zxcW3vxunlZ9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,420</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzqtT_zRN1xZw4As23" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,605</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzqtT_zNfdAvpl1cwk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,482</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z6gPLHIOA7ta" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,275</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,207</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zq4rtcOZJyl3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    current maturities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,552</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current
    lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,655</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zVnUXhSrhKya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zzn3iY9kBeoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211;<span id="xdx_828_zqfcTbLvFBs9"> Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. We recorded $<span id="xdx_90F_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20220101__20220630__dei--LegalEntityAxis__custom--CorLystLLCMember_pp0p0" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2022-01-012022-06-30_custom_CorLystLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,689</ix:nonFraction></span> and $<span id="xdx_90B_ecustom--ProceedsFromRentAndOtherCostsReimbursements_pp0p0_c20210101__20210630__dei--LegalEntityAxis__custom--CorLystLLCMember_zqrqLek1iGl1" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2021-01-012021-06-30_custom_CorLystLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,549</ix:nonFraction></span> of reimbursements during the six months ended June 30, 2022 and 2021, respectively.
<span id="xdx_90B_eus-gaap--DueFromRelatedPartiesCurrent_iI_pp0p0_do_c20220630__dei--LegalEntityAxis__custom--CorLystLLCMember_z3DF2K33OtAk" title="Due from related parties"><span id="xdx_90F_eus-gaap--DueFromRelatedPartiesCurrent_iI_pp0p0_do_c20210630__dei--LegalEntityAxis__custom--CorLystLLCMember_zjLL1F74KLl4" title="Due from related parties"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2022-06-30_custom_CorLystLLCMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2021-06-30_custom_CorLystLLCMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> amounts were due from CorLyst at June 30, 2022 or 2021. Our CEO is also the CEO of CorLyst, and CorLyst is a shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="PCSA:ElionLicenseAgreementDisclosureTextBlock"><p id="xdx_802_ecustom--ElionLicenseAgreementDisclosureTextBlock_zlWvBa07maU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 &#8211; <span id="xdx_822_z1u0KhmUOMQh">Elion License Agreement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 17, 2022, we amended the third Milestone Event
of Section 6.4 of our License Agreement with Elion Oncology, Inc. changing the third Milestone Event from &#8220;1<sup>st</sup> Patient
in Dose Confirmation Study&#8221; to (a) determination of the maximum tolerated dose (MTD) or (b) determination of the recommended Phase
2 Dose. Prior to this amendment, the third milestone was not considered probable since it was unknown when, or if a dose confirmation
study was going to be conducted. As a result of the modification, we consider it probable that the MTD could be determined in connection
with our current Phase 1B trial for PCS6422. We recorded an expense and related liability of $<span id="xdx_908_ecustom--ExpenseAndRelatedLiability_c20220516__20220517__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmKftoJb6egj" title="Expense and related liability"><ix:nonFraction name="PCSA:ExpenseAndRelatedLiability" contextRef="From2022-05-162022-05-17_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction></span> representing the value of the shares
we anticipate issuing to Elion at the fair value on the date of modification. No other terms or conditions of the License Agreement were
modified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-06-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zalTIWw4lCKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_823_zZvhZaVcLR17">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with contract research organizations and subcontractors to further develop our
products. The contracts are cancellable, with varying provisions regarding termination. If we terminated a cancellable contract with
a specific vendor, we would only be obligated for products or services that we received as of the effective date of the termination
and any applicable cancellation fees. As of June 30, we are contractually obligated to pay up to approximately $<span id="xdx_908_eus-gaap--PurchaseObligation_iI_pn5n6_c20220630__us-gaap--TypeOfArrangementAxis__custom--AgreementsMember__dei--LegalEntityAxis__custom--ContractResearchOrganizationsMember_zfRC0J7EiMd2" title="Purchase obligation"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2022-06-30_custom_AgreementsMember_custom_ContractResearchOrganizationsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span> million of
future services under the agreements with the CROs, but our actual contractual obligations will vary depending on the progress and
results of the clinical trials.</span></p>

</ix:nonNumeric><p id="xdx_819_zJxMhPikeLeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward
Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; that reflect, when made, the Company&#8217;s expectations
or beliefs concerning future events that involve risks and uncertainties. Forward-looking statements frequently are identified by the
words &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;project,&#8221;
&#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely result,&#8221; or other similar words and phrases. Similarly,
statements herein that describe the Company&#8217;s objectives, plans or goals also are forward-looking statements. Actual results could
differ materially from those projected, implied or anticipated by the Company&#8217;s forward-looking statements. Some of the factors
that could cause actual results to differ include: our limited operating history, limited cash and history of losses; our ability to
achieve profitability; our ability to obtain adequate financing to fund our business operations in the future; the impact of the global
pandemic caused by the novel coronavirus, COVID-19, including its impact on our ability to obtain financing or complete clinical trials;
our ability to secure required FDA or other governmental approvals for our product candidates and the breadth of the indication sought;
the impact of competitive or alternative products, technologies and pricing; whether we are successful in developing and commercializing
our technology, including through licensing; the adequacy of protections afforded to us and/or our licensor by the anticipated patents
that we own or license and the cost to us of maintaining, enforcing and defending those patents; our and our licensor&#8217;s ability
to protect non-patented intellectual property rights; our exposure to and ability to defend third-party claims and challenges to our
and our licensor&#8217;s anticipated patents and other intellectual property rights; and our ability to continue as a going concern.
For a discussion of these and all other known risks and uncertainties that could cause actual results to differ from those contained
in the forward-looking statements, see &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended
December 31, 2021, which is available on the SEC&#8217;s website at www.sec.gov. All forward-looking statements are qualified in their
entirety by this cautionary statement, and the Company undertakes no obligation to revise or update this Quarterly Report on Form 10-Q
to reflect events or circumstances after the date hereof.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>For
purposes of this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, references to the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to the operations of Processa Pharmaceuticals, Inc. and its direct and
indirect subsidiaries for the periods described herein.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to develop drug products that improve the survival and/or quality of life for patients with high unmet medical need conditions
for which few or no treatment options currently exist. We are a clinical-stage development company, not a discovery company, that seeks
to identify and develop drugs for patients who need better treatment options. To increase the probability of development success, our
pipeline only includes drugs which have previously demonstrated some efficacy in the targeted population or a drug with very similar
pharmacological properties that has been shown to be effective in the population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
screening criteria for identifying and selecting new candidates include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    an unmet or underserved clinical need,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
    demonstrated evidence of efficacy in humans, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">leveraging
    our regulatory science approach to improve the probability of approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
many instances, these clinical candidates have significant pre-clinical and clinical data that we may leverage to high value inflection
points while de-risking the programs and adding in optionality to potential future indications. Our regulatory science approach developed
by our team over decades of work with regulatory authorities attempts to balance the &#8220;benefit/risk&#8221; equation to identify
a regulatory path with higher clinical benefit and/or lower clinical risk with shorter timelines to deliver better treatment options
to patients, physicians, and caregivers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline includes drugs that (i) already have clinical proof-of-concept data demonstrating the desired pharmacological activity in humans
or, minimally, clinical evidence in the form of case studies or clinical experience demonstrating the drug or a similar drug pharmacologically
can successfully treat patients with the targeted indication; (ii) target indications for which a single positive pivotal study demonstrating
efficacy might provide enough evidence that the clinical benefits of the drug and its approval outweighs the risks associated with the
drug or the present standard of care (e.g., some orphan indications, many serious life-threatening conditions, some serious quality of
life conditions); and/or (iii) target indications where the prevalence of the condition and the likelihood of patients enrolling in a
study meet the desired timeframe to demonstrate that the drug can, at some level, treat or potentially treat patients with the condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
advance our mission, we have assembled an experienced and successful development team with a track record of drug approvals and successful
exits. Our team is experienced in developing drug products through all principal regulatory tiers from IND enabling studies to NDA submission.
Throughout their careers, the combined scientific, development and regulatory experience of our team members have resulted in more than
30 drug approvals by the FDA, over 100 meetings with the FDA, and involvement with more than 50 drug development programs, including
drug products targeted to patients who have an unmet medical need. Although we believe that the skills and experience of our team members
in drug development and commercialization is an important indicator of our future success, the past successes of our team members in
developing and commercializing pharmaceutical products do not guarantee that they will successfully develop and commercialize drugs in
our current pipeline. In addition, the growth in revenues of companies in which our executive officers and directors served was due to
many factors and does not guarantee that they will successfully operate or manage us or that we will experience similar growth in revenues,
even if they continue to serve as executive officers and/or directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate meaningful revenue from any products depends on our ability to out-license the drugs before or after we obtain FDA
NDA approval. Even if our products are authorized and approved by the FDA, it should be noted that the products must still meet the challenges
of successful marketing, distribution, and consumer acceptance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to obtain and develop drugs that will not only treat patients with unmet medical need conditions, but, with our regulatory
science approach, have the potential to be more efficiently developed with a greater probability of development success than what typically
occurs in the biotech-pharma industry, as well as a better return on investment given lower development costs, more efficient development,
and high commercial value. Given the prior successes of our regulatory science approach, we have selected drugs for our portfolio which
may have a greater chance for approval in a population of patients who desperately need better treatment options. We have applied rigorous
standards to identify drugs for our portfolio, namely:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    drug must represent a treatment option to patients with a high unmet medical need condition by improving survival and/or quality
    of life for these patients,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    drug or its metabolite or a drug with similar pharmacological properties must have demonstrated some evidence of efficacy in the
    target population, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    drug presents opportunities to be developed such that within 2-4 years, critical value-added clinical milestones can be achieved
    while advancing the drug closer to commercialization and adding to the potential for a high return on investment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
add significant value to our in-licensed drugs within 2 to 4 years, the drugs must be in the clinical development stage and not in discovery
stage, and during those 2 to 4 years we must be able to obtain clinical data to support the added value. The additional clinical data
could range from clinical proof-of-concept data which further demonstrate that the proposed pharmacology occurs clinically in the targeted
patient population to a pivotal well-designed randomized controlled trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2022, we entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC
(&#8220;Lincoln Park&#8221;), pursuant to which Lincoln Park has committed to purchase up to $15.0 million of shares (the
&#8220;Purchase Shares&#8221;) of our common stock, $0.0001 par value per share (&#8220;Common Stock&#8221;), subject to the terms
and conditions in the Purchase Agreement. We issued 123,609 shares of common stock (valued at $450,000) to Lincoln Park as a
commitment fee in connection with entering into the Purchase Agreement and agreed to reimburse Lincoln Park $25,000 for fees
incurred in connection with the Purchase Agreement. Concurrent with entering into the Purchase Agreement, we also entered into a
registration rights agreement with Lincoln Park (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we agreed to
take certain actions relating to the registration under the Securities Act of 1933, as amended, of the offer and sale of the shares
of common stock available for issuance under the Purchase Agreement. See Note 3 to the Condensed Consolidated Financial Statements
for additional details concerning the Purchase Agreement. <span style="color: #1D2228">We put this facility in place to ensure that
financing will not hinder the continued development of our pipeline should we run into unexpected circumstances in the
future.</span></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic continues to create uncertainties in expected timelines by causing delays in clinical trials and disruptions in
the supply chain for raw materials used in clinical trial work. We have experienced delays in the enrollment of patients in our
PCS499 Phase 2B trial due to COVID-19. Some potential patients have died from COVID-19 prior to screening and others continue to be
reluctant to travel to our testing sites for fear of contracting COVID-19. Delays in enrollment lengthen the time of studies and
increase their costs, which could materially impact our business in future periods. <span style="background-color: white">Furthermore,
the spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. </span>While we are hopeful
the infection rate of COVID-19 will continue to decline, we cannot predict the future impact COVID-19 will have on our current and
future clinical trials. Continued delays could materially impact our business in future periods and further extend our
timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Drug Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have five drugs: four in various stages of clinical development (PCS499, PCS12852, PCS6422, and PCS3117) and one in nonclinical
development (PCS11T). We group our drugs into non-oncology (PCS499 and PCS12852) and oncology (PCS6422, PCS3117, and PCS11T). A summary
of each drug is provided below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><img src="form10-q_001.jpg" alt="" style="height: 272px; width: 570px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Key</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FPI
    &#8211; First Patient In (i.e., randomized)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MTD
    &#8211; Maximum Tolerated Dose</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">PCS499</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS499,
an oral tablet of a deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental<sup>&#174;</sup>), is classified
by FDA as a new molecular entity. PCS499 and its metabolites act on multiple pharmacological targets that are important in a variety
of conditions. We have targeted ulcerative Necrobiosis Lipoidica (uNL) as our lead indication for PCS499. NL is a chronic, disfiguring
condition affecting the skin and tissue under the skin typically on the lower extremities with no currently approved FDA treatments.
NL presents more commonly in women than in men and occurs more often in people with diabetes. Ulceration has been reported to occur in
up to 30% of NL patients, which can lead to more severe complications, such as deep tissue infections and osteonecrosis threatening the
life of the limb.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degeneration of tissue occurring at the NL lesion site may be caused by a number of pathophysiological changes, which makes it extremely
difficult to develop effective treatments for this condition. Because PCS499 and its metabolites appear to affect most of the biological
pathways that contribute to the pathophysiology associated with NL, PCS499 may provide a novel treatment solution for NL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2018, the FDA granted orphan-drug designation for PCS499 for the treatment of NL. On September 28, 2018, the IND for PCS499
in NL became effective, such that we initiated and completed a Phase 2A multicenter, open-label prospective trial designed to determine
the safety and tolerability of PCS499 in patients with NL. The study initially had a six-month treatment phase and a six-month optional
extension phase. In December 2019, we informed patients and sites that the study would conclude after the treatment phase and there would
no longer be an extension phase. The first NL patient enrolled in this Phase 2A clinical trial was dosed on January 29, 2019, and the
study completed enrollment on August 23, 2019. The last patient visit took place in February 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objective of the Phase 2A trial was to evaluate the safety and tolerability of PCS499 in patients with ulcerated and non-ulcerated
NL and to use the safety and efficacy data to design future clinical trials. Based on toxicology studies and healthy human volunteer
studies, we and the FDA agreed that a PCS499 dose of 1.8 grams/day would be the highest dose administered to NL patients in this Phase
2A trial. As anticipated, the PCS499 dose of 1.8 grams/day, 50% greater than the maximum tolerated dose of PTX, appeared to be well tolerated
with no serious adverse events (SAEs) reported. All adverse events (AEs) reported in the study were mild in severity. As expected, gastrointestinal
symptoms were the most frequent AEs and were reported in four patients, all of which resolved within 1-2 weeks of starting dosing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
of the twelve patients in the study presented with uNL and had ulcers for more than two months prior to dosing. At baseline, the reference
ulcer in one of the two patients measured 3.5 cm<sup>2</sup> and had completely closed by Month 2 of treatment. The second patient had
a baseline reference ulcer of 1.2 cm<sup>2</sup> which completely closed by Month 9 during the patient&#8217;s treatment extension period.
In addition, while in the trial, both patients also developed small ulcers at other sites, possibly related to contact trauma, and these
ulcers resolved within one month. The other ten patients, presenting with mild to moderate non-ulcerated NL, had more limited improvement
of the NL lesions during treatment. Historically, 13 - 20% of all the patients with NL naturally progress to complete healing over many
years after presenting with NL. Although the natural healing of the uNL patients has not been evaluated independently, medical experts
who treat NL patients suggest that the natural progression of an open ulcerated wound to complete closure may be significantly less than
13% over 1-2 years and likely close to 0% in patients with the larger ulcers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2020, we met with the FDA and discussed the clinical program, as well as the nonclinical and clinical pharmacology plans to
ultimately support the submission of the PCS499 New Drug Application (NDA) in the U.S. for the treatment of ulcers in NL patients. With
input from the FDA, we designed the next trial as a randomized, placebo-controlled Phase 2B study to evaluate the ability of PCS499 to
completely close ulcers in patients with uNL and better understand the potential response of uNL patients on drug and on placebo. We
currently have selected six clinical trial sites in the United States and are evaluating additional sites to add to our study. We had
four sites in Europe, but these sites were unable to recruit patients timely, largely due to COVID-19, so we decided to close them and
concentrate our efforts on recruiting patients within the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
began recruiting for the clinical trial in the first half of 2021. On May 19, 2021, we dosed our first patient in the randomized, placebo-controlled
trial and are planning to complete an interim analysis of the data from this trial during the first half of 2023. After obtaining the
results from this Phase 2B study, we expect to have an end of Phase 2 meeting with the FDA to agree on the design of the Phase 3 study,
with the intent to define a Special Protocol Assessment for the Phase 3 study and to agree on the next steps to obtain approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced delays in the enrollment of patients in the PCS499 Phase 2B trial due to COVID-19. Many potential patients also have
co-morbidities, such as diabetes, and have been unwilling to travel to the testing sites for fear of contracting COVID-19. Potential
patients in this trial have died from COVID-19 prior to screening. We have initiated a number of programs to hopefully increase the enrollment
rate in this study, including paying for travel to study sites and informing physicians who might be treating these patients that a trial
is occurring.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">PCS12852</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2020, we in-licensed PCS12852 from Yuhan Corporation (&#8220;Yuhan&#8221;), pursuant to which we acquired an exclusive license
to develop, manufacture and commercialize PCS12852 globally, excluding South Korea.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4
selectivity have been shown to successfully treat gastrointestinal (GI) motility disorders such as gastroparesis, chronic constipation,
constipation-predominant irritable bowel syndrome and functional dyspepsia. Less selective 5-HT4 agonists, such as cisapride, have been
either removed from the market or not approved because of the cardiovascular side effects associated with the drugs binding to other
receptors, especially receptors other than 5-HT4. PCS12852 has been shown in nonclinical studies to have a cardiovascular side effect
only at concentrations greater than 1,000 times the maximum concentration seen in humans.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
clinical studies, both of which have demonstrated the effectiveness of PCS12852 on GI motility, have been previously conducted by Yuhan
with PCS12852. In a Phase 1 trial (Protocol YH12852-101), the initial safety and tolerability of PCS12852 were evaluated after single
and multiple oral doses in healthy subjects. PCS12852 was shown to increase GI motility in this study, increasing stool frequency with
faster onset when compared to prucalopride, a less specific 5-HT4 agonist FDA-approved drug for the treatment of chronic idiopathic constipation.
Based on an increase of &#8805;1 spontaneous bowel movement (SBM)/week from baseline during 7-day multiple dosing, the PCS12852 dose group
had a higher percentage of patients with an increase than the prucalopride group. All doses of PCS12852 were safe and well tolerated
and no SAEs occurred during the study. The most frequently reported AEs were headache, nausea and diarrhea which were temporal, manageable
and reversible within 24 hours. There were no clinically significant changes in platelet aggregation and ECG parameters including a change
in QTc prolongation in the study. In a Phase 1/2A clinical trial (Protocol YH12852-102), the safety, tolerability, gastric emptying rate
and pharmacokinetics of multiple doses of a PCS12852 immediate release (IR) formulation and a delayed release (DR) formulation were evaluated.
PCS12852 was safe and well tolerated after single and multiple administrations. The most frequent AEs for both the IR and DR formulations
of PCS12852 were headache, nausea and diarrhea, but the incidences of these AEs were comparable with those of the 2mg prucalopride group.
These AEs, which were transient and mostly mild in severity, are also commonly observed with other 5-HT4 agonists. Both formulations
of PCS12852 also increased the gastric emptying rate and increased GI motility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuhan
had also conducted extensive toxicological studies for the product that demonstrated that the product is safe for use and can be moved
into Phase 2 studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received guidance from the FDA in the first half of 2021 and in October 2021 we received notice of safe to proceed for PCS12852 evaluation
in a Phase 2A randomized, placebo-controlled study in patients with gastroparesis. We enrolled our first patient on April 5, 2022, anticipate
completing enrollment in the second half of 2022 with top-line results by the end of 2022, and should complete our final analysis in
the first half of 2023. The purpose of the Phase 2A trial is to evaluate the safety, efficacy, and pharmacokinetics of two different
dosing regimens for PCS12852. Data obtained from this study will be used to better design a future Phase 2/3 efficacy study. Since patients
with gastroparesis have an abnormal pattern of upper GI motility in the absence of mechanical obstruction, the Phase 2A study was designed
to evaluate the change in gastric emptying in patients with gastroparesis from two different dosing regimens of PCS12852 compared to
placebo. The only FDA-approved drug to treat gastroparesis is metoclopramide, a dopamine D2 receptor antagonist that has documented serious
side effects which limit dosing to no more than 12 weeks. Other 5-HT4 drugs have been used clinically but the side effects, mainly caused
by binding to other receptors, has resulted in these drugs not being a viable option to treat patients with gastroparesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">PCS6422
(&#8220;Next Generation Capecitabine&#8221; when administered with Capecitabine)</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2020, we in-licensed PCS6422 from Elion Oncology, Inc. (&#8220;Elion&#8221;), pursuant to which we acquired an exclusive license
to develop, manufacture and commercialize PCS6422 globally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS6422
is an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the enzyme that rapidly metabolizes
a common chemotherapy drug known as 5-FU, into inactive metabolites, such as &#945;-fluoro-&#946;-alanine (F-Bal). F-Bal is a metabolite
that has no anti-cancer activity but causes unwanted side effects, which notably leads to dose interruptions and significantly affects
a patient&#8217;s quality of life. F-Bal is thought to cause the neurotoxicity and Hand&#8211;Foot Syndrome (HFS) associated with 5-FU,
and greater formation of F-Bal appears to be associated with a decrease in the antitumor activity of 5-FU. HFS can affect activities
of daily living, quality of life, and requires dose interruptions/adjustments and even therapy discontinuation resulting in suboptimal
tumor effects. We believe that the inhibition of DPD by PCS6422 will significantly reduce 5-FU side effects related to a decrease in
F-Bal, although the timeframe and magnitude for DPD inhibition have been shown to vary, ranging from 2-14 days depending on the de novo
formation of DPD within a patient and the dosage regimen of PCS6422. With the inhibition of DPD, the level of the 5-FU anti-cancer metabolites
could also be potentially higher within cancer and normal cells leading to an improved efficacy profile and/or increased side effects
associated with these antimetabolites such as neutropenia. By combining capecitabine (an oral pro-drug form of 5-FU) with PCS6422, the
change in 5-FU metabolism should result in an increase in the systemic exposure of 5-FU based on the 5-FU Area Under the Plasma Concentration
Curve (AUC) per mg of capecitabine dosed. This results in needing less capecitabine to kill cancer cells and treat each patient, making
the combination of PCS6422 and capecitabine (the &#8220;Next Generation Capecitabine&#8221;) more potent than current FDA approved capecitabine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluoropyrimidines
(e.g., 5-FU, capecitabine) remain the cornerstone of treatment for many types of cancers, either as monotherapy or in combination with
other chemotherapy agents by an estimated two million patients annually. Xeloda<sup>&#174;</sup>, the brand name of capecitabine, is an
oral pro-drug of 5-FU and approved as first-line therapy for metastatic colorectal and breast cancer. However, its use is limited by
adverse effects such as the development of HFS in up to 60% of patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elion
evaluated the potential for the combination of PCS6422 with capecitabine as a treatment of advanced gastrointestinal (GI) tumors. Nonclinical
efficacy data indicated that in colorectal cancer models, pretreatment with PCS6422 enhanced the antitumor activity of capecitabine.
PCS6422 dramatically increased the antitumor potency of capecitabine without increasing the toxicity. The antitumor efficacy of the combination
of PCS6422 and capecitabine was tested in several xenograft animal models with human breast, pancreatic and colorectal cancer cells.
These preclinical xenograft models demonstrate that PCS6422 potentiates the antitumor activity of capecitabine and significantly reduces
the dose of capecitabine required to be efficacious.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
DPD enzyme inhibitors (e.g., Gimeracil used in Teysuno&#174; approved only outside the US) act as competitive reversible inhibitors. These
agents must be present when 5-FU or capecitabine are administered to inhibit 5-FU breakdown by DPD in order to improve the efficacy and
safety profiles of 5-FU. Given the reversible nature of their effect on DPD, over time 5-FU metabolism to F-Bal will return if the reversible
inhibitor is not present, decreasing the amount of 5-FU in the cancer cells and decreasing the potential cytotoxicity on the cancer cells.
There is also evidence that administering large amounts of DPD inhibitors directly with 5-FU may also decrease the antitumor effect of
the 5-FU. Because PCS6422 is an irreversible inactivator of DPD, it is dosed the day before capecitabine administration and its effect
on DPD can last longer than the reversible DPD inhibitors and beyond the time 5-FU exists in the cancer cell, even after PCS6422 has
been completely eliminated out of the body. We believe this can optimize the potential cytotoxic effect of the 5-FU nucleotide metabolites
and minimize the catabolism of 5-FU to F-Bal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to Elion&#8217;s involvement, two multicenter Phase 3 studies were conducted in patients with colorectal cancer with PCS6422 administered
in 10-fold excess to 5-FU and administered with the 5-FU. Unfortunately, we believe the dose of PCS6422 during these trials was not optimal
and that PCS6422 was not administered early enough to irreversibly affect the DPD enzyme, thus the regimen tended to produce less antitumor
benefit than the control arm with the standard regimen of 5-FU/leucovorin (LV) without PCS6422. In addition, later preclinical work suggested
that when PCS6422 was present in excess to 5-FU and at the same time, it diminished the antitumor activity of 5-FU, which we believe
supports the rationale of dosing PCS6422 such that the exposure at the time of 5-FU or capecitabine administration is as low as possible,
yet continues to inhibit DPD activity to less than 10% of normal activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elion
met with the FDA in 2019 and agreed upon the clinical development program required for the combination of PCS6422 and capecitabine as
first-line therapy for metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred. On May 17, 2020,
an IND for the Phase 1B study was granted safe to proceed by the FDA. This Phase 1B study was designed to evaluate: (i) the safety and
tolerability of PCS6422 and several doses of capecitabine in advanced GI tumor patients; (ii) the pharmacokinetics of PCS6422, capecitabine,
5-FU and selected metabolites; (iii) the activity of DPD over time after PCS6422 administration; and (iv) the maximum tolerated dose
in up to 30 patients over multiple cycles. We began patient recruitment in the study during the second half of 2021 and enrolled our
first patient on August 2, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of Cohorts 1 and 2 was conducted in the fourth quarter of 2021. DLTs, drug related adverse events of greater than Grade
1 and hand-foot syndrome were not observed in these patients. Also, this Next Generation Capecitabine effectively inhibited DPD enzyme
activity 24-48 hours after PCS6422 administration with &lt;10% of 5-FU metabolized to F-Bal as compared to ~80% with the FDA approved
capecitabine. Additionally, 5-FU potency based on the 5-FU AUC systemic exposure per mg of capecitabine dosed was 50 times greater with
Next Generation Capecitabine. The interim analysis showed, however, that the improved metabolic profile and increased potency was not
sustained at Day 7 after the single dose administration of PCS6422 on Day 1. In February 2022, we submitted a modified Phase 1B trial
protocol to the FDA to not only determine the MTD of capecitabine, but also to further evaluate the timeline of DPD inhibition and de
novo formation as a function of PCS6422 dosing, as well as the potential for using individualized/personalized treatment of patients
with Next Generation Capecitabine.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that this additional data will allow us to select PCS6422 dosage regimens that will maintain DPD inhibition throughout capecitabine
dosing and allow more of the drug to be metabolized to active tumor killing metabolites instead of metabolites that only cause side effects
for each patient treated with this Next Generation Capecitabine. After interacting with the FDA and making protocol modifications, we
restarted the Phase 1B study in April 2022 and expect to complete enrollment while defining the Next Generation Capecitabine regimens
by the end of 2022. We expect that our overall timeline has not changed with a Phase 2B or 3 trial starting in 2023-2024 and NDA submission
in 2027-2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">PCS3117</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2021, we executed a License Agreement with Ocuphire Pharma, Inc. (&#8220;Ocuphire Agreement&#8221;) under which we received
a license to research, develop and commercialize PCS3117 globally, excluding <span style="background-color: white">Republic of Singapore,
China, Hong Kong, Macau, and Taiwan</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117
is a novel, investigational, oral small molecule nucleoside compound. PCS3117 is an analog of the endogenous nucleoside, cytidine, and
an analog of the cancer drug gemcitabine. Once intracellularly activated (phosphorylated) by the enzyme UCK2, it is incorporated into
the DNA or RNA of cells and inhibits both DNA and RNA synthesis, which induces apoptotic cell death of tumor cells. PCS3117 has received
orphan drug designation from the FDA and the European Commission for the treatment of patients with pancreatic cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gemcitabine
is usually used as second line therapy for metastatic pancreatic cancer and non-small cell lung cancer, as well as used as second line
therapy for other types of cancer. The difference between PCS3117 and gemcitabine is how they are activated to cancer killing nucleotides.
PCS3117 also has additional pharmacological pathways which will result in cancer cell apoptosis. Since 45% - 85% of pancreatic cancer
and non-small cell lung cancer patients are inherently resistant or acquire resistance to gemcitabine, the differences between PCS3117
and gemcitabine could potentially provide a therapeutic alternative to patients who do not or will not respond to gemcitabine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resistance
to gemcitabine or PCS3117 is likely caused by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in the cytidine deaminase (CDA) enzyme which breaks down gemcitabine and PCS3117,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    deficiency in transportation of gemcitabine or PCS3117 across the cell membrane,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">down
    regulation of the activation enzyme (dCK for gemcitabine, UCK2 for PCS3117),</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    change in ribonucleotide reductase activity, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-genetic
    influences that alter gene expression.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117
has shown broad spectrum anti-tumor activity against over 100 different human cancer cell lines and efficacy in 17 different mouse xenograft
models. In preclinical trials, PCS3117 retained its anti-tumor activity in human cancer cell lines made resistant to the anti-tumor effects
of gemcitabine. In August 2012, the completion of an exploratory Phase 1 clinical trial of PCS3117 in cancer patients to investigate
the oral bioavailability, safety and tolerability of the compound was reported. In that study, oral administration of a 50 mg dose of
PCS3117 indicated an oral bioavailability of 56% and a plasma half-life (T<sub>1/2</sub>) of 14 hours. In addition, PCS3117 appeared
to be well tolerated in all subjects throughout the dose range evaluated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final
results from a Phase 1B clinical trial of PCS3117 were presented in June 2016 showing evidence of single agent activity. Patients in
the study had generally received four or more cancer therapies prior to enrollment. In this study, 12 patients experienced stable disease
persisting for up to 276 days and three patients showed evidence of tumor burden reduction. A maximum tolerated dose of 700 mg was identified
in the study. At the doses evaluated, PCS3117 appeared to be well tolerated with a predictable pharmacokinetic profile following oral
administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2016, a multi-center Phase 2A clinical trial of PCS3117 in patients with relapsed or refractory pancreatic cancer was initiated
to further evaluate safety and efficacy. The study was designed as a two-stage study with 10 patients in stage 1 and an additional 40
patients in stage 2. According to pre-set criteria, if greater than 20% of the patients had an increase in progression free survival
of more than four months, or an objective clinical response rate and reduction in tumor size, additional pancreatic cancer patients would
be enrolled into stage 2. Secondary endpoints included time to disease progression, overall response rate and duration of response, as
well as pharmacokinetic assessments and safety parameters. In January 2018, the final data from this trial showed evidence of tumor shrinkage
in some patients with metastatic pancreatic cancer that was resistant to gemcitabine and who had failed on multiple prior treatments
was presented. In this study, 31% of patients experienced progression free survival for two months or more and five patients, or 12%,
had disease stabilization for greater than four months. Although the pre-set criteria of 20% of the patients having an increase in progression
free survival for four months was not met, some of the gemcitabine refractory patients did respond to PCS3117. However, an evaluation
of why patients were resistant to PCS3117 was not undertaken within the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2017, a Phase 2A trial of PCS3117 in combination with ABRAXANE in patients newly diagnosed with metastatic pancreatic cancer
was initiated. The multicenter, single-arm, open-label study was designed to evaluate PCS3117 in combination with ABRAXANE in first line
metastatic pancreatic cancer patients. In February 2019, the target enrollment of 40 evaluable patients in this trial was reached. An
overall response rate of 23% had been observed in 40 patients that had at least one scan on treatment. Preliminary and unaudited data
indicated that the median progression free survival for patients in the study was approximately 5.6 months. The most commonly reported
related adverse events were nausea, diarrhea, fatigue, alopecia, decreased appetite, rash, vomiting, and anemia. Again, an evaluation
of the cause of treatment resistance to PCS3117 was not undertaken.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently defining the potential paths to approval, which include an evaluation of which population of pancreatic cancer patients
to target, FDA acceptable primary endpoints for the population, and other ways (e.g., biomarkers) to identify patients likely to respond
to PCS3117 over gemcitabine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">PCS11T</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2020, we in-licensed PCS11T from Aposense, Ltd. (&#8220;Aposense&#8221;), pursuant to which we were granted Aposense&#8217;s
patent rights and Know-How to develop and commercialize their next generation irinotecan cancer drug, PCS11T.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS11T
is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan.
This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The
proprietary molecule in PCS11T has been designed to allow PCS11T to bind to cell membranes to form an inactive pro-drug depot on the
cell with SN-38 preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic may make the
therapeutic window of PCS11T wider than other irinotecan products such that the antitumor effect of PCS11T could occur at a much lower
dose with a milder adverse effect profile than irinotecan. Despite the widespread use of commercially marketed irinotecan products in
the treatment of metastatic colorectal cancer and other cancers resulting in peak annual sales of approximately $1.1 billion, irinotecan
has a narrow therapeutic window and includes an FDA &#8220;Black Box&#8221; warning for both neutropenia and severe diarrhea. Therefore,
there is a substantial unmet need to overcome the limitations of the current commercially marketed irinotecan products, improving efficacy
and reducing the severity of treatment emergent AEs. We believe the potential wider therapeutic window of PCS11T will likely lead to
more patients responding with less side effects when on PCS11T compared to other irinotecan products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
studies conducted to date showed that PCS11T demonstrated tumor eradication at much lower doses than irinotecan across various tumor
xenograft models. PCS11T does not affect acetylcholine esterase (AChE) activity in human and rat plasma in vitro, which would suggest
that PCS11T will show an improved safety profile, compared to irinotecan, which is known for its cholinergic-related side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating the manufacturing process and sites for drug substance and drug product. In addition, we are defining the potential
paths to approval, which include defining the targeted patient population and type of cancer. We hope to submit an IND in the first half
of 2024, followed by a Phase 1B trial in oncology patients with solid tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the three and six months ended June 30, 2022 and 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our operations during the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and
    development expenses</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,137,292</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,614,954</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,522,338</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,181,912</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,086,401</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,095,511</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Acquisition of in-process
    research and development</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">515,630</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(515,630</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">515,630</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(515,630</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,034,456</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,329,213</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">705,243</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,218,550</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,051,073</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,167,477</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,171,748</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,459,797</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,400,462</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,653,104</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Forgiveness of PPP loan
    and related accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">163,771</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(163,771</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">163,771</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(163,771</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(362</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">362</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,380</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,814</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,566</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,963</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,755</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,208</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Operating Loss Before
    Income Tax Benefit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,164,368</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,294,212</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,870,156</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,391,499</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,482,940</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,908,559</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income
    Tax Benefit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">137,169</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(137,169</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">226,417</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(226,417</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,164,368</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,157,043</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,391,499</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,256,523</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any revenue under contract or any immediate sales prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development costs are expensed as incurred. Research and development expenses include: (i) amortization of the exclusive
PCS499 license intangible asset used in research and development activities, (ii) internal research and development staff related salaries
and other payroll costs including stock-based compensation, payroll taxes and employee benefits, and (iii) program and testing related
expenses including external consulting and professional fees related to the product testing and our development activities. Non-refundable
advance payments for goods and services to be used in future research and development activities are recorded as prepaid expenses and
expensed when the research and development activities are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses increased during both the three and six month periods ended June 30, 2022 when compared to the same
periods in 2021 as shown below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of intangible assets</span></td><td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">197,124</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">198,832</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394,248</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">397,664</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development salaries and benefits</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,037,768</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">453,721</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,565,020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">702,390</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preclinical, clinical
    trial and other costs</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,902,400</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">962,401</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,222,644</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,986,347</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,137,292</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,614,954</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,181,912</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,086,401</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses increased during both the three and six month periods ended June 30, 2022 when compared to the same
periods in 2021. The majority of our increase in research and development expenses was due to increases in preclinical, clinical trial
and other costs. These increases result from activity in our three active clinical trials. Expenses include costs we paid contract research
organizations, regulatory filing and maintenance fees, drug product testing and stability, consulting, and other clinical fees. Additionally,
on May 17, 2022, we amended the third Milestone Event of our License Agreement with Elion changing the third Milestone Event as described
in Note 8 to our condensed consolidated financial statements. As a result, we recorded research and development expense and a related
liability of $189,000 representing the value of the shares we anticipate issuing to Elion at the fair value on the date of modification.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the same period in 2021, we were beginning our Phase 2B clinical trial for PCS499 and Phase 1B clinical trial for PCS6422 and conducting
pre-IND tasks for PCS12852.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and six months ended June 30, 2022, when compared to the same period in 2021, we also experienced increases in payroll and
related costs of approximately $88,000 and $228,000, respectively and increases in stock-based compensation of approximately $494,000
and $632,000, respectively, as a result of expanding our development team, and increasing salary rates and stock-based compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate our research and development costs to increase in the future as we continue our clinical trials, including the cost of having
drug product manufactured, and continue evaluating the remaining drugs in our portfolio and expanding our development team.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
funding necessary to bring a drug candidate to market is subject to numerous uncertainties. Once a drug candidate is identified, the
further development of that drug candidate may be halted or abandoned at any time due to a number of factors. These factors include,
but are not limited to, funding constraints, safety or a change in market demand. For each of our drug candidate programs, we periodically
assess the scientific progress and merits of the programs to determine if continued research and development is economically viable.
Some programs may be terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization. As noted
above, we anticipate our research and development costs to increase in the future as we conduct the Phase 2B trial to evaluate the ability
of PCS499 to completely close ulcers in patients with NL, conduct our Phase 1B clinical trial for PCS6422 in gastrointestinal tumors
and conduct our Phase 2 trial for PCS12852 in gastroparesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trial cost accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as
estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct
and manage clinical trials on our behalf. At June 30, 2022, we recorded $1.1 million in prepaid expenses for advanced payments made to
our CROs related to our three current clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and
clinical research organizations that conduct and manage preclinical studies and clinical trials on our behalf. In accruing service fees,
we estimate the time-period over which services will be performed and the level of patient enrollment and activity expended in each period.
If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.
Payments made to third parties under these arrangements in advance of the receipt of the related series are recorded as prepaid expenses
until the services are rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses for the three months ended June 30, 2022 increased by approximately $705,000 to $2.0 million from
$1.3 million for the three months ended June 30, 2021. The majority of the increase was due to an increase in employee stock-based compensation
of approximately $702,000 and in payroll and other related costs of $58,300. We also experienced increases in insurance, office, tax,
and other expenses of approximately $36,000, which were offset by a decrease of approximately $89,000 in professional fees, and other
miscellaneous expenses. Reimbursements from CorLyst totaled approximately $32,000 for rent and other costs during the three months ended
June 30, 2022, approximately $1,600 more than reimbursements for the same period in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six month period ended June 30, 2022, our general and administrative expenses increased by approximately $1.2 million to $3.2
million from $2.0 million for the six months ended June 30, 2021. The majority of the increase was due to an increase in employee
stock-based compensation of approximately $983,000 and in payroll and other related costs of approximately $68,000. We also
experienced net increases in other expenses including insurance, office, and tax of
approximately $118,000. Reimbursements from CorLyst totaled approximately $64,000 for rent and other costs during the six months ended
June 30, 2022, approximately $2,000 more than reimbursements for the same period in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the general and administrative expenses to continue to increase as we add staff to support our growing research and development
activities and the administration required to operate as a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income and (Expense)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
other income and (expense) was approximately $7,400 and $166,000 for the three months ended June 30, 2022 and 2021, respectively, and
approximately $9,000 and $170,000 for the six months ended June 30, 2022 and 2021, respectively. During the three and six months ended
June 30, 2021, we recognized $163,771 as other income for the principal amount and accrued interest related to the forgiveness of our
PPP loan. Interest income represents interest earned on money market funds. Interest expense in 2021 was related to our Paycheck Protection
Program loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Tax Benefit</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not recognize any income tax benefit for the three or six months ended June 30, 2022 compared to the $137,169 and $226,417 income
tax benefit we recognized for the three and six months ended June 30, 2021, respectively, as a result of our recording and amortizing
the deferred tax liability created in connection with our acquisition of CoNCERT&#8217;s license and &#8220;Know-How&#8221; in exchange
for Processa stock that had been issued in the Internal Revenue Code Section 351 transaction on March 19, 2018. The Section 351 transaction
treated the acquisition of the Know-How for stock as a tax-free exchange. As a result, under ASC 740-10-25-51 <i>Income Taxes</i>, we
recorded a deferred tax liability of $3,037,147 for the acquired temporary difference between the financial reporting basis of $11,038,929
and the tax basis of $1,782. The deferred tax liability has been reduced for the effect of the non-deductibility of the amortization
of the intangible asset and has been offset by the deferred tax assets resulting from net operating tax losses that was fully amortized
at December 31, 2021. This offset resulted in the recognition of a deferred tax benefit shown in the consolidated statements of operations
in 2021 and prior periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our sources and uses of cash and cash equivalents for the six months ended June 30, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six months ended</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash (used in) provided by:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating activities</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,133,439</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,437,494</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing
    activities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(300,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,852,465</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease)
    in cash</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,433,439</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,414,971</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash used in operating activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We
used net cash in our operating activities of $4,133,439 and $4,437,494 during the six months ended June 30, 2022 and 2021, respectively.
The decrease in cash used in operating activities during the six months ended June 30, 2022 compared to the same period in 2021 was primarily related to the impact of non-cash operating activities, the utilization of prepaid expenses by our CROs
in clinical trials and the timing of payments made to our vendors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022, our prepaid expense and other balance consisted primarily of $1.1 million for advanced payments we made to our CROs
that have not yet been applied to our clinical trials, representing a $200,000 reduction from the prepaid amount recorded at
December 31, 2021 of $1.3 million. Our prepaid expense and other at June 30, 2022 also included the unamortized non-cash commitment
fee we paid to Lincoln Park of $409,000 and the unamortized ATM offering related costs of $186,000. The remainder of the change in
prepaid expenses and other was the result of several other operating activities, none of which, individually or in the aggregate
were considered significant by management.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss for the six months ended June 30, 2022 of $8.4 million was $3.1 million greater than the comparable period in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue our three clinical trials and evaluate the other drugs in our portfolio, we anticipate our research and development efforts
and ongoing general and administrative costs will continue to generate negative cash flows from operating activities for the foreseeable
future. We expect these amounts to increase in the future as the drugs in our pipeline continue to advance and if new or additional clinical
trials begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash (used in) provided by financing activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used net cash in financing activities during the six months ended June 30, 2022 of $300,000 to purchase 100,000 shares of our common
stock from a licensee. During the six months ended June 30, 2021, we closed a private offering raising net proceeds of $9,875,550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022, we had $12.0 million in cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2022, we entered into the Purchase Agreement with Lincoln Park under which we have the right, but not the obligation, to sell
to Lincoln Park, and Lincoln Park is obligated to purchase up to $15,000,000 of our shares of common stock, par value $0.0001 per share,
subject to the terms and conditions in the Purchase Agreement, during the term of the Purchase Agreement as more fully described in Note
3 to the Consolidated Financial Statements. In addition, on August 20, 2021, we entered into the Sales Agreement with the Sales Agent
under which we may issue and sell up to $30.0 million from time to time under the ATM Offering. We expect to use net proceeds from the
ATM Offering over time as a source for working capital and general corporate purposes. During the year ended December 31, 2021, we sold
21,597 shares of our common stock under the ATM Offering at an average price of approximately $8.33 per share for aggregate gross proceeds
of approximately $180,000 prior to deducting sales commissions. We did not sell any shares during the six months ended June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses and net cash used in our operating activities during the six months ended June 30, 2022, which we expect to continue
for the foreseeable future. We do not currently nor have since our inception had any sales. We have incurred losses since our inception,
devoting substantially all of our efforts toward research and development, and have an accumulated deficit of approximately $45.2 million
at June 30, 2022. During the six months ended June 30, 2022, we generated a net loss of approximately $8.4 million, of which $3.5 million
are non-cash expenses. Based on our current plans, we believe our current cash balance is adequate for at least the next twelve months
without considering amounts available from the Purchase Agreement with Lincoln Park or potential sales under our ATM Offering. Our ability
to execute our longer-term operating plans, including unplanned future clinical trials for our portfolio of drugs depend on our ability
to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions. We
plan to continue to actively pursue financing alternatives, but there can be no assurance that we will obtain the necessary funding in
the future when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
estimate of future cash needs is based on assumptions that may prove to be wrong, and we could utilize our available cash sooner than
we currently expect. Our ultimate success depends on the outcome of our planned clinical trials and our research and development activities,
as disclosed above. We expect to incur additional losses in the future, and we will need to raise additional capital to fully implement
our business plan if the costs of our clinical trials are greater than we expect or they take longer than anticipated. We also expect
to incur increased general and administrative expenses in the future. In addition, there may be costs we incur as we develop these drug
products that we do not currently anticipate, requiring us to need additional capital sooner than currently expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials for PCS499, PCS6422 and PCS12852, and the cost of third-party manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    delays in patient enrollment due to the COVID-19 pandemic;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, progress, timing, costs and results of drug manufacturing, pre-clinical studies, and clinical trials of PCS3117 and PCS11T,
    as well as any other future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of product candidates that we pursue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing, and costs of seeking regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with hiring additional personnel and consultants as our pre-clinical and clinical activities increase;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    emergence of competing therapies and other adverse market developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, expanding, defending, and enforcing patent claims, including litigation
    costs and the outcome of such litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we in-license or acquire other products and technologies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time as we can generate substantial product revenues to support our capital requirements, if ever, we expect to finance our cash
needs through a combination of public or private equity offerings, debt financings, collaborations and licensing arrangements or other
capital sources. We currently have an effective S-3 shelf registration statement on file with the SEC, which provides us flexibility
and optionality to raise capital, including pursuant to the ATM Offering and the Purchase Agreement with Lincoln Park, but there can
be no assurance that capital will continue to be available to us on acceptable terms or at all. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted,
and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no significant changes to the contractual obligations reported in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off
Balance Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022, we did not have any off-balance sheet arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Use of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations are based upon our Unaudited Condensed Consolidated Financial
Statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent
assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the estimates, assumptions, and judgments involved in the accounting policies described in the &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of our most recent Annual Report on Form 10-K
have the greatest potential impact on our financial statements, so we consider these to be our critical accounting policies. Actual results
could differ from the estimates we use in applying our critical accounting policies. We are not currently aware of any reasonably likely
events or circumstances that would result in materially different amounts being reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in our critical accounting policies since our most recent Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have evaluated recently issued accounting pronouncements and determined that there is no material impact on our financial position or
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
3 is not applicable to us as a smaller reporting company and has been omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">As
of June 30</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">, 2022</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">,
management, with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act. Based on the evaluation of its disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures were effective as of June 30</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">,
2022</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">to provide reasonable assurance
that information required to be disclosed in our reports under the Exchange Act is (i) recorded, processed, summarized and reported within
the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management, as appropriate,
to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving
their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative
to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting during the quarter ended June 30, 2022 that have materially affected
or are reasonably likely to materially affect our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_008"></span><b>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently not a party to any material legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_009"></span><b>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material changes to our risk factors as described in Item 1A of our Annual Report on Form 10-K for the year ended December
31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_010"></span><b>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)
Recent Sale of Unregistered Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">There
were no sales of unregistered securities during the three months ended June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
Use of Proceeds from Public Offering of Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)
Issuer Purchases of Equity Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2022, we purchased 100,000 shares of our common stock from Aposense Ltd. for $300,000 in a private transaction
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and are holding these shares as treasury stock until
they are reissued or retired at the discretion of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Item
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">None.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_013"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 25, 2022, we changed our transfer agent from Equiniti Trust Ltd.
to Continental Stock Transfer and Trust Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_014"></span><b>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    Ref. No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Rule 153-14(a) Certification by Principal Executive Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Rule 153-14(a) Certification by Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Section 1350 Certification of Principal Executive Officer and Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Files</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">++
This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350 and are not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into
any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing
herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROCESSA
    PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Young</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Young</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    James Stanker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Stanker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</span>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5in; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
David Young, Chief Executive Officer of PROCESSA PHARMACEUTICALS, INC. certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the period ended June 30, 2022;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of registrant&rsquo;s board of directors (or persons performing equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Young</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Young</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
James Stanker, Chief Financial Officer of PROCESSA PHARMACEUTICALS, INC. certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the period ended June 30, 2022;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of registrant&rsquo;s board of directors (or persons performing equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Stanker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Stanker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Written
Statement of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. &sect;1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for the purposes of complying with 18 U.S.C. &sect;1350, I, the undersigned Chief Executive Officer of Processa Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the
quarter ended June 30, 2022 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;/s/
    David Young</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Young</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for the purposes of complying with 18 U.S.C. &sect;1350, I, the undersigned Chief Financial Officer of Processa Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the
quarter ended June 30, 2022 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Stanker</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Stanker</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form10-q_001.jpg
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (K!(H# 2(  A$! Q$!_\0
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M* "BBB@ HHHH **** "BBB@#)_YF[_MP_P#:E:U9/_,W?]N'_M2M:L:'VO\
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MDD9]>0*SHM%N8IM-EWPEK8$2#)^8GJ0<<FM)>V3C:[V_/_(SC[!\W-;^EO\
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M?E_X#_4</9>R?,US=/O7Z7(]-U*_O[02K% 66X\N3&0-G<CGK5>;7KLV,]]
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M#2I]7DY.ZZ_DK?B;E%%%>B>6%9.H?\C#H_\ VV_] %:U9.H?\C#H_P#VV_\
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M*L%6-B1D]3D@?E6E6#E4BTMGV_7R,J,U"$KO1IK?]-B]63XF_P"1>NO^ ?\
MH8K6K)\3?\B]=?\  /\ T,56)_@S]'^1&%_CP]5^9K4445L8!1110 4444 %
M%%% !1110 4444 <]XG^_IO_ %\#^E;5T,QIQG]XG_H0JKJ^F'4H8]D@CEB<
M.A(R,^AJQ&MS*$^TK$FTY(C<MN_,#'-<T(2C4G=;V_(ZI3BZ4+/6-RBU_>G7
M7T^,P!/*\Q79"2/KSS^E0KX@V:9-/+$OVB*7R-BG 9O4>U,<R#Q@YB"%_LW1
MS@'GU[?E3CX>\S2YX)95$\LIF+J,A6]/I6"E7?,X:_%^:M;SW.CEH14?:*UU
M'];_ *%[[5=VJ7$E['&88DWK)%QN]1@DG\:K1ZQ,@L9;A(_*O#A0@.8R>F3G
MG]*N"VGN=.:VO?+!9-C&)B<^_(&*I1Z1._V&*X>+R;,Y4H3F0CID8X_,UK+V
MJDN6]M/SUO\ +^KF4/8V?/:_EVL]OG81=4O7U'4+4"WQ;)O5BC<]\$9_PJO_
M &_>#3K:_:& 122B-D&23UR0>W3IS5A-,O$U'4+G]P5N4*J/,.1V&?EJJ^A7
M[:+;V -MNBE+EO,;!'/^S[_I6'^T6Z]?_2M/_)3>/U:ZO;I^3O\ C8MK*W_"
M521>7#N^SY67:=P'H><&JHUZ^&EW%XR6Y\B?RRH5OF''OQU]ZNK87HUTZ@5M
M]AB\O:)#G_T'UJA_86H'2KFSS;9FF\S=YC<>WW?:B2KI/E3^U^:M^H0=!VYV
MMH_K<TKG4Y1?6EG;JBR7"%]\@)"C&>@(S^=+HU]<7RW!N/*!BE,>(T(Y'?))
MJCJJ7K/906]O!+<)&2R[R"O09#94X_&K6B2W($MI<V4=LT6&_=G(.<^YYX]:
MUA4DZ]FW;7IIT_+4RG3@J%XI7]==WK\]"+Q)8F[MC)&/WT"&1".O!&:GM;P:
MII=OC[TPVR>P'WO\/QJX1<&\SY<1@V[=WF'=^6W'ZU3T[2CI@NC#M=I')C5F
M("KZ=#C\NPJO9R51R2TEO\MOO6A*J1=%1D]5JOGNOU,G2"8O#NILBQG:[DJZ
MDJ0 .."*2Z<2:5H;B-8P9EPJ9P/SYJY::1?VVEWMF1;,;C<0PD;@D8_NTDFC
MW[6&GVX^S;K5]Y/F-AL'C^&N54ZG)&/*]H_>I7_(ZW5I>T<N9?%^'+;\R:[U
MT0W-U%&\"?9E!(E/,IZ[5Y'Y\_2GG6U:[@B4QQ++")4,H/SD_P (/0?K3X].
MN+75Y;RW:)HK@#S8W)!4CN"!S3]3T^2_MWA*P.& ",^08SW88'/TX^M='[_E
M;ZWV^_KZ6_7J<O\ L]XJVEM_E_G_ , I:A+=GQ!IT*S(BLI<*4R V#G/(S5F
M34YY+RZ@MA%BU0,YD!.\]<#!X^O/THFTJ;[?I]S%(K?9DV,)"02,8S]:)-,G
MCO+N>U,1%T@5Q(2-IZ9& <_3CZTG&JN:U]6_RT_$?-1:BG;1?CS=?D5[G79O
ML-C=VR1[;B01LD@)(/L0?;TJS;:G*=5O+*X$>($$@= 1Q@=<D^M5KG0Y_L%C
M:6K1$6\GF,TC$;C^ /K4T&FW0UJZO)A#Y,\?EE5<D@8'^S[4)XCVFM^GI\/_
M ,D5)8=P=K=?7=6_"Y#!XB65K>0M#Y<\OEB$']XGHQY_3'?K5JSU1KN[FA!B
M5XY"AA8$.%!^]UY_I2Z3876FQ-:L\;VX8F-P3N /8C&/UILVER7%_;7#B%6A
M?<94R&8=E(QT]\_A50]O:+?S7]??V_ F?U?FDEMT?Y:?AW-6BBBNPX HHHH
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MGV77_P#H3O$W_@LDH^RZ_P#]"=XF_P#!9)1]=P_\Z_KY!]1Q/\C_ *^9E?\
M,W?]N'_M2M:LCR-7_P"$MV?\(UKOVG[#G[+]A?SMGF??V==F>,^O%:WV77_^
MA.\3?^"R2L:6,H+FO-;O]#:M@\0^6T'LOU\Q:*3[+K__ $)WB;_P624?9=?_
M .A.\3?^"R2MOKN'_G7]?(Q^HXG^1_U\Q:*3[+K_ /T)WB;_ ,%DE'V77_\
MH3O$W_@LDH^NX?\ G7]?(/J.)_D?]?,6BD^RZ_\ ]"=XF_\ !9)1]EU__H3O
M$W_@LDH^NX?^=?U\@^HXG^1_U\Q:*3[+K_\ T)WB;_P624?9=?\ ^A.\3?\
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M7_\ H3O$W_@LDH^RZ_\ ]"=XF_\ !9)1]=P_\Z_KY!]1Q/\ (_Z^8M9.H?\
M(PZ/_P!MO_0!6K]EU_\ Z$[Q-_X+)*R;^#5QX@T=9/#6NQ3-YWE026+K)-\@
MSL7JV!R<=!6-;&4)124UNOS1M0P>(C)MP>S_ "?F:]%)]EU__H3O$W_@LDH^
MRZ__ -"=XF_\%DE;?7</_.OZ^1C]1Q/\C_KYBT4GV77_ /H3O$W_ (+)*/LN
MO_\ 0G>)O_!9)1]=P_\ .OZ^0?4<3_(_Z^8M%)]EU_\ Z$[Q-_X+)*/LNO\
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M;_P624EC,,MI+^OD4\%BGO!_U\Q:*3[+K_\ T)WB;_P624?9=?\ ^A.\3?\
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M_P#T)WB;_P %DE'UW#_SK^OD'U'$_P C_KYBT4GV77_^A.\3?^"R2C[+K_\
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M1110 4444 >?_P#-PO\ W*G_ +=UZ!7G_P#S<+_W*G_MW7H% !1110 4444
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M*TN5MTEK:QQ.?]H 9_6M>KFDI-+8(-N*;"BBBI*"BBB@#S__ )N%_P"Y4_\
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M?X4?V+%_S\3_ )C_  H_M;#>?W!]6J]D=K]LM?\ GYA_[[%<'- EYXBO9(I
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M;^<[23_9;F6#SV8DDR>6PWYS_%GTJ_\ V[I']I_V9_:MC_:!_P"77[0GF_\
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M+I_A37(["\CU&(R6]U8Q/"4(SPZ,[\<=0U>@4+5)H+ZV"BBB@84444 >?_\
M-PO_ '*G_MW7H%>?_P#-PO\ W*G_ +=UZ!0 4444 %%%% 'CGQ$\#74WB*Y\
M2^$T2TUO3(8;K9 @7[3N:7>3CJV%'7KR*U/#&N>'?B2-$UBXTNQ?6+68Q723
M0*TD3"-V&"1G;D;AZ'W%=A:3Z@?&-\9-$NXK*2WBB2\:6$HQ0R$_*)"X!WC'
MR^N<5@P?#J#2OB@GBG2PL5M=0RI>6XX D(X=1[\Y'J<]S2C[MDMMUY/7\'^
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MY.<Y-<_XX^(.K>!M,L+Z\\/V=S'=.(66'4V!20@G',/*X'7@^W>K^M>,M4T
MZ*+SPU-.M_*([F:RF:6*TW,%4EB@)SN'4+]35*[=UWM\_P#AB7:WRO\ (WM7
M\/Z9KGD&_MR\ENV^&:*5XI8CW*R(0RY]CS5&Z\#>'+WP\-!FT[&F>9YC01SR
M1[VSG+E6!<YY^8GG![5G^,?&NI>&(9KFR\+W>J6=J UY<K.L2Q+C)V@Y9R 1
MG P/7@U>@\5G4_"=IKFAZ5=:DUY&'AM49(V]PS,0JXY[_3-1IRME;27?^O\
M,AN/AWX9NFTQI[.Y=M+4+9$ZA<9A .1C]YUZ<]< #H!4@\ >'!JM_J@M+E;W
M4(VCNIA?W ,BL,$??P!Z8Z8XQ5;P+XZ7QDFHPSZ7-IFHZ=-Y-U:R.'VGG&&
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M\#%:U'F).X4444#"BBN2^(7C.;P+H,>K)IB7\1F6*1#<F)EW="/D;/3VHO\
MUZC2N=;13(9/.@CEQC>H;'ID5D^(_$UAX9M();R0>9<SI;V\(;#2NS <>PSD
MGT%#T=B4TU?IO^ILT444#"BBB@ HHHH **** "BBB@#G_'?_ "3SQ+_V"KK_
M -%-1X$_Y)YX:_[!5K_Z*6CQW_R3SQ+_ -@JZ_\ 134>!/\ DGGAK_L%6O\
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MCF8<J[&/_P (QI?_ #R;_OLT?\(QI?\ SR;_ +[-;%%',PY5V,?_ (1C2_\
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MNO0*\_\ ^;A?^Y4_]NZ] H **** "BBB@ HHHH **** "BBB@ HHHH *\_\
M%O\ R5[X=?\ <3_])UKT"O/_ !;_ ,E>^'7_ '$__2=: /0**** "BBB@ HH
MHH **** "BBB@ HHHH \_P#%O_)7OAU_W$__ $G6O0*\_P#%O_)7OAU_W$__
M $G6O0* "BBB@ HHHH **** "BBB@ HHHH \_P#A9_S.O_8UWW_LE>@5Y_\
M"S_F=?\ L:[[_P!DKT"@ HHHH **** "BBB@ HHHH *\_P#C;_R2'7?^W?\
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MG%1=E_6B)@^97]?S84445)04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <_X[_P"2>>)?
M^P5=?^BFH\"?\D\\-?\ 8*M?_12T>._^2>>)?^P5=?\ HIJ/ G_)//#7_8*M
M?_12T '@3_DGGAK_ +!5K_Z*6N@K@_!?C3PK:^!?#UO<>)=&AGBTRV22.2_B
M5D81*"""V00>,5N?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\
MP8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\ P8P__%4?
M\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&
MO0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P
M_P#Q5 '045S_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '0
M45S_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG
M?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O
M0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\ P8P_
M_%4?\)WX/_Z&O0__  8P_P#Q5 '/_P#-PO\ W*G_ +=UZ!7D_P#PEGAO_A>O
M]H_\)!I7V'_A&O(^T_;8_+\S[3NV;LXW8YQUQ7<?\)WX/_Z&O0__  8P_P#Q
M5 '045S_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_
M /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__
M *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\
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M *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\
MP8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\ P8P__%4?
M\)WX/_Z&O0__  8P_P#Q5 '05Y_XM_Y*]\.O^XG_ .DZUT'_  G?@_\ Z&O0
M_P#P8P__ !5</XG\6>&[CXI> KR'Q!I4EK:_VA]HF2]C*1;H%"[F!PN3P,]:
M /6**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__
M (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\
M]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@Q
MA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^
M$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0
MUZ'_ .#&'_XJ@#G_ !;_ ,E>^'7_ '$__2=:] KR?Q/XL\-W'Q2\!7D/B#2I
M+6U_M#[1,E[&4BW0*%W,#A<G@9ZUW'_"=^#_ /H:]#_\&,/_ ,50!T%%<_\
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M4?\ "=^#_P#H:]#_ /!C#_\ %4 =!7G_ ,;?^20Z[_V[_P#I1'70?\)WX/\
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M+4[M+N_T73KNYC 5)I[5)'4#D ,1D8I=/\.:'I-R]SINC:=9W#@J\MM:I&S
MG)!*@$C-4O\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ -6QT
MO3],$HL+&VM!,YDD$$*Q[V/5C@<GWJW7/_\ "=^#_P#H:]#_ /!C#_\ %4?\
M)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\
MH:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\
MP8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5
M '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<_
M_P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#
M_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0
M_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/
M_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\
M)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\
MH:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\
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M *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\
MP70__$T?\()X/_Z%30__  70_P#Q-=!10!Y/_P (GX;_ .%Z_P!G?\(_I7V'
M_A&O/^S?8H_+\S[3MW[<8W8XSUQ7<?\ "">#_P#H5-#_ /!=#_\ $US_ /S<
M+_W*G_MW7H% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$U
MT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\
M_"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">#_\
MH5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">#_\ H5-#_P#!
M=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">#_\ H5-#_P#!=#_\31_P
M@G@__H5-#_\ !=#_ /$UT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-
M#_\ !=#_ /$UT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_
M /$UT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%%
M'/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">
M#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% 'D__  B?AO\ X7K_
M &=_PC^E?8?^$:\_[-]BC\OS/M.W?MQC=CC/7%=Q_P ()X/_ .A4T/\ \%T/
M_P 37/\ _-PO_<J?^W=>@4 <_P#\()X/_P"A4T/_ ,%T/_Q-'_"">#_^A4T/
M_P %T/\ \37044 <_P#\()X/_P"A4T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\
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M?\)=]L\/Z5<>1XEO((?.LHW\N-=FU%R.%&3@#@5W'_"">#_^A4T/_P %T/\
M\37/_"S_ )G7_L:[[_V2O0* .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\
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M.Y2QY./E[]37I-/HFNJO]XD]UVT.?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\
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MP$<,K9^5LMDGCDH& ]:$[VMU_7;_ "]1MVW_ *Z_EJ=#_P ()X/_ .A4T/\
M\%T/_P 31_P@G@__ *%30_\ P70__$U0NOB#9VWC"3PNND:K/J0@\^,0I$4F
M3'56,@QW^]MZ?3/+^//&,&O?"75=9T*]U"QN[&X2-PDK6\T$H<*R/L;GACQD
MC\JERM'F_K>WYCBKRY?ZVO\ D=O_ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\
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MN%;Q#I%]JE[IT]O(J6L^H2W(<J_RO'YK'!8*>I'44D[QYO7\!RTER^GXE_\
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M-H>N76M:TVH^:9)7DU*>1)0LA&UHV?;@@8Z>]*.M_*WXW_R"6EO._P"!V/\
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M2;N$S7;ZOC[!;0*/-G)&> Q &!U+$ >M*^E_3\=OO*>CL_/\-Q__  @G@_\
MZ%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\35S0=?LO$5E)<69D5H9F@GAE
M $D,BG#(P!(R/8D>AK4H Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_
M ."Z'_XFN@HH X/QIX+\*VO@7Q#<6_AK1H9XM,N7CDCL(E9&$3$$$+D$'G-;
MG@3_ ))YX:_[!5K_ .BEH\=_\D\\2_\ 8*NO_134>!/^2>>&O^P5:_\ HI:
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M>L^#O%Z:G"EE=MMN4  /]X< = !1":J+S.O+,R5=>SJ?%^9V=%%%4>R%%%%
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M_HIJ/ G_ "3SPU_V"K7_ -%+1X[_ .2>>)?^P5=?^BFH\"?\D\\-?]@JU_\
M12T '@3_ ))YX:_[!5K_ .BEKH*Y_P "?\D\\-?]@JU_]%+704 %%%% '/\
MB#P3H/BBXAFUBVN+AH"&B47L\:(PZ,%1PH;GKC/O6W;6Z6EM';QM*R1KM4RR
MM(Q'NS$L3[DDTZ8RK#(8$1Y0IV*[E5)[ D X'O@_2O.-,^)>N:J=?^S^%;1C
MH<K1W2#56W/MSDQ@P@-]T]2M*Z5U\_\ @A;K\CKK[P?H6H:B=1DLWAOV&&NK
M.XDMI7'HSQ,I;\35I= TL:=/8-9I);7'^O64ES-_OLQ)?ICDGBN&N?B_;G2_
M#NJ:?I1N;+6+K[&WF7/ER6\F0""NQ@P[YR*]+I\ME;Y?D_U0KIO^O3]##3P?
MH<=U%.+21O)8-# ]S*T$1'0I"6,:D=B%&*@U_P ">'O%%U'<:S:W%T\1!C'V
MZ=$C([JBN%4^X&:Z.B@9SFM>!/#WB/3[2QUBTGO+>T_U*RWLY(/J6WY8^[$F
MDT/P#X7\.65[9Z7I$45M? +<QR.\HE !&#O)XY/%=)03@9-'?S#MY&!IW@O0
M-+O(+NVLG,UNI6W,]Q+,+<'J(U=B(Q[*!3+;P+X;LM3N]0MM.,,]X2;E8YY!
M%,3UW1;MA_%:Y[6?B?<>']9LH]4\+WMMHM[*(8=3>9,ECT)B'*CO\Q!QVKN=
M1U"WTO3+G4+IPEO;1-+(Q/10,FES6CS]K_\ !"UWR&)XD\ >&?%UU#<:[IS7
M<D*;(\W,J!1[*K ?I5_P[X8T?PIIS:?HED+2U:0R%!(SY8X!.6)/8=ZK^#O%
M%MXQ\,6FM6L?E+,"'B+;C&P."I.!FMZJLXW0KJ6H4444AA1110!Y_P#\W"_]
MRI_[=UZ!7G__ #<+_P!RI_[=UZ!0 4444 >0>(M;O/%/QFM/ XN9K?1K6/SK
MV.)RAN2$W[2PYV\J,?6NRU+X?Z-)IWDZ-:Q:/<*RLLE@/($F#]V0)C>I'!#9
MZUD>)/ U^GC^Q\<>'_*DO85\N[LI7\L7"8*Y5\'#8/?C@<UC>-_!6H_$#5]'
MN8O"ZZ5);SA[VYOW@)FCX^3,3N6Q@_>QU^M*&T5UOK]^_I:WY6%/>3Z6T^[5
M>M_TU.J\1>/3I&I:EIUCIHO+K3;'[?<B:<P*8N?N$(VYN.AP/>H9_B98#PYH
M.K6\"@ZW*(H%O)O(CC;G/F.%; XP, Y)%8_B+PIXEU;7M2TZ.T@'AE=*:#3(
M8Y$CABG*X!:,<DCG'&!QC'-&B^$;UOAAI?ASQ!X8^U)!'*+B#SXO-5LY1HF#
M[=QW'J5[Y(Z%)OE;]/S=_P $OZ>C>]O7\E;\;_ETU3XK^*]<TWP"9K2S6S-W
M=&RF,LN7"G/*;1@A@#SG@'IGIKZ]XZU#PK-X<M]0T6V?^U9A;,UO?,WDMD 8
M!B&[@@]N>/>N2U3X<^)[GX/V^A(3<7UMJ'VF"VGG4ND )VQ[\[=P!]<=@:VO
M'VC^(M:O_"%U8:!/.--NQ=7*K<P JH(^7YG&6P.V1[FKCH[?WE]UOZ^9+;:T
M[2^^^GZ&OJ?Q!DT6VF_M+0KBWO'U$6%A;M*,7A.,.&QPO/)P<>YXI\7CV0S:
M[IDVF11:[I%O]I>U^U$Q31XW9279GH>Z#G\ZB^(GA2^\2V^B7^GH&O-)O4NQ
M;.X7S5!!9,] W QSCWK(7PSJ+:[XO\9:C:M8"[TQK:WM))$>0*(QEG*%E&2O
M !-92;4)/LG^"5OO=[_H6E>2MUM^+U7R7]=!;7XN3OX3T[Q3>>'1;Z-<W'V>
M61+X/)"=Q4-LV ,N1Z@^W<[6O_$ :9?ZA8Z=IZWMQI]A_:%QYTYA4P\_<8(V
MYO8X'/6O,?#>A:SXO^".C>';'3\0S7K22WS3((XHUE8G*D[]V>@"D>XKL_$?
MA?Q5K.O:E8/$LWA\:2T&G SJJ+<%<;I$SEF'.#C XQCFM*J<6TNC=O\ P%/\
M]N^WF33=VK_/_P "M^7W;E[6_BBFG> =-\7V6E?:K.\=4>*6X\EXB21V1@W(
M/I6GJ/CK^Q;?5[[5](N;73;&"*6&ZW!A=&3HBC PP.!C/?G%<#J?@[Q3<?!/
M1_#,6@S-JEO<AI8_M, 555F;.[S,'.1C'XXKN?'7AB\\;_#J72XHS9WSK'+'
M%<,IVNI!VL5)'J,@D43T4FN_X67Y:BA=\O-VU];O\U8C7XBQV<M[!K6G&SN;
M?3?[4CC@F\_S(.>,[5PXQR.1[FI8_%5SK'A&ZU"+3()(9+"2X1[>_)C8 ?<\
MP)E9,$Y&W@C@GDBKX:\/M9^'!(/ ^DZ;K<=L8) T< %PV #\\>3L;OGGV-8>
MF^!]0T+4_$UQHNDW5GI=YI[0II9N8F$URV1OC^?"H!TW$'KP.E356DHKL_U_
M/3Y]%?1TV_=;[J_X7^[5^G735O@[QOINA?#3PW]DLVB%_<R6MNFH7_R(0S$F
M281\#C@!.X'O7J&G7<UY;-)/:/:N'9/+=@V0#C<"."#U'M7EWA?P;J*?#&S\
M,^)/"IN8X7G::'[1#YF2=R-"P? ;YB.2O0\^O7_#C0M3\.>$(M.U261W261H
M8Y9 [0Q$_(A8<$@>G'/%:RUE+^NW_!_X%B5=)?/]?Z_X<ZVBBBH+"BBB@#R3
MXH?\C1;?]>:_^AO7%UVGQ/Y\4VRCD_8E.!_OO7&;'_N-^585H2<DTCXS-*<W
MBI-(2BEV/_<;\J-C_P!QORK'V<^QY_LI_P K$HI=C_W&_*C8_P#<;\J/9S[!
M[*?\K$HI=C_W&_*C8_\ <;\J/9S[![*?\K$HI=C_ -QORHV/_<;\J/9S[![*
M?\K$HI=C_P!QORHV/_<;\J/9S[![*?\ *Q**78_]QORHV/\ W&_*CV<^P>RG
M_*Q**78_]QORI""&"D$$]!CK1[.?8/93_E844NQ_[C?E1L?^XWY4>SGV#V4_
MY6)12['_ +C?E1L?^XWY4>SGV#V4_P"5B44NQ_[C?E1L?^XWY4>SGV#V4_Y6
M)12['_N-^5&Q_P"XWY4>SGV#V4_Y6)12['_N-^5&Q_[C?E1[.?8/93_E8E%+
ML?\ N-^5&Q_[C?E1[.?8/93_ )6)1000P4@@GH,=:78_]QORH]G/L'LI_P K
M$HI=C_W&_*D((.""#[TG"2U:$Z<TKM!4D,LD,RR1$AU.5(]:C ). ,DUW_@S
MP6;EDU#48R(0<I&P^]T/(/;!K2C!R=UI8ZL#A:N(JI0TMU['9^$[V^OM$BEO
M8]C] 2>2!6[2*JHBHHPJC  ["EKK;NS[B*<8I-W"BBBD4%%%% 'G_P +/^9U
M_P"QKOO_ &2O0*\_^%G_ #.O_8UWW_LE>@4 %%%% !1110 4444 %%%% !7G
M_P ;?^20Z[_V[_\ I1'7H%>?_&W_ ))#KO\ V[_^E$= ' _8/".F_M ZO;:Q
M:Z):Z4+!66*\CB2 2$(<@-\NX\^_6NF^%]O=V_BGQ+=:?YT?@MVSI_F9$18?
M>:('^#[W(XZ5!'X;UR\^+NIZ[J'A.Z?0]1L_L3I)/:E@"$!9E$I^7Y3TR?;/
M%3>$O"_BCP5J^I>'$L)=1\(WA;[/<I<1![7?P<JS D#O@=LC.<5,;J"MORNW
MK=[_ (6"I9R?:Z_);?.]S;L_BA;78L;_ /L\IH=_?G3[:],V9&EY 8Q;>$)!
M .XGU K0T;QP-=U*^@L+%)8+2\^QR%;@><A#;6=XMORIUP023W ZCE/AY\/Y
M/#L<VDZWX3TN[DM[@R6FM-%!)O3.1G/[P,.W&/<=:L:EX)O[SQSI6O6&E'2M
M22[+WU];W">1/;@GY63.XR,-N?EQR?F/%6K72Z?\-O\ C?;?2]M8;=GW_P"'
M_-6^?:^EH_$^\%QXNMSH$'G^'(Q*X^WG;.O).#Y7RG SC!YXSWKDOBAJ\/BK
MX:>$_$;6"6\]QJ$952P=HU.[*A\#@[0>@Z#TK4U'P7XDM]>\?R6NF"[@U^SV
MVDJ7$:*K[2"K!B"#SQP1ZD=L[6/!WBN\^$_A?P_#X>G.H:?="2X0W-N%54W<
M@^9@YW<?0YQQF(?9;_N?F[_DBG>[2V][_P!)5OQ;-_5?$?B%OC7I.@6\%D]G
M#9M<QQ-<,GF;E*EV8(V& #84#'/7GCI-&\<#7=2OH+"Q26"TO/L<A6X'G(0V
MUG>+;\J=<$$D]P.HQKWPYKA^+ND^*X-.,EE_9QMI4,R*\#D-]_GD?,.5W=ZJ
MZEX)O[SQSI6O6&E'2M22[+WU];W">1/;@GY63.XR,-N?EQR?F/%.'V4_._W_
M .7^:[$N^K79?E^=_P#@]SU&BBBF6%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '/^._^2>>)?^P5=?\ HIJ/ G_)//#7_8*M?_12T>._^2>>)?\
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M7??^R5Z!0 4444 %%%% !1110 4444 %>?\ QM_Y)#KO_;O_ .E$=>@5Y_\
M&W_DD.N_]N__ *41T >@45Y'XT%W9_&7P7&-3OI+>[FD=[:2;]TI7IA  ._4
MY/ K,_:%L+%;?0+XV</VF2]$4DPB!D>,#.TD#)'M4IW47W=OQL#=FUV5_P &
M_P!#V^BOGKXT-X=F\-Z*-+T:6SFBNDB#R:--: 1;6.P,\:@C)SM!]3BO>M,L
M;33=-@M;&UAM;=%^6*",(BYY. ..M6E>+?G;]17U2[JY;HKSOXI^$M+U3PQJ
MNKZA-=-=VD!DLF6X95@<#Y0J [22W<@GG /2N6\?Z9<_\,^6D_B"!)M:MH8/
MW\R!I8BSKD;CR#C //.*ARM%M]+?B4E>27>_X'MM%?/FM-X;;X P01Z+*E^E
MG#(MP=%F11*2@=Q,8PF2!C=NYXY-=3I7@BQ\0_!31;"VM'@FN(H;AGLI%MR\
MH'#R-@[AZ\$],>HN2:<EV:7WDIW47WO^!ZU17'^)/!6EZYX=%OX@NKF>WM+,
M+G[0T:JRKS*0" S< _-D#'3K6/\ #+3M1N?A1;V_B">^*2[V0+(ZS&WS\J[E
M^?D=,8." *7\WE_G;]+^@7^'S_RO_P #U/2**\5^%$FDP?$CQ-9Z)?7-KINQ
M3%I5YY@D+<;I,/R,'(Y.[GFO:J.B?=7"^K78***\R^.]C:3_  SO;N6UADN;
M=XO)F:,%X]TBAMK=1D=<=:F4N57*BKNQZ;17E \30_#7X5>'-2L- MKB&[C@
M6X6*86[&1XP=YPAW$X.22#TZ]NFT[QS+=>.;GPK=Z4MM=I9B[@D6Y\Q9%..&
M^4;3SVW"M)*TG%=&U]RN_P -2%*\5)]?\[?F=C17B>A>*;C3O!7CO5=%T[[/
M?VE_(\XN[]KA _1F3]VO [*>O<U4UG6;I?A+X3GU[33<V\UU RS6NJM',S\L
MK.#"1R=V1DXXP<])CK;_ +=_\F_KY^0V]_\ M[_R4]WHKB_$'CXZ3J&HZ?8Z
M:+NZTVP_M"Y$\YA4Q<_<8(VYN.AP/>N?\>^/KV7X/Q>(_#Z+!'J 6)WF8B6$
M,2IV@#!;.1G(QUYJ7+2Z\OQ=E^)2U:7];7_)GJE%<2?%]SI</A_1GTZWEUW4
MH_W%M'=MY*QJN2[R&/(X[!#SZ]:V_"WB6W\4:7)=PQ-#)!/);7$+'=Y<J'##
M/<>A]ZMK5I=/\[?G^)"E=)OK_E<VZ*\0^(%CX>M/C?X8FU2UTR&RN()'O7NH
MXUCD.& ,A;@GIR?:JVCVK7+?$)-.B:3P4;*0V:2*3!YH3.8@>, @G(XZ>U1S
M>YS>3_!V_'H7;WE'O;\?\NI[Q17B/P_\<-X4^'_@^WNM+,EEJ-U):"X6?#HQ
MD.#LV\KS_>!XZ5VWB'XB#2+W6;6RTP7<FC6RW5[YTY@S&W/[OY&#D>^T>]7.
MT7]_X6O^:(C*Z_KNU^AW%%<5=?$>P33?#MU;11[]>_X]Q>3^1&@ R=SA6P><
M 8Y/<=:M:OXT&DV^G12:;(-5U.Z:UM+*20+N8,1N9\'"XP<@'@C&:3T^^WS&
MI)J_E?Y'5T5@^&?$R>(!J$#V_P!FOM.N3;7< D\Q5<<@JV!N4CH< ^PK#^)/
MA+2-;\.ZEJ&L37.ZTMFEMBMPR) RJ2"%!VLQ/=@?08J92Y5S=/T*BN9V.ZHK
MP[Q5IEX?V<()O$4*SZO;Q1M'-<)NEB#2K@;CD@[< UA:P-&'A+PC%X=L3H_B
M2408U-K5K",_+\^Z5PHDR>>-V:NWO./9I??_ )=2.;W%+NF_N_S/HZBJSS_8
M]-,]R^_R8=\K*.N!DD"N:\-^,KCQ1ID5_8Z; 8;A)'AD2\WJA7&$FPF8W.>@
M# 8ZFI;2OY?U^@T]$^YUU%>0?#[QEXAO?"_BGQ'=V5G=>5=33%?MCQG*(G[M
M5\M@%"C@YR3VYS6@?B[,-!\,:O\ V GD:Y=&UV_;CN@;?MS_ *OYA@9[>GO5
M6U2]/QV!NUV^E_PW/3Z*XO5/%$.J^([_ ,(6FD0ZG]GM?-U#[1*%C13T0 JV
M]CD<':/>O//AIXAOO"GP:O=8LM(744MK^5IX3<^2R1X7+#Y6SCN..*A26K>U
MK_C8;Z)=[?A<]WHKF=,\37NKP:!<6>G6DMOJ<!GG=;UO]'4 =!Y?S\D#^'G\
MZZ:K::T8E)/5!1112&%%%% !1110 4444 <_X[_Y)YXE_P"P5=?^BFH\"?\
M)//#7_8*M?\ T4M'CO\ Y)YXE_[!5U_Z*:CP)_R3SPU_V"K7_P!%+0 >!/\
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MA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C=
M'H%%>?\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-T '_ #<+_P!R
MI_[=UZ!7A_\ PM+P;_PN3^W_ .V?^)9_PC_V+S_LLW^N^T;]NW9N^[SG&/>N
MP_X7;\//^AA_\DKC_P"-T >@45Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&
M'_R2N/\ XW0!Z!17G_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C=
M 'H%%>?_ /"[?AY_T,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW0!Z!17G_ /PN
MWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C= 'H%%>?_\ "[?AY_T,/_DE
M<?\ QNC_ (7;\//^AA_\DKC_ .-T >@45Y__ ,+M^'G_ $,/_DE<?_&Z/^%V
M_#S_ *&'_P DKC_XW0!Z!17G_P#PNWX>?]##_P"25Q_\;H_X7;\//^AA_P#)
M*X_^-T >@45Y_P#\+M^'G_0P_P#DE<?_ !NC_A=OP\_Z&'_R2N/_ (W0!Z!1
M7G__  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?_)*X_P#C= 'H%%>?_P#"[?AY
M_P!##_Y)7'_QNC_A=OP\_P"AA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?
M_&Z/^%V_#S_H8?\ R2N/_C= !_S<+_W*G_MW7H%>'_\ "TO!O_"Y/[?_ +9_
MXEG_  C_ -B\_P"RS?Z[[1OV[=F[[O.<8]Z[#_A=OP\_Z&'_ ,DKC_XW0!Z!
M17G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C= 'H%%>?_\ "[?A
MY_T,/_DE<?\ QNC_ (7;\//^AA_\DKC_ .-T >@45Y__ ,+M^'G_ $,/_DE<
M?_&Z/^%V_#S_ *&'_P DKC_XW0!Z!17G_P#PNWX>?]##_P"25Q_\;H_X7;\/
M/^AA_P#)*X_^-T >@45Y_P#\+M^'G_0P_P#DE<?_ !NC_A=OP\_Z&'_R2N/_
M (W0!Z!17G__  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?_)*X_P#C= 'H%>?^
M+?\ DKWPZ_[B?_I.M'_"[?AY_P!##_Y)7'_QNN/\1?%+P;??$?P7JUMK.^QT
MW[=]KE^RS#R_,A"IP4R<D8X!QWH ]PHKS_\ X7;\//\ H8?_ "2N/_C='_"[
M?AY_T,/_ ))7'_QN@#T"BO/_ /A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25
MQ_\ &Z /0**\_P#^%V_#S_H8?_)*X_\ C='_  NWX>?]##_Y)7'_ ,;H ] H
MKS__ (7;\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&Z /0**\__ .%V_#S_
M *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;H ] HKS_P#X7;\//^AA_P#)*X_^
M-T?\+M^'G_0P_P#DE<?_ !N@ \6_\E>^'7_<3_\ 2=:] KP_Q%\4O!M]\1_!
M>K6VL[['3?MWVN7[+,/+\R$*G!3)R1C@''>NP_X7;\//^AA_\DKC_P"-T >@
M45Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW0!Z!17G_\ PNWX
M>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C= 'H%%>?_ /"[?AY_T,/_ ))7
M'_QNC_A=OP\_Z&'_ ,DKC_XW0!Z!17G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#
MS_H8?_)*X_\ C= 'H%%>?_\ "[?AY_T,/_DE<?\ QNC_ (7;\//^AA_\DKC_
M .-T 'PL_P"9U_[&N^_]DKT"O#_ 'Q2\&Z)_PE']HZSY/V[Q!=WMO_HLS;X7
MV[6X0XS@\'!]J[#_ (7;\//^AA_\DKC_ .-T >@45Y__ ,+M^'G_ $,/_DE<
M?_&Z/^%V_#S_ *&'_P DKC_XW0!Z!17G_P#PNWX>?]##_P"25Q_\;H_X7;\/
M/^AA_P#)*X_^-T >@45Y_P#\+M^'G_0P_P#DE<?_ !NC_A=OP\_Z&'_R2N/_
M (W0!Z!17G__  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?_)*X_P#C= 'H%>?_
M !M_Y)#KO_;O_P"E$='_  NWX>?]##_Y)7'_ ,;KC_BE\4O!OB/X<:MI.DZS
M]HOI_)\N+[+,F[;,C'ED ' )Y- &[XRTKQ)J?Q+\.:S8>&KR>PT=W\V3[3;*
M9@V.4!E!QQ_%BF?%_P /^(O%D6BV^C:#<S_9+@7,LC3P(N,?<&9,EA],>A-:
MW_"[?AY_T,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW22LDNSO\[W_,35VWW5C&
M^+.B^)/&>@:38Z3X:O/-AN%N93-<6RA,!EV?ZTY;D'C(YZUW0T2#6X8;R_AU
MFPN-@1K==5FAVX]5@FV9]QD^M<]_PNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_
M "2N/_C=-:)KSO\ H%MO)6*/CM_'\FM64'AKPM;7^F60#A[^Y0K-*/NMM,JL
M=O;=GGG&0#4'C'3O&OBCX4_V7>:()=>O7#RQVLL*0VP60$*2\F3E1V+<YY'%
M:O\ PNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C=)QO'E?\ 6MRKV::,
MC5M'\27GP4A\+1>&KW^T_LT=JRM<6P12FTEMWF_=.#C'/'(%=A\/K;4-.\%Z
M;IFIZ;/8W5E L#K+)$X<@?>4H[<?7!]JQO\ A=OP\_Z&'_R2N/\ XW1_PNWX
M>?\ 0P_^25Q_\;JW)MR?\VI/+HEVO^(OQ)?QG<1VMAX8\.P:E;,WF7;7,Z+'
M(!TC*F16(SR>QQCD$BDT_4OB6GAG[;>>'],;51=JITV*98U^S <E6WL-Y/JV
M,#I1_P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW4+16_K^NGH-ZM?
MU_7<O6?AM]2\=VWB^ZTYM-F@LC;^1(R-+(['DL4++@#@<DG/;%=%J>C6NK>7
M]IEOD\O.W[+?SVV<^OE.N[IWS7'_ /"[?AY_T,/_ ))7'_QNC_A=OP\_Z&'_
M ,DKC_XW3TM;^NXEH[_UV.FM?"VGV=U'<17&KL\;;E$NL7<J$^ZM*5(]B#7/
M?%K2=7\0^";C1=&TJ:]N;ED.]98D2/:ZM\Q=U/.#C /OBHO^%V_#S_H8?_)*
MX_\ C='_  NWX>?]##_Y)7'_ ,;I27,K,I.SN<WXM\-^*-<^%.A:!:^&[I=0
MLY(1,DES;!0(TP6!\W!!)X[\'('&=*RT7Q#_ ,+E'B63P_=Q::VFBU+M<6Y9
M7P#RHD)QGCCO[<UI?\+M^'G_ $,/_DE<?_&Z/^%V_#S_ *&'_P DKC_XW57?
M,Y=VW]ZL1RKE4>RM^-_S.7\/^"?$Q\*>.]*O-):QGUF:2>T::>)E.XG"G8[$
M'\,>],\1>$O%>H_"[PMH-OX>F:^T^:)YU^U0 *(U(/)?'.>,9Z'.*ZO_ (7;
M\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&ZE*UK=.7_ ,EV';]?_)MS/\1^
M'_%WB37M2AN+7_B1R:2T=C"\Z!8[EEQF103N8'.#R!Q@]ZS+KP+XCO\ X"VW
MAC^SQ#J]LZL8))X\/MD+?*RL5Y![D5T?_"[?AY_T,/\ Y)7'_P ;H_X7;\//
M^AA_\DKC_P"-T65FO3\'?^O(:W3[?Y)?I]YB^+/!.K:KJ_ACQ''H-OJ#6$(M
M[W2+IXF+Q^H+'RR1ECC/8<UZ1HFFV>F612RTFUTN*1M_V:"%(\' ^]L^4MQV
MS]:Y'_A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\ &ZJ^Z\V_OU_,E1M;
MR27W;&=XGTCQ#>?%O0=?M/#MY/IVEQO')(MQ;J9-P;E%:4''S=\'VKN?%,-U
M=>$M5MK*TDN;J>UDBCA1D4EF4J.6( QG/7M7+_\ "[?AY_T,/_DE<?\ QNC_
M (7;\//^AA_\DKC_ .-U#BG#DZ:_CN6G:?/Z?@<&_@KQ@/!'@W2U\-W!NM'U
M!KFY'VJVP4W[AM/F<DY_0^U=/XI\->+_ !-K'B*&YMEDTJ333'I*&X58TE8#
M)= >7ZC<<@9X/6M7_A=OP\_Z&'_R2N/_ (W1_P +M^'G_0P_^25Q_P#&Z<US
M7OUN_O27Z:$I6V_K5O\ 4H6OA&ZN_AMHWA_7_#!NX[:U=9XEN(A/%*"-AB;?
MMY!;.6'3\#@ZC\,?$<GA;PM++'!JVH:+<.SV%Y(K"6!F!$19OE) 4#GCGVKK
M?^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;IO63EUNG]W]6]-!**24
M>R:^_P#K[]3I_#VEV>GVKO9Z!:Z*)MI>VAAB1\@?QF,E3[8)^O.!R'Q#E\=W
M&IVEMX:\+VFHZ? 1-*][/&$ED'*C9YBG"GGG@G''%6/^%V_#S_H8?_)*X_\
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M*QZ!17G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C=(9Z!17G_\
MPNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C= 'H%%>?_ /"[?AY_T,/_
M ))7'_QNC_A=OP\_Z&'_ ,DKC_XW0!Z!17G_ /PNWX>?]##_ .25Q_\ &Z/^
M%V_#S_H8?_)*X_\ C= '0>._^2>>)?\ L%77_HIJ/ G_ "3SPU_V"K7_ -%+
M7#^+/B_X$U/P;KEA9Z[YEU=:?<0PI]DG&YVC8*,E,#)(ZUW'@3_DGGAK_L%6
MO_HI: #P)_R3SPU_V"K7_P!%+705S_@3_DGGAK_L%6O_ **6N@H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_\ ^;A?^Y4_]NZ] KS_
M /YN%_[E3_V[KT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** //_\ FX7_ +E3_P!NZ] KS_\ YN%_[E3_ -NZ] H ****
M "BBB@ HHHH **** "BBB@ HHHH *\_\6_\ )7OAU_W$_P#TG6O0*\_\6_\
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M'_\ 0UZ'_P"#&'_XJC_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\
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M_P#BJ/\ A._!_P#T->A_^#&'_P"*H_X03P?_ -"IH?\ X+H?_B:/^$$\'_\
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MX03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (F@ _X3OP?_ -#7H?\
MX,8?_BJ/^$[\'_\ 0UZ'_P"#&'_XJC_A!/!__0J:'_X+H?\ XFC_ (03P?\
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MI5W=2>1LA@O8Y';$\9.%!R< $_A7<?\ "">#_P#H5-#_ /!=#_\ $UP_Q?\
M"?AO3/A;K-Y8>']*M+J/R-DT%E'&ZYGC!PP&1D$C\: .X_X3OP?_ -#7H?\
MX,8?_BJ/^$[\'_\ 0UZ'_P"#&'_XJC_A!/!__0J:'_X+H?\ XFC_ (03P?\
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M&'_XJC_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B: #_A._!_\
MT->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8?_BJ/^$$\'_]"IH?_@NA_P#B:/\
MA!/!_P#T*FA_^"Z'_P")H /^$[\'_P#0UZ'_ .#&'_XJC_A._!__ $->A_\
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MOP?_ -#7H?\ X,8?_BJ/^$[\'_\ 0UZ'_P"#&'_XJC_A!/!__0J:'_X+H?\
MXFC_ (03P?\ ]"IH?_@NA_\ B: #_A._!_\ T->A_P#@QA_^*H_X3OP?_P!#
M7H?_ (,8?_BJ/^$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")H /^
M$[\'_P#0UZ'_ .#&'_XJC_A._!__ $->A_\ @QA_^*H_X03P?_T*FA_^"Z'_
M .)H_P"$$\'_ /0J:'_X+H?_ (F@ _X3OP?_ -#7H?\ X,8?_BJ/^$[\'_\
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MZ] H **** "BBB@ HHHH **** "BBB@ HHHH *\_\6_\E>^'7_<3_P#2=:]
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MW]#6E7.>+KVW\-:1J'BL6_FW=E9.BCIO!((!]MP'YFN(M/&^NZ5+X)N]1O\
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M@8;  Y'   P>G%>JUY'X#\5^)+[Q']FO? .I:?-?R&6]U6\$@7"@X4 QJ
M%4;N.O)SGURBS44G_6OZ;?(I?$_Z_J^X4444B@HHHH \_P#^;A?^Y4_]NZ]
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MS_\ YN%_[E3_ -NZ] H **** "BBB@ HHHH **** "BBB@ HHHH *\_\6_\
M)7OAU_W$_P#TG6O0*\_\6_\ )7OAU_W$_P#TG6@#T"BBB@ HHHH **** "BF
M32K!!)*_W44L?H!FJ>DZQ9ZS:K<6DFY3V/!'X4[.UQ75[%^BBBD,**** //_
M !;_ ,E>^'7_ '$__2=:] KS_P 6_P#)7OAU_P!Q/_TG6O0* "BBB@ HHHH
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M9MC)Y5Q,\$B;'XXVLH8GD=!70V]Q%=VT5S;R"2&5 Z..C*1D&ERZ<O\ 7?\
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MLJE5S_LJ2<#VR?K4U5UOK9KV6S$RFXAC662/NJL2 3]=K?E2O9?>_P#,$O\
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M.V:T\23/JD;:SK\?E7-X;4^7&F-NU(M^1QZL><=<8KN))$BC:21@B("S,QP
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MNUU-<CE4$6PAA@<[4Z<Y&*X/7O%>K^*OV=9M:N[MX+L3"";[-A%G7S I##'
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METG_ )_(O^_B_P"-?/VYO4T;F]31_9R_F#^T'V/H'_A)=)_Y_(O^_B_XT?\
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MU";"X()$\0<'&?H,@^@(ZBO4[C3-6E\3VVI1:G:1V4,31&U:R9G96*EOWGF
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M_HIJ/ G_ "3SPU_V"K7_ -%+1X[_ .2>>)?^P5=?^BFH\"?\D\\-?]@JU_\
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M&;QT(;N"3SF0Q;) ?,"\-M]<=\5[#15)^]?_ !?^36_*PN71+M;\&W^IY_\
M\W"_]RI_[=UZ!7G_ /S<+_W*G_MW7H%(H*YE_&]C-J]QI>D65]K-W:D+<BQ6
M/9">>&>1T3/'0$FM/Q&]Y'X9U1]/!-ZMI*8,==^TX_6O//V?C WP[E="#<M?
M2FX)^\6XQG\,4HZR:[*_WNP2T2\W;\+GH.F>(+35-0N]/CBN8;NT5&GBGB*%
M-V=N#T;[IY4D>]:I. 3C/M7(_$/5Y/"W@[6/$%A$G]HI D2R$9P"^%)'?!<F
MN-@UK5/#OB7P%%'J-[=Q>(+<_;TN[AI@SE5.]=Q.S!;HN!CM33YG;T7S:;_0
M4GRJ[]?DK7_%G=^%?&MCXLNM4MK6SO;6?3)O(N$NE08?D8!1V!Z&NEKY_P!'
M\077ABP^*NK6*@W4.I8B)&0K-(R[L>V<_A700:UJ?A[Q)X#BCU&]NXO$%N?M
MZ7=PTP9RJG>FXG9@MT7 QVI0?,H^:7WM-_H$WRN7DW]R:7ZGL%%>.^&;;6->
M\3>/]#3Q)JMK#;W$:VDOVJ25[<Y8_+N;('&" 1G\*JSZ_P")_$7BCQ9I^F1Z
MO-=Z0$@TY;2ZC@CCD&<R3*TB^9N(Z$,,=A0G=)]U?Y#>C?D['ME4=6U>ST6R
M%U?2B.-I$B4=V=F"JH'J2:\VN-;U?7OB1I?A+4[BZTR/^R/M5S'9W!B>2X(Z
M>9&V<+@G .#@YS6)\4-#N+"Q\#VNIZM=:G=KJBPO=L[1%U+9'RJV P&!N'S<
M=::W2[NWXM?I^OD2Y:-]E?\ "_\ 7],]RKG_ !AXNM/!6B_VM?V=Y<6HD6-S
M:JA*9X!(9EXSQQFN8\7/<6&N6&F#5Y_[.>QD6*PMKN<7TDRY(E,@8$H .2[@
M=>I-<!JNNZCXA_9G>]U6Y:YNEO$B,K_>8+*,9/<^]2Y73:Z6_P#2K?U_2*^T
MD^O^5_Z_IGT#:W"7=I#<QA@DT:R*&Z@$9&:9?7UKIMC->WL\<%M A>260X50
M.YJ#1/\ D :=_P!>L7_H(KSK]H'[9_PK8_9MWD_:X_M.W^YSC/MNVTZSY&[=
M[?C85'WXQ;ZJ_P"%SHT^(EK-I3ZS!H6MS:,H+_V@L$80H.KA"XD*^X2MZW\0
MZ3=Z!_;L%]"^F>49C< X4*.N?3'IUJKH?V3_ (073_*V?9/[.CQTV[?+'I7S
M?I=M</\ L_\ B.:5IA:1ZE$;4"1E7.5#< X8<CKGGGK14]USBNG^=O\ @_@%
M-\RA)]?\K_\  9] ZY\0--T!=#>ZLK^2'661+>6)8RJLV,!P7!'!SP#765X5
M\0+".T\,?#N&"6Y'F7]NV^6=YF4E%Z%RV!Z#H/2M33_$^IZ%XX^(5M]KN[RR
MTRR%Y;V]Q,TNQ]@)"EB2 23P.*<FH\U^CE]RM_F3!N2B^ZC][;1[#17CW@?4
M?%VKIX;UN"WU6XANWD_M:>YO(C;.A) ,47FDIM([(I/?-)X9MM8U[Q-X_P!#
M3Q)JMK#;W$:VDOVJ25[<Y8_+N;('&" 1G\*+._+Z_A;_ #_!CYDU?T_&_P#D
M>Q44V-2D2(SERJ@%CU/O3J"D?/7B3_D9]6_Z_9O_ $,UF5UNJ^'+F^^)E]HJ
M.HFGMY-45L<"-IBH'UR:N_\ "L=2_P">\?\ WR:]RGBJ2BDV>+/#57)M(X6B
MNZ_X5CJ7_/>/_ODT?\*QU+_GO'_WR:KZW1[D_5:O8X6BNZ_X5CJ7_/>/_ODT
M?\*QU+_GO'_WR:/K='N'U6KV.%HKNO\ A6.I?\]X_P#ODT?\*QU+_GO'_P!\
MFCZW1[A]5J]CA:*[K_A6.I?\]X_^^31_PK'4O^>\?_?)H^MT>X?5:O8X6BNZ
M_P"%8ZE_SWC_ .^31_PK'4O^>\?_ 'R:/K='N'U6KV.%HKNO^%8ZE_SWC_[Y
M-'_"L=2_Y[Q_]\FCZW1[A]5J]CA:*[K_ (5CJ7_/>/\ [Y-8VH^$KO3O$FB:
M+)(IFU7S_*8 X'E('.?P-'UNCW#ZK5['/45W7_"L=2_Y[Q_]\FC_ (5CJ7_/
M>/\ [Y-'UNCW#ZK5['"T5W7_  K'4O\ GO'_ -\FC_A6.I?\]X_^^31];H]P
M^JU>QPM%=U_PK'4O^>\?_?)H_P"%8ZE_SWC_ .^31];H]P^JU>QPM%=M/\-M
M1@MY)FF0K&I8_*>PS7%!2[A5&23@"M*=:%3X69SHSA\2!5+L%4$DG  KUGX>
M>'KZQA-]<R21QR+\D.XC.=I!QCI5'P/X)SY>IZBG'#11D=?ND'Z=:]+5510J
M@!0,  < 5YV,Q2E^[B>AA,,X^_(6BBBO./0//_%O_)7OAU_W$_\ TG6O0*\_
M\6_\E>^'7_<3_P#2=:] H **** "BBB@ HHHH **** "BBB@#S_X6?\ ,Z_]
MC7??^R5Z!7G_ ,+/^9U_[&N^_P#9*] H **** "BBB@ HHHH **** "O/_C;
M_P DAUW_ +=__2B.O0*\_P#C;_R2'7?^W?\ ]*(Z -_5_&6F:3JT.CHEQ?ZO
M,N]+"R0/+M_O,20J#W8BA/%]NFIV6FZAINI:=>WKE+>*XB5@Y )/SQLR< 9Q
MNS[5YE\*6F?XO^.#J7_(1WD+OZ[/,/3VQL_#%=GJWC_3;?QE9>&;SPYJ\NJ-
M)YUGM6W*MPP\Q6\W@8#=<'':E'50?\RO_7I_F*6\O[IW=%>&VGB/Q?XKG\1W
MFBVVJ3:E8:D(;%(;N**UAC5N5EC:1=Y8 \E6]B*T)YM1N/C7>Z5+JFJP64FC
M&Y>TCOY0B2E1G;AOEP?[N*7-[JEW3?\ Y+S?E^(WNUVT_%+]3V*BO ['X@^(
M+#X!_P!JF]FGU)KXV27<AWNB$_>)/4XR 3ZBNKM8_$L<.NK+;:S:Z"^DF6">
M\U)9+A+E022KI*[@'@XSCCH!Q3F^52?1?Y7_ "_'[Q1=[+O_ )V_/\#U&BO+
M_AE;:QKW@SPUK=UXBU RV[SF6-Y6D6Z4EE D).3@\YY]/>N1U?Q1KFF-H]['
MKTM[J/\ ;9L[NYM)I#921DDB(1L0A8#J57CIN)JFK3Y.O^;2_4GG]QS_ *TN
M_P!#W";5[.#6+727E'VVYC>5(QUV+C+'T&2!5/2?$]EK.MZOI5O%=)/I<BQS
MM+%M1BPR-I[_ *?E7FITNWF_:5F1GNP#I@GREW*AW9'&0P.W_9^[[52T_P 4
M:MH.H_$^9+Z\NTTH*;.*[N7F6$DL.-Q/'3\JA2]U2?:3^YV+:U:7>*^]'N-%
M>+6_B#5M"?X>WZZE?7;>(<)J,=S.TJ.6VG<JDD1XW'[@ P.16?+=ZF=8^)\
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MU_Z*:CP)_P D\\-?]@JU_P#12T '@3_DGGAK_L%6O_HI:Z"N?\"?\D\\-?\
M8*M?_12UT% '->/?%B>"_"%YK+1"66/"0QD\-(QP,^W<^PK*\'Z'?:OX?LM;
M\0:SJDVI7L0GVP7DEO% &Y55C0A3@$?>!K0^(GA-O&G@R\TB*18[EL2P,WW?
M,4Y /L>GXUG>#=>N]+\-V&C:]HVKV^J6<*V[>78RSQR[> RRQAD&0!]XC\J4
M?M7WTMZ=;?/YBE]GMK?]#1&KGPAIBIXAU*2]N;F^:&S8A%DN-Q_=H!\J XXR
M=HXSWI+'Q_INH6>M2165^MYHV?ME@ZQB9,9/'S[#P#T;M63\0+G7IM%T@67A
M[S9I[]!*P@6ZEL4SQ(HP0'QWY"\\GK7,^'M'U#2/$/Q(:[L+Z*WN[4O;3SH[
M+*H1_P#EH>">1GG-2Y-1D^R?X)?\'UZ;,I)72[M?BVOZ_P K'56GQ9T6YTBP
MUA].U:WTJ]G^SK>S0Q^7')DC# .6QQU (]\YK:UCQIIVDZC)IZV]W?74-N;J
MXCLU5C!#_?;<RC'L,L>P->*Z59WWB/X#Z/X:TW3KV:\N;XD2+ QA1!*Q+M)]
MU<=,$@^U=-=>$[C3/BM=W6JV.L7NA:K9QP?:-.DN!Y;JJKMD$!#;3M/7CD5I
M--2<5W=O_ 4_ST_X)FI:7?\ 7O6_+7\=CT*\\<Z1 FF"S$^IW&J1^;9VUDJF
M25 ,EOF954 >I'IUKD/&?CRQO_"&D:G8WVNZ=;7.HK&9[.% ZNC<Q2*TBG!P
M>1D<<YZ&GJGAN]\(>/O#7B#2-'O)M"MK0V,MK;![B6V0EL';RQ^^"<9Q@^U6
M/C,E[K7AK2(M.TG4[F0:BD^R&RE=A&JG+, OR\L.&P?:DK73_O+Y>]_EK_P-
M"M=4^S^?NO\ 7^MF:.J^.-3B^+.F>&;?2KI[9;=KB3RI(@]QE2 WS. $7DX)
MR2.G SKZS\2=%T9K\O#=W4&FRI%?SVRH5M68@#<&<,>O\(;O7.7UAJ"?'#1O
M$*Z;?2:9+I1A$T=NQVR88[7&,IU'WL"N>\9:9XC\00>.8%\/7-N$>+['':6N
MT7H5@3*S@9F;:.%YQGID9J+M17SO\I6_+^K7''63[>[^*_S_ .";7C+6[FW^
M*/@>;3=1U V.HJS26\%Q)Y<ZC!7]WG;_ !>GUZ5U:^.+'4M-U^*&WU&VU'2H
MV^U696,7$8QD.OS[&XY!W5Q&HZ5JLFM_#K5X])U![32;/-[BV;S(>%7&PC<3
MG/R@$\=*N6&BWYUKQ[XMEL;V.UU*U^SV4#6S^?* @&[RL;QD@8! /M3J*T)1
M73G_ #T^_P#X8FFVY*3Z\GZW^[_AR;0_B-I_ASX8:/K-_)KNKVT\SV_VR6*+
MSM^YL;U,IXX.,%NG-=?IOC?3M1\4W'AUK:\M-0BMUN56Y10)(SCYE*L?7H<'
MVKQ2[TG6'^!&C:(N@ZR=2AU,R26XTV?<JAF;=]WIAAS]?0UUL=M>7_QMEOTT
MW5HK"YT;[(MW)I\\:+(5S@DJ,?4]^*TF_>E;7?\ "":_'02TBOZ^U;\M3M[;
MXAZ)=7<"1K<BRN+HV4&HE5%O+.,_(#NW=C@E=I[&H[+69]'\=_\ "+7L\D]O
M=VQNM/FE.YQM.'B9NK8X()YQP2:X3X<^"X8-/&@^*-#U<ZCIMZ9[9VGN19O@
MY61"K>4".>V3Z'FNCURSDU/XZ>&S;[B-,L)I[DKT0/E5!^I[>U))<T5?>_W<
MM_P8-NTO+\[V_%'I%%%%(L\__P";A?\ N5/_ &[KT"O/_P#FX7_N5/\ V[KT
M"@ KE8_ >GV.IW5_H=]J&BS7;;[A;%XS'*WJ8Y4=0?< 5U5%'6X>1E/X=T^?
M3;RRO%>\2]39<O<-N:48Q@]  ,G 4 #/ K*TSP%IFG:A97LEU?7TNGPF"P%V
MZ,+5#QA-JC)QQEMQQWKJJ*.M_P"OZU8K*UCC-'^&ND:2VMA[R_OX=:R;V&\:
M(H[$DEAL12#R>AQ5K2_ 6F:;J-C?275[?RZ=$8; 7CHPM4/9-JC)QQEMQQWK
MJ::[K&C.[!4499F. !ZT;:]OZ_S&U??K_7^1S'A_P-:^'?$&IZS;ZKJ4\^I-
MONH[@Q&-FSP0%C!&,G&#]<TY_ VG+XMD\2V5U?6%_,FRY6V=1'<CC[ZLIYXZ
MC!IMAXZM-:DD.AZ7J>J6D<AC>]MTC6$$=<&1U+X_V0U;&CZU::Y;S36?G!(9
MF@<31-&P=0,C:P!XSC\/3FA=+=%^'^0G;5/K^?\ F9.N>!=*UO4]/U02W=AJ
M6GC;;W=DZJZK_=(965AUZ@]33O$/@C3?$UC9P7T]X);.X%U#=1R#S%D'?D%?
MPVX] *Z6BA:???YC>OY'+W7@/2KSQ1!XAEGO?MT5J;1L3#;+&<YW#&<\GH1U
M^E9+_"31F\'-X534]6CTIKG[0462+=G.=NXQGY<X/KQUKOJ*5E:W];W_ #U"
MVM_ZVM^6APL?@3R/'&CZS#>:B3IUI]GDFFG39.FTJ$V*HYY!)^4?*."3D=G>
M6=MJ%G-9WD$<]M,I22*1<JP/8BIZ*;U5GY_B[B2L[K^K'(+\/K.+2FT>#6M9
MBT5E*'3EF0QA#U4.4,H7V#U?U#P5H6H^$'\+M:>1I10*L<#;2F#D$'USSSG/
M?-=!10U=68UH[HXK6/AI8:W9:/:W6LZP%TEE>W9'AR74 *S9C(R  ,  >V3F
MI]/^'NGV'BC4M?;4=1NKC4XS%=PW!B,4B$ 8VK&", #H?KFNNHH>M_G^._WB
MLDK>GX;?<<SX9\$6'A2*2VTZ\OVT\R>;'932*\4+>J_+N]\%B,\]:9X?\#6O
MAWQ!J>LV^JZE//J3;[J.X,1C9L\$!8P1C)Q@_7-=311?6_R"RM8****!GG__
M #<+_P!RI_[=UZ!7G_\ S<+_ -RI_P"W=>@4 %%%% !1110 4444 %%%% !1
M110 4444 %>?^+?^2O?#K_N)_P#I.M>@5Y_XM_Y*]\.O^XG_ .DZT >@4444
M %%%% !1110!6U!2^FW2*,LT+@#WP:\^\%>!F1TU#4X\$$&.,_@0>#[5Z516
MD*LH1<5U,Y4XRDI/H(%"J%4  < #M2T45F:!1110!Y_XM_Y*]\.O^XG_ .DZ
MUZ!7G_BW_DKWPZ_[B?\ Z3K7H% !1110 4444 %%%% !1110 4444 >?_"S_
M )G7_L:[[_V2O0*\_P#A9_S.O_8UWW_LE>@4 %%%% !1110 4444 %%%% !7
MG_QM_P"20Z[_ -N__I1'7H%>?_&W_DD.N_\ ;O\ ^E$= &_JW@S3-3UB/68W
MN=/U>-=@OK)PDA7^ZP(*N/9E-06O@734\20>(;^ZO=4U>W3RX;F[9%\M>> L
M2HO<]03S3[SQYX?LO$MGX>:[:74[J3RTBBC+!3SG<WW1C!XSGVJKXR^(5CX(
MEMAJ6E:G-#=,(X9[9865G_NX:0,#]1CWI1:5FOE_P >MT_G_ ,$GM/ FFZ;X
MEO-;TZZOK)[XYO+6&1?(G/\ >*E20>>JD56N?AW9S^+9_$J:SJMO?S6YML1&
M#8D9&-JAHCTZ\DFF>)_B/:^$+*SN]8T'68X;HA%9!;OM<Y^1L3=<#/&1[U/J
MOQ!TW0IM%@U:QU"SFU:3RXD>-&\HY &]D<J,Y'0D\]*$D[)>GW]/N_ 3:5V_
M7[NI6TSX7:#IWA"[\+R37M]I=S)YNRZ=-T;>JLBJ0<@'G-:EKX2CMO#3Z&=8
MU.>,P&V2XF:)IHXR,%0=F#QQD@GWJKXJ^(.E^$6/VNRU2Z2,C[1+96IDCMP>
MAD<D*O;C.>1Q6A+XLTQ?#UOK=L+J^MKE ]O'9V[2RR@_W4 SQWSC'>AM.+;V
MZC2LTNNZ(_"WA*T\)^'_ .Q+6\O+JR&[8+ID+(&Z@%%7C))YSUKGU^$'AU-!
MMM'2ZU-;>UO?MMNPF4M%)Z#*XQ]03QUK<\'^-])\:VEQ-IHN89;63R[BVNH]
MDL3>X!(['OVKI*IWOS/?3_-$I)JW37_)G-S>"M.F\7P>)Q<7D6I1V_V>0QR*
M%F3T8;>/^ E:IZ7\.=+TS5=:OWOK^]_MI2M]!=&(QR9SV6-2,9(X/>F^*OB-
M8^$-7LM.O](U65[Y]EK+;B$I*W P-TH(P6 ^8"KEIXXTZ77HM"U"VO-)U292
MT-O?(@\X?[#HS(WT#9J4DUIYK]6BG[N_D_\ )D.F?#W2M.O=.N&N;Z\32U*:
M=!=.C): _P!W"@D] "Q8C%9[_"O3WN]>N?[<UE9-<0QWN&@PRD]!^ZXXX^A]
M>:[RL+Q%XLT[PU)907*S3WE](8[6TMPIDE(ZXW$* /4D42:Z_P!7W^^VOH"7
M;^K?Y$WACP]!X6T&WT>UNKFXMK?(B:Y*%U4G.,JJ@C\,U5USP9I6NZC;ZI)Y
M]IJML"L-_9R>7*@YXS@AAST8$?K5+PE\1='\97TMIIMOJ$4D5NL[&YM]BX8D
M8SDY((^GH3S7754D[W8HVMRHR;/0_(GCN+W4K[4YXB3$]V8P$R,9"QHBYP2,
MD$X)YYKEYOA#X<FT?4]*,^HK:ZA=_;' F7,4GJF5_GGK7?44O/\ K>_YJX_Z
M_K[SQ[Q=IEX?B[X4DBMM:EL["V,4VH6]E(_EL0P4[D3:3R,\$>HQFNXLO &B
M6NF:O97"SW_]L.7OY[IP9)B?]T*%QVV@8JK<?$6&#Q8_AE?#NM2ZHL1F6./[
M-AXQGYP3,!@XZ'!]JU/#'C#2O%D5U]@,T=Q:2>5=6UQ'LEA?T8<CL>02.*2U
MC;??[F]?Q_X(G92]++[EI^'_   \/>%+;P[IJ:='>WMY9Q K!%>,CB%3_"I"
M@D8X^;) XJKX?\!Z=X7EN5TJ]U"&QN)?.-@95,*/ZK\NX=.F[![BNIHI];A9
M6L<?H7PZTW0IM:=;_4;Q-9W&]CNFCVN6SDC8BD'YCT..>E57^%.A2^$HO#4E
MWJ36$$XG@)F4/$0Q.%(7&/F/4$\]>!7=5QUQ\2-+@T36=66PU.6WTBY-M=*L
M*JV0<%E#, 5Y]<^U*Z7RM]R>GW,>[]7^+6OWHM67@;3;#Q9<^(X+J]%Y=6XM
M[A&=2DH  W$%<AN!T(''2LVV^%6A6NE#2([K4O[(:19I[!IE,=Q("#N<[=_)
M )"LJ\=*ZO1M5@US1;+5;9)$@NX5FC64 ,%89&0"1G\:R-*\;6.J^,-2\,)9
M7T%_IZ>9*TRIY;*<8*E7)Y!!Y _#I56:ER]5^CO^#U%IRWZ?TO\ @$&I> ;'
M4O%NF^(VU'4(+K3E"6T,)B$2+W7!C)(()!Y^F*SW^%>GO=Z]<_VYK*R:XACO
M<-!AE)Z#]UQQQ]#Z\UWE9GB#6E\/Z-/JDEC=7<-NI>5;;R]RH 26P[*"!CL<
M^U2[):[:_CO]Y23;T\OPV.<?X7:'-X5T_0)[G4)8M.D\RRNC(BSVYSGY65 /
MS!_05UEA9&R@"/<SW<N 'N)]N]\=,[0!^0'?UKC(OBQI']DV.L7FEZO8Z1?/
MLAOYXXFCSG'S".1F7H>H'2N[1UD171@RL,@CH15:Z_UK_5B%RZ6_I?\ #F6-
M%E'B!M6_MB_*LGE_8R(?)V^G^KW]3G[V?PXJIIW@[3]&LM4M](EN+!M2N&N9
M9H=C.K-U"[U9<=>"#C)K4U;5K/1--EO[Z41PQX'NS$X"CU)) %8^L^-K'0_%
M.DZ!=V5\9]5.VVGC5#%G/(/S[AC(_A[]ZFR?N]]/UM^I3=M7Z_I<B\&> [/P
M-;SVVFZGJ,UK,YD:&Z,3*'.,L"L:MG '&<>U5+;X;VUMXQ;Q4-?UE]4D 21V
M^S[73CY"HA  P .,'WS7:T55W?FZA;1KN<CXT^'MCXZ^SIJFJ:G%;V[!XX+9
MHE4/R-V6C+9P?7'M4R>!-.FU2SU+5[R]UFZLN;4WS1[83QR$C1%)X')!-;6K
M:O9Z+9"ZOI1'&TB1*.[.S!54#U)-7J2TV[_C_G83UW_I!117':[\0[;0/$MG
MH-SH>KRW=\VVT:$0%)_7!:48Z_Q 47UL/I<[&BN9;Q?<QW@M)O"FNQ3-$TL8
M;[,5DVXRH99BH;!S@D< UBZ/\6=.UW3+K4[#P_KTEA:.4N)Q%"?*P,G*"4N0
M!_=4T70'H%%9^B:YIOB+2H=3TJZ2YM)1\KKZ]P0>01Z&J\WB?3(/%=MX;>4C
M4;BW:Y1<<;0<8)]3R1]#3:L[/<5U:_0V****0PHHHH **** "BBB@#G_ !W_
M ,D\\2_]@JZ_]%-1X$_Y)YX:_P"P5:_^BEH\=_\ )//$O_8*NO\ T4U'@3_D
MGGAK_L%6O_HI: #P)_R3SPU_V"K7_P!%+705S_@3_DGGAK_L%6O_ **6N@H
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MHHH **** //_ (6?\SK_ -C7??\ LE>@5Y_\+/\ F=?^QKOO_9*] H ****
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M44#"BBB@#S__ )N%_P"Y4_\ ;NO0*\__ .;A?^Y4_P#;NO0* "BBB@ HHHH
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M_P#BJ/\ A._!_P#T->A_^#&'_P"*H Z"BN?_ .$[\'_]#7H?_@QA_P#BJ/\
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M#H**Y_\ X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (J@#H**Y_\
MX3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (J@#H**Y_\ X3OP?_T-
M>A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (J@#H**Y_\ X3OP?_T->A_^#&'_
M .*H_P"$[\'_ /0UZ'_X,8?_ (J@#H**Y_\ X3OP?_T->A_^#&'_ .*H_P"$
M[\'_ /0UZ'_X,8?_ (J@#H**Y_\ X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0U
MZ'_X,8?_ (J@#H**Y_\ X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_
M (J@#H**Y_\ X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (J@#H**
MY_\ X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (J@#H**Y_\ X3OP
M?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (J@#H**Y_\ X3OP?_T->A_^
M#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (J@#G_^;A?^Y4_]NZ] KR?_ (2SPW_P
MO7^T?^$@TK[#_P (UY'VG[;'Y?F?:=VS=G&['..N*[C_ (3OP?\ ]#7H?_@Q
MA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .
M@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A
M._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ
M'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\
MXJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3O
MP?\ ]#7H?_@QA_\ BJ .@KS_ ,6_\E>^'7_<3_\ 2=:Z#_A._!__ $->A_\
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M_H:]#_\ !C#_ /%4 =!17/\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\
M!C#_ /%4 <_XM_Y*]\.O^XG_ .DZUZ!7D_B?Q9X;N/BEX"O(?$&E26MK_:'V
MB9+V,I%N@4+N8'"Y/ SUKN/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\
M]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@Q
MA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^
M$[\'_P#0UZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0
MUZ'_ .#&'_XJ@#H**Y__ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&
M'_XJ@#G_ (6?\SK_ -C7??\ LE>@5Y/\-O%GANQ_X2[[9X@TJW\_Q+>3P^=>
MQIYD;;-KKD\J<'!'!KN/^$[\'_\ 0UZ'_P"#&'_XJ@#H**Y__A._!_\ T->A
M_P#@QA_^*H_X3OP?_P!#7H?_ (,8?_BJ .@HKG_^$[\'_P#0UZ'_ .#&'_XJ
MC_A._!__ $->A_\ @QA_^*H Z"BN?_X3OP?_ -#7H?\ X,8?_BJ/^$[\'_\
M0UZ'_P"#&'_XJ@#H**Y__A._!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8
M?_BJ .@KS_XV_P#)(==_[=__ $HCKH/^$[\'_P#0UZ'_ .#&'_XJN'^+_BSP
MWJ?PMUFSL/$&E7=U)Y&R&"]CD=L3QDX4')P 3^% 'H&C>&-+T![EM.6[0W+%
MI?-OIY@S'JV'=@&]QS67;?#WPUI6L/K]GI]XVK %C-_:,[22G'0[Y,-G &&X
MJY_PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5)K_(/(X#X=_#N9
M=/U>R\7>'YX5N+\W<8-XICE4XPCK%(=V",X8$5=\=>&-6U3X@^%KZQT"6[TG
M2PPG:*:&/AL8"!I%.1CV[8KLO^$[\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_
M^#&'_P"*I]8^5OP5OR$U?FOUO^+N/MO!VAVFG7]C#:2+%J!)NW-S*9IL]=TI
M;>?3[U3^'_#>E>%M/^P:/!);VFXL(FN))0I/7;O8X'L*J_\ "=^#_P#H:]#_
M /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 [!_PA'AW^T/MO\ 9J^9YWVCR_-?
MR?-_YZ>5NV;_ /:VY]ZU-2TFQU>*&*_MDG2&9)XPV?ED0Y5N/0UE_P#"=^#_
M /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50M%8"WK?AK2/$:6R:M9+
M<BUE$T)+LI1QT(*D&J?_  @_AX7.I7"6+Q2ZG&(KQH;F6/S5 QR%88^HP>OK
M2_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5*R M^'_#>E>%
MM._L_1K=[>TWEQ$T\D@4GKC>QQ]!Q6K7/_\ "=^#_P#H:]#_ /!C#_\ %4?\
M)WX/_P"AKT/_ ,&,/_Q54VWN"5CH**Y__A._!_\ T->A_P#@QA_^*H_X3OP?
M_P!#7H?_ (,8?_BJ0'045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#
M_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '04
M5S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )
MWX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H
M:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P
M8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 5
M1_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/
M_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#
M_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '04
M5S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )
MWX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H
M:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P
M8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 5
M1_PG?@__ *&O0_\ P8P__%4 'CO_ ))YXE_[!5U_Z*:CP)_R3SPU_P!@JU_]
M%+6'XT\:>%;KP+XAM[?Q+HTT\NF7*1QQW\3,[&)@  &R23QBMSP)_P D\\-?
M]@JU_P#12T 8?@OP7X5NO OAZXN/#6C33RZ9;/)))81,SL8E)))7))/.:W/^
M$$\'_P#0J:'_ ."Z'_XFCP)_R3SPU_V"K7_T4M=!0!S_ /P@G@__ *%30_\
MP70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?
M\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%
M30__  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70
M_P#Q-=!10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!1
M0!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@
MG@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%3
M0_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\ P70_
M_$T?\()X/_Z%30__  70_P#Q-=!10!Y/_P (GX;_ .%Z_P!G?\(_I7V'_A&O
M/^S?8H_+\S[3MW[<8W8XSUQ7<?\ "">#_P#H5-#_ /!=#_\ $US_ /S<+_W*
MG_MW7H% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%%
M'/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">
M#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">#_\ H5-#
M_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">#_\ H5-#_P#!=#_\
M31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@_
M_H5-#_\ !=#_ /$UT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\
M!=#_ /$UT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$U
MT%% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\
M_"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%% '/\ _"">#_\
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M!_\ T*FA_P#@NA_^)KH** /)_$_A/PW;_%+P%9P^']*CM;K^T/M$*64827;
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M@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\
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M:7PSELM,G\1^%?%=O"=1.I->QPW4(8W0.,.@(^<Y7(QSS5V]ZWK\[2M^6O\
MP">9\M_\/RO&_P">G_!/1I/'/AV'5;_3);]H[RPA,]S$]M*NV,8^8$KAAR/N
MDYJ2?QCH,%C979O_ #(KZ/S;9889)9)4QDL$12V .IQQWKSRPO=,E_:0U1);
MFV8OIBVZ*SCYI/ERF.[8SQ]:K>*[9M"^,NF7ES?7&BZ'/IWV*WO+:.(1P-S^
M[.]&1 >.PZU";:C_ 'OTYOSLO^#H4W9R\K?C;\KO^KGJ<WB71X=/M;[[:DL%
MV,VWD*TKS\9^1$!9C@= #5"?QWH:^%+[Q#:32WMI9AA*D$+^8K+U5D(!0^NX
M#'4UY_K&GZ1X/D\&:)I]M/<NU](;/5KXEA:AB"Y 3:K$Y.T,,<9YK(\(6\S^
M#_BCIRI+)?-/<$0%?WK95L':!W]A2D])-=$[?)Q_S_I!%^]%/JU^-_\ +^M#
MJ+CXC3W?PJCUQ-1.CZA/( +FYTV=X(\N2%!$9##:-NX C/O7<7?BG2M(LK%]
M1OLRW,0>-8())'E 4%F6- 6QW/''>O%==U&S/[,>G6HN8O/#11[-W.\2DE?J
M "2.H'6MAM131?B=X:\1W\J-X?O-%2SBOLYAB?'(9N@Y]?7VK1KWG%=[?^2W
M_%Z?\$B,G9-]G_Z5;\$>Q:7JMCK6G0ZAIMU'=6DPRDL9R#VJOXCUVV\->'K[
M6;L$PVD1<J#RQ[*/<G K#O/&?AKPK>Z-HR6SV\.IRF.U-K;!8 <XSQC@D]0#
MG.>G-7/'OAV7Q7X(U/1H'"SSQ@Q%C@;U(90?8D8J*C?*W'^MK_<:T[<R4C \
M(S^*O&?AN/Q!<:_)I1N]S6MG9VT+QH@) WF1&9B<<X*_A5+PU\5O,T/Q!_PD
M%JW]J>'V9;I;.)F$P!*[U'\(R.<\#KP*D^'WBO3O#_@BST;Q%<QZ5JNG*T$E
MI=MY<DF&.TQJ?]8",8VYKD_#_A/57\,_$'Q-<6%Q#+K<%Q]CM&C/FF,[F!*]
M<G(P/:G4=G+EV2_RM^O](F&JCS?%?_._W:?YZFQKGQ U>[^#!\4Z9=W.GZE'
M(C/FS'ED/(5"@RQ[7 !'S+W')ZUW7A_QEI6I'3M,?4 ^KSV,=R8VB9!*"HRR
M-@*W.?NDUY)K.HV9_9?M+;[3%YP$46PMSO$N2ONP )(Z@5875M.D^+OP_DBO
MK9HQHR1;ED! =D<!<^I.!BJ2]]Q7?_VQO\U^)";Y%)]F_P#R9+\FSUZ7Q?H,
M.JG37U!1<+*L+D1N8TD;HC2 ;%<]E)!]JCE\:^'[?7;G19KYX]0MH3/)"]O*
MO[L?Q!BNUASV)KQWP?H$.HOXA\)>)M9U2QOAJ1O!91"%#=_,"LB%XRS'*]FQ
MC'O70->Z</VE8TENX"RZ2+<;Y%SYIS\G^]@]/>IC=\J[I_\ I-_ST_R>A4GR
M\WE_G;\M?^ >JZ7JEEK6EV^I:=.)[.X3?%( 1N'T(!'XU<J*WMH+.WCM[:&.
M"",;4CB4*JCT ' J6J=KZ#5^IY__ ,W"_P#<J_\ MW7H&1ZUXQ\1[F6S^)1G
M@?9+_8]NF[ /!FG)'/T%8']O:G_S]'_OA?\ "NNE@Y5(*29RU<7&G+E:/H;(
M]:,CUKYY_M[4_P#GZ/\ WPO^%']O:G_S]'_OA?\ "M/[/GW,_K\.Q]#9'K1D
M>M?//]O:G_S]'_OA?\*/[>U/_GZ/_?"_X4?V?/N'U^'8^ALCUHR/6OGG^WM3
M_P"?H_\ ?"_X4?V]J?\ S]'_ +X7_"C^SY]P^OP['T-D>M&1ZU\\_P!O:G_S
M]'_OA?\ "C^WM3_Y^C_WPO\ A1_9\^X?7X=CZ&R/6C(]:^>?[>U/_GZ/_?"_
MX4?V]J?_ #]'_OA?\*/[/GW#Z_#L?0V1ZT9'K7SS_;VI_P#/T?\ OA?\*/[>
MU/\ Y^C_ -\+_A1_9\^X?7X=CZ&R/6O/_%O_ "5[X=?]Q+_T0M><_P!O:G_S
M]'_OA?\ "J\NI7<]W;W4DVZ>WW>4VT?+N&#^E']GS[A]?AV/H[(]:,CUKYY_
MM[4_^?H_]\+_ (4?V]J?_/T?^^%_PH_L^?</K\.Q]#9'K1D>M?//]O:G_P _
M1_[X7_"C^WM3_P"?H_\ ?"_X4?V?/N'U^'8^ALCUHR/6OGG^WM3_ .?H_P#?
M"_X4?V]J?_/T?^^%_P */[/GW#Z_#L?0V1ZT9'K7SS_;VI_\_1_[X7_"C^WM
M3_Y^C_WPO^%']GS[A]?AV/H;(]:,CUKYY_M[4_\ GZ/_ 'PO^%']O:G_ ,_1
M_P"^%_PH_L^?</K\.Q]#9'K1D>M?//\ ;VI_\_1_[X7_  H_M[4_^?H_]\+_
M (4?V?/N'U^'8]&\6_\ )7OAU_W$O_1"UZ!D>M?.,NI7<]W;W4DVZ>WW>4VT
M?+N&#^E6/[>U/_GZ/_?"_P"%']GS[A]?AV/H;(]:,CUKYY_M[4_^?H_]\+_A
M1_;VI_\ /T?^^%_PH_L^?</K\.Q]#9'K1D>M?//]O:G_ ,_1_P"^%_PH_M[4
M_P#GZ/\ WPO^%']GS[A]?AV/H4D;3SVKPMM:N=$\52W5NV,,-R\<C SU%9W]
MO:G_ ,_1_P"^%_PK/DD:5R[G+'J:Z,/@W!OGU3,*^+4TN71H^@=!UVVU[3EN
MK<X;I(G/RM@'&2!GK6K7SWH.N7.@ZDEU;GC($B\?,N02.AQTKW'0];MM<T]+
MFW89(&]>ZM@9'ZUPXG#.D[K8[</B%55GN:=%%%<ITGG_ ,+/^9U_[&N^_P#9
M*] KS_X6?\SK_P!C7??^R5Z!0 4444 %%%% !1110 4444 %>?\ QM_Y)#KO
M_;O_ .E$=>@5Y_\ &W_DD.N_]N__ *41T 9GQ%UCQSX5M5\2VFJV/V".Y6-M
M)^R [D9L*3*?F+'C(7:!GOCF'XM>)O$?ARTT*_T?6+BQ.H3+#+;&""14R,DC
M<A;=SCKCCI6?XR^+7A%?%J:=J,5_?66E2B39:1H\<MP,_>+.N0G8<@MSV&:'
MQTUFRU'1?"RRR01W+W"7,MF\BL\<;+U9?3MG&.M3'51[.2^[_@ZOR0I;R_PO
M[_\ @;>IO_%G6O$G@S0-)OM)\2WGFS7"VTHFM[9@^0S;_P#5##< <8''2M[Q
M"_BW3Y_#D6C:U%=;IA]LBNX4,]TA9<D;$"JJ@G)PN..2>#YK\:(/!EKX;T5M
M AT**ZENDE+6"0J[P[6&[*<E<CKTR*]ZTR^M-2TV"ZL;J&ZMW7Y98) Z-C@X
M(XZU<?A;[2_1:>A+Z+O'^OF<A\07\8VFDWVK:'K-IIUOIT1F\AK596N0HRVY
MVX0=0 !GCJ,\6=)U+Q%XM\!:5?6,]OI-_?0"26Y>#SA%[I&2 <]1DX ]:YKX
MH?$CP[I-['X9U%KR:&4!]02R16?9U$1+,H&[OU..,?-D:-]\4]&TOX<V_B..
MVFM8;G,.GVKHOF, =H.T'  P3C/0#GFH37(WTNOU_-_D6[\Z777^OEO\Q_PS
M\1^(M4O/$&C>(I(KNXTBY$ OHHP@ESG@@8&> > .M>A5YM\*?%^A:_%=V&A6
M>HCR<W%[=WRHKS3.?O?*S9)PWI@  >W::A;^();G=INIZ9;6^T?)<Z=),V>Y
MW+.@Q[8_&K::M?LO^'^9,>MNYJUR?Q$US6O#GA&]U;1H[$M;1[W-UN..0/E4
M=3@GJ>PX.:U]/M_$$5SNU+4],N;?:?DMM.DA;/8[FG<8]L?C7+?&/5+"R^&^
MK6MU>00W%U#MMX7D >4AESM7J<=\=*RJMJ%T:0UE8L)JFJZA\(H-;74Y;;4O
M[,%XT\,41W.(]V"K*RX)] /8BL#P!J_B/Q-\,;O7;[Q+>B_/F^6T=O;!8_+R
M1@>5SGOG/MBIM+U[2/\ A0BM_:EF!'I!M7S.ORS>5CRSSPW^SUKC?AI;^"9/
MA'>7&L0: ^H0>=ODNTA,R9SY>2WS#)Z?I6E?25:W1:?>]OP_#OK%/6-._5_I
MU.B\#Z]XM\2?"W4-<D\3(FJL[PP/=V\*P0[2OS82/<6.2.=PY'RFNTLU\7:E
MX,T^,WMMI^LRQ9N;QK;S-A[%8CMY/!P<8YR.U<?^SY?V<G@ V"7<#7D=S)(]
MN)!YBJ<88KU ]Z[+Q[XVL/ WA]K^[?,\I\NWB4;F=O7&1D#J>1Z9YHJVC?SM
M_7S)I7DEY7_/]$C#^'7B/Q/J<OB/1M;>WO+[1[CR8[U4$:3$YX8*..@/ [U6
ML]8\9:=\5[;0;K5[36["YMVGN$@M%@-B!D G!)Y./O,<Y[54\"?$7PXV@ZK+
MI.F:S+%8(;N_N)84,UQ*[<D*K$$GYCU   [=*T^BZ!XC\8^&_%/@2:);E[OS
M-1>T^51#C<YE7^%R3C!P3N[XS32?/&_E?YIZV[7UOY>=@;]R5O.WWK3UM^?D
M>Q5R/Q+OM3TCP/J&K:3J<UC=64?F*8XXG63D##!T;CGM@UTM^E]):,NG7%O;
MW.1MDN(&F0#OE5="?^^J\_\ B=<W.G_"[6X==U;39+BYCV6PA@-MO.02H5I7
M+'OQV[5E5;4';^MC6'Q(R8=>\86WPJL_&\6NO?W"PB>ZL;JVA$3INPVTQHK*
M0!GDGO7<:3X[T?4?!UCXDGF^S6]V HC(+OYN<&-54$LV00 !D^E>9V7B*QG^
M -MX?TV5=1UNZLC:K86A$LR%F()95Y4 '.3BL[6_"VK>"O#?@&2YFN8K73;I
MY=0FM560VKR,&W?,K+\HR,D$?G6LOBDNETE\]_T^;W,8M\L7UL[_ "V_KJCU
M?Q#XZLM.\#ZAX@TPM=M;JR*GD2924?PR+MW1X/7<!CVS7GEKXS\5"VT#5+OQ
M9;VMCJKP_N[S29-Q?/[R-&2';M((VDDD\_-P36GXFT_1-$^&/BZ_M-=FOUUE
M/,^U7,L6V>4CI'L503@= .WL:X[Q+J^FR?##X<1IJ%JSP7<)E595)CV#YMPS
MQC(SGID4H?'KW@OOO?\ K^FZC?)IVE^"T_K^E[7<^//#MIK=QHLUY,NI6\9E
M>W%G,6* 9)7"?/Q_=S5RR\4Z'J'AXZ_;:E VE!2S7+$HJ@=<[L$'V/->4W>M
MZ5%^T#?7,FI6:6XT1D,K3*%W;=V,YQG'.*Y'2K:[U;]G6ZMM*)GGM=4\ZYMX
M<,_EY!Y7KZ'\*E2]V[[+_P!*<?RU_P" 7]NWG_[;?\]#Z'TCQ#I>N&5;"X9Y
M(@I>*6%XI%#?=;8X#;3V.,'M7'?&+6];\,^%8]8T35YK.9)TA:(0PR(X;/)W
MH3D8[$#VJQX'L-(U+48_%MCK^H:K<W-BMO(93 $C4$$(RQQKA@<]>>OM6%^T
M%?6<?@)+*2ZA6[ENHW2 R .RC.6"]2!ZTYKE<5YK\_\ +]?4*3YM7_6G^99U
M#Q-K_A3QSX9TN;5)-8L=;&UTN((EEA;CYE,2J".>X[&NRE\:^'8-1>QDU)5E
MCE$$DGE/Y*2'HC2XV!O]DMGVJGX<\.^&FAM]=TL+>W4D&R._DO)+ME&,$*[L
MVT9R,#'>O&WM;FV^%.N>#KD,WB:;6 4LNLTX+J?,4=64@$[NGO3;:?+_ %K)
M*WR3O_P-2(ZQ4K[V_P#26V_F]/\ @GO-_P")=(TV^-G=W>R98O.D B=EB3GY
MI&4$(#@X+$9QQ27GBC1K"Z%M<7FV3R?/?$3LL4?9I& (C!P<%B,XXKRSQI97
M.B2IK^DZTUGXAL[2"TNK*Y&Z'4\(#Y:#^-^3P.?IU+O'"7%E=?\ "5:1J1TK
MQ!%:PPW.F7"YAO@5#>2@_C8;L;1S].I5_P [?G;U6WGY#3;^Y/\ *_IU\O/<
M[&X\2RR_%"RT6WUR*&V>Q=WL&LI!+(Y&5D20IL( _P!KJ",$].=\!_$29+?Q
M&_BO6)9XK#4FMHIS:9\N,$@%_)3"C(^\V!6=<ZI _P"T'X::YD@MY_[($<T/
MF#]U*RN1'['D8'N*Q=%NHM.\(_$33[S=#>:I=W L+=U(DN\EE'E+U?G^[G%*
M[2OOI+\)V_+^K!>[7_;OXQ;_ #_X)W7Q%\4:MH^K^$)=%U8I9:G>I!-&L<4B
M2QDJ<ABI(R#U!KL-2\6Z'I%Z;.]OQ'.JAY L;N(5)P&D901&">[$"O%?%</_
M  CN@?"[3-5N(H;RTNHY;A)) #$NY22W/ '3/3BKL.FI+\2_&&B>(M:OM,MM
M=P]L\0A"7L6/N!WC;D!@ %(/6J[Q7>7X<NGY_=H'-HI/31?BWK^7WZGNC?O8
M3LD*[E^5TP2,]QG(KR+0-5\5ZQXF\9:4_B^\B312!:R&TM2&^]_K/W7(^4=-
MM>I:9;0Z5HEK;"2006MNJ![@C<%5<98C S@<UXKX*A\.>)OBCXV@O+]9X;N=
M3;1P:B\2W2C<6P(W E&.QR*35YN,7T?Z695[03EW7_!.V^'_ ,1?[>\#P:OK
MVRWNC</;*(8V8W#*,_NT7+,<=E!Z&N@7QMH<WA_4-9LYY;J"PW"XBB@?SHV7
MJK1D!E/U ]>E<G\0?[)\.KX2TVST2W0_;U2RN"K+#8GC+E4(W'G(!X."3G%<
MUX*AEW?%/3B9)+V1Y62-U ED!63#;0!UR.@[TISNI./1.WRY?\_^'U""LXJ7
M5K[FW^5OZT-:[^(6J:K\'+_Q-IUS<Z?J5O(95/V/]WL,Q54#2(4?"XR5.<CD
MCI76^%?&^FZE9:'87FHAM:O;!+C:T+()CM^8JVT(3G.0IXQTKRZ._M(OV79K
M22=$N$!A:-C@B3SR=G^]@$XZXYIJ:MII\9_"EEOK8I%IZI(1*N$8KM /H=P(
M^HK6R]HXK:Z7_DK?YI$.3Y%+RE^:_P"">V'Q/HXU"6R-V?.BD6%R(G\L2,0
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M%G_,Z_\ 8UWW_LE>@5Y_\+/^9U_[&N^_]DKT"@ HHHH **** "BBB@ HHHH
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MU'@3_DGGAK_L%6O_ **6CQW_ ,D\\2_]@JZ_]%-1X$_Y)YX:_P"P5:_^BEH
M/ G_ "3SPU_V"K7_ -%+705S_@3_ ))YX:_[!5K_ .BEKH* "BBB@!KN(XV=
M@Q"@D[5+'\ .37C'@O1;/4/B=XJO-;\,7,MO?3K)I\VHZ-+LXW$D-)'A.W7&
M>*]IHH6DN;R:^_\ X8'K'E/+OC?I]U>^#+#3]+TR\NY1>QR"*SM'E"(H.<[
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M%H?_ #P/_?*?_$UT]%/VL^XO90[',?\ "!:'_P \#_WRG_Q-'_"!:'_SP/\
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M!:'_ ,\#_P!\I_\ $T?\(%H?_/ _]\I_\373T4>UGW#V4.QS'_"!:'_SP/\
MWRG_ ,31_P (%H?_ #P/_?*?_$UT]%'M9]P]E#L<Q_P@6A_\\#_WRG_Q-'_"
M!:'_ ,\#_P!\I_\ $UT]%'M9]P]E#L>4^(O#>GV/Q&\&:7#&1:ZC]N^T+A>?
M+A#+T&.I[@UU_P#P@6A_\\#_ -\I_P#$UC>+?^2O?#K_ +B?_I.M>@4>UGW#
MV4.QS'_"!:'_ ,\#_P!\I_\ $T?\(%H?_/ _]\I_\373T4>UGW#V4.QS'_"!
M:'_SP/\ WRG_ ,31_P (%H?_ #P/_?*?_$UT]%'M9]P]E#L<N? 6AX/[@_\
M?*?_ !->/:G:B+5Y;:!2?F 50.>0/2OHD\@UQ>C>"4@UNXU&_P!DI)'E+C('
M'<$>U=&'Q+A=R=S#$8=3LHJQ1\#^"5M%34M1C!G(!CC8?<Z$$@KP<@]Z]"
M&!P!0  , 8%%<]2I*I+FD=%.G&G'EB%%%%9EGG_PL_YG7_L:[[_V2O0*\_\
MA9_S.O\ V-=]_P"R5Z!0 4444 %%%% !1110 4444 %>?_&W_DD.N_\ ;O\
M^E$=>@5Y_P#&W_DD.N_]N_\ Z41T <Y;-/)\?;K6)-'U@:5-9"T6X?2K@1L^
M%&#E.%Z\GCWQS77^/;1+'X9:EI&GV5W,TMH]M:P6EK),<D' PBG:/<X%=I14
MN-Z:A_6]QI^^Y?UM8\4\/R:O#\$U\*6N@:NVN3P2VYAGL98(XP[M\S22*$P
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M8UO5?!OA'PB-+O;>_P!+U'S;V66!E@CC4L=RRD;7R&& I)]<5U_C?PQJDWQ
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MW_D[<?\ QR@#T"BO/_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H
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M[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H /^;A?^Y4_P#;NO0*\/\ ^%6^#?\
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M ).W'_QR@#T"BO/_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <H ]
MHKS_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QR@#T"BO/_\ A27P
M\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H ] HKS_\ X4E\//\ H7O_ "=N
M/_CE'_"DOAY_T+W_ ).W'_QR@#T"BO/_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?
M]"]_Y.W'_P <H ] HKS_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\
MQR@ _P";A?\ N5/_ &[KT"O#_P#A5O@W_A<G]@?V-_Q+/^$?^V^1]JF_UWVC
M9NW;]WW>,9Q[5V'_  I+X>?]"]_Y.W'_ ,<H ] HKS__ (4E\//^A>_\G;C_
M ..4?\*2^'G_ $+W_D[<?_'* /0**\__ .%)?#S_ *%[_P G;C_XY1_PI+X>
M?]"]_P"3MQ_\<H ] HKS_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\
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M_P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY0!Z!17G_\ PI+X>?\
M0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE 'H%%>?_ /"DOAY_T+W_ ).W'_QR
MC_A27P\_Z%[_ ,G;C_XY0!Z!17G_ /PI+X>?]"]_Y.W'_P <H_X4E\//^A>_
M\G;C_P".4 >@45Y__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY0
M>+?^2O?#K_N)_P#I.M>@5X?XB^%O@VQ^(_@O2;;1MECJ7V[[7%]JF/F>7"&3
MDOD8)SP1GO78?\*2^'G_ $+W_D[<?_'* /0**\__ .%)?#S_ *%[_P G;C_X
MY1_PI+X>?]"]_P"3MQ_\<H ] HKS_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O
M?^3MQ_\ '* /0**\_P#^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_ ,<H
M ] HKS__ (4E\//^A>_\G;C_ ..4?\*2^'G_ $+W_D[<?_'* /0**\__ .%)
M?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<H /A9_S.O\ V-=]_P"R5Z!7
MA_@#X6^#=;_X2C^T=&\[[#X@N[*W_P!*F79"FW:O#C.,GDY/O78?\*2^'G_0
MO?\ D[<?_'* /0**\_\ ^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !R@
M#T"BO/\ _A27P\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ_P#'* /0**\__P"%
M)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QR@#T"BO/_P#A27P\_P"A>_\
M)VX_^.4?\*2^'G_0O?\ D[<?_'* /0*\_P#C;_R2'7?^W?\ ]*(Z/^%)?#S_
M *%[_P G;C_XY7'_ !2^%O@WPY\.-6U;2=&^SWT'D^7+]JF?;NF13PSD'@D<
MB@#W"BO/_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'* /0**\_\
M^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !R@#T"BO/\ _A27P\_Z%[_R
M=N/_ (Y1_P *2^'G_0O?^3MQ_P#'* /0**\__P"%)?#S_H7O_)VX_P#CE'_"
MDOAY_P!"]_Y.W'_QR@#T"BO/_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\
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M27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'* /0**\_\ ^%)?#S_H7O\
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M*** "BBB@ HHHH **** //\ X6?\SK_V-=]_[)7H%>?_  L_YG7_ +&N^_\
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M5'T=55#IK3*T;*.BLY7S2.G&_%39IW7_  /F7>ZU_P"#\CC/C==17WPDMKN
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MGMG./4EJYCX^0_9M#\+0Q?-Y5\J+O;KA<#)K8UOX7>*=8\07FJQ?$>_L#<$
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M77_HIJ/ G_)//#7_ &"K7_T4M26'@3_DGGAK_L%6O_HI:Z"N?\"?\D\\-?\
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M>'O2Z_[^_P#UJO\ M"GV9G]0J=T>,T5[-_PK+P]Z77_?W_ZU'_"LO#WI=?\
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MC< SC*Y('!SSR!S7->"O$%XVO_\ ",^*9-6L=?S*T@DN':"^&T_-$<_N\ Y
M3 X]>G%_VCJ&H_ SQI]OU"[O6@U011O=3M*RH'CP 6).*AMV;79/_P F2_4N
M-G))][?@W^A]#:=>Q:EIMK?PJZQ7,2RH' # ,,C.._-8>A^-K'7?$VK:!%97
MUO>Z7CS_ +0J;2">"I5VSG@\XZUY_<:CJ/AF^^'$FGWU[+'JL<=M=VTLS/$Z
M[4P0G1"-QY4#IS5*VUB7P_\ $/XI:M @>:TLTDC4C(W!1C/MFKFU&3[+F_\
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M,U;XBVVC^*[;PY-H.L2W]WDVOE"WV3@9Y#-*,=#][!]JB^$WB74/%7@*VO\
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M] KS_P 6_P#)7OAU_P!Q/_TG6O0* "BBB@ HHHH **** "BBB@ HHHH \_\
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MQA_^*H_X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B: #_ (3OP?\
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MNA_^)H_X03P?_P!"IH?_ (+H?_B: #_A._!__0UZ'_X,8?\ XJC_ (3OP?\
M]#7H?_@QA_\ BJ/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H
M/^$[\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*H_X03P?_ -"IH?\
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M>QE(MT"A=S X7)X&>M=Q_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
MP70__$T '_"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4?\ "">#
M_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q- !_PG?@__H:]#_\ !C#_
M /%4?\)WX/\ ^AKT/_P8P_\ Q5'_  @G@_\ Z%30_P#P70__ !-'_"">#_\
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MNA_^)H_X03P?_P!"IH?_ (+H?_B: #_A._!__0UZ'_X,8?\ XJC_ (3OP?\
M]#7H?_@QA_\ BJ/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H
M/^$[\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*H_X03P?_ -"IH?\
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M2KNZD\C9#!>QR.V)XR<*#DX )_"NX_X03P?_ -"IH?\ X+H?_B:/^$$\'_\
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M_P!"IH?_ (+H?_B: #_A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\
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MNA_^)H_X03P?_P!"IH?_ (+H?_B: #_A._!__0UZ'_X,8?\ XJC_ (3OP?\
M]#7H?_@QA_\ BJ/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H
M/^$[\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*H_X03P?_ -"IH?\
MX+H?_B:/^$$\'_\ 0J:'_P""Z'_XF@##\:>-/"MUX%\0V]OXET::>73+E(XX
M[^)F=C$P  #9))XQ6YX$_P"2>>&O^P5:_P#HI:/^$$\'_P#0J:'_ ."Z'_XF
=MR""&UMXK>WBCA@B0)''&H544#   X  XQ0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pcsa-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamMSbP9z5Z8aekhvWBybUk6DyAst1/EviO8ql/GUb8D -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:PCSA="http://processapharmaceuticals.com/20220630" elementFormDefault="qualified" targetNamespace="http://processapharmaceuticals.com/20220630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
	  <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000009 - Disclosure - Intangible Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000010 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000011 - Disclosure - Stock-based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" id="NetLossPerShareOfCommonStock">
	  <link:definition>00000012 - Disclosure - Net Loss per Share of Common Stock</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OperatingLeases" id="OperatingLeases">
	  <link:definition>00000013 - Disclosure - Operating Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000014 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ElionLicenseAgreement" id="ElionLicenseAgreement">
	  <link:definition>00000015 - Disclosure - Elion License Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000016 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000018 - Disclosure - Intangible Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000019 - Disclosure - Stock-based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" id="NetLossPerShareOfCommonStockTables">
	  <link:definition>00000020 - Disclosure - Net Loss per Share of Common Stock (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
	  <link:definition>00000021 - Disclosure - Operating Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails" id="SummaryOfIntangibleAssetsDetails">
	  <link:definition>00000023 - Disclosure - Summary of Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000024 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000025 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
	  <link:definition>00000026 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails" id="ScheduleOfInformationAboutRsuOutstandingDetails">
	  <link:definition>00000027 - Disclosure - Schedule of Information About RSU Outstanding (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Stock-based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" id="ScheduleOfNetLossPerShareBasicAndDilutedDetails">
	  <link:definition>00000029 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" id="NetLossPerShareOfCommonStockDetailsNarrative">
	  <link:definition>00000030 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" id="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails">
	  <link:definition>00000031 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" id="ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Maturities of Lease Liabilities for all Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Operating Leases (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000034 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative" id="ElionLicenseAgreementDetailsNarrative">
	  <link:definition>00000035 - Disclosure - Elion License Agreement (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="PCSA_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AposenseLtdMember" name="AposenseLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandAndNineteenPlanMember" name="TwoThousandAndNineteenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OriginalMember" name="OriginalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DirectorsMember" name="DirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandTwentyTwoMember" name="TwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandTwentyThreeMember" name="TwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_BaseCompensationMember" name="BaseCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember" name="AprilOneTwoThousandTwentyTwo2022GrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FacilityLeaseMember" name="FacilityLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EquipmentLeaseMember" name="EquipmentLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CorLystLLCMember" name="CorLystLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AgreementsMember" name="AgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ContractResearchOrganizationsMember" name="ContractResearchOrganizationsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DueFromTaxAgencies" name="DueFromTaxAgencies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DueToLicensor" name="DueToLicensor" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" name="ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" name="SharesIssuedInConnectionWithPurchaseAgreementValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" name="SharesIssuedInConnectionWithPurchaseAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement" name="NoncashMilestoneExpenseInConnectionWithLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment" name="NonCashAcquisitionOfInprocessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" name="ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DisclosureElionLicenseAgreementAbstract" name="DisclosureElionLicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ElionLicenseAgreementDisclosureTextBlock" name="ElionLicenseAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" name="BusinessActivitiesAndOrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ImpactOfCovidNineteenPolicyTextBlock" name="ImpactOfCovidNineteenPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" name="MaximumNumberOfSharesToBeSoldAtMarketOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MaximumCommitmenttoPurchaseCommonStockValue" name="MaximumCommitmenttoPurchaseCommonStockValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" name="StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ReimbursementFees" name="ReimbursementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NumberOfCommonStockSharesinRegularPurchase" name="NumberOfCommonStockSharesinRegularPurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NumberOfCommonStockSharesExceedingRegularPurchase" name="NumberOfCommonStockSharesExceedingRegularPurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DailyMaximumCommittedPurchaseObligationsValue" name="DailyMaximumCommittedPurchaseObligationsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MaximumNumberOfSharesSoldInTransaction" name="MaximumNumberOfSharesSoldInTransaction" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PercentageOfExchangeCapitalization" name="PercentageOfExchangeCapitalization" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_BeneficialOwnershipLimitationPercentage" name="BeneficialOwnershipLimitationPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AccruedDirectorsFees" name="AccruedDirectorsFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_UnrecognizedShareBasedCompensationExpense" name="UnrecognizedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MinimumPricePerShareOfEquityCompensation" name="MinimumPricePerShareOfEquityCompensation" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ProceedsFromRentAndOtherCostsReimbursements" name="ProceedsFromRentAndOtherCostsReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ExpenseAndRelatedLiability" name="ExpenseAndRelatedLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedDuringPeriodSharesNewIssuedInCommitmentFee" name="StockIssuedDuringPeriodSharesNewIssuedInCommitmentFee" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_RestrictedStockAwardsValueExpectedToBeRecognized" name="RestrictedStockAwardsValueExpectedToBeRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pcsa-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20220630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20220630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20220630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="pcsa-20220630.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20220630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20220630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssets" xlink:href="pcsa-20220630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20220630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20220630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeases" xlink:href="pcsa-20220630.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20220630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ElionLicenseAgreement" xlink:href="pcsa-20220630.xsd#ElionLicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20220630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssetsTables" xlink:href="pcsa-20220630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20220630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:href="pcsa-20220630.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails" xlink:href="pcsa-20220630.xsd#SummaryOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative" xlink:href="pcsa-20220630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20220630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfInformationAboutRsuOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20220630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:href="pcsa-20220630.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20220630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative" xlink:href="pcsa-20220630.xsd#ElionLicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20220630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DueFromTaxAgencies" xlink:label="loc_PCSADueFromTaxAgencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_PCSADueFromTaxAgencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DueToLicensor" xlink:label="loc_PCSADueToLicensor" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_PCSADueToLicensor" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaapResearchAndDevelopmentInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentInProcess" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" xlink:label="loc_PCSAForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_PCSAForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement" xlink:label="loc_PCSANoncashMilestoneExpenseInConnectionWithLicenseAgreement" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PCSANoncashMilestoneExpenseInConnectionWithLicenseAgreement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment" xlink:label="loc_PCSANonCashAcquisitionOfInprocessResearchAndDevelopment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PCSANonCashAcquisitionOfInprocessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" xlink:label="loc_PCSAForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PCSAForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="loc_us-gaapProceedsFromRepurchaseOfEquity" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepurchaseOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssets" xlink:title="00000009 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="00000011 - Disclosure - Stock-based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="00000012 - Disclosure - Net Loss per Share of Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeases" xlink:title="00000013 - Disclosure - Operating Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ElionLicenseAgreement" xlink:title="00000015 - Disclosure - Elion License Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssetsTables" xlink:title="00000018 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="00000019 - Disclosure - Stock-based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000020 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:title="00000021 - Disclosure - Operating Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails" xlink:title="00000023 - Disclosure - Summary of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000024 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000025 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000026 - Disclosure - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails" xlink:title="00000027 - Disclosure - Schedule of Information About RSU Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000028 - Disclosure - Stock-based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="00000029 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="00000030 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:title="00000031 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="00000032 - Disclosure - Schedule of Maturities of Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000033 - Disclosure - Operating Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000034 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative" xlink:title="00000035 - Disclosure - Elion License Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pcsa-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20220630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20220630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20220630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="pcsa-20220630.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20220630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20220630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssets" xlink:href="pcsa-20220630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20220630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20220630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeases" xlink:href="pcsa-20220630.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20220630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ElionLicenseAgreement" xlink:href="pcsa-20220630.xsd#ElionLicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20220630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssetsTables" xlink:href="pcsa-20220630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20220630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:href="pcsa-20220630.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails" xlink:href="pcsa-20220630.xsd#SummaryOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative" xlink:href="pcsa-20220630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20220630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfInformationAboutRsuOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20220630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:href="pcsa-20220630.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20220630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative" xlink:href="pcsa-20220630.xsd#ElionLicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20220630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementValue_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssets" xlink:title="00000009 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="00000011 - Disclosure - Stock-based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="00000012 - Disclosure - Net Loss per Share of Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeases" xlink:title="00000013 - Disclosure - Operating Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ElionLicenseAgreement" xlink:title="00000015 - Disclosure - Elion License Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssetsTables" xlink:title="00000018 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="00000019 - Disclosure - Stock-based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000020 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:title="00000021 - Disclosure - Operating Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_EquityDistributionAgreementMember" xlink:label="loc_PCSAEquityDistributionAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAEquityDistributionAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherNoncashExpense_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:label="loc_PCSAMaximumNumberOfSharesToBeSoldAtMarketOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PCSAMaximumNumberOfSharesToBeSoldAtMarketOffering_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:label="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails" xlink:title="00000023 - Disclosure - Summary of Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000024 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000025 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_EquityDistributionAgreementMember" xlink:label="loc_PCSAEquityDistributionAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAEquityDistributionAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AposenseLtdMember" xlink:label="loc_PCSAAposenseLtdMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAAposenseLtdMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:label="loc_PCSAMaximumNumberOfSharesToBeSoldAtMarketOffering_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAMaximumNumberOfSharesToBeSoldAtMarketOffering_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:label="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" xlink:label="loc_PCSAStockIssuedDuringPeriodValueNewIssuedInCommitmentFee_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodValueNewIssuedInCommitmentFee_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ReimbursementFees" xlink:label="loc_PCSAReimbursementFees_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAReimbursementFees_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NumberOfCommonStockSharesinRegularPurchase" xlink:label="loc_PCSANumberOfCommonStockSharesinRegularPurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSANumberOfCommonStockSharesinRegularPurchase_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NumberOfCommonStockSharesExceedingRegularPurchase" xlink:label="loc_PCSANumberOfCommonStockSharesExceedingRegularPurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSANumberOfCommonStockSharesExceedingRegularPurchase_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DailyMaximumCommittedPurchaseObligationsValue" xlink:label="loc_PCSADailyMaximumCommittedPurchaseObligationsValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSADailyMaximumCommittedPurchaseObligationsValue_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumNumberOfSharesSoldInTransaction" xlink:label="loc_PCSAMaximumNumberOfSharesSoldInTransaction_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAMaximumNumberOfSharesSoldInTransaction_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PercentageOfExchangeCapitalization" xlink:label="loc_PCSAPercentageOfExchangeCapitalization_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAPercentageOfExchangeCapitalization_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_BeneficialOwnershipLimitationPercentage" xlink:label="loc_PCSABeneficialOwnershipLimitationPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSABeneficialOwnershipLimitationPercentage_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_90" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000026 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails" xlink:title="00000027 - Disclosure - Schedule of Information About RSU Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000028 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_OriginalMember" xlink:label="loc_PCSAOriginalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAOriginalMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DirectorsMember" xlink:label="loc_PCSADirectorsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSADirectorsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ConsultantMember" xlink:label="loc_PCSAConsultantMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAConsultantMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandTwentyTwoMember" xlink:label="loc_PCSATwoThousandTwentyTwoMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSATwoThousandTwentyTwoMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandTwentyThreeMember" xlink:label="loc_PCSATwoThousandTwentyThreeMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSATwoThousandTwentyThreeMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_BaseCompensationMember" xlink:label="loc_PCSABaseCompensationMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSABaseCompensationMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember" xlink:label="loc_PCSAAprilOneTwoThousandTwentyTwo2022GrantMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_PCSAAprilOneTwoThousandTwentyTwo2022GrantMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_240" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AccruedDirectorsFees" xlink:label="loc_PCSAAccruedDirectorsFees_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAAccruedDirectorsFees_240" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_240" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_240" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_240" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_240" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_240" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_240" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_240" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense_240" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MinimumPricePerShareOfEquityCompensation" xlink:label="loc_PCSAMinimumPricePerShareOfEquityCompensation_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAMinimumPricePerShareOfEquityCompensation_240" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_240" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_240" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_240" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_240" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_240" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="00000029 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="00000030 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:title="00000031 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_PCSAFacilityLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_EquipmentLeaseMember" xlink:label="loc_PCSAEquipmentLeaseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_PCSAEquipmentLeaseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="00000032 - Disclosure - Schedule of Maturities of Lease Liabilities for all Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000033 - Disclosure - Operating Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000034 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSACorLystLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="loc_PCSAProceedsFromRentAndOtherCostsReimbursements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAProceedsFromRentAndOtherCostsReimbursements_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative" xlink:title="00000035 - Disclosure - Elion License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LicenseAgreementMember" xlink:label="loc_PCSALicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSALicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ExpenseAndRelatedLiability" xlink:label="loc_PCSAExpenseAndRelatedLiability_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PCSAExpenseAndRelatedLiability_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AgreementsMember" xlink:label="loc_PCSAAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ContractResearchOrganizationsMember" xlink:label="loc_PCSAContractResearchOrganizationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAContractResearchOrganizationsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pcsa-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PurchaseAgreementMember" xlink:label="PCSA_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="PCSA_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LincolnParkCapitalFundLLCMember" xlink:to="PCSA_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_EquityDistributionAgreementMember" xlink:label="PCSA_EquityDistributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EquityDistributionAgreementMember" xlink:to="PCSA_EquityDistributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_EquityDistributionAgreementMember_lbl" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AposenseLtdMember" xlink:label="PCSA_AposenseLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AposenseLtdMember" xlink:to="PCSA_AposenseLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AposenseLtdMember_lbl" xml:lang="en-US">Aposense, Ltd. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="PCSA_TwoThousandAndNineteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_lbl" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_OriginalMember" xlink:label="PCSA_OriginalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OriginalMember" xlink:to="PCSA_OriginalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OriginalMember_lbl" xml:lang="en-US">Original [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DirectorsMember" xlink:label="PCSA_DirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DirectorsMember" xlink:to="PCSA_DirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandTwentyTwoMember" xlink:label="PCSA_TwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandTwentyTwoMember" xlink:to="PCSA_TwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TwoThousandTwentyTwoMember_lbl" xml:lang="en-US">2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandTwentyThreeMember" xlink:label="PCSA_TwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandTwentyThreeMember" xlink:to="PCSA_TwoThousandTwentyThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TwoThousandTwentyThreeMember_lbl" xml:lang="en-US">2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_BaseCompensationMember" xlink:label="PCSA_BaseCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BaseCompensationMember" xlink:to="PCSA_BaseCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_BaseCompensationMember_lbl" xml:lang="en-US">Base Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember" xlink:label="PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember" xlink:to="PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember_lbl" xml:lang="en-US">April 1, 2022 Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ConsultantMember" xlink:label="PCSA_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultantMember" xlink:to="PCSA_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_FacilityLeaseMember" xlink:label="PCSA_FacilityLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FacilityLeaseMember_lbl" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_EquipmentLeaseMember" xlink:label="PCSA_EquipmentLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EquipmentLeaseMember" xlink:to="PCSA_EquipmentLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_EquipmentLeaseMember_lbl" xml:lang="en-US">Equipment Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_CorLystLLCMember" xlink:label="PCSA_CorLystLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CorLystLLCMember_lbl" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LicenseAgreementMember" xlink:label="PCSA_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementMember" xlink:to="PCSA_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AgreementsMember" xlink:label="PCSA_AgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AgreementsMember" xlink:to="PCSA_AgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AgreementsMember_lbl" xml:lang="en-US">Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ContractResearchOrganizationsMember" xlink:label="PCSA_ContractResearchOrganizationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ContractResearchOrganizationsMember" xlink:to="PCSA_ContractResearchOrganizationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ContractResearchOrganizationsMember_lbl" xml:lang="en-US">Contract Research Organizations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DueFromTaxAgencies" xlink:label="PCSA_DueFromTaxAgencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueFromTaxAgencies" xlink:to="PCSA_DueFromTaxAgencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DueFromTaxAgencies_lbl" xml:lang="en-US">Due from tax agencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net of accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DueToLicensor" xlink:label="PCSA_DueToLicensor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueToLicensor" xlink:to="PCSA_DueToLicensor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DueToLicensor_lbl" xml:lang="en-US">Due to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001, 50,000,000 shares authorized: 15,919,317 issued and 15,819,317 outstanding at June 30, 2022, and 15,710,246 issued and outstanding at December 31, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock at cost &#8212; 100,000 shares at June 30, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Acquisition of in-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" xlink:label="PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" xlink:to="PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest_lbl" xml:lang="en-US">Forgiveness of PPP loan and related accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net Operating Loss Before Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss per Common Share - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in private placement, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in private placement, net of transaction costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued in connection with license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued in connection with license agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Acquisition of treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Acquisition of treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue_lbl" xml:lang="en-US">Shares issued in connection with the Purchase Agreement with Lincoln Park</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_lbl" xml:lang="en-US">Shares issued in connection with the Purchase Agreement with Lincoln Park, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense for right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement" xlink:label="PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement" xlink:to="PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement_lbl" xml:lang="en-US">Non-cash milestone expense in connection with license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment" xlink:label="PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment" xlink:to="PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment_lbl" xml:lang="en-US">Non-cash acquisition of in-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" xlink:label="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" xlink:to="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest_lbl" xml:lang="en-US">Forgiveness of PPP loan and related accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Due (from) to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepurchaseOfEquity" xlink:to="us-gaap_ProceedsFromRepurchaseOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity_lbl" xml:lang="en-US">Acquisition of treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase (Decrease) in Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents &#8211; Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents &#8211; End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-Cash Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of 123,609 shares of common stock in connection with the Purchase Agreement with Lincoln Park</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="PCSA_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureOperatingLeasesAbstract" xlink:to="PCSA_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureElionLicenseAgreementAbstract" xlink:label="PCSA_DisclosureElionLicenseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureElionLicenseAgreementAbstract" xlink:to="PCSA_DisclosureElionLicenseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DisclosureElionLicenseAgreementAbstract_lbl" xml:lang="en-US">Elion License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ElionLicenseAgreementDisclosureTextBlock" xlink:label="PCSA_ElionLicenseAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ElionLicenseAgreementDisclosureTextBlock" xlink:to="PCSA_ElionLicenseAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_ElionLicenseAgreementDisclosureTextBlock_lbl" xml:lang="en-US">Elion License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:to="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_lbl" xml:lang="en-US">Business Activities and Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ImpactOfCovidNineteenPolicyTextBlock" xlink:label="PCSA_ImpactOfCovidNineteenPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ImpactOfCovidNineteenPolicyTextBlock" xlink:to="PCSA_ImpactOfCovidNineteenPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ImpactOfCovidNineteenPolicyTextBlock_lbl" xml:lang="en-US">Impact of COVID-19</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LiquidityPolicyTextBlock" xlink:label="PCSA_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LiquidityPolicyTextBlock" xlink:to="PCSA_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Summary of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Information About RSU Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Loss Per Share Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities for all Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non cash expenditures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:label="PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:to="PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering_lbl" xml:lang="en-US">Maximum number of shares to be sold at the market offering</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:label="PCSA_MaximumCommitmenttoPurchaseCommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:to="PCSA_MaximumCommitmenttoPurchaseCommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MaximumCommitmenttoPurchaseCommonStockValue_lbl" xml:lang="en-US">Commitment to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total intangible assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Future amortization expenses, annual periods thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_2_lbl" xml:lang="en-US">Number of common stock issued on commitment fees, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" xlink:label="PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" xlink:to="PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee_lbl" xml:lang="en-US">Number of common stock issued on commitment fees, value</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ReimbursementFees" xlink:label="PCSA_ReimbursementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ReimbursementFees" xlink:to="PCSA_ReimbursementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ReimbursementFees_lbl" xml:lang="en-US">Reimbursement fee</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NumberOfCommonStockSharesinRegularPurchase" xlink:label="PCSA_NumberOfCommonStockSharesinRegularPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NumberOfCommonStockSharesinRegularPurchase" xlink:to="PCSA_NumberOfCommonStockSharesinRegularPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NumberOfCommonStockSharesinRegularPurchase_lbl" xml:lang="en-US">Number of common stock shares in regular purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NumberOfCommonStockSharesExceedingRegularPurchase" xlink:label="PCSA_NumberOfCommonStockSharesExceedingRegularPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NumberOfCommonStockSharesExceedingRegularPurchase" xlink:to="PCSA_NumberOfCommonStockSharesExceedingRegularPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NumberOfCommonStockSharesExceedingRegularPurchase_lbl" xml:lang="en-US">Number of common stock shares exceeding regular purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DailyMaximumCommittedPurchaseObligationsValue" xlink:label="PCSA_DailyMaximumCommittedPurchaseObligationsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DailyMaximumCommittedPurchaseObligationsValue" xlink:to="PCSA_DailyMaximumCommittedPurchaseObligationsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DailyMaximumCommittedPurchaseObligationsValue_lbl" xml:lang="en-US">Daily maximum committed purchase obligations, value</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumNumberOfSharesSoldInTransaction" xlink:label="PCSA_MaximumNumberOfSharesSoldInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumNumberOfSharesSoldInTransaction" xlink:to="PCSA_MaximumNumberOfSharesSoldInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MaximumNumberOfSharesSoldInTransaction_lbl" xml:lang="en-US">Maximum number of shares issued sold</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PercentageOfExchangeCapitalization" xlink:label="PCSA_PercentageOfExchangeCapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PercentageOfExchangeCapitalization" xlink:to="PCSA_PercentageOfExchangeCapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PercentageOfExchangeCapitalization_lbl" xml:lang="en-US">Nasdaq's exchange cap percent</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_BeneficialOwnershipLimitationPercentage" xlink:label="PCSA_BeneficialOwnershipLimitationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BeneficialOwnershipLimitationPercentage" xlink:to="PCSA_BeneficialOwnershipLimitationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_BeneficialOwnershipLimitationPercentage_lbl" xml:lang="en-US">Beneficial ownership limitation percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xml:lang="en-US">Number of repurchase of common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xml:lang="en-US">Repurchase of common stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xml:lang="en-US">Number of shares, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, awarded</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, awarded</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xml:lang="en-US">Number of shares, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xml:lang="en-US">Number of shares, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_lbl" xml:lang="en-US">Number of shares, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Maximum equity available for issuance under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares available for future grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Stock option cancelled or forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding options for the purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of stock option outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Stock options outstanding, weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of option exercisable during period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of options exercisable, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Stock options exercisable, weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized stock option expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Common stock available for future issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of unvested restricted stock award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AccruedDirectorsFees" xlink:label="PCSA_AccruedDirectorsFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccruedDirectorsFees" xlink:to="PCSA_AccruedDirectorsFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AccruedDirectorsFees_lbl" xml:lang="en-US">Directors' fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Restricted stock units forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of restricted stock expected to vest, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average period, restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xml:lang="en-US">Unrecognized restricted stock expense</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MinimumPricePerShareOfEquityCompensation" xlink:label="PCSA_MinimumPricePerShareOfEquityCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MinimumPricePerShareOfEquityCompensation" xlink:to="PCSA_MinimumPricePerShareOfEquityCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MinimumPricePerShareOfEquityCompensation_lbl" xml:lang="en-US">Minimum price per share of equity compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Restricted stock fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Fair value amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Warrant cancelled or forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of common shares-basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate for our facility and equipment leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureOperatingLeasesAbstract" xlink:to="PCSA_DisclosureOperatingLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_DisclosureOperatingLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Maturities Of Lease Liabilities For All Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xml:lang="en-US">Operating lease borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:to="PCSA_ProceedsFromRentAndOtherCostsReimbursements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements_lbl" xml:lang="en-US">Rent and other costs reimbursements received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ExpenseAndRelatedLiability" xlink:label="PCSA_ExpenseAndRelatedLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ExpenseAndRelatedLiability" xlink:to="PCSA_ExpenseAndRelatedLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ExpenseAndRelatedLiability_lbl" xml:lang="en-US">Expense and related liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Purchase obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueFromTaxAgencies" xlink:to="PCSA_DueFromTaxAgencies_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DueFromTaxAgencies_doc" xml:lang="en-US">Due from tax agencies.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueToLicensor" xlink:to="PCSA_DueToLicensor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DueToLicensor_doc" xml:lang="en-US">Due to licensor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" xlink:to="PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest_doc" xml:lang="en-US">Forgiveness of payroll protection program loan and related accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue_doc" xml:lang="en-US">Shares issued in connection with purchase agreement value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:to="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares_doc" xml:lang="en-US">Shares issued in connection with purchase agreement shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement" xlink:to="PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement_doc" xml:lang="en-US">Non cash milestone expense in connection with license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment" xlink:to="PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment_doc" xml:lang="en-US">Non cash acquisition of in process research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" xlink:to="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest_doc" xml:lang="en-US">Forgiveness of paycheck protection program loan and related accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LincolnParkCapitalFundLLCMember" xlink:to="PCSA_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Lincoln Park Capital Fund LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operating Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:to="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_doc" xml:lang="en-US">Business Activities And Organization [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ImpactOfCovidNineteenPolicyTextBlock" xlink:to="PCSA_ImpactOfCovidNineteenPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ImpactOfCovidNineteenPolicyTextBlock_doc" xml:lang="en-US">Impact Of Covid Nineteen [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LiquidityPolicyTextBlock" xlink:to="PCSA_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:to="PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering_doc" xml:lang="en-US">Maximum number of shares to be sold at the market offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EquityDistributionAgreementMember" xlink:to="PCSA_EquityDistributionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_EquityDistributionAgreementMember_doc" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:to="PCSA_MaximumCommitmenttoPurchaseCommonStockValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_MaximumCommitmenttoPurchaseCommonStockValue_doc" xml:lang="en-US">Maximum amount committed to purchase.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_StockIssuedDuringPeriodSharesNewIssuedInCommitmentFee" xlink:label="PCSA_StockIssuedDuringPeriodSharesNewIssuedInCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesNewIssuedInCommitmentFee" xlink:to="PCSA_StockIssuedDuringPeriodSharesNewIssuedInCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedDuringPeriodSharesNewIssuedInCommitmentFee_doc" xml:lang="en-US">Stock issued during period shares new issued in commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" xlink:to="PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee_doc" xml:lang="en-US">Stock issued during period values new issue on commitment fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ReimbursementFees" xlink:to="PCSA_ReimbursementFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ReimbursementFees_doc" xml:lang="en-US">Reimbursement fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NumberOfCommonStockSharesinRegularPurchase" xlink:to="PCSA_NumberOfCommonStockSharesinRegularPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NumberOfCommonStockSharesinRegularPurchase_doc" xml:lang="en-US">Number of common stock shares in regular purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NumberOfCommonStockSharesExceedingRegularPurchase" xlink:to="PCSA_NumberOfCommonStockSharesExceedingRegularPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NumberOfCommonStockSharesExceedingRegularPurchase_doc" xml:lang="en-US">Number of common stock shares exceeding a regular purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DailyMaximumCommittedPurchaseObligationsValue" xlink:to="PCSA_DailyMaximumCommittedPurchaseObligationsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DailyMaximumCommittedPurchaseObligationsValue_doc" xml:lang="en-US">Daily maximum committed purchase obligations, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumNumberOfSharesSoldInTransaction" xlink:to="PCSA_MaximumNumberOfSharesSoldInTransaction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_MaximumNumberOfSharesSoldInTransaction_doc" xml:lang="en-US">Maximum number of shares sold in transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PercentageOfExchangeCapitalization" xlink:to="PCSA_PercentageOfExchangeCapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PercentageOfExchangeCapitalization_doc" xml:lang="en-US">Percentage of exchange capitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BeneficialOwnershipLimitationPercentage" xlink:to="PCSA_BeneficialOwnershipLimitationPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_BeneficialOwnershipLimitationPercentage_doc" xml:lang="en-US">Beneficial ownership limitation percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AposenseLtdMember" xlink:to="PCSA_AposenseLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AposenseLtdMember_doc" xml:lang="en-US">Aposense, Ltd. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_doc" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailable" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailable" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailable_doc" xml:lang="en-US">Number of common shares available for future grants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DirectorsMember" xlink:to="PCSA_DirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DirectorsMember_doc" xml:lang="en-US">Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AccruedDirectorsFees" xlink:to="PCSA_AccruedDirectorsFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AccruedDirectorsFees_doc" xml:lang="en-US">Accrued directors' fees.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_doc" xml:lang="en-US">ShareBased compensation arrangement by sharebased payment award other than options expected to vest outstanding number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandTwentyTwoMember" xlink:to="PCSA_TwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandTwentyTwoMember_doc" xml:lang="en-US">2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandTwentyThreeMember" xlink:to="PCSA_TwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandTwentyThreeMember_doc" xml:lang="en-US">2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options unvested weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xml:lang="en-US">Unrecognized share based compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term1.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FacilityLeaseMember_doc" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EquipmentLeaseMember" xlink:to="PCSA_EquipmentLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_EquipmentLeaseMember_doc" xml:lang="en-US">Equipment Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:to="PCSA_ProceedsFromRentAndOtherCostsReimbursements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements_doc" xml:lang="en-US">Rent and other costs reimbursements received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CorLystLLCMember_doc" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_doc" xml:lang="en-US">ShareBased compensation arrangement by sharebased payment award other than options expected to vest outstanding number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MinimumPricePerShareOfEquityCompensation" xlink:to="PCSA_MinimumPricePerShareOfEquityCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_MinimumPricePerShareOfEquityCompensation_doc" xml:lang="en-US">Minimum price per share of equity compensation.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_RestrictedStockAwardsValueExpectedToBeRecognized" xlink:label="PCSA_RestrictedStockAwardsValueExpectedToBeRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RestrictedStockAwardsValueExpectedToBeRecognized" xlink:to="PCSA_RestrictedStockAwardsValueExpectedToBeRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_RestrictedStockAwardsValueExpectedToBeRecognized_doc" xml:lang="en-US">Restricted stock awards value expected to be recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OriginalMember" xlink:to="PCSA_OriginalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OriginalMember_doc" xml:lang="en-US">Original [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award other than options nonvested awards total compensation cost not yet recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember" xlink:to="PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember_doc" xml:lang="en-US">April 1, 2022 Grant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BaseCompensationMember" xlink:to="PCSA_BaseCompensationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_BaseCompensationMember_doc" xml:lang="en-US">Base Compensation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ElionLicenseAgreementDisclosureTextBlock" xlink:to="PCSA_ElionLicenseAgreementDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ElionLicenseAgreementDisclosureTextBlock_doc" xml:lang="en-US">Elion License Agreement Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementMember" xlink:to="PCSA_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ExpenseAndRelatedLiability" xlink:to="PCSA_ExpenseAndRelatedLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ExpenseAndRelatedLiability_doc" xml:lang="en-US">Expense and related liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AgreementsMember" xlink:to="PCSA_AgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AgreementsMember_doc" xml:lang="en-US">Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ContractResearchOrganizationsMember" xlink:to="PCSA_ContractResearchOrganizationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ContractResearchOrganizationsMember_doc" xml:lang="en-US">Contract Research Organizations [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" xlink:to="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest_3_lbl" xml:lang="en-US">ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ElionLicenseAgreementDisclosureTextBlock" xlink:to="PCSA_ElionLicenseAgreementDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ElionLicenseAgreementDisclosureTextBlock_3_lbl" xml:lang="en-US">ElionLicenseAgreementDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pcsa-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20220630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20220630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20220630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="pcsa-20220630.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20220630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20220630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssets" xlink:href="pcsa-20220630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20220630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20220630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeases" xlink:href="pcsa-20220630.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20220630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ElionLicenseAgreement" xlink:href="pcsa-20220630.xsd#ElionLicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20220630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssetsTables" xlink:href="pcsa-20220630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20220630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:href="pcsa-20220630.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20220630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails" xlink:href="pcsa-20220630.xsd#SummaryOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative" xlink:href="pcsa-20220630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20220630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfInformationAboutRsuOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20220630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20220630.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20220630.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:href="pcsa-20220630.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20220630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative" xlink:href="pcsa-20220630.xsd#ElionLicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20220630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DueFromTaxAgencies" xlink:label="loc_PCSADueFromTaxAgencies" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_PCSADueFromTaxAgencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="loc_us-gaapOtherAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DueToLicensor" xlink:label="loc_PCSADueToLicensor" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSADueToLicensor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaapResearchAndDevelopmentInProcess" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" xlink:label="loc_PCSAForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_PCSAForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement" xlink:label="loc_PCSANoncashMilestoneExpenseInConnectionWithLicenseAgreement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PCSANoncashMilestoneExpenseInConnectionWithLicenseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment" xlink:label="loc_PCSANonCashAcquisitionOfInprocessResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PCSANonCashAcquisitionOfInprocessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" xlink:label="loc_PCSAForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PCSAForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="loc_us-gaapProceedsFromRepurchaseOfEquity" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepurchaseOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Organization and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssets" xlink:title="00000009 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="00000011 - Disclosure - Stock-based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="00000012 - Disclosure - Net Loss per Share of Common Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeases" xlink:title="00000013 - Disclosure - Operating Leases">
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ElionLicenseAgreement" xlink:title="00000015 - Disclosure - Elion License Agreement">
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureElionLicenseAgreementAbstract" xlink:label="loc_PCSADisclosureElionLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ElionLicenseAgreementDisclosureTextBlock" xlink:label="loc_PCSAElionLicenseAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureElionLicenseAgreementAbstract" xlink:to="loc_PCSAElionLicenseAgreementDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:label="loc_PCSABusinessActivitiesAndOrganizationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSABusinessActivitiesAndOrganizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ImpactOfCovidNineteenPolicyTextBlock" xlink:label="loc_PCSAImpactOfCovidNineteenPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSAImpactOfCovidNineteenPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LiquidityPolicyTextBlock" xlink:label="loc_PCSALiquidityPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSALiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssetsTables" xlink:title="00000018 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="00000019 - Disclosure - Stock-based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="00000020 - Disclosure - Net Loss per Share of Common Stock (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesTables" xlink:title="00000021 - Disclosure - Operating Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:label="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_EquityDistributionAgreementMember" xlink:label="loc_PCSAEquityDistributionAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAEquityDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:label="loc_PCSAMaximumNumberOfSharesToBeSoldAtMarketOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PCSAMaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:label="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails" xlink:title="00000023 - Disclosure - Summary of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000024 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000025 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_EquityDistributionAgreementMember" xlink:label="loc_PCSAEquityDistributionAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAEquityDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LincolnParkCapitalFundLLCMember" xlink:label="loc_PCSALincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSALincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AposenseLtdMember" xlink:label="loc_PCSAAposenseLtdMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAAposenseLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:label="loc_PCSAMaximumNumberOfSharesToBeSoldAtMarketOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAMaximumNumberOfSharesToBeSoldAtMarketOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumCommitmenttoPurchaseCommonStockValue" xlink:label="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAMaximumCommitmenttoPurchaseCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares" xlink:label="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedInConnectionWithPurchaseAgreementShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee" xlink:label="loc_PCSAStockIssuedDuringPeriodValueNewIssuedInCommitmentFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodValueNewIssuedInCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ReimbursementFees" xlink:label="loc_PCSAReimbursementFees" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAReimbursementFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NumberOfCommonStockSharesinRegularPurchase" xlink:label="loc_PCSANumberOfCommonStockSharesinRegularPurchase" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSANumberOfCommonStockSharesinRegularPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_NumberOfCommonStockSharesExceedingRegularPurchase" xlink:label="loc_PCSANumberOfCommonStockSharesExceedingRegularPurchase" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSANumberOfCommonStockSharesExceedingRegularPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DailyMaximumCommittedPurchaseObligationsValue" xlink:label="loc_PCSADailyMaximumCommittedPurchaseObligationsValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSADailyMaximumCommittedPurchaseObligationsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MaximumNumberOfSharesSoldInTransaction" xlink:label="loc_PCSAMaximumNumberOfSharesSoldInTransaction" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAMaximumNumberOfSharesSoldInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_PercentageOfExchangeCapitalization" xlink:label="loc_PCSAPercentageOfExchangeCapitalization" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAPercentageOfExchangeCapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_BeneficialOwnershipLimitationPercentage" xlink:label="loc_PCSABeneficialOwnershipLimitationPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSABeneficialOwnershipLimitationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000026 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails" xlink:title="00000027 - Disclosure - Schedule of Information About RSU Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000028 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_OriginalMember" xlink:label="loc_PCSAOriginalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAOriginalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DirectorsMember" xlink:label="loc_PCSADirectorsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSADirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ConsultantMember" xlink:label="loc_PCSAConsultantMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandTwentyTwoMember" xlink:label="loc_PCSATwoThousandTwentyTwoMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSATwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_TwoThousandTwentyThreeMember" xlink:label="loc_PCSATwoThousandTwentyThreeMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSATwoThousandTwentyThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_BaseCompensationMember" xlink:label="loc_PCSABaseCompensationMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSABaseCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember" xlink:label="loc_PCSAAprilOneTwoThousandTwentyTwo2022GrantMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_PCSAAprilOneTwoThousandTwentyTwo2022GrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AccruedDirectorsFees" xlink:label="loc_PCSAAccruedDirectorsFees" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAAccruedDirectorsFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_MinimumPricePerShareOfEquityCompensation" xlink:label="loc_PCSAMinimumPricePerShareOfEquityCompensation" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAMinimumPricePerShareOfEquityCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="00000029 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="00000030 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails" xlink:title="00000031 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_PCSAFacilityLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_EquipmentLeaseMember" xlink:label="loc_PCSAEquipmentLeaseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_PCSAEquipmentLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="00000032 - Disclosure - Schedule of Maturities of Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000033 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureOperatingLeasesAbstract" xlink:label="loc_PCSADisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000034 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSACorLystLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="loc_PCSAProceedsFromRentAndOtherCostsReimbursements" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAProceedsFromRentAndOtherCostsReimbursements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative" xlink:title="00000035 - Disclosure - Elion License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_DisclosureElionLicenseAgreementAbstract" xlink:label="loc_PCSADisclosureElionLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureElionLicenseAgreementAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_LicenseAgreementMember" xlink:label="loc_PCSALicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSALicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ExpenseAndRelatedLiability" xlink:label="loc_PCSAExpenseAndRelatedLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PCSAExpenseAndRelatedLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_AgreementsMember" xlink:label="loc_PCSAAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20220630.xsd#PCSA_ContractResearchOrganizationsMember" xlink:label="loc_PCSAContractResearchOrganizationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSAContractResearchOrganizationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258491936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Processa
Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1539785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7380
Coca Cola Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hanover<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">776-3133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCSA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,856,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038255549616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,064,142<span></span>
</td>
<td class="nump">$ 16,497,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_DueFromTaxAgencies', window );">Due from tax agencies</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">70,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,896,633<span></span>
</td>
<td class="nump">1,759,296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">13,960,775<span></span>
</td>
<td class="nump">18,327,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net of accumulated amortization</a></td>
<td class="nump">28,890<span></span>
</td>
<td class="nump">74,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">7,662,390<span></span>
</td>
<td class="nump">8,056,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">5,535<span></span>
</td>
<td class="nump">5,535<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total Other Assets</a></td>
<td class="nump">7,696,815<span></span>
</td>
<td class="nump">8,136,354<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">21,657,590<span></span>
</td>
<td class="nump">26,463,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liability</a></td>
<td class="nump">26,552<span></span>
</td>
<td class="nump">71,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">648,104<span></span>
</td>
<td class="nump">218,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_DueToLicensor', window );">Due to licensor</a></td>
<td class="nump">589,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">307,412<span></span>
</td>
<td class="nump">279,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,571,068<span></span>
</td>
<td class="nump">971,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">4,655<span></span>
</td>
<td class="nump">7,385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,575,723<span></span>
</td>
<td class="nump">978,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001, 50,000,000 shares authorized: 15,919,317 issued and 15,819,317 outstanding at June 30, 2022, and 15,710,246 issued and outstanding at December 31, 2021</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">65,595,106<span></span>
</td>
<td class="nump">62,306,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost &#8212; 100,000 shares at June 30, 2022</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(45,214,831)<span></span>
</td>
<td class="num">(36,823,332)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">20,081,867<span></span>
</td>
<td class="nump">25,485,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 21,657,590<span></span>
</td>
<td class="nump">$ 26,463,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DueFromTaxAgencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due from tax agencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DueFromTaxAgencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DueToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due to licensor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DueToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258431360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">15,919,317<span></span>
</td>
<td class="nump">15,710,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">15,819,317<span></span>
</td>
<td class="nump">15,710,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258192240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 3,137,292<span></span>
</td>
<td class="nump">$ 1,614,954<span></span>
</td>
<td class="nump">$ 5,181,912<span></span>
</td>
<td class="nump">$ 3,086,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquisition of in-process research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">515,630<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">515,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,034,456<span></span>
</td>
<td class="nump">1,329,213<span></span>
</td>
<td class="nump">3,218,550<span></span>
</td>
<td class="nump">2,051,073<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(5,171,748)<span></span>
</td>
<td class="num">(3,459,797)<span></span>
</td>
<td class="num">(8,400,462)<span></span>
</td>
<td class="num">(5,653,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest', window );">Forgiveness of PPP loan and related accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">163,771<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">163,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7,380<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
<td class="nump">8,963<span></span>
</td>
<td class="nump">6,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Operating Loss Before Income Tax Benefit</a></td>
<td class="num">(5,164,368)<span></span>
</td>
<td class="num">(3,294,212)<span></span>
</td>
<td class="num">(8,391,499)<span></span>
</td>
<td class="num">(5,482,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">137,169<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">226,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (5,164,368)<span></span>
</td>
<td class="num">$ (3,157,043)<span></span>
</td>
<td class="num">$ (8,391,499)<span></span>
</td>
<td class="num">$ (5,256,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per Common Share - Basic and Diluted</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted</a></td>
<td class="nump">15,940,510<span></span>
</td>
<td class="nump">15,406,363<span></span>
</td>
<td class="nump">15,886,116<span></span>
</td>
<td class="nump">14,997,303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of payroll protection program loan and related accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038260332672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="nump">$ 48,333,857<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (25,395,798)<span></span>
</td>
<td class="nump">$ 22,939,478<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">14,187,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">620,590<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">620,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in private placement, net of transaction costs</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">9,875,418<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,875,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in private placement, net of transaction costs, shares</a></td>
<td class="nump">1,321,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,099,480)<span></span>
</td>
<td class="num">(2,099,480)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 1,552<span></span>
</td>
<td class="nump">58,829,865<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(27,495,278)<span></span>
</td>
<td class="nump">31,336,139<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="nump">15,521,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="nump">48,333,857<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,395,798)<span></span>
</td>
<td class="nump">22,939,478<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">14,187,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,256,523)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="nump">59,892,453<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(30,652,321)<span></span>
</td>
<td class="nump">29,241,692<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="nump">15,604,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 1,552<span></span>
</td>
<td class="nump">58,829,865<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(27,495,278)<span></span>
</td>
<td class="nump">31,336,139<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="nump">15,521,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">762,592<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">762,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">38,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,157,043)<span></span>
</td>
<td class="num">(3,157,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with license agreement</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">299,996<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in connection with license agreement, shares</a></td>
<td class="nump">44,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="nump">59,892,453<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(30,652,321)<span></span>
</td>
<td class="nump">29,241,692<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="nump">15,604,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="nump">62,306,861<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,823,332)<span></span>
</td>
<td class="nump">25,485,100<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">15,710,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">828,887<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">828,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">103,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,227,131)<span></span>
</td>
<td class="num">(3,227,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Acquisition of treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Acquisition of treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue', window );">Shares issued in connection with the Purchase Agreement with Lincoln Park</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">449,988<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares', window );">Shares issued in connection with the Purchase Agreement with Lincoln Park, shares</a></td>
<td class="nump">123,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 1,593<span></span>
</td>
<td class="nump">63,585,736<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(40,050,463)<span></span>
</td>
<td class="nump">23,236,866<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="nump">15,937,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="nump">62,306,861<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,823,332)<span></span>
</td>
<td class="nump">25,485,100<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">15,710,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,391,499)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">65,595,106<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(45,214,831)<span></span>
</td>
<td class="nump">20,081,867<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">15,919,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 1,593<span></span>
</td>
<td class="nump">63,585,736<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(40,050,463)<span></span>
</td>
<td class="nump">23,236,866<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="nump">15,937,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">2,009,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,009,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="num">(18,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,164,368)<span></span>
</td>
<td class="num">(5,164,368)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 65,595,106<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">$ (45,214,831)<span></span>
</td>
<td class="nump">$ 20,081,867<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">15,919,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued in connection with purchase agreement shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued in connection with purchase agreement value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038255336272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,391,499)<span></span>
</td>
<td class="num">$ (5,256,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense for right-of-use assets</a></td>
<td class="nump">45,291<span></span>
</td>
<td class="nump">41,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement', window );">Non-cash milestone expense in connection with license agreement</a></td>
<td class="nump">189,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment', window );">Non-cash acquisition of in-process research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of issuance costs</a></td>
<td class="nump">40,613<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible asset</a></td>
<td class="nump">394,248<span></span>
</td>
<td class="nump">397,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(226,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,838,266<span></span>
</td>
<td class="nump">1,173,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest', window );">Forgiveness of PPP loan and related accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(163,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">272,050<span></span>
</td>
<td class="num">(876,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(47,256)<span></span>
</td>
<td class="num">(42,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">429,199<span></span>
</td>
<td class="num">(32,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due (from) to related parties</a></td>
<td class="num">(1,772)<span></span>
</td>
<td class="nump">96,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">70,274<span></span>
</td>
<td class="nump">6,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">28,147<span></span>
</td>
<td class="nump">144,434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,133,439)<span></span>
</td>
<td class="num">(4,437,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,875,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfEquity', window );">Acquisition of treasury stock</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(23,085)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="nump">9,852,465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash</a></td>
<td class="num">(4,433,439)<span></span>
</td>
<td class="nump">5,414,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents &#8211; Beginning of Period</a></td>
<td class="nump">16,497,581<span></span>
</td>
<td class="nump">15,416,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents &#8211; End of Period</a></td>
<td class="nump">12,064,142<span></span>
</td>
<td class="nump">20,831,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of 123,609 shares of common stock in connection with the Purchase Agreement with Lincoln Park</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of paycheck protection program loan and related accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash acquisition of in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash milestone expense in connection with license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow resulting from the entity's share transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261877504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock shares</a></td>
<td class="nump">123,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261693760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zXzowtam2pMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82B_zmamq9bf2mG8">Organization and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zMWUacrsjTU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_864_zCJHWuIXcEg4">Business
Activities and Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for
patients who have a high unmet medical need condition that affects survival or the patient&#8217;s quality of life and for which few
or no treatment options currently exist. We currently have five drugs: four in various stages of clinical development (PCS499, PCS12852,
PCS6422 and PCS3117) and one in nonclinical development (PCS11T). We group our drugs into non-oncology (PCS499 and PCS12852) and oncology
(PCS3117, PCS6422 and PCS11T). A summary of each drug is provided below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    most advanced product candidate, PCS499, is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline
    (PTX or Trental&#174;). We completed a Phase 2A trial for PCS499 in patients with ulcerative and non-ulcerative necrobiosis lipoidica
    (NL) in late 2020, and in May 2021 we enrolled the first patient in our Phase 2B trial for the treatment of ulcerative NL. We expect
    to complete our interim analysis and complete enrollment of the Phase 2B trial during the first half of 2023; and, depending on the
    results, begin a pivotal Phase 3 trial in 2023. We have experienced delays in the enrollment of patients for this trial due in part
    to COVID-19 and the rare nature of this disease. We have initiated a number of recruitment programs to increase the enrollment of
    patients in this study and continue to evaluate additional options to meet our enrollment goals.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
    is a highly specific and potent 5HT4 agonist which has already been evaluated in clinical studies in South Korea for gastric emptying
    and gastrointestinal motility. In October 2021, the FDA cleared our IND application to proceed with a Phase 2A trial for the treatment
    of gastroparesis. We enrolled our first patient on April 5, 2022, anticipate completing enrollment in the second half of 2022 with
    top-line results by the end of 2022, and should complete our final analysis in the first half of 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS6422
    is an orally administered irreversible enzyme inhibitor administered in combination with capecitabine. When combining capecitabine
    with PCS6422 (the &#8220;Next Generation Capecitabine&#8221;), capecitabine becomes a more potent cancer chemotherapy agent than
    current FDA approved capecitabine. On August 2, 2021, we enrolled the first patient in our Phase 1B dose-escalation maximum tolerated
    dose trial in patients with advanced refractory gastrointestinal (GI) tract tumors. Our interim analysis of Cohorts 1 and 2 found
    no dose-limiting toxicities (DLTs), no drug related adverse events greater than Grade 1, and no hand-foot syndrome. In addition,
    the interim analysis revealed when PCS6422 inhibits the DPD enzyme, 5-FU metabolism can be significantly decreased (&lt;10% metabolized
    to F-Bal compared to typically 80%) and the potency of capecitabine significantly increased compared to the present regimens of capecitabine
    (at least 50 times greater 5-FU potency based on systemic exposure per mg of capecitabine administered). The single dose of PCS6422,
    however, did not sustain the DPD inhibition throughout 7 days of capecitabine dosing which was needed to maintain the improved potency
    of capecitabine. Therefore, in an effort to define 6422 regimens that will maintain DPD inhibition throughout capecitabine dosing,
    we modified the protocol for the Phase 1B trial to not only determine the MTD of capecitabine, but to also further evaluate the timeline
    of DPD inhibition and de novo formation. We began enrolling patients in the amended Phase 1B trial in April 2022 and expect to complete
    enrollment while defining the Next Generation Capecitabine regimen (i.e., the PCS6422 regimens and the corresponding capecitabine
    regimens) by the end of 2022. We expect that our overall timeline has not changed with a Phase 2B or 3 trial starting in 2023-2024
    and NDA submission in 2027-2028.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117
    is a cytosine analog that is similar to gemcitabine (Gemzar&#174;), but different enough in chemical structure that some patients
    are more likely to respond to PCS3117 than gemcitabine. We continue to evaluate the potential use of PCS3117 in patients with pancreatic
    cancer and to evaluate ways to identify patients who are more likely to respond to PCS3117 than gemcitabine. We anticipate initiating
    a Phase 2B trial or adaptive designed Phase 3 trial in 2023 subject to meeting with FDA and obtaining additional funding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    only nonclinical drug candidate is PCS11T, an analog of SN38 (SN38 being the active metabolite of irinotecan) and a next generation
    irinotecan drug for multiple types of cancers. The manufacturing process and sites for drug substance and drug product are presently
    being evaluated. In addition, we are defining the potential paths to approval, which include defining the targeted patient population
    and the type of cancer. We hope to submit an IND in the first half of 2024, followed by a Phase 1B maximum tolerated dose trial.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--ImpactOfCovidNineteenPolicyTextBlock_zcdJIDH53Fod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_868_zaFIwlDyvJTk">Impact
of COVID-19</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
COVID-19 pandemic continues to create uncertainties in expected timelines by causing delays in clinical trials and disruptions in
the supply chain for raw materials used in clinical trial work.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced delays in the enrollment of patients in our PCS499 Phase 2B trial due to COVID-19. Some potential patients have
died from COVID-19 prior to screening and others continue to be reluctant to travel to our testing sites for fear of contracting
COVID-19. Delays in enrollment lengthen the time of studies and increase their costs, which <span style="background-color: white">could
materially impact our business in future periods. Furthermore, the spread of COVID-19, which has caused a broad impact globally, may
materially affect us economically. </span>While we are hopeful the infection rate of COVID-19 will continue to decline, we cannot
predict the future impact COVID-19 will have on our current and future clinical trials. Continued delays could materially impact our business in future periods
and further extend our timelines. <span style="background-color: white">For
more information on the risks associated with COVID-19, refer to Part I, Item 1A, &#8220;Risk Factors&#8221; included in our Annual
Report on Form 10-K for the year ended December 31, 2021.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZnbC26CFdXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_zMWxLCSR8en8">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2021, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--LiquidityPolicyTextBlock_zHWpnKAKdawk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zMTOusaVyIpi">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception, devoting substantially all of our efforts toward moving the drugs in our pipeline through the
regulatory process and other research and development activities, and have an accumulated deficit of approximately $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220630_zVhIVPBP50Y1" title="Accumulated deficit">45.2</span>
million as of June 30, 2022. During the six months ended June 30, 2022, we generated a net loss of approximately $<span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220630_zaSsid8WhRua" title="Net loss">8.4</span>
million, of which $<span id="xdx_90E_eus-gaap--OtherNoncashExpense_pn5n6_c20220101__20220630_zsxPy5JPfXhf" title="Non cash expenditures">3.5</span>
million represented non-cash expenditures. Net cash used in our operating activities during the six months ended June 30, 2022 was
approximately $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220630_zClKBTC41KGl" title="Net cash used in operating activities">4.1</span>
million. We expect to continue to generate operating losses and negative cash flow from operations for the foreseeable future. Based on our
current plans, we believe our current cash balances are adequate for at least the next twelve months without considering amounts
available from the Purchase Agreement with Lincoln Park (see below and Note 3) or potential sales under our ATM Offering (see
below). Our ability to execute our longer-term operating plans, including unplanned future clinical trials for our portfolio of
drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or
other funding transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we
will obtain the necessary funding in the future when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had <span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20220101__20220630_zDJabtiVwReg" title="Revenue">no</span> revenue during the six months ended June 30, 2022 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and operating expenses. Cash
used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2021, we entered into an equity distribution agreement (the &#8220;Sales Agreement&#8221;) with Oppenheimer &amp; Co. Inc.
under which we may issue and sell in a registered &#8220;at-the-market&#8221; offering shares of our common stock having an aggregate
offering price of up to $<span id="xdx_900_ecustom--MaximumNumberOfSharesToBeSoldAtMarketOffering_pn6n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3z7EJdaZN94" title="Maximum number of shares to be sold at the market offering">30.0</span> million from time to time through or to our Sales Agent (the &#8220;ATM Offering&#8221;). We expect to
use net proceeds from the ATM Offering over time as a source for working capital and general corporate purposes. The shares under the
ATM Offering will be sold and issued pursuant to our S-3 shelf registration statement (Registration No. 333-257588) filed on July 30,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2022, we entered into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;) under which we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase
up to $<span id="xdx_900_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zzjDFAExIyvl" title="Commitment to purchase common stock">15,000,000</span> of our shares of common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Common stock, par value">0.0001</span> per share, subject to the terms and conditions in the Purchase Agreement,
during the term of the Purchase Agreement. See Note 3 for additional details concerning the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--UseOfEstimates_zRBk2jRRQwn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zeTPnvxMEa34">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and
regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements
and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zwEDbNApiuN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zjzbQWC9g9Nk">Income
Taxes</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of June 30, 2022 and December 31, 2021, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets related to deferred start-up costs, federal orphan drug tax credit and certain other minor temporary differences
since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained
until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, we recognized the
tax benefit from our projected ordinary tax loss, which was used to offset the deferred tax liabilities related to the intangible asset
and resulted in the recognition of a deferred tax benefit shown in the condensed consolidated statements of operations for six months
ended June 30, 2021 and the remainder of 2021. No current income tax benefit or expense was recorded or is expected for 2022 or in the
foreseeable future since the deferred tax liability has been offset completely as of December 31, 2021 and we expect to generate future
taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zaQecVRfIK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_865_zlU3Z9kcO4Dh">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2022 exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSuMBt3ZNdFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zcDX0pnUpr0b">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>

<p id="xdx_852_zhpGSOtIXb14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038264116736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zkhVwNUtVMFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82B_zVNYBLTGuTG9">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zaSHc5ft7Xul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets at June 30, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zIoYM0uGKiV7" style="display: none">Summary of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20220630_z54gRZ5GHxp1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20211231_zcVpqQnWfmF1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANz27j_zDn42NPjVvD2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross intangible assets</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,059,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,059,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANz27j_z4tugYEL164e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated amortization</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,397,039</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,002,791</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANz27j_zx3xyiJkeKNd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total intangible assets,
    net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,662,390</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,056,638</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zmsgYKTj69Pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
intangible assets consist primarily of costs we capitalized when we acquired the license rights to PCS499 in 2018. Amortization expense
was $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20220630_pp0p0" title="Amortization expense">394,248</span> and $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20210630_zSbiHnFLgeCc" title="Amortization expense">397,664</span> for the six months ended June 30, 2022 and 2021, respectively, and is included within research and development
expense in the accompanying condensed consolidated statements of operations. As of June 30, 2022, our estimated amortization expense
for the year ended December 31, 2022 and for annual periods thereafter until the asset is fully amortized is approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20220630_zVlHmcVNjhId" title="Future amortization expenses, annual periods thereafter">788,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038264063120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWgnKNqUNlNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82E_zhg7TJuti5Yd">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20220630_zOU1wwkaD26f" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220630_zvFjlcwrOUOd" title="Preferred stock, shares outstanding"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_zkQu1uKEC4lf" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zMrPgrgSQMod" title="Preferred stock, shares outstanding">no</span></span></span></span> issued or outstanding shares of preferred stock at either June 30, 2022 or December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Increase
in Our Authorized Number of Shares</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2022, we amended our Certificate of Incorporation to increase the number of authorized shares of our common stock from <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_z0g57LEKZpYe" title="Common stock, shares authorized">30,000,000</span>
to <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20220101_zMMgI2LTe1dg" title="Common stock, shares authorized">50,000,000</span>. We believe <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20220630_zdi5m4HUqIf6" title="Common stock, shares authorized">50,000,000</span> authorized shares of common stock better aligns our capital structure with our future needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">ATM
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2021, we entered into the Sales Agreement with the Sales Agent under which we may issue and sell up to $<span id="xdx_901_ecustom--MaximumNumberOfSharesToBeSoldAtMarketOffering_pn6n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zCMm2Sn0mWKj" title="Maximum number of shares to be sold at the market offering">30.0</span>
million of our common stock from time to time under the ATM Offering. We expect to use net proceeds from the ATM Offering over time
as a source for working capital and general corporate purposes. We did not sell any shares during the six months ended June 30,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Lincoln
Park Capital Fund, LLC Purchase Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 23, 2022, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up
to $<span id="xdx_90B_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_pn6n6_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zPNxcNoCPIV5" title="Commitment to purchase common stock">15.0</span> million of shares (the &#8220;Purchase Shares&#8221;) of our common stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUJv2yld8u8h" title="Common stock par value">0.0001</span> par value per share, subject to the terms
and conditions in the Purchase Agreement. We issued <span id="xdx_905_ecustom--SharesIssuedInConnectionWithPurchaseAgreementShares_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgpmkgcm7Hsa" title="Number of common stock issued on commitment fees, shares">123,609</span> shares of common stock (valued at $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssuedInCommitmentFee_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_ziIkTXUy1lt8" title="Number of common stock issued on commitment fees, value">450,000</span>) to Lincoln Park as a commitment
fee in connection with entering into the Purchase Agreement and agreed to reimburse Lincoln Park $<span id="xdx_905_ecustom--ReimbursementFees_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIMuBOCSaCjf" title="Reimbursement fee">25,000</span> for fees incurred in connection
with the Purchase Agreement. Concurrent with entering into the Purchase Agreement, we also entered into a registration rights agreement
with Lincoln Park (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we agreed to take certain actions relating to
the registration under the Securities Act of 1933, as amended, of the offer and sale of the shares of common stock available for issuance
under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Beginning
on March 23, 2022, we have the right to present Lincoln Park with a purchase notice (a &#8220;Regular Purchase Notice&#8221;), directing
Lincoln Park to purchase up to <span id="xdx_904_ecustom--NumberOfCommonStockSharesinRegularPurchase_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Number of common stock shares in regular purchase">25,000</span> Purchase Shares (the &#8220;Regular Purchase Amount&#8221;) provided that the closing sale price
of the common stock on the purchase date is not below a threshold price set forth in the Purchase Agreement (a &#8220;Regular Purchase&#8221;).
The Regular Purchase Amount may be increased to up to <span id="xdx_907_ecustom--NumberOfCommonStockSharesExceedingRegularPurchase_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Number of common stock shares exceeding regular purchase">75,000</span> shares if the closing sale price of our common stock on the applicable purchase
date equals or exceeds certain higher threshold prices set forth in the Purchase Agreement. We and Lincoln Park may mutually agree to
increase the Regular Purchase Amount with respect to any Regular Purchase under the Purchase Agreement, provided that Lincoln Park&#8217;s
maximum committed purchase obligation under any single Regular Purchase shall not exceed $<span id="xdx_901_ecustom--DailyMaximumCommittedPurchaseObligationsValue_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zBeQtTHwO741" title="Daily maximum committed purchase obligations, value">1,250,000</span>. The above-referenced share amount
limitations and closing sale price thresholds are subject to adjustment for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement. The purchase price per share for
each Regular Purchase will be based on prevailing market prices of the common stock immediately preceding the time of sale as computed
in accordance with the terms set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park
must pay for shares of common stock under the Purchase Agreement. Lincoln Park may not assign or transfer its rights and obligations
under the Purchase Agreement.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
aggregate number of shares that we can issue to Lincoln Park under the Purchase Agreement may not exceed <span id="xdx_90F_ecustom--MaximumNumberOfSharesSoldInTransaction_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Maximum number of shares issued sold">3,142,430</span> shares (subject to
proportional adjustments for stock splits, reverse stock splits and similar events as described above), which is equal to <span id="xdx_905_ecustom--PercentageOfExchangeCapitalization_pid_dp_uPure_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zGUgQFBi9hfk" title="Nasdaq's exchange cap percent">19.99</span>% of the
outstanding shares of common stock immediately prior to the execution of the Purchase Agreement (the &#8220;Exchange Cap&#8221;), unless
(i) stockholder approval is obtained to issue shares of common stock in excess of the Exchange Cap, in which case the Exchange Cap will
no longer apply, or (ii) the average price of all sales of Purchase Shares to Lincoln Park under the Purchase Agreement equals or exceeds
the lower of (i) the Nasdaq official closing price immediately preceding the execution of the Purchase Agreement or (ii) the arithmetic
average of the five Nasdaq official closing prices for the common stock immediately preceding the execution of the Purchase Agreement,
plus an incremental amount to take into account the issuance of the commitment shares to Lincoln Park under the Purchase Agreement, such
that the transactions contemplated by the Purchase Agreement are exempt from the Exchange Cap limitation under applicable Nasdaq rules.
In all instances, we may not sell shares of our common stock to Lincoln Park under the Purchase Agreement if it would result in Lincoln
Park beneficially owning more than <span id="xdx_901_ecustom--BeneficialOwnershipLimitationPercentage_pid_dp_uPure_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zEdNwYslR3a4" title="Beneficial ownership limitation percentage">9.99</span>% of the outstanding shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
may terminate the Purchase Agreement at any time, at our sole discretion, without any cost or penalty, by giving one business day notice
to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any
direct or indirect short selling or hedging of the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">There
are no limitations on use of proceeds, financial or business covenants, restrictions on future financings (other than restrictions on
our ability to enter into variable rate transactions described in the Purchase Agreement), rights of first refusal, participation rights,
penalties or liquidated damages in the Purchase Agreement. We may deliver Purchase Notices under the Purchase Agreement, subject to market
conditions, and in light of our capital needs from time to time and under the limitations contained in the Purchase Agreement. Any proceeds
that we receive under the Purchase Agreement are expected to be used for working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Repurchase
of Shares from Aposense, Ltd.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 29, 2022, we purchased <span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20220327__20220329__dei--LegalEntityAxis__custom--AposenseLtdMember_zCAQ2NSIwDHh" title="Number of repurchase of common stock, shares">100,000</span> shares of our common stock from Aposense Ltd. for $<span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodValue_c20220327__20220329__dei--LegalEntityAxis__custom--AposenseLtdMember_z0SP8I9Wa62b" title="Repurchase of common stock value">300,000</span> in a private transaction</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
are holding these shares as treasury stock until they are reissued or retired at the discretion of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261465328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z8JtaEh7JkH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Note
4 - <span id="xdx_820_zcodFvqfEepe">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 19, 2019, our stockholders approved, and we adopted the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019
Plan&#8221;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan <span style="background-color: white">originally provided</span> for the aggregate issuance of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember__us-gaap--AwardTypeAxis__custom--OriginalMember_zPLUoL0p8H1l" title="Maximum equity available for issuance under the plan">3,000,000</span> shares of our common stock, with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zzBjr0Z4Z2Z9" title="Shares available for future grants">627,086</span>
<span style="background-color: white">shares available for future grants at June 30, 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
July 11, 2022, our shareholders approved an increase in the aggregate number of shares of our common stock available for issuance under
our 2019 plan by 3,000,000 shares to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220711__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zIvB9HTYmFVb" title="Maximum equity available for issuance under the plan">6,000,000</span> shares in total.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Compensation Expense</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7ClB0UYcF0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six month periods ended June 30, 2022 and 2021 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_z5I4ignx7VS2" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three
                                            Months Ended</span></p>
                                                                                <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">June
                                            30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Six
                                            Months Ended</span></p>
                                                                                <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">June
                                            30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxd3g4OmvjTi" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">685,624</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdPAS0onR9R1" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">191,594</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3BGzipHAmE5" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">877,500</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVSSqQb6Zdsl" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">245,385</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYUiMYF3lsyb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,323,745</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxL6dtq5NF0k" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">673,729</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWZhN4qivM24" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,960,766</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuOBCXBQstQb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">928,237</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630_zumQss4QUm9e" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">2,009,369</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630_zKmuV1SQigKb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">865,323</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630_zYSqQzlJrZXc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">2,838,266</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_z42VtXLe2e08" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,173,622</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zKydv2SBxYPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No
tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred
tax assets relating to this expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zANKSZJgIGHc" title="Stock option granted"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_do_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFajQdW0bOX5" title="Stock option cancelled or forfeited">No</span></span>
stock options were granted, cancelled or forfeited during the six months ended June 30, 2022. At June 30, 2022, we had outstanding options
for the purchase of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Outstanding options for the purchase shares">178,496</span> shares with a weighted average exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted average exercise price of stock option outstanding">17.07</span> and a weighted average remaining contractual life
of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXfX60nIth6g" title="Stock options outstanding, weighted average remaining contractual term">3.1</span> years. Options </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercisable at June 30, 2022 <span style="background-color: white">for
the purchase of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of option exercisable during period">176,315</span> shares of our common stock had a weighted average exercise price $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of options exercisable, weighted average exercise price">17.02</span> and a weighted average remaining contractual
life of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1TmoAx9Hzt" title="Stock options exercisable, weighted average remaining contractual term">3.0</span> years. We had, a</span>s of June 30, 2022, total unrecognized stock-based compensation expense for these stock options of
approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" title="Unrecognized stock option expense">37,000</span>, which is expected to be fully recognized by the end of the third quarter of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Awards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 4, 2022, we granted and issued Restricted Stock Awards (&#8220;RSAs&#8221;) for <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220103__20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zv6a2kr27iPg" title="Stock granted during period restricted stock, shares">9,766</span> shares of our common stock to a consultant
for services to be provided in 2022. These RSAs had a fair market value of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdp0" title="Stock based compensation">50,000</span> on the date of grant and were expensed as stock-based
compensation during the six months ended June 30, 2022. Effective January 1, 2022, we also granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220103__20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zs5tsmjgjFje" title="Stock granted during period restricted stock, shares">72,832</span> RSAs to our directors for their
2022 service which had a fair market value of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pp0p0_c20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zGAt2x1foFdg" title="Restricted stock fair value">252,000</span> on the date of grant and will cliff vest on December 31, 2022. Additionally, on
March 31, 2022, we issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220320__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zjuqygceQcte" title="Number of restricted shares issued">17,572</span> RSAs to our directors in satisfaction of the $<span id="xdx_90B_ecustom--AccruedDirectorsFees_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_pp0p0" title="Directors' fees">120,000</span> of directors&#8217; fees we had accrued at December
31, 2021. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2022, a director did not seek reelection
and forfeited the <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pp0p0_c20220529__20220531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zqNjQVcX4BG5" title="Restricted stock units forfeited">18,208</span> RSAs related to their 2022 service. <span style="background-color: white">We did not cancel any RSAs during
the six months ended June 30, 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
June 30, 2022, we had unvested RSAs for </span><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEUH56MJ2p51" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Number of unvested restricted stock award">145,733
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares with a weighted average
grant date fair value of $</span><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z37CbNwR5w58" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Weighted average grant date fair value">6.13</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.
Unvested RSAs representing <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_c20220101__20220630__us-gaap--VestingAxis__custom--TwoThousandTwentyTwoMember_z1Y1uf8BZ5e6" title="Number of restricted stock expected to vest, shares">120,733
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares are expected
to vest at various dates in 2022, <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_c20220101__20220630__us-gaap--VestingAxis__custom--TwoThousandTwentyThreeMember_z0R7GjGrcc8a" title="Number of restricted stock expected to vest, shares">12,500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares are expected
to vest in 2023, and the remainder are expected to vest in 2024. As of June 30, 2022, the total unrecognized stock-based compensation
expense related to the outstanding RSAs was approximately $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1xfV1PTzb23" title="Unrecognized share based compensation expense">310,000</span> which is expected to be recognized over a weighted average period
of approximately <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEoAOQqh3IAk" title="Weighted average period">0.8</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Units</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z8d5T3Ki4Ot9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2022 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zjf0Q6rBUrB7" style="display: none">Schedule of Information About RSU Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Number
                                            of</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">shares</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Weighted-</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">average</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">grant-date
                    fair</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">value
                    per share</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsnTJ8vUfM6k" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Number of shares, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">439,593</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Awarded</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, awarded"><span style="font-family: Times New Roman, Times, Serif">1,363,917</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, awarded"><span style="font-family: Times New Roman, Times, Serif">3.01</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09vNXbV5Ka9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif">(22,088</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif">7.81</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyHTyRw8XB09" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, shares issued"><span style="font-family: Times New Roman, Times, Serif">(3,500</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, shares issued"><span style="font-family: Times New Roman, Times, Serif">6.65</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at June 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z04qac9KvjA6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,777,922</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zykyPXnb3Pmj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, ending balance"><span style="font-family: Times New Roman, Times, Serif">4.12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and unissued</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and unissued"><span style="font-family: Times New Roman, Times, Serif">(440,374</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"><span style="font-family: Times New Roman, Times, Serif">4.97</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at June 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, unvested"><span style="font-family: Times New Roman, Times, Serif">1,337,548</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, unvested"><span style="font-family: Times New Roman, Times, Serif">3.83</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zmqsT1P0r5F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, unrecognized stock-based compensation expense of approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn6n6_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkLtwdKbPSuk" title="Unrecognized share based compensation expense">4.0</span> million for RSUs is expected to be fully recognized
over a weighted average period of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVnPTLJki7b5" title="Weighted average period, restricted stock units">0.8</span> years. The unrecognized expense excludes approximately $<span id="xdx_909_ecustom--UnrecognizedShareBasedCompensationExpense_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Unrecognized restricted stock expense">349,000</span> of expense related to certain RSUs
with a performance milestone that is not probable of occurring at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2022, we grant<span style="background-color: white">ed</span> RSUs related to the future issuance of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__custom--BaseCompensationMember_zexw2rKte1sj" title="Restricted stock units awarded">243,131</span>
<span style="background-color: white">shares of our common stock p</span>ursuant to agreements with our Executive team and certain other
employees where a portion of their base compensation is paid in RSUs<span style="background-color: white">. The value of an RSU award
is based on the average share price of the month services were provided. </span>These RSUs are vested but must meet distribution requirements
before any shares of common stock are issued. Effective July 1, 2022, we established a $<span id="xdx_908_ecustom--MinimumPricePerShareOfEquityCompensation_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zICUThFSRYra" title="Minimum price per share of equity compensation">5.00</span> per share floor for the computation of the
number of shares our Executive team members could earn under this program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Included
in RSUs awarded during the six months ended June 30, 2022 are RSUs awarded on April 1, 2022 for <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zEX0L8T1Xui5" title="Restricted stock units awarded">1,979,818</span>
shares of our common stock, of which RSUs related to the future issuance of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztmn0BWRNbE7" title="Common stock available for future issuance">879,819</span>
shares were subject to shareholder approval, which was received on July 11, 2022. These RSUs vest on January 1, 2023 and are subject
to distribution requirements before any shares of common stock are issued. The RSUs that were not subject to shareholder approval
ha<span style="background-color: white">d</span> a fair value on April 1, 2022 of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn5n6_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zk59jOiyljcb" title="Restricted stock fair value">3.3</span>
million while the RSUs that were approved by the shareholders on July 11, 2022 have a fair value, as of the approval date, of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pn5n6_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zknx6KVREl7" title="Fair value amount">2.9</span>
million. <span style="background-color: white">The $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn5n6_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zRX2toEn2kW2" title="Restricted stock fair value">3.3</span> million is being recognized ratably over the period April 1, 2022 through
December 31, 2022, while the $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pn5n6_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5jT5L5VY8Me" title="Fair value amount">2.9</span> million will be recognized </span> ratably over the remainder
of 2022</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">beginning in the third quarter of 2022<span style="background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs <span style="background-color: white">will be </span> issue<span style="background-color: white">d</span> shares of our common stock upon the <span style="background-color: white">satisfaction </span> of the distribution restrictions contained
in their Restricted Stock Unit Award Agreement. The distribution restrictions are typically different (longer) than the vesting schedule,
imposing an additional restriction on the holder. Unlike RSAs, while employees may hold fully vested RSUs, the individual does not hold
any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU
converts into one share of our common stock. The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_do_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzLc42kaaYeg" title="Warrant cancelled or forfeited">No</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock purchase warrants were <span style="background-color: white">granted,
cancelled </span>or forfeited during the six months ended June 30, 2022. At June 30, 2022, we had outstanding and vested stock purchase
warrants for the purchase of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants to purchase shares">303,725</span> <span style="background-color: white">shares with a weighted average exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants, weighted average exercise price">10.66</span> and
a weighted average remaining contractual life of <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zV9lLDVAgu61" title="Weighted average remaining contractual life">1.3</span> years.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective
May 3, 2022, we extended the expiration date of a warrant held by a consultant by one year in connection with the extension of their
service agreement. No other terms of the warrant, including the exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220503__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zOjmhbIxK9u5">7.18</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">,
were changed. We will recognize expense of approximately $<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220503__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zN1LYkVhjkr9">33,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">related to this warrant
modification over a one-year period beginning May 2022.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038264136448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zDF0u2yO1cW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_820_zHjiZb7GB7Va">Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
and six month periods ended June 30, 2022 and 2021 excludes the impact of potentially dilutive common shares since those shares would
have an anti-dilutive effect on net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkOIJnlxehlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six month periods ended June 30, 2022 and 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zvhqEF0fMs0f" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20220401__20220630_za3vl8QvOkGg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20210401__20210630_z4cGDc2c6kI5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220101__20220630_zKB8vE2ktCra" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20210630_zLQu56bq0xP4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss
    per share:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zhV6ROILpGcj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss available to common stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,164,368</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,157,043</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,391,499</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,256,523</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zcCqDBb6YXbe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of common shares-basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,940,510</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,406,363</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,886,116</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,997,303</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_z6yzRSdmFfK2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net
    loss per share</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.20</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.53</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.35</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p id="xdx_8A4_zwkZqaCPibTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the three and six month periods ended June 30, 2022 and 2021 excluded <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630_zINBxLXBCiAi" title="Antidilutive securities excluded from computation of earnings per share, amount">1,965,502</span> and <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount">709,954</span> of potentially
dilutive common shares, respectively, related to outstanding stock options, stock purchase warrants and unvested restricted stock since
those shares would have had an anti-dilutive effect on net loss per share during the periods then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261770112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zPx7jmldjMie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82B_zo8oVMn90yXj">Operating Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220630_zpE5BH8pWdT6" title="Operating lease borrowing rate">8</span>% to determine the present value of the lease payments based
on the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our condensed consolidated statements of operations totaled $<span id="xdx_904_eus-gaap--LeaseCost_pp0p0_c20220401__20220630_zYGHmnKkTkba" title="Lease cost">24,137</span> and $<span id="xdx_902_eus-gaap--LeaseCost_pp0p0_c20210401__20210630_zMIPf1X54VF" title="Lease cost">21,801</span> for the three months ended June 30
and 2021, respectively, and $<span id="xdx_906_eus-gaap--LeaseCost_c20220101__20220630_pp0p0" title="Lease cost">48,528</span> and $<span id="xdx_904_eus-gaap--LeaseCost_c20210101__20210630_pp0p0" title="Lease cost">45,831</span> for the six months ended June 30, 2022 and 2021, respectively. The weighted average remaining
lease terms and discount rate for our operating leases were as follows at June 30, 2022:</span></p>

<p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zuCRzYZinoD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z0C2VaxiisOb" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remaining lease term (years) for
    our facility lease</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--FacilityLeaseMember_zvLor31lWt9b" title="Operating lease, weighted average remaining lease term">0.3</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remaining lease term (years) for our equipment
    lease</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--EquipmentLeaseMember_zhcGBsJnb3b" title="Operating lease, weighted average remaining lease term">1.8</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining lease term (years)
    for our facility and equipment leases</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630_zRQthivWEHP7" title="Operating lease, weighted average remaining lease term">0.7</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average discount rate for our facility
    and equipment leases</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220630_zpEBInSr38r" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average discount rate for our facility and equipment leases"><span style="font-family: Times New Roman, Times, Serif">8.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p id="xdx_8AE_zgZ8r5AqpuJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zkPy1Uev7nlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for all operating leases were as follows as of June 30, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zTnvStVTQxq4" style="display: none">Schedule of Maturities of Lease Liabilities for all Operating Leases</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20220630_z7iZtEbovtTa" style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzqtT_zxmLcTtIplP4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,457</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzqtT_zxcW3vxunlZ9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,420</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzqtT_zRN1xZw4As23" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,605</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzqtT_zNfdAvpl1cwk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,482</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z6gPLHIOA7ta" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,275</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,207</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zq4rtcOZJyl3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    current maturities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,552</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current
    lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,655</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_zVnUXhSrhKya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038264158224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zzn3iY9kBeoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211;<span id="xdx_828_zqfcTbLvFBs9"> Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. We recorded $<span id="xdx_90F_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20220101__20220630__dei--LegalEntityAxis__custom--CorLystLLCMember_pp0p0" title="Rent and other costs reimbursements received">63,689</span> and $<span id="xdx_90B_ecustom--ProceedsFromRentAndOtherCostsReimbursements_pp0p0_c20210101__20210630__dei--LegalEntityAxis__custom--CorLystLLCMember_zqrqLek1iGl1" title="Rent and other costs reimbursements received">61,549</span> of reimbursements during the six months ended June 30, 2022 and 2021, respectively.
<span id="xdx_90B_eus-gaap--DueFromRelatedPartiesCurrent_iI_pp0p0_do_c20220630__dei--LegalEntityAxis__custom--CorLystLLCMember_z3DF2K33OtAk" title="Due from related parties"><span id="xdx_90F_eus-gaap--DueFromRelatedPartiesCurrent_iI_pp0p0_do_c20210630__dei--LegalEntityAxis__custom--CorLystLLCMember_zjLL1F74KLl4" title="Due from related parties">No</span></span> amounts were due from CorLyst at June 30, 2022 or 2021. Our CEO is also the CEO of CorLyst, and CorLyst is a shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038274899744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Elion License Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_DisclosureElionLicenseAgreementAbstract', window );"><strong>Elion License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ElionLicenseAgreementDisclosureTextBlock', window );">Elion License Agreement</a></td>
<td class="text"><p id="xdx_802_ecustom--ElionLicenseAgreementDisclosureTextBlock_zlWvBa07maU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 &#8211; <span id="xdx_822_z1u0KhmUOMQh">Elion License Agreement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 17, 2022, we amended the third Milestone Event
of Section 6.4 of our License Agreement with Elion Oncology, Inc. changing the third Milestone Event from &#8220;1<sup>st</sup> Patient
in Dose Confirmation Study&#8221; to (a) determination of the maximum tolerated dose (MTD) or (b) determination of the recommended Phase
2 Dose. Prior to this amendment, the third milestone was not considered probable since it was unknown when, or if a dose confirmation
study was going to be conducted. As a result of the modification, we consider it probable that the MTD could be determined in connection
with our current Phase 1B trial for PCS6422. We recorded an expense and related liability of $<span id="xdx_908_ecustom--ExpenseAndRelatedLiability_c20220516__20220517__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmKftoJb6egj" title="Expense and related liability">189,000</span> representing the value of the shares
we anticipate issuing to Elion at the fair value on the date of modification. No other terms or conditions of the License Agreement were
modified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureElionLicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureElionLicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ElionLicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Elion License Agreement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ElionLicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261743552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zalTIWw4lCKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_823_zZvhZaVcLR17">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with contract research organizations and subcontractors to further develop our
products. The contracts are cancellable, with varying provisions regarding termination. If we terminated a cancellable contract with
a specific vendor, we would only be obligated for products or services that we received as of the effective date of the termination
and any applicable cancellation fees. As of June 30, we are contractually obligated to pay up to approximately $<span id="xdx_908_eus-gaap--PurchaseObligation_iI_pn5n6_c20220630__us-gaap--TypeOfArrangementAxis__custom--AgreementsMember__dei--LegalEntityAxis__custom--ContractResearchOrganizationsMember_zfRC0J7EiMd2" title="Purchase obligation">5.5</span> million of
future services under the agreements with the CROs, but our actual contractual obligations will vary depending on the progress and
results of the clinical trials.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258374256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock', window );">Business Activities and Organization</a></td>
<td class="text"><p id="xdx_847_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zMWUacrsjTU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_864_zCJHWuIXcEg4">Business
Activities and Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for
patients who have a high unmet medical need condition that affects survival or the patient&#8217;s quality of life and for which few
or no treatment options currently exist. We currently have five drugs: four in various stages of clinical development (PCS499, PCS12852,
PCS6422 and PCS3117) and one in nonclinical development (PCS11T). We group our drugs into non-oncology (PCS499 and PCS12852) and oncology
(PCS3117, PCS6422 and PCS11T). A summary of each drug is provided below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    most advanced product candidate, PCS499, is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline
    (PTX or Trental&#174;). We completed a Phase 2A trial for PCS499 in patients with ulcerative and non-ulcerative necrobiosis lipoidica
    (NL) in late 2020, and in May 2021 we enrolled the first patient in our Phase 2B trial for the treatment of ulcerative NL. We expect
    to complete our interim analysis and complete enrollment of the Phase 2B trial during the first half of 2023; and, depending on the
    results, begin a pivotal Phase 3 trial in 2023. We have experienced delays in the enrollment of patients for this trial due in part
    to COVID-19 and the rare nature of this disease. We have initiated a number of recruitment programs to increase the enrollment of
    patients in this study and continue to evaluate additional options to meet our enrollment goals.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
    is a highly specific and potent 5HT4 agonist which has already been evaluated in clinical studies in South Korea for gastric emptying
    and gastrointestinal motility. In October 2021, the FDA cleared our IND application to proceed with a Phase 2A trial for the treatment
    of gastroparesis. We enrolled our first patient on April 5, 2022, anticipate completing enrollment in the second half of 2022 with
    top-line results by the end of 2022, and should complete our final analysis in the first half of 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS6422
    is an orally administered irreversible enzyme inhibitor administered in combination with capecitabine. When combining capecitabine
    with PCS6422 (the &#8220;Next Generation Capecitabine&#8221;), capecitabine becomes a more potent cancer chemotherapy agent than
    current FDA approved capecitabine. On August 2, 2021, we enrolled the first patient in our Phase 1B dose-escalation maximum tolerated
    dose trial in patients with advanced refractory gastrointestinal (GI) tract tumors. Our interim analysis of Cohorts 1 and 2 found
    no dose-limiting toxicities (DLTs), no drug related adverse events greater than Grade 1, and no hand-foot syndrome. In addition,
    the interim analysis revealed when PCS6422 inhibits the DPD enzyme, 5-FU metabolism can be significantly decreased (&lt;10% metabolized
    to F-Bal compared to typically 80%) and the potency of capecitabine significantly increased compared to the present regimens of capecitabine
    (at least 50 times greater 5-FU potency based on systemic exposure per mg of capecitabine administered). The single dose of PCS6422,
    however, did not sustain the DPD inhibition throughout 7 days of capecitabine dosing which was needed to maintain the improved potency
    of capecitabine. Therefore, in an effort to define 6422 regimens that will maintain DPD inhibition throughout capecitabine dosing,
    we modified the protocol for the Phase 1B trial to not only determine the MTD of capecitabine, but to also further evaluate the timeline
    of DPD inhibition and de novo formation. We began enrolling patients in the amended Phase 1B trial in April 2022 and expect to complete
    enrollment while defining the Next Generation Capecitabine regimen (i.e., the PCS6422 regimens and the corresponding capecitabine
    regimens) by the end of 2022. We expect that our overall timeline has not changed with a Phase 2B or 3 trial starting in 2023-2024
    and NDA submission in 2027-2028.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117
    is a cytosine analog that is similar to gemcitabine (Gemzar&#174;), but different enough in chemical structure that some patients
    are more likely to respond to PCS3117 than gemcitabine. We continue to evaluate the potential use of PCS3117 in patients with pancreatic
    cancer and to evaluate ways to identify patients who are more likely to respond to PCS3117 than gemcitabine. We anticipate initiating
    a Phase 2B trial or adaptive designed Phase 3 trial in 2023 subject to meeting with FDA and obtaining additional funding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    only nonclinical drug candidate is PCS11T, an analog of SN38 (SN38 being the active metabolite of irinotecan) and a next generation
    irinotecan drug for multiple types of cancers. The manufacturing process and sites for drug substance and drug product are presently
    being evaluated. In addition, we are defining the potential paths to approval, which include defining the targeted patient population
    and the type of cancer. We hope to submit an IND in the first half of 2024, followed by a Phase 1B maximum tolerated dose trial.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ImpactOfCovidNineteenPolicyTextBlock', window );">Impact of COVID-19</a></td>
<td class="text"><p id="xdx_840_ecustom--ImpactOfCovidNineteenPolicyTextBlock_zcdJIDH53Fod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_868_zaFIwlDyvJTk">Impact
of COVID-19</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
COVID-19 pandemic continues to create uncertainties in expected timelines by causing delays in clinical trials and disruptions in
the supply chain for raw materials used in clinical trial work.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced delays in the enrollment of patients in our PCS499 Phase 2B trial due to COVID-19. Some potential patients have
died from COVID-19 prior to screening and others continue to be reluctant to travel to our testing sites for fear of contracting
COVID-19. Delays in enrollment lengthen the time of studies and increase their costs, which <span style="background-color: white">could
materially impact our business in future periods. Furthermore, the spread of COVID-19, which has caused a broad impact globally, may
materially affect us economically. </span>While we are hopeful the infection rate of COVID-19 will continue to decline, we cannot
predict the future impact COVID-19 will have on our current and future clinical trials. Continued delays could materially impact our business in future periods
and further extend our timelines. <span style="background-color: white">For
more information on the risks associated with COVID-19, refer to Part I, Item 1A, &#8220;Risk Factors&#8221; included in our Annual
Report on Form 10-K for the year ended December 31, 2021.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZnbC26CFdXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86C_zMWxLCSR8en8">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2021, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_843_ecustom--LiquidityPolicyTextBlock_zHWpnKAKdawk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zMTOusaVyIpi">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception, devoting substantially all of our efforts toward moving the drugs in our pipeline through the
regulatory process and other research and development activities, and have an accumulated deficit of approximately $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220630_zVhIVPBP50Y1" title="Accumulated deficit">45.2</span>
million as of June 30, 2022. During the six months ended June 30, 2022, we generated a net loss of approximately $<span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220630_zaSsid8WhRua" title="Net loss">8.4</span>
million, of which $<span id="xdx_90E_eus-gaap--OtherNoncashExpense_pn5n6_c20220101__20220630_zsxPy5JPfXhf" title="Non cash expenditures">3.5</span>
million represented non-cash expenditures. Net cash used in our operating activities during the six months ended June 30, 2022 was
approximately $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220630_zClKBTC41KGl" title="Net cash used in operating activities">4.1</span>
million. We expect to continue to generate operating losses and negative cash flow from operations for the foreseeable future. Based on our
current plans, we believe our current cash balances are adequate for at least the next twelve months without considering amounts
available from the Purchase Agreement with Lincoln Park (see below and Note 3) or potential sales under our ATM Offering (see
below). Our ability to execute our longer-term operating plans, including unplanned future clinical trials for our portfolio of
drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or
other funding transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we
will obtain the necessary funding in the future when necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had <span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20220101__20220630_zDJabtiVwReg" title="Revenue">no</span> revenue during the six months ended June 30, 2022 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and operating expenses. Cash
used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2021, we entered into an equity distribution agreement (the &#8220;Sales Agreement&#8221;) with Oppenheimer &amp; Co. Inc.
under which we may issue and sell in a registered &#8220;at-the-market&#8221; offering shares of our common stock having an aggregate
offering price of up to $<span id="xdx_900_ecustom--MaximumNumberOfSharesToBeSoldAtMarketOffering_pn6n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3z7EJdaZN94" title="Maximum number of shares to be sold at the market offering">30.0</span> million from time to time through or to our Sales Agent (the &#8220;ATM Offering&#8221;). We expect to
use net proceeds from the ATM Offering over time as a source for working capital and general corporate purposes. The shares under the
ATM Offering will be sold and issued pursuant to our S-3 shelf registration statement (Registration No. 333-257588) filed on July 30,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2022, we entered into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;) under which we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase
up to $<span id="xdx_900_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zzjDFAExIyvl" title="Commitment to purchase common stock">15,000,000</span> of our shares of common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Common stock, par value">0.0001</span> per share, subject to the terms and conditions in the Purchase Agreement,
during the term of the Purchase Agreement. See Note 3 for additional details concerning the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_849_eus-gaap--UseOfEstimates_zRBk2jRRQwn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zeTPnvxMEa34">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and
regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements
and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zwEDbNApiuN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zjzbQWC9g9Nk">Income
Taxes</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of June 30, 2022 and December 31, 2021, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets related to deferred start-up costs, federal orphan drug tax credit and certain other minor temporary differences
since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained
until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, we recognized the
tax benefit from our projected ordinary tax loss, which was used to offset the deferred tax liabilities related to the intangible asset
and resulted in the recognition of a deferred tax benefit shown in the condensed consolidated statements of operations for six months
ended June 30, 2021 and the remainder of 2021. No current income tax benefit or expense was recorded or is expected for 2022 or in the
foreseeable future since the deferred tax liability has been offset completely as of December 31, 2021 and we expect to generate future
taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zaQecVRfIK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_865_zlU3Z9kcO4Dh">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2022 exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSuMBt3ZNdFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_zcDX0pnUpr0b">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Activities And Organization [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ImpactOfCovidNineteenPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impact Of Covid Nineteen [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ImpactOfCovidNineteenPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261501088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zaSHc5ft7Xul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets at June 30, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zIoYM0uGKiV7" style="display: none">Summary of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20220630_z54gRZ5GHxp1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20211231_zcVpqQnWfmF1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANz27j_zDn42NPjVvD2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross intangible assets</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,059,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,059,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANz27j_z4tugYEL164e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated amortization</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,397,039</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,002,791</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANz27j_zx3xyiJkeKNd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total intangible assets,
    net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,662,390</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,056,638</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261606736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7ClB0UYcF0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six month periods ended June 30, 2022 and 2021 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_z5I4ignx7VS2" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three
                                            Months Ended</span></p>
                                                                                <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">June
                                            30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Six
                                            Months Ended</span></p>
                                                                                <p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">June
                                            30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxd3g4OmvjTi" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">685,624</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdPAS0onR9R1" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">191,594</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3BGzipHAmE5" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">877,500</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVSSqQb6Zdsl" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">245,385</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYUiMYF3lsyb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,323,745</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxL6dtq5NF0k" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">673,729</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWZhN4qivM24" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,960,766</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuOBCXBQstQb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">928,237</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630_zumQss4QUm9e" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">2,009,369</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630_zKmuV1SQigKb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">865,323</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630_zYSqQzlJrZXc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">2,838,266</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_z42VtXLe2e08" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,173,622</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Information About RSU Outstanding</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z8d5T3Ki4Ot9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2022 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zjf0Q6rBUrB7" style="display: none">Schedule of Information About RSU Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Number
                                            of</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">shares</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Weighted-</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">average</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">grant-date
                    fair</span></p>
                    <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">value
                    per share</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsnTJ8vUfM6k" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Number of shares, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">439,593</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Awarded</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, awarded"><span style="font-family: Times New Roman, Times, Serif">1,363,917</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, awarded"><span style="font-family: Times New Roman, Times, Serif">3.01</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09vNXbV5Ka9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif">(22,088</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"><span style="font-family: Times New Roman, Times, Serif">7.81</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyHTyRw8XB09" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, shares issued"><span style="font-family: Times New Roman, Times, Serif">(3,500</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, shares issued"><span style="font-family: Times New Roman, Times, Serif">6.65</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at June 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z04qac9KvjA6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,777,922</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zykyPXnb3Pmj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, ending balance"><span style="font-family: Times New Roman, Times, Serif">4.12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and unissued</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and unissued"><span style="font-family: Times New Roman, Times, Serif">(440,374</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"><span style="font-family: Times New Roman, Times, Serif">4.97</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested at June 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, unvested"><span style="font-family: Times New Roman, Times, Serif">1,337,548</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, unvested"><span style="font-family: Times New Roman, Times, Serif">3.83</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261749952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Basic and Diluted</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkOIJnlxehlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six month periods ended June 30, 2022 and 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zvhqEF0fMs0f" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20220401__20220630_za3vl8QvOkGg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20210401__20210630_z4cGDc2c6kI5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220101__20220630_zKB8vE2ktCra" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20210630_zLQu56bq0xP4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net loss
    per share:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zhV6ROILpGcj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss available to common stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,164,368</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,157,043</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,391,499</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,256,523</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zcCqDBb6YXbe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of common shares-basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,940,510</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,406,363</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,886,116</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,997,303</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_z6yzRSdmFfK2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted net
    loss per share</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.20</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.53</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.35</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261693760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zuCRzYZinoD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z0C2VaxiisOb" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remaining lease term (years) for
    our facility lease</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--FacilityLeaseMember_zvLor31lWt9b" title="Operating lease, weighted average remaining lease term">0.3</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remaining lease term (years) for our equipment
    lease</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--EquipmentLeaseMember_zhcGBsJnb3b" title="Operating lease, weighted average remaining lease term">1.8</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining lease term (years)
    for our facility and equipment leases</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630_zRQthivWEHP7" title="Operating lease, weighted average remaining lease term">0.7</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average discount rate for our facility
    and equipment leases</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220630_zpEBInSr38r" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average discount rate for our facility and equipment leases"><span style="font-family: Times New Roman, Times, Serif">8.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities for all Operating Leases</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zkPy1Uev7nlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for all operating leases were as follows as of June 30, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zTnvStVTQxq4" style="display: none">Schedule of Maturities of Lease Liabilities for all Operating Leases</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20220630_z7iZtEbovtTa" style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzqtT_zxmLcTtIplP4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,457</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzqtT_zxcW3vxunlZ9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,420</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzqtT_zRN1xZw4As23" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,605</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzqtT_zNfdAvpl1cwk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,482</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z6gPLHIOA7ta" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    Interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,275</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,207</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zq4rtcOZJyl3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    current maturities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,552</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current
    lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,655</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operating Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038260410160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Aug. 20, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,214,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,214,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,823,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,164,368<span></span>
</td>
<td class="nump">$ 3,227,131<span></span>
</td>
<td class="nump">$ 3,157,043<span></span>
</td>
<td class="nump">$ 2,099,480<span></span>
</td>
<td class="nump">8,391,499<span></span>
</td>
<td class="nump">$ 5,256,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non cash expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,133,439<span></span>
</td>
<td class="nump">$ 4,437,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering', window );">Maximum number of shares to be sold at the market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_MaximumCommitmenttoPurchaseCommonStockValue', window );">Commitment to purchase common stock</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MaximumCommitmenttoPurchaseCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount committed to purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MaximumCommitmenttoPurchaseCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares to be sold at the market offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258377936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 11,059,429<span></span>
</td>
<td class="nump">$ 11,059,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(3,397,039)<span></span>
</td>
<td class="num">(3,002,791)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">$ 7,662,390<span></span>
</td>
<td class="nump">$ 8,056,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258407232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 394,248<span></span>
</td>
<td class="nump">$ 397,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future amortization expenses, annual periods thereafter</a></td>
<td class="nump">$ 788,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258586352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2022</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Aug. 20, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=PCSA_AposenseLtdMember', window );">Aposense, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of repurchase of common stock, shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock value</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering', window );">Maximum number of shares to be sold at the market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares', window );">Number of common stock issued on commitment fees, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee', window );">Number of common stock issued on commitment fees, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ReimbursementFees', window );">Reimbursement fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_PercentageOfExchangeCapitalization', window );">Nasdaq's exchange cap percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_MaximumCommitmenttoPurchaseCommonStockValue', window );">Commitment to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_NumberOfCommonStockSharesinRegularPurchase', window );">Number of common stock shares in regular purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_NumberOfCommonStockSharesExceedingRegularPurchase', window );">Number of common stock shares exceeding regular purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_DailyMaximumCommittedPurchaseObligationsValue', window );">Daily maximum committed purchase obligations, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_MaximumNumberOfSharesSoldInTransaction', window );">Maximum number of shares issued sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,142,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_BeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_BeneficialOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership limitation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_BeneficialOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DailyMaximumCommittedPurchaseObligationsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Daily maximum committed purchase obligations, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DailyMaximumCommittedPurchaseObligationsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MaximumCommitmenttoPurchaseCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount committed to purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MaximumCommitmenttoPurchaseCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MaximumNumberOfSharesSoldInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares sold in transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MaximumNumberOfSharesSoldInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares to be sold at the market offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NumberOfCommonStockSharesExceedingRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares exceeding a regular purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NumberOfCommonStockSharesExceedingRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NumberOfCommonStockSharesinRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares in regular purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NumberOfCommonStockSharesinRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PercentageOfExchangeCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of exchange capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PercentageOfExchangeCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued in connection with purchase agreement shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period values new issue on commitment fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_AposenseLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_AposenseLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038255481680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 2,009,369<span></span>
</td>
<td class="nump">$ 865,323<span></span>
</td>
<td class="nump">$ 2,838,266<span></span>
</td>
<td class="nump">$ 1,173,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">685,624<span></span>
</td>
<td class="nump">191,594<span></span>
</td>
<td class="nump">877,500<span></span>
</td>
<td class="nump">245,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 1,323,745<span></span>
</td>
<td class="nump">$ 673,729<span></span>
</td>
<td class="nump">$ 1,960,766<span></span>
</td>
<td class="nump">$ 928,237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258512800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Information About RSU Outstanding (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, Beginning balance</a></td>
<td class="nump">439,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, awarded</a></td>
<td class="nump">1,363,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, awarded | $ / shares</a></td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited</a></td>
<td class="num">(22,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, forfeited | $ / shares</a></td>
<td class="nump">$ 7.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, shares issued</a></td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, shares issued | $ / shares</a></td>
<td class="nump">$ 6.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, ending balance</a></td>
<td class="nump">1,777,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, ending balance | $ / shares</a></td>
<td class="nump">$ 4.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued', window );">Number of shares, vested and unissued</a></td>
<td class="num">(440,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, vested and unissued | $ / shares</a></td>
<td class="nump">$ 4.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber', window );">Number of shares, unvested</a></td>
<td class="nump">1,337,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, unvested | $ / shares</a></td>
<td class="nump">$ 3.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options unvested weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038185872752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 04, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,009,369<span></span>
</td>
<td class="nump">$ 865,323<span></span>
</td>
<td class="nump">$ 2,838,266<span></span>
</td>
<td class="nump">$ 1,173,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=PCSA_TwoThousandTwentyTwoMember', window );">2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber', window );">Number of restricted stock expected to vest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=PCSA_TwoThousandTwentyThreeMember', window );">2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber', window );">Number of restricted stock expected to vest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock option cancelled or forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options for the purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Stock options outstanding, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of option exercisable during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Number of options exercisable, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options exercisable, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested restricted stock award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested restricted stock award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_AccruedDirectorsFees', window );">Directors' fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average period, restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_UnrecognizedShareBasedCompensationExpense', window );">Unrecognized restricted stock expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_MinimumPricePerShareOfEquityCompensation', window );">Minimum price per share of equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | April 1, 2022 Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,979,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Base Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for future issuance</a></td>
<td class="nump">879,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value amount</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Warrant cancelled or forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum equity available for issuance under the plan</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member] | Original [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum equity available for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_AccruedDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued directors' fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_AccruedDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MinimumPricePerShareOfEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum price per share of equity compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MinimumPricePerShareOfEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBased compensation arrangement by sharebased payment award other than options expected to vest outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award other than options nonvested awards total compensation cost not yet recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_UnrecognizedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_UnrecognizedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_TwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_TwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_TwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_TwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=PCSA_BaseCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=PCSA_BaseCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_OriginalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_OriginalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038258154960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (5,164,368)<span></span>
</td>
<td class="num">$ (3,227,131)<span></span>
</td>
<td class="num">$ (3,157,043)<span></span>
</td>
<td class="num">$ (2,099,480)<span></span>
</td>
<td class="num">$ (8,391,499)<span></span>
</td>
<td class="num">$ (5,256,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic and diluted</a></td>
<td class="nump">15,940,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,406,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,886,116<span></span>
</td>
<td class="nump">14,997,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261448896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,965,502<span></span>
</td>
<td class="nump">709,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038260199856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for our facility and equipment leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=PCSA_FacilityLeaseMember', window );">Facility Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=PCSA_EquipmentLeaseMember', window );">Equipment Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=PCSA_FacilityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=PCSA_FacilityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=PCSA_EquipmentLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=PCSA_EquipmentLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038185727792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities of Lease Liabilities for all Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 26,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">6,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">34,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(3,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">31,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="num">(26,552)<span></span>
</td>
<td class="num">$ (71,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="nump">$ 4,655<span></span>
</td>
<td class="nump">$ 7,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261136304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease borrowing rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 24,137<span></span>
</td>
<td class="nump">$ 21,801<span></span>
</td>
<td class="nump">$ 48,528<span></span>
</td>
<td class="nump">$ 45,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261913552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - CorLyst, LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ProceedsFromRentAndOtherCostsReimbursements', window );">Rent and other costs reimbursements received</a></td>
<td class="nump">$ 63,689<span></span>
</td>
<td class="nump">$ 61,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ProceedsFromRentAndOtherCostsReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent and other costs reimbursements received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ProceedsFromRentAndOtherCostsReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_CorLystLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_CorLystLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261435216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Elion License Agreement (Details Narrative)<br></strong></div></th>
<th class="th">
<div>May 17, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PCSA_ExpenseAndRelatedLiability', window );">Expense and related liability</a></td>
<td class="nump">$ 189,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ExpenseAndRelatedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense and related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ExpenseAndRelatedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140038261488464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_AgreementsMember', window );">Agreements [Member] | Contract Research Organizations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_AgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_AgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_ContractResearchOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_ContractResearchOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:PCSA="http://processapharmaceuticals.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcsa-20220630.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2022-08-04</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-08-182021-08-20_custom_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-18</startDate>
            <endDate>2021-08-20</endDate>
        </period>
    </context>
    <context id="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="AsOf2022-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="From2022-03-272022-03-29_custom_AposenseLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:AposenseLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-27</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_TwoThousandAndNineteenPlanMember_custom_OriginalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:OriginalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-07-11_us-gaap_SubsequentEventMember_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-11</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-032022-01-04_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-032022-01-04_us-gaap_RestrictedStockMember_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-04_us-gaap_RestrictedStockMember_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-04</instant>
        </period>
    </context>
    <context id="From2022-03-202022-03-31_us-gaap_RestrictedStockMember_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-20</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockMember_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-05-292022-05-31_us-gaap_RestrictedStockMember_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:DirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-29</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_TwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_TwoThousandTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_BaseCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:BaseCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_AprilOneTwoThousandTwentyTwo2022GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">PCSA:AprilOneTwoThousandTwentyTwo2022GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-102022-07-11_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-10</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-05-03_us-gaap_WarrantMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_EquipmentLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">PCSA:EquipmentLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2022-05-162022-05-17_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_AgreementsMember_custom_ContractResearchOrganizationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:AgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:ContractResearchOrganizationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-06-30">0001533743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <PCSA:DueFromTaxAgencies
      contextRef="AsOf2022-06-30"
      id="xdx2ixbrl0059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-06-30"
      id="xdx2ixbrl0068"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0069"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2022-06-30"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-06-30"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0123"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0149"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0174"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0192"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0194"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2021-04-012021-06-30"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0240"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0272"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0304"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0314"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:NoncashMilestoneExpenseInConnectionWithLicenseAgreement
      contextRef="From2021-01-012021-06-30"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:NonCashAcquisitionOfInprocessResearchAndDevelopment
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2021-01-012021-06-30"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepurchaseOfEquity
      contextRef="From2021-01-012021-06-30"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="From2022-01-01to2022-06-30"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-06-30"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-01-01to2022-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-06-30">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-06-30">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-06-30">001-39531</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-06-30">Processa Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-06-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-06-30">45-1539785</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-06-30">7380 Coca Cola Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-06-30">Suite 106</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-06-30">Hanover</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-06-30">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-06-30">21076</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-06-30">443</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-06-30">776-3133</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-06-30">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-06-30">PCSA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-08-04" decimals="INF" unitRef="Shares">15856205</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">12064142</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16497581</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <PCSA:DueFromTaxAgencies contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">70274</PCSA:DueFromTaxAgencies>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1896633</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1759296</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">13960775</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">18327151</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">28890</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">74181</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">7662390</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">8056638</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:SecurityDeposit contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">5535</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5535</us-gaap:SecurityDeposit>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">7696815</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">8136354</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">21657590</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">26463505</us-gaap:Assets>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">26552</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">71078</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">648104</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">218905</us-gaap:AccountsPayableCurrent>
    <PCSA:DueToLicensor contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">589000</PCSA:DueToLicensor>
    <PCSA:DueToLicensor contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">400000</PCSA:DueToLicensor>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1772</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">307412</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">279265</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1571068</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">971020</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">4655</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7385</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1575723</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">978405</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-06-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">15919317</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">15819317</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">15710246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">15710246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1592</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1571</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">65595106</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">62306861</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">100000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">-45214831</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-36823332</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">20081867</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">25485100</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">21657590</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">26463505</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3137292</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1614954</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">5181912</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">3086401</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">515630</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">515630</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">2034456</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1329213</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">3218550</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">2051073</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-5171748</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-3459797</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-8400462</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-5653104</us-gaap:OperatingIncomeLoss>
    <PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">163771</PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest>
    <PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">163771</PCSA:ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">362</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">7380</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1814</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">8963</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">6755</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-5164368</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-3294212</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-8391499</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-5482940</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-137169</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-226417</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-5164368</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-3157043</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-8391499</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-5256523</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">15940510</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">15406363</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-06-30"
      decimals="INF"
      unitRef="Shares">15886116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-06-30"
      decimals="INF"
      unitRef="Shares">14997303</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14187984</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1419</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">48333857</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-25395798</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">22939478</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">620590</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">620591</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1321132</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">132</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">9875418</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">9875550</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2099480</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2099480</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15521616</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1552</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">58829865</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-27495278</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">31336139</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">38300</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">762592</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">762596</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">44689</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">299996</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3157043</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-3157043</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15604605</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1560</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">59892453</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-30652321</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">29241692</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15710246</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1571</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">62306861</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-36823332</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">25485100</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">103670</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">828887</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">828897</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">123609</PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">12</PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">449988</PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">450000</PCSA:SharesIssuedInConnectionWithPurchaseAgreementValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3227131</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-3227131</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15937525</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1593</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">63585736</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">-100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-40050463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">23236866</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">-18208</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">-1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2009370</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">2009369</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5164368</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-5164368</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15919317</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1592</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">65595106</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">-100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-45214831</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">20081867</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-8391499</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-5256523</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">484</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">45291</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">41322</us-gaap:OperatingLeaseExpense>
    <PCSA:NoncashMilestoneExpenseInConnectionWithLicenseAgreement
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">189000</PCSA:NoncashMilestoneExpenseInConnectionWithLicenseAgreement>
    <PCSA:NonCashAcquisitionOfInprocessResearchAndDevelopment
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">300000</PCSA:NonCashAcquisitionOfInprocessResearchAndDevelopment>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">40613</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">394248</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">397664</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-226417</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">2838266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">1173622</us-gaap:ShareBasedCompensation>
    <PCSA:ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">163771</PCSA:ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-272050</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">876899</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-47256</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-42320</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">362</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">429199</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-32816</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1772</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">96614</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-70274</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-6750</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">28147</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">144434</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-4133439</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-4437494</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">9875550</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromRepurchaseOfEquity
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-300000</us-gaap:ProceedsFromRepurchaseOfEquity>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-23085</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">9852465</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-4433439</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">5414971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16497581</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">15416224</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">12064142</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">20831195</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">123609</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssued1
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">450000</us-gaap:StockIssued1>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_80D_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zXzowtam2pMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82B_zmamq9bf2mG8"&gt;Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zMWUacrsjTU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zCJHWuIXcEg4"&gt;Business
Activities and Organization&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
are a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for
patients who have a high unmet medical need condition that affects survival or the patient&#x2019;s quality of life and for which few
or no treatment options currently exist. We currently have five drugs: four in various stages of clinical development (PCS499, PCS12852,
PCS6422 and PCS3117) and one in nonclinical development (PCS11T). We group our drugs into non-oncology (PCS499 and PCS12852) and oncology
(PCS3117, PCS6422 and PCS11T). A summary of each drug is provided below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
    most advanced product candidate, PCS499, is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline
    (PTX or Trental&#xae;). We completed a Phase 2A trial for PCS499 in patients with ulcerative and non-ulcerative necrobiosis lipoidica
    (NL) in late 2020, and in May 2021 we enrolled the first patient in our Phase 2B trial for the treatment of ulcerative NL. We expect
    to complete our interim analysis and complete enrollment of the Phase 2B trial during the first half of 2023; and, depending on the
    results, begin a pivotal Phase 3 trial in 2023. We have experienced delays in the enrollment of patients for this trial due in part
    to COVID-19 and the rare nature of this disease. We have initiated a number of recruitment programs to increase the enrollment of
    patients in this study and continue to evaluate additional options to meet our enrollment goals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS12852
    is a highly specific and potent 5HT4 agonist which has already been evaluated in clinical studies in South Korea for gastric emptying
    and gastrointestinal motility. In October 2021, the FDA cleared our IND application to proceed with a Phase 2A trial for the treatment
    of gastroparesis. We enrolled our first patient on April 5, 2022, anticipate completing enrollment in the second half of 2022 with
    top-line results by the end of 2022, and should complete our final analysis in the first half of 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS6422
    is an orally administered irreversible enzyme inhibitor administered in combination with capecitabine. When combining capecitabine
    with PCS6422 (the &#x201c;Next Generation Capecitabine&#x201d;), capecitabine becomes a more potent cancer chemotherapy agent than
    current FDA approved capecitabine. On August 2, 2021, we enrolled the first patient in our Phase 1B dose-escalation maximum tolerated
    dose trial in patients with advanced refractory gastrointestinal (GI) tract tumors. Our interim analysis of Cohorts 1 and 2 found
    no dose-limiting toxicities (DLTs), no drug related adverse events greater than Grade 1, and no hand-foot syndrome. In addition,
    the interim analysis revealed when PCS6422 inhibits the DPD enzyme, 5-FU metabolism can be significantly decreased (&amp;lt;10% metabolized
    to F-Bal compared to typically 80%) and the potency of capecitabine significantly increased compared to the present regimens of capecitabine
    (at least 50 times greater 5-FU potency based on systemic exposure per mg of capecitabine administered). The single dose of PCS6422,
    however, did not sustain the DPD inhibition throughout 7 days of capecitabine dosing which was needed to maintain the improved potency
    of capecitabine. Therefore, in an effort to define 6422 regimens that will maintain DPD inhibition throughout capecitabine dosing,
    we modified the protocol for the Phase 1B trial to not only determine the MTD of capecitabine, but to also further evaluate the timeline
    of DPD inhibition and de novo formation. We began enrolling patients in the amended Phase 1B trial in April 2022 and expect to complete
    enrollment while defining the Next Generation Capecitabine regimen (i.e., the PCS6422 regimens and the corresponding capecitabine
    regimens) by the end of 2022. We expect that our overall timeline has not changed with a Phase 2B or 3 trial starting in 2023-2024
    and NDA submission in 2027-2028.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS3117
    is a cytosine analog that is similar to gemcitabine (Gemzar&#xae;), but different enough in chemical structure that some patients
    are more likely to respond to PCS3117 than gemcitabine. We continue to evaluate the potential use of PCS3117 in patients with pancreatic
    cancer and to evaluate ways to identify patients who are more likely to respond to PCS3117 than gemcitabine. We anticipate initiating
    a Phase 2B trial or adaptive designed Phase 3 trial in 2023 subject to meeting with FDA and obtaining additional funding.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
    only nonclinical drug candidate is PCS11T, an analog of SN38 (SN38 being the active metabolite of irinotecan) and a next generation
    irinotecan drug for multiple types of cancers. The manufacturing process and sites for drug substance and drug product are presently
    being evaluated. In addition, we are defining the potential paths to approval, which include defining the targeted patient population
    and the type of cancer. We hope to submit an IND in the first half of 2024, followed by a Phase 1B maximum tolerated dose trial.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--ImpactOfCovidNineteenPolicyTextBlock_zcdJIDH53Fod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zaFIwlDyvJTk"&gt;Impact
of COVID-19&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
COVID-19 pandemic continues to create uncertainties in expected timelines by causing delays in clinical trials and disruptions in
the supply chain for raw materials used in clinical trial work.&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have experienced delays in the enrollment of patients in our PCS499 Phase 2B trial due to COVID-19. Some potential patients have
died from COVID-19 prior to screening and others continue to be reluctant to travel to our testing sites for fear of contracting
COVID-19. Delays in enrollment lengthen the time of studies and increase their costs, which &lt;span style="background-color: white"&gt;could
materially impact our business in future periods. Furthermore, the spread of COVID-19, which has caused a broad impact globally, may
materially affect us economically. &lt;/span&gt;While we are hopeful the infection rate of COVID-19 will continue to decline, we cannot
predict the future impact COVID-19 will have on our current and future clinical trials. Continued delays could materially impact our business in future periods
and further extend our timelines. &lt;span style="background-color: white"&gt;For
more information on the risks associated with COVID-19, refer to Part I, Item 1A, &#x201c;Risk Factors&#x201d; included in our Annual
Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZnbC26CFdXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zMWxLCSR8en8"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) on Form 10-Q and Article 8 of Regulation S-X.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2021, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--LiquidityPolicyTextBlock_zHWpnKAKdawk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zMTOusaVyIpi"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred losses since inception, devoting substantially all of our efforts toward moving the drugs in our pipeline through the
regulatory process and other research and development activities, and have an accumulated deficit of approximately $&lt;span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220630_zVhIVPBP50Y1" title="Accumulated deficit"&gt;45.2&lt;/span&gt;
million as of June 30, 2022. During the six months ended June 30, 2022, we generated a net loss of approximately $&lt;span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220630_zaSsid8WhRua" title="Net loss"&gt;8.4&lt;/span&gt;
million, of which $&lt;span id="xdx_90E_eus-gaap--OtherNoncashExpense_pn5n6_c20220101__20220630_zsxPy5JPfXhf" title="Non cash expenditures"&gt;3.5&lt;/span&gt;
million represented non-cash expenditures. Net cash used in our operating activities during the six months ended June 30, 2022 was
approximately $&lt;span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220630_zClKBTC41KGl" title="Net cash used in operating activities"&gt;4.1&lt;/span&gt;
million. We expect to continue to generate operating losses and negative cash flow from operations for the foreseeable future. Based on our
current plans, we believe our current cash balances are adequate for at least the next twelve months without considering amounts
available from the Purchase Agreement with Lincoln Park (see below and Note 3) or potential sales under our ATM Offering (see
below). Our ability to execute our longer-term operating plans, including unplanned future clinical trials for our portfolio of
drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or
other funding transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we
will obtain the necessary funding in the future when necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
had &lt;span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20220101__20220630_zDJabtiVwReg" title="Revenue"&gt;no&lt;/span&gt; revenue during the six months ended June 30, 2022 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and operating expenses. Cash
used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 20, 2021, we entered into an equity distribution agreement (the &#x201c;Sales Agreement&#x201d;) with Oppenheimer &amp;amp; Co. Inc.
under which we may issue and sell in a registered &#x201c;at-the-market&#x201d; offering shares of our common stock having an aggregate
offering price of up to $&lt;span id="xdx_900_ecustom--MaximumNumberOfSharesToBeSoldAtMarketOffering_pn6n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3z7EJdaZN94" title="Maximum number of shares to be sold at the market offering"&gt;30.0&lt;/span&gt; million from time to time through or to our Sales Agent (the &#x201c;ATM Offering&#x201d;). We expect to
use net proceeds from the ATM Offering over time as a source for working capital and general corporate purposes. The shares under the
ATM Offering will be sold and issued pursuant to our S-3 shelf registration statement (Registration No. 333-257588) filed on July 30,
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 23, 2022, we entered into a Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln
Park&#x201d;) under which we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase
up to $&lt;span id="xdx_900_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zzjDFAExIyvl" title="Commitment to purchase common stock"&gt;15,000,000&lt;/span&gt; of our shares of common stock, par value $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, subject to the terms and conditions in the Purchase Agreement,
during the term of the Purchase Agreement. See Note 3 for additional details concerning the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zRBk2jRRQwn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zeTPnvxMEa34"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and
regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements
and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#x2019;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zwEDbNApiuN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zjzbQWC9g9Nk"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of June 30, 2022 and December 31, 2021, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets related to deferred start-up costs, federal orphan drug tax credit and certain other minor temporary differences
since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained
until sufficient positive evidence exists to support its reversal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ACS 740-270 &lt;i&gt;Income Taxes &#x2013; Interim Reporting&lt;/i&gt;, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, we recognized the
tax benefit from our projected ordinary tax loss, which was used to offset the deferred tax liabilities related to the intangible asset
and resulted in the recognition of a deferred tax benefit shown in the condensed consolidated statements of operations for six months
ended June 30, 2021 and the remainder of 2021. No current income tax benefit or expense was recorded or is expected for 2022 or in the
foreseeable future since the deferred tax liability has been offset completely as of December 31, 2021 and we expect to generate future
taxable net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zaQecVRfIK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zlU3Z9kcO4Dh"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2022 exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSuMBt3ZNdFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zcDX0pnUpr0b"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_852_zhpGSOtIXb14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_847_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zMWUacrsjTU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zCJHWuIXcEg4"&gt;Business
Activities and Organization&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
are a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for
patients who have a high unmet medical need condition that affects survival or the patient&#x2019;s quality of life and for which few
or no treatment options currently exist. We currently have five drugs: four in various stages of clinical development (PCS499, PCS12852,
PCS6422 and PCS3117) and one in nonclinical development (PCS11T). We group our drugs into non-oncology (PCS499 and PCS12852) and oncology
(PCS3117, PCS6422 and PCS11T). A summary of each drug is provided below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
    most advanced product candidate, PCS499, is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline
    (PTX or Trental&#xae;). We completed a Phase 2A trial for PCS499 in patients with ulcerative and non-ulcerative necrobiosis lipoidica
    (NL) in late 2020, and in May 2021 we enrolled the first patient in our Phase 2B trial for the treatment of ulcerative NL. We expect
    to complete our interim analysis and complete enrollment of the Phase 2B trial during the first half of 2023; and, depending on the
    results, begin a pivotal Phase 3 trial in 2023. We have experienced delays in the enrollment of patients for this trial due in part
    to COVID-19 and the rare nature of this disease. We have initiated a number of recruitment programs to increase the enrollment of
    patients in this study and continue to evaluate additional options to meet our enrollment goals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS12852
    is a highly specific and potent 5HT4 agonist which has already been evaluated in clinical studies in South Korea for gastric emptying
    and gastrointestinal motility. In October 2021, the FDA cleared our IND application to proceed with a Phase 2A trial for the treatment
    of gastroparesis. We enrolled our first patient on April 5, 2022, anticipate completing enrollment in the second half of 2022 with
    top-line results by the end of 2022, and should complete our final analysis in the first half of 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS6422
    is an orally administered irreversible enzyme inhibitor administered in combination with capecitabine. When combining capecitabine
    with PCS6422 (the &#x201c;Next Generation Capecitabine&#x201d;), capecitabine becomes a more potent cancer chemotherapy agent than
    current FDA approved capecitabine. On August 2, 2021, we enrolled the first patient in our Phase 1B dose-escalation maximum tolerated
    dose trial in patients with advanced refractory gastrointestinal (GI) tract tumors. Our interim analysis of Cohorts 1 and 2 found
    no dose-limiting toxicities (DLTs), no drug related adverse events greater than Grade 1, and no hand-foot syndrome. In addition,
    the interim analysis revealed when PCS6422 inhibits the DPD enzyme, 5-FU metabolism can be significantly decreased (&amp;lt;10% metabolized
    to F-Bal compared to typically 80%) and the potency of capecitabine significantly increased compared to the present regimens of capecitabine
    (at least 50 times greater 5-FU potency based on systemic exposure per mg of capecitabine administered). The single dose of PCS6422,
    however, did not sustain the DPD inhibition throughout 7 days of capecitabine dosing which was needed to maintain the improved potency
    of capecitabine. Therefore, in an effort to define 6422 regimens that will maintain DPD inhibition throughout capecitabine dosing,
    we modified the protocol for the Phase 1B trial to not only determine the MTD of capecitabine, but to also further evaluate the timeline
    of DPD inhibition and de novo formation. We began enrolling patients in the amended Phase 1B trial in April 2022 and expect to complete
    enrollment while defining the Next Generation Capecitabine regimen (i.e., the PCS6422 regimens and the corresponding capecitabine
    regimens) by the end of 2022. We expect that our overall timeline has not changed with a Phase 2B or 3 trial starting in 2023-2024
    and NDA submission in 2027-2028.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PCS3117
    is a cytosine analog that is similar to gemcitabine (Gemzar&#xae;), but different enough in chemical structure that some patients
    are more likely to respond to PCS3117 than gemcitabine. We continue to evaluate the potential use of PCS3117 in patients with pancreatic
    cancer and to evaluate ways to identify patients who are more likely to respond to PCS3117 than gemcitabine. We anticipate initiating
    a Phase 2B trial or adaptive designed Phase 3 trial in 2023 subject to meeting with FDA and obtaining additional funding.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
    only nonclinical drug candidate is PCS11T, an analog of SN38 (SN38 being the active metabolite of irinotecan) and a next generation
    irinotecan drug for multiple types of cancers. The manufacturing process and sites for drug substance and drug product are presently
    being evaluated. In addition, we are defining the potential paths to approval, which include defining the targeted patient population
    and the type of cancer. We hope to submit an IND in the first half of 2024, followed by a Phase 1B maximum tolerated dose trial.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock>
    <PCSA:ImpactOfCovidNineteenPolicyTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_840_ecustom--ImpactOfCovidNineteenPolicyTextBlock_zcdJIDH53Fod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zaFIwlDyvJTk"&gt;Impact
of COVID-19&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
COVID-19 pandemic continues to create uncertainties in expected timelines by causing delays in clinical trials and disruptions in
the supply chain for raw materials used in clinical trial work.&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have experienced delays in the enrollment of patients in our PCS499 Phase 2B trial due to COVID-19. Some potential patients have
died from COVID-19 prior to screening and others continue to be reluctant to travel to our testing sites for fear of contracting
COVID-19. Delays in enrollment lengthen the time of studies and increase their costs, which &lt;span style="background-color: white"&gt;could
materially impact our business in future periods. Furthermore, the spread of COVID-19, which has caused a broad impact globally, may
materially affect us economically. &lt;/span&gt;While we are hopeful the infection rate of COVID-19 will continue to decline, we cannot
predict the future impact COVID-19 will have on our current and future clinical trials. Continued delays could materially impact our business in future periods
and further extend our timelines. &lt;span style="background-color: white"&gt;For
more information on the risks associated with COVID-19, refer to Part I, Item 1A, &#x201c;Risk Factors&#x201d; included in our Annual
Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:ImpactOfCovidNineteenPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zZnbC26CFdXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zMWxLCSR8en8"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) on Form 10-Q and Article 8 of Regulation S-X.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2021, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <PCSA:LiquidityPolicyTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_843_ecustom--LiquidityPolicyTextBlock_zHWpnKAKdawk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zMTOusaVyIpi"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred losses since inception, devoting substantially all of our efforts toward moving the drugs in our pipeline through the
regulatory process and other research and development activities, and have an accumulated deficit of approximately $&lt;span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220630_zVhIVPBP50Y1" title="Accumulated deficit"&gt;45.2&lt;/span&gt;
million as of June 30, 2022. During the six months ended June 30, 2022, we generated a net loss of approximately $&lt;span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20220101__20220630_zaSsid8WhRua" title="Net loss"&gt;8.4&lt;/span&gt;
million, of which $&lt;span id="xdx_90E_eus-gaap--OtherNoncashExpense_pn5n6_c20220101__20220630_zsxPy5JPfXhf" title="Non cash expenditures"&gt;3.5&lt;/span&gt;
million represented non-cash expenditures. Net cash used in our operating activities during the six months ended June 30, 2022 was
approximately $&lt;span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220630_zClKBTC41KGl" title="Net cash used in operating activities"&gt;4.1&lt;/span&gt;
million. We expect to continue to generate operating losses and negative cash flow from operations for the foreseeable future. Based on our
current plans, we believe our current cash balances are adequate for at least the next twelve months without considering amounts
available from the Purchase Agreement with Lincoln Park (see below and Note 3) or potential sales under our ATM Offering (see
below). Our ability to execute our longer-term operating plans, including unplanned future clinical trials for our portfolio of
drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or
other funding transactions. We plan to continue to actively pursue financing alternatives, but there can be no assurance that we
will obtain the necessary funding in the future when necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
had &lt;span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_do_c20220101__20220630_zDJabtiVwReg" title="Revenue"&gt;no&lt;/span&gt; revenue during the six months ended June 30, 2022 and do not have any revenue under contract or any immediate sales prospects.
Our primary uses of cash are to fund our planned clinical trials, research and development expenditures and operating expenses. Cash
used to fund operating expenses is impacted by the timing of when we incur and pay these expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 20, 2021, we entered into an equity distribution agreement (the &#x201c;Sales Agreement&#x201d;) with Oppenheimer &amp;amp; Co. Inc.
under which we may issue and sell in a registered &#x201c;at-the-market&#x201d; offering shares of our common stock having an aggregate
offering price of up to $&lt;span id="xdx_900_ecustom--MaximumNumberOfSharesToBeSoldAtMarketOffering_pn6n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3z7EJdaZN94" title="Maximum number of shares to be sold at the market offering"&gt;30.0&lt;/span&gt; million from time to time through or to our Sales Agent (the &#x201c;ATM Offering&#x201d;). We expect to
use net proceeds from the ATM Offering over time as a source for working capital and general corporate purposes. The shares under the
ATM Offering will be sold and issued pursuant to our S-3 shelf registration statement (Registration No. 333-257588) filed on July 30,
2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 23, 2022, we entered into a Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln
Park&#x201d;) under which we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase
up to $&lt;span id="xdx_900_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zzjDFAExIyvl" title="Commitment to purchase common stock"&gt;15,000,000&lt;/span&gt; of our shares of common stock, par value $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, subject to the terms and conditions in the Purchase Agreement,
during the term of the Purchase Agreement. See Note 3 for additional details concerning the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-06-30" decimals="-5" unitRef="USD">-45200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="-5"
      unitRef="USD">-8400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-01-01to2022-06-30"
      decimals="-5"
      unitRef="USD">3500000</us-gaap:OtherNoncashExpense>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-06-30"
      decimals="-5"
      unitRef="USD">-4100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <PCSA:MaximumNumberOfSharesToBeSoldAtMarketOffering
      contextRef="From2021-08-182021-08-20_custom_EquityDistributionAgreementMember"
      decimals="-6"
      unitRef="USD">30000000.0</PCSA:MaximumNumberOfSharesToBeSoldAtMarketOffering>
    <PCSA:MaximumCommitmenttoPurchaseCommonStockValue
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">15000000</PCSA:MaximumCommitmenttoPurchaseCommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_849_eus-gaap--UseOfEstimates_zRBk2jRRQwn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zeTPnvxMEa34"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and
regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements
and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#x2019;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zwEDbNApiuN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zjzbQWC9g9Nk"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. As of June 30, 2022 and December 31, 2021, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets related to deferred start-up costs, federal orphan drug tax credit and certain other minor temporary differences
since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained
until sufficient positive evidence exists to support its reversal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ACS 740-270 &lt;i&gt;Income Taxes &#x2013; Interim Reporting&lt;/i&gt;, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, we recognized the
tax benefit from our projected ordinary tax loss, which was used to offset the deferred tax liabilities related to the intangible asset
and resulted in the recognition of a deferred tax benefit shown in the condensed consolidated statements of operations for six months
ended June 30, 2021 and the remainder of 2021. No current income tax benefit or expense was recorded or is expected for 2022 or in the
foreseeable future since the deferred tax liability has been offset completely as of December 31, 2021 and we expect to generate future
taxable net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zaQecVRfIK6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zlU3Z9kcO4Dh"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2022 exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSuMBt3ZNdFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zcDX0pnUpr0b"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zkhVwNUtVMFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_82B_zVNYBLTGuTG9"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zaSHc5ft7Xul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets at June 30, 2022 and December 31, 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zIoYM0uGKiV7" style="display: none"&gt;Summary of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220630_z54gRZ5GHxp1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_zcVpqQnWfmF1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANz27j_zDn42NPjVvD2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,059,429&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,059,429&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANz27j_z4tugYEL164e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,397,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,002,791&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANz27j_zx3xyiJkeKNd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total intangible assets,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,662,390&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,056,638&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zmsgYKTj69Pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross
intangible assets consist primarily of costs we capitalized when we acquired the license rights to PCS499 in 2018. Amortization expense
was $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20220630_pp0p0" title="Amortization expense"&gt;394,248&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20210630_zSbiHnFLgeCc" title="Amortization expense"&gt;397,664&lt;/span&gt; for the six months ended June 30, 2022 and 2021, respectively, and is included within research and development
expense in the accompanying condensed consolidated statements of operations. As of June 30, 2022, our estimated amortization expense
for the year ended December 31, 2022 and for annual periods thereafter until the asset is fully amortized is approximately $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20220630_zVlHmcVNjhId" title="Future amortization expenses, annual periods thereafter"&gt;788,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zaSHc5ft7Xul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets at June 30, 2022 and December 31, 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zIoYM0uGKiV7" style="display: none"&gt;Summary of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220630_z54gRZ5GHxp1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_zcVpqQnWfmF1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANz27j_zDn42NPjVvD2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,059,429&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,059,429&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANz27j_z4tugYEL164e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,397,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,002,791&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANz27j_zx3xyiJkeKNd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total intangible assets,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,662,390&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,056,638&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">11059429</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11059429</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">3397039</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3002791</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">7662390</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">8056638</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">394248</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">397664</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">788000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWgnKNqUNlNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82E_zhg7TJuti5Yd"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20220630_zOU1wwkaD26f" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220630_zvFjlcwrOUOd" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_zkQu1uKEC4lf" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zMrPgrgSQMod" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; issued or outstanding shares of preferred stock at either June 30, 2022 or December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Increase
in Our Authorized Number of Shares&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 1, 2022, we amended our Certificate of Incorporation to increase the number of authorized shares of our common stock from &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_z0g57LEKZpYe" title="Common stock, shares authorized"&gt;30,000,000&lt;/span&gt;
to &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20220101_zMMgI2LTe1dg" title="Common stock, shares authorized"&gt;50,000,000&lt;/span&gt;. We believe &lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20220630_zdi5m4HUqIf6" title="Common stock, shares authorized"&gt;50,000,000&lt;/span&gt; authorized shares of common stock better aligns our capital structure with our future needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;ATM
Offering&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 20, 2021, we entered into the Sales Agreement with the Sales Agent under which we may issue and sell up to $&lt;span id="xdx_901_ecustom--MaximumNumberOfSharesToBeSoldAtMarketOffering_pn6n6_c20210818__20210820__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zCMm2Sn0mWKj" title="Maximum number of shares to be sold at the market offering"&gt;30.0&lt;/span&gt;
million of our common stock from time to time under the ATM Offering. We expect to use net proceeds from the ATM Offering over time
as a source for working capital and general corporate purposes. We did not sell any shares during the six months ended June 30,
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Lincoln
Park Capital Fund, LLC Purchase Agreement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
March 23, 2022, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up
to $&lt;span id="xdx_90B_ecustom--MaximumCommitmenttoPurchaseCommonStockValue_pn6n6_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zPNxcNoCPIV5" title="Commitment to purchase common stock"&gt;15.0&lt;/span&gt; million of shares (the &#x201c;Purchase Shares&#x201d;) of our common stock, $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUJv2yld8u8h" title="Common stock par value"&gt;0.0001&lt;/span&gt; par value per share, subject to the terms
and conditions in the Purchase Agreement. We issued &lt;span id="xdx_905_ecustom--SharesIssuedInConnectionWithPurchaseAgreementShares_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgpmkgcm7Hsa" title="Number of common stock issued on commitment fees, shares"&gt;123,609&lt;/span&gt; shares of common stock (valued at $&lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssuedInCommitmentFee_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_ziIkTXUy1lt8" title="Number of common stock issued on commitment fees, value"&gt;450,000&lt;/span&gt;) to Lincoln Park as a commitment
fee in connection with entering into the Purchase Agreement and agreed to reimburse Lincoln Park $&lt;span id="xdx_905_ecustom--ReimbursementFees_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIMuBOCSaCjf" title="Reimbursement fee"&gt;25,000&lt;/span&gt; for fees incurred in connection
with the Purchase Agreement. Concurrent with entering into the Purchase Agreement, we also entered into a registration rights agreement
with Lincoln Park (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which we agreed to take certain actions relating to
the registration under the Securities Act of 1933, as amended, of the offer and sale of the shares of common stock available for issuance
under the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Beginning
on March 23, 2022, we have the right to present Lincoln Park with a purchase notice (a &#x201c;Regular Purchase Notice&#x201d;), directing
Lincoln Park to purchase up to &lt;span id="xdx_904_ecustom--NumberOfCommonStockSharesinRegularPurchase_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Number of common stock shares in regular purchase"&gt;25,000&lt;/span&gt; Purchase Shares (the &#x201c;Regular Purchase Amount&#x201d;) provided that the closing sale price
of the common stock on the purchase date is not below a threshold price set forth in the Purchase Agreement (a &#x201c;Regular Purchase&#x201d;).
The Regular Purchase Amount may be increased to up to &lt;span id="xdx_907_ecustom--NumberOfCommonStockSharesExceedingRegularPurchase_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Number of common stock shares exceeding regular purchase"&gt;75,000&lt;/span&gt; shares if the closing sale price of our common stock on the applicable purchase
date equals or exceeds certain higher threshold prices set forth in the Purchase Agreement. We and Lincoln Park may mutually agree to
increase the Regular Purchase Amount with respect to any Regular Purchase under the Purchase Agreement, provided that Lincoln Park&#x2019;s
maximum committed purchase obligation under any single Regular Purchase shall not exceed $&lt;span id="xdx_901_ecustom--DailyMaximumCommittedPurchaseObligationsValue_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zBeQtTHwO741" title="Daily maximum committed purchase obligations, value"&gt;1,250,000&lt;/span&gt;. The above-referenced share amount
limitations and closing sale price thresholds are subject to adjustment for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement. The purchase price per share for
each Regular Purchase will be based on prevailing market prices of the common stock immediately preceding the time of sale as computed
in accordance with the terms set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park
must pay for shares of common stock under the Purchase Agreement. Lincoln Park may not assign or transfer its rights and obligations
under the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
aggregate number of shares that we can issue to Lincoln Park under the Purchase Agreement may not exceed &lt;span id="xdx_90F_ecustom--MaximumNumberOfSharesSoldInTransaction_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Maximum number of shares issued sold"&gt;3,142,430&lt;/span&gt; shares (subject to
proportional adjustments for stock splits, reverse stock splits and similar events as described above), which is equal to &lt;span id="xdx_905_ecustom--PercentageOfExchangeCapitalization_pid_dp_uPure_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zGUgQFBi9hfk" title="Nasdaq's exchange cap percent"&gt;19.99&lt;/span&gt;% of the
outstanding shares of common stock immediately prior to the execution of the Purchase Agreement (the &#x201c;Exchange Cap&#x201d;), unless
(i) stockholder approval is obtained to issue shares of common stock in excess of the Exchange Cap, in which case the Exchange Cap will
no longer apply, or (ii) the average price of all sales of Purchase Shares to Lincoln Park under the Purchase Agreement equals or exceeds
the lower of (i) the Nasdaq official closing price immediately preceding the execution of the Purchase Agreement or (ii) the arithmetic
average of the five Nasdaq official closing prices for the common stock immediately preceding the execution of the Purchase Agreement,
plus an incremental amount to take into account the issuance of the commitment shares to Lincoln Park under the Purchase Agreement, such
that the transactions contemplated by the Purchase Agreement are exempt from the Exchange Cap limitation under applicable Nasdaq rules.
In all instances, we may not sell shares of our common stock to Lincoln Park under the Purchase Agreement if it would result in Lincoln
Park beneficially owning more than &lt;span id="xdx_901_ecustom--BeneficialOwnershipLimitationPercentage_pid_dp_uPure_c20220321__20220323__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__srt--RangeAxis__srt--MaximumMember_zEdNwYslR3a4" title="Beneficial ownership limitation percentage"&gt;9.99&lt;/span&gt;% of the outstanding shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
may terminate the Purchase Agreement at any time, at our sole discretion, without any cost or penalty, by giving one business day notice
to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any
direct or indirect short selling or hedging of the common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;There
are no limitations on use of proceeds, financial or business covenants, restrictions on future financings (other than restrictions on
our ability to enter into variable rate transactions described in the Purchase Agreement), rights of first refusal, participation rights,
penalties or liquidated damages in the Purchase Agreement. We may deliver Purchase Notices under the Purchase Agreement, subject to market
conditions, and in light of our capital needs from time to time and under the limitations contained in the Purchase Agreement. Any proceeds
that we receive under the Purchase Agreement are expected to be used for working capital and general corporate purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Repurchase
of Shares from Aposense, Ltd.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
March 29, 2022, we purchased &lt;span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20220327__20220329__dei--LegalEntityAxis__custom--AposenseLtdMember_zCAQ2NSIwDHh" title="Number of repurchase of common stock, shares"&gt;100,000&lt;/span&gt; shares of our common stock from Aposense Ltd. for $&lt;span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodValue_c20220327__20220329__dei--LegalEntityAxis__custom--AposenseLtdMember_z0SP8I9Wa62b" title="Repurchase of common stock value"&gt;300,000&lt;/span&gt; in a private transaction&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
are holding these shares as treasury stock until they are reissued or retired at the discretion of our Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-01-01" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <PCSA:MaximumNumberOfSharesToBeSoldAtMarketOffering
      contextRef="From2021-08-182021-08-20_custom_EquityDistributionAgreementMember"
      decimals="-6"
      unitRef="USD">30000000.0</PCSA:MaximumNumberOfSharesToBeSoldAtMarketOffering>
    <PCSA:MaximumCommitmenttoPurchaseCommonStockValue
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember"
      decimals="-6"
      unitRef="USD">15000000.0</PCSA:MaximumCommitmenttoPurchaseCommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">123609</PCSA:SharesIssuedInConnectionWithPurchaseAgreementShares>
    <PCSA:StockIssuedDuringPeriodValueNewIssuedInCommitmentFee
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">450000</PCSA:StockIssuedDuringPeriodValueNewIssuedInCommitmentFee>
    <PCSA:ReimbursementFees
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">25000</PCSA:ReimbursementFees>
    <PCSA:NumberOfCommonStockSharesinRegularPurchase
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">25000</PCSA:NumberOfCommonStockSharesinRegularPurchase>
    <PCSA:NumberOfCommonStockSharesExceedingRegularPurchase
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">75000</PCSA:NumberOfCommonStockSharesExceedingRegularPurchase>
    <PCSA:DailyMaximumCommittedPurchaseObligationsValue
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">1250000</PCSA:DailyMaximumCommittedPurchaseObligationsValue>
    <PCSA:MaximumNumberOfSharesSoldInTransaction
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">3142430</PCSA:MaximumNumberOfSharesSoldInTransaction>
    <PCSA:PercentageOfExchangeCapitalization
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Pure">0.1999</PCSA:PercentageOfExchangeCapitalization>
    <PCSA:BeneficialOwnershipLimitationPercentage
      contextRef="From2022-03-212022-03-23_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0999</PCSA:BeneficialOwnershipLimitationPercentage>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-03-272022-03-29_custom_AposenseLtdMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-03-272022-03-29_custom_AposenseLtdMember"
      decimals="0"
      unitRef="USD">300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z8JtaEh7JkH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;Note
4 - &lt;span id="xdx_820_zcodFvqfEepe"&gt;Stock-based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
June 19, 2019, our stockholders approved, and we adopted the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#x201c;2019
Plan&#x201d;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan &lt;span style="background-color: white"&gt;originally provided&lt;/span&gt; for the aggregate issuance of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember__us-gaap--AwardTypeAxis__custom--OriginalMember_zPLUoL0p8H1l" title="Maximum equity available for issuance under the plan"&gt;3,000,000&lt;/span&gt; shares of our common stock, with &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zzBjr0Z4Z2Z9" title="Shares available for future grants"&gt;627,086&lt;/span&gt;
&lt;span style="background-color: white"&gt;shares available for future grants at June 30, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
July 11, 2022, our shareholders approved an increase in the aggregate number of shares of our common stock available for issuance under
our 2019 plan by 3,000,000 shares to &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220711__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zIvB9HTYmFVb" title="Maximum equity available for issuance under the plan"&gt;6,000,000&lt;/span&gt; shares in total.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Compensation Expense&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7ClB0UYcF0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the three and six month periods ended June 30, 2022 and 2021 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_z5I4ignx7VS2" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
                                            Months Ended&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
                                            30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
                                            Months Ended&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
                                            30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxd3g4OmvjTi" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;685,624&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdPAS0onR9R1" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;191,594&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3BGzipHAmE5" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;877,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVSSqQb6Zdsl" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;245,385&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYUiMYF3lsyb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,323,745&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxL6dtq5NF0k" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;673,729&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWZhN4qivM24" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,960,766&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuOBCXBQstQb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;928,237&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630_zumQss4QUm9e" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,009,369&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630_zKmuV1SQigKb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;865,323&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630_zYSqQzlJrZXc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,838,266&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_z42VtXLe2e08" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,173,622&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zKydv2SBxYPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;No
tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred
tax assets relating to this expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Options&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zANKSZJgIGHc" title="Stock option granted"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_do_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFajQdW0bOX5" title="Stock option cancelled or forfeited"&gt;No&lt;/span&gt;&lt;/span&gt;
stock options were granted, cancelled or forfeited during the six months ended June 30, 2022. At June 30, 2022, we had outstanding options
for the purchase of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Outstanding options for the purchase shares"&gt;178,496&lt;/span&gt; shares with a weighted average exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted average exercise price of stock option outstanding"&gt;17.07&lt;/span&gt; and a weighted average remaining contractual life
of &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXfX60nIth6g" title="Stock options outstanding, weighted average remaining contractual term"&gt;3.1&lt;/span&gt; years. Options &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercisable at June 30, 2022 &lt;span style="background-color: white"&gt;for
the purchase of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of option exercisable during period"&gt;176,315&lt;/span&gt; shares of our common stock had a weighted average exercise price $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of options exercisable, weighted average exercise price"&gt;17.02&lt;/span&gt; and a weighted average remaining contractual
life of &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1TmoAx9Hzt" title="Stock options exercisable, weighted average remaining contractual term"&gt;3.0&lt;/span&gt; years. We had, a&lt;/span&gt;s of June 30, 2022, total unrecognized stock-based compensation expense for these stock options of
approximately $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" title="Unrecognized stock option expense"&gt;37,000&lt;/span&gt;, which is expected to be fully recognized by the end of the third quarter of 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock Awards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
January 4, 2022, we granted and issued Restricted Stock Awards (&#x201c;RSAs&#x201d;) for &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220103__20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zv6a2kr27iPg" title="Stock granted during period restricted stock, shares"&gt;9,766&lt;/span&gt; shares of our common stock to a consultant
for services to be provided in 2022. These RSAs had a fair market value of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdp0" title="Stock based compensation"&gt;50,000&lt;/span&gt; on the date of grant and were expensed as stock-based
compensation during the six months ended June 30, 2022. Effective January 1, 2022, we also granted &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220103__20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zs5tsmjgjFje" title="Stock granted during period restricted stock, shares"&gt;72,832&lt;/span&gt; RSAs to our directors for their
2022 service which had a fair market value of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pp0p0_c20220104__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zGAt2x1foFdg" title="Restricted stock fair value"&gt;252,000&lt;/span&gt; on the date of grant and will cliff vest on December 31, 2022. Additionally, on
March 31, 2022, we issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220320__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zjuqygceQcte" title="Number of restricted shares issued"&gt;17,572&lt;/span&gt; RSAs to our directors in satisfaction of the $&lt;span id="xdx_90B_ecustom--AccruedDirectorsFees_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_pp0p0" title="Directors' fees"&gt;120,000&lt;/span&gt; of directors&#x2019; fees we had accrued at December
31, 2021. &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 31, 2022, a director did not seek reelection
and forfeited the &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pp0p0_c20220529__20220531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zqNjQVcX4BG5" title="Restricted stock units forfeited"&gt;18,208&lt;/span&gt; RSAs related to their 2022 service. &lt;span style="background-color: white"&gt;We did not cancel any RSAs during
the six months ended June 30, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;At
June 30, 2022, we had unvested RSAs for &lt;/span&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEUH56MJ2p51" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Number of unvested restricted stock award"&gt;145,733
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares with a weighted average
grant date fair value of $&lt;/span&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z37CbNwR5w58" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Weighted average grant date fair value"&gt;6.13&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;.
Unvested RSAs representing &lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_c20220101__20220630__us-gaap--VestingAxis__custom--TwoThousandTwentyTwoMember_z1Y1uf8BZ5e6" title="Number of restricted stock expected to vest, shares"&gt;120,733
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares are expected
to vest at various dates in 2022, &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber_c20220101__20220630__us-gaap--VestingAxis__custom--TwoThousandTwentyThreeMember_z0R7GjGrcc8a" title="Number of restricted stock expected to vest, shares"&gt;12,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares are expected
to vest in 2023, and the remainder are expected to vest in 2024. As of June 30, 2022, the total unrecognized stock-based compensation
expense related to the outstanding RSAs was approximately $&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1xfV1PTzb23" title="Unrecognized share based compensation expense"&gt;310,000&lt;/span&gt; which is expected to be recognized over a weighted average period
of approximately &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEoAOQqh3IAk" title="Weighted average period"&gt;0.8&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock Units&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z8d5T3Ki4Ot9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Units (&#x201c;RSUs&#x201d;) during the six months ended June 30, 2022 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zjf0Q6rBUrB7" style="display: none"&gt;Schedule of Information About RSU Outstanding&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
                                            of&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;average&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;grant-date
                    fair&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;value
                    per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 56%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsnTJ8vUfM6k" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Number of shares, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;439,593&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, awarded"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,363,917&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, awarded"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09vNXbV5Ka9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(22,088&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.81&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyHTyRw8XB09" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z04qac9KvjA6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,777,922&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zykyPXnb3Pmj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and unissued&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and unissued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(440,374&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,337,548&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zmqsT1P0r5F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2022, unrecognized stock-based compensation expense of approximately $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn6n6_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkLtwdKbPSuk" title="Unrecognized share based compensation expense"&gt;4.0&lt;/span&gt; million for RSUs is expected to be fully recognized
over a weighted average period of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVnPTLJki7b5" title="Weighted average period, restricted stock units"&gt;0.8&lt;/span&gt; years. The unrecognized expense excludes approximately $&lt;span id="xdx_909_ecustom--UnrecognizedShareBasedCompensationExpense_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pp0p0" title="Unrecognized restricted stock expense"&gt;349,000&lt;/span&gt; of expense related to certain RSUs
with a performance milestone that is not probable of occurring at this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the six months ended June 30, 2022, we grant&lt;span style="background-color: white"&gt;ed&lt;/span&gt; RSUs related to the future issuance of &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__custom--BaseCompensationMember_zexw2rKte1sj" title="Restricted stock units awarded"&gt;243,131&lt;/span&gt;
&lt;span style="background-color: white"&gt;shares of our common stock p&lt;/span&gt;ursuant to agreements with our Executive team and certain other
employees where a portion of their base compensation is paid in RSUs&lt;span style="background-color: white"&gt;. The value of an RSU award
is based on the average share price of the month services were provided. &lt;/span&gt;These RSUs are vested but must meet distribution requirements
before any shares of common stock are issued. Effective July 1, 2022, we established a $&lt;span id="xdx_908_ecustom--MinimumPricePerShareOfEquityCompensation_iI_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zICUThFSRYra" title="Minimum price per share of equity compensation"&gt;5.00&lt;/span&gt; per share floor for the computation of the
number of shares our Executive team members could earn under this program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Included
in RSUs awarded during the six months ended June 30, 2022 are RSUs awarded on April 1, 2022 for &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zEX0L8T1Xui5" title="Restricted stock units awarded"&gt;1,979,818&lt;/span&gt;
shares of our common stock, of which RSUs related to the future issuance of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztmn0BWRNbE7" title="Common stock available for future issuance"&gt;879,819&lt;/span&gt;
shares were subject to shareholder approval, which was received on July 11, 2022. These RSUs vest on January 1, 2023 and are subject
to distribution requirements before any shares of common stock are issued. The RSUs that were not subject to shareholder approval
ha&lt;span style="background-color: white"&gt;d&lt;/span&gt; a fair value on April 1, 2022 of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn5n6_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zk59jOiyljcb" title="Restricted stock fair value"&gt;3.3&lt;/span&gt;
million while the RSUs that were approved by the shareholders on July 11, 2022 have a fair value, as of the approval date, of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pn5n6_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zknx6KVREl7" title="Fair value amount"&gt;2.9&lt;/span&gt;
million. &lt;span style="background-color: white"&gt;The $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn5n6_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--AprilOneTwoThousandTwentyTwo2022GrantMember_zRX2toEn2kW2" title="Restricted stock fair value"&gt;3.3&lt;/span&gt; million is being recognized ratably over the period April 1, 2022 through
December 31, 2022, while the $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pn5n6_c20220710__20220711__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5jT5L5VY8Me" title="Fair value amount"&gt;2.9&lt;/span&gt; million will be recognized &lt;/span&gt; ratably over the remainder
of 2022&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;beginning in the third quarter of 2022&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Holders
of our vested RSUs &lt;span style="background-color: white"&gt;will be &lt;/span&gt; issue&lt;span style="background-color: white"&gt;d&lt;/span&gt; shares of our common stock upon the &lt;span style="background-color: white"&gt;satisfaction &lt;/span&gt; of the distribution restrictions contained
in their Restricted Stock Unit Award Agreement. The distribution restrictions are typically different (longer) than the vesting schedule,
imposing an additional restriction on the holder. Unlike RSAs, while employees may hold fully vested RSUs, the individual does not hold
any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU
converts into one share of our common stock. The RSUs contain dividend equivalent rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_do_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzLc42kaaYeg" title="Warrant cancelled or forfeited"&gt;No&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;stock purchase warrants were &lt;span style="background-color: white"&gt;granted,
cancelled &lt;/span&gt;or forfeited during the six months ended June 30, 2022. At June 30, 2022, we had outstanding and vested stock purchase
warrants for the purchase of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants to purchase shares"&gt;303,725&lt;/span&gt; &lt;span style="background-color: white"&gt;shares with a weighted average exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Warrants, weighted average exercise price"&gt;10.66&lt;/span&gt; and
a weighted average remaining contractual life of &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zV9lLDVAgu61" title="Weighted average remaining contractual life"&gt;1.3&lt;/span&gt; years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Effective
May 3, 2022, we extended the expiration date of a warrant held by a consultant by one year in connection with the extension of their
service agreement. No other terms of the warrant, including the exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220503__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zOjmhbIxK9u5"&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;,
were changed. We will recognize expense of approximately $&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220503__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zN1LYkVhjkr9"&gt;33,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;related to this warrant
modification over a one-year period beginning May 2022.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-06-30_custom_TwoThousandAndNineteenPlanMember_custom_OriginalMember"
      decimals="INF"
      unitRef="Shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-06-30_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      unitRef="Shares">627086</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-07-11_us-gaap_SubsequentEventMember_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7ClB0UYcF0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the three and six month periods ended June 30, 2022 and 2021 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_z5I4ignx7VS2" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
                                            Months Ended&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
                                            30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
                                            Months Ended&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
                                            30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxd3g4OmvjTi" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;685,624&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zdPAS0onR9R1" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;191,594&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3BGzipHAmE5" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;877,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVSSqQb6Zdsl" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;245,385&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYUiMYF3lsyb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,323,745&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zxL6dtq5NF0k" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;673,729&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWZhN4qivM24" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,960,766&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuOBCXBQstQb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;928,237&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630_zumQss4QUm9e" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,009,369&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20210401__20210630_zKmuV1SQigKb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;865,323&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220630_zYSqQzlJrZXc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,838,266&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_z42VtXLe2e08" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,173,622&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">685624</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">191594</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">877500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">245385</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1323745</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">673729</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1960766</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">928237</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">2009369</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">865323</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">2838266</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">1173622</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">178496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">17.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">176315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">17.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">37000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-032022-01-04_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">9766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-032022-01-04_us-gaap_RestrictedStockMember_custom_DirectorsMember"
      decimals="INF"
      unitRef="Shares">72832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-01-04_us-gaap_RestrictedStockMember_custom_DirectorsMember"
      decimals="0"
      unitRef="Shares">252000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-03-202022-03-31_us-gaap_RestrictedStockMember_custom_DirectorsMember"
      decimals="INF"
      unitRef="Shares">17572</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <PCSA:AccruedDirectorsFees
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockMember_custom_DirectorsMember"
      decimals="0"
      unitRef="USD">120000</PCSA:AccruedDirectorsFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-05-292022-05-31_us-gaap_RestrictedStockMember_custom_DirectorsMember"
      decimals="0"
      unitRef="Shares">18208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">145733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">6.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber
      contextRef="From2022-01-012022-06-30_custom_TwoThousandTwentyTwoMember"
      decimals="INF"
      unitRef="Shares">120733</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber
      contextRef="From2022-01-012022-06-30_custom_TwoThousandTwentyThreeMember"
      decimals="INF"
      unitRef="Shares">12500</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">310000</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockMember">P0Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_897_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z8d5T3Ki4Ot9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Units (&#x201c;RSUs&#x201d;) during the six months ended June 30, 2022 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zjf0Q6rBUrB7" style="display: none"&gt;Schedule of Information About RSU Outstanding&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"&gt;&lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
                                            of&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;average&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;grant-date
                    fair&lt;/span&gt;&lt;/p&gt;
                    &lt;p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;value
                    per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 56%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsnTJ8vUfM6k" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Number of shares, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;439,593&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, awarded"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,363,917&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, awarded"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09vNXbV5Ka9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(22,088&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.81&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyHTyRw8XB09" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, shares issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z04qac9KvjA6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,777,922&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zykyPXnb3Pmj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and unissued&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, vested and unissued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(440,374&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of shares, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,337,548&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue_c20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">439593</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1363917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">22088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">7.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">3500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">6.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1777922</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">4.12</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">-440374</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">4.97</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1337548</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.83</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-6"
      unitRef="USD">4000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">P0Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <PCSA:UnrecognizedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">349000</PCSA:UnrecognizedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_BaseCompensationMember"
      decimals="INF"
      unitRef="Shares">243131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <PCSA:MinimumPricePerShareOfEquityCompensation
      contextRef="AsOf2022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">5.00</PCSA:MinimumPricePerShareOfEquityCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_AprilOneTwoThousandTwentyTwo2022GrantMember"
      decimals="INF"
      unitRef="Shares">1979818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-07-102022-07-11_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">879819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_AprilOneTwoThousandTwentyTwo2022GrantMember"
      decimals="-5"
      unitRef="USD">3300000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-102022-07-11_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USDPShares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_AprilOneTwoThousandTwentyTwo2022GrantMember"
      decimals="-5"
      unitRef="USD">3300000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-102022-07-11_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USDPShares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">303725</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">10.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember">P1Y3M18D</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-03_us-gaap_WarrantMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="USDPShares">7.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-05-03_us-gaap_WarrantMember_custom_ConsultantMember"
      decimals="0"
      unitRef="USD">33000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zDF0u2yO1cW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_820_zHjiZb7GB7Va"&gt;Net Loss per Share of Common Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
and six month periods ended June 30, 2022 and 2021 excludes the impact of potentially dilutive common shares since those shares would
have an anti-dilutive effect on net loss per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkOIJnlxehlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the three and six month periods ended June 30, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zvhqEF0fMs0f" style="display: none"&gt;Schedule of Net Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220401__20220630_za3vl8QvOkGg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210401__20210630_z4cGDc2c6kI5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20220630_zKB8vE2ktCra" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20210630_zLQu56bq0xP4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted net loss
    per share:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--NetIncomeLoss_zhV6ROILpGcj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,164,368&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,157,043&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,391,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,256,523&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zcCqDBb6YXbe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number
    of common shares-basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,940,510&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,406,363&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,886,116&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,997,303&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareBasic_z6yzRSdmFfK2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted net
    loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.20&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.53&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.35&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zwkZqaCPibTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
diluted net loss per share for the three and six month periods ended June 30, 2022 and 2021 excluded &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630_zINBxLXBCiAi" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;1,965,502&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;709,954&lt;/span&gt; of potentially
dilutive common shares, respectively, related to outstanding stock options, stock purchase warrants and unvested restricted stock since
those shares would have had an anti-dilutive effect on net loss per share during the periods then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkOIJnlxehlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the three and six month periods ended June 30, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zvhqEF0fMs0f" style="display: none"&gt;Schedule of Net Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220401__20220630_za3vl8QvOkGg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210401__20210630_z4cGDc2c6kI5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20220630_zKB8vE2ktCra" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20210630_zLQu56bq0xP4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted net loss
    per share:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--NetIncomeLoss_zhV6ROILpGcj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,164,368&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,157,043&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,391,499&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,256,523&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zcCqDBb6YXbe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number
    of common shares-basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,940,510&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,406,363&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,886,116&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,997,303&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareBasic_z6yzRSdmFfK2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted net
    loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.20&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.53&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.35&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-5164368</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-3157043</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">-8391499</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">-5256523</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">15940510</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">15406363</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-06-30"
      decimals="INF"
      unitRef="Shares">15886116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-06-30"
      decimals="INF"
      unitRef="Shares">14997303</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-06-30"
      decimals="INF"
      unitRef="Shares">1965502</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-06-30"
      decimals="INF"
      unitRef="Shares">709954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zPx7jmldjMie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_82B_zo8oVMn90yXj"&gt;Operating Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under an operating lease. Our leases do not provide an
implicit rate and, as such, we have used our incremental borrowing rate of &lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220630_zpE5BH8pWdT6" title="Operating lease borrowing rate"&gt;8&lt;/span&gt;% to determine the present value of the lease payments based
on the information available at the lease commencement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
costs included in our condensed consolidated statements of operations totaled $&lt;span id="xdx_904_eus-gaap--LeaseCost_pp0p0_c20220401__20220630_zYGHmnKkTkba" title="Lease cost"&gt;24,137&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--LeaseCost_pp0p0_c20210401__20210630_zMIPf1X54VF" title="Lease cost"&gt;21,801&lt;/span&gt; for the three months ended June 30
and 2021, respectively, and $&lt;span id="xdx_906_eus-gaap--LeaseCost_c20220101__20220630_pp0p0" title="Lease cost"&gt;48,528&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--LeaseCost_c20210101__20210630_pp0p0" title="Lease cost"&gt;45,831&lt;/span&gt; for the six months ended June 30, 2022 and 2021, respectively. The weighted average remaining
lease terms and discount rate for our operating leases were as follows at June 30, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zuCRzYZinoD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z0C2VaxiisOb" style="display: none"&gt;Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining lease term (years) for
    our facility lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--FacilityLeaseMember_zvLor31lWt9b" title="Operating lease, weighted average remaining lease term"&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining lease term (years) for our equipment
    lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--EquipmentLeaseMember_zhcGBsJnb3b" title="Operating lease, weighted average remaining lease term"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average remaining lease term (years)
    for our facility and equipment leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630_zRQthivWEHP7" title="Operating lease, weighted average remaining lease term"&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average discount rate for our facility
    and equipment leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220630_zpEBInSr38r" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average discount rate for our facility and equipment leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zgZ8r5AqpuJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zkPy1Uev7nlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for all operating leases were as follows as of June 30, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zTnvStVTQxq4" style="display: none"&gt;Schedule of Maturities of Lease Liabilities for all Operating Leases&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20220630_z7iZtEbovtTa" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzqtT_zxmLcTtIplP4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 74%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,457&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzqtT_zxcW3vxunlZ9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,420&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzqtT_zRN1xZw4As23" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,605&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzqtT_zNfdAvpl1cwk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,482&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z6gPLHIOA7ta" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,275&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zq4rtcOZJyl3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    current maturities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(26,552&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current
    lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,655&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zVnUXhSrhKya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-06-30" decimals="INF" unitRef="Pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">24137</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">21801</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-01to2022-06-30"
      decimals="0"
      unitRef="USD">48528</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-01-012021-06-30"
      decimals="0"
      unitRef="USD">45831</us-gaap:LeaseCost>
    <PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock_zuCRzYZinoD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z0C2VaxiisOb" style="display: none"&gt;Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining lease term (years) for
    our facility lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--FacilityLeaseMember_zvLor31lWt9b" title="Operating lease, weighted average remaining lease term"&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining lease term (years) for our equipment
    lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--EquipmentLeaseMember_zhcGBsJnb3b" title="Operating lease, weighted average remaining lease term"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average remaining lease term (years)
    for our facility and equipment leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630_zRQthivWEHP7" title="Operating lease, weighted average remaining lease term"&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average discount rate for our facility
    and equipment leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220630_zpEBInSr38r" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average discount rate for our facility and equipment leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-06-30_custom_FacilityLeaseMember">P0Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-06-30_custom_EquipmentLeaseMember">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-06-30">P0Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-06-30" decimals="INF" unitRef="Pure">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zkPy1Uev7nlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for all operating leases were as follows as of June 30, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zTnvStVTQxq4" style="display: none"&gt;Schedule of Maturities of Lease Liabilities for all Operating Leases&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20220630_z7iZtEbovtTa" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzqtT_zxmLcTtIplP4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 74%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,457&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzqtT_zxcW3vxunlZ9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,420&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzqtT_zRN1xZw4As23" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,605&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzqtT_zNfdAvpl1cwk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,482&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z6gPLHIOA7ta" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    Interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,275&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zq4rtcOZJyl3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    current maturities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(26,552&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current
    lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,655&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">26457</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">6420</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">1605</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">34482</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">3275</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">31207</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">26552</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">4655</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zzn3iY9kBeoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013;&lt;span id="xdx_828_zqfcTbLvFBs9"&gt; Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CorLyst,
LLC (&#x201c;CorLyst&#x201d;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. We recorded $&lt;span id="xdx_90F_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20220101__20220630__dei--LegalEntityAxis__custom--CorLystLLCMember_pp0p0" title="Rent and other costs reimbursements received"&gt;63,689&lt;/span&gt; and $&lt;span id="xdx_90B_ecustom--ProceedsFromRentAndOtherCostsReimbursements_pp0p0_c20210101__20210630__dei--LegalEntityAxis__custom--CorLystLLCMember_zqrqLek1iGl1" title="Rent and other costs reimbursements received"&gt;61,549&lt;/span&gt; of reimbursements during the six months ended June 30, 2022 and 2021, respectively.
&lt;span id="xdx_90B_eus-gaap--DueFromRelatedPartiesCurrent_iI_pp0p0_do_c20220630__dei--LegalEntityAxis__custom--CorLystLLCMember_z3DF2K33OtAk" title="Due from related parties"&gt;&lt;span id="xdx_90F_eus-gaap--DueFromRelatedPartiesCurrent_iI_pp0p0_do_c20210630__dei--LegalEntityAxis__custom--CorLystLLCMember_zjLL1F74KLl4" title="Due from related parties"&gt;No&lt;/span&gt;&lt;/span&gt; amounts were due from CorLyst at June 30, 2022 or 2021. Our CEO is also the CEO of CorLyst, and CorLyst is a shareholder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2022-01-012022-06-30_custom_CorLystLLCMember"
      decimals="0"
      unitRef="USD">63689</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2021-01-012021-06-30_custom_CorLystLLCMember"
      decimals="0"
      unitRef="USD">61549</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="AsOf2022-06-30_custom_CorLystLLCMember"
      decimals="0"
      unitRef="USD">0</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="AsOf2021-06-30_custom_CorLystLLCMember"
      decimals="0"
      unitRef="USD">0</us-gaap:DueFromRelatedPartiesCurrent>
    <PCSA:ElionLicenseAgreementDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_802_ecustom--ElionLicenseAgreementDisclosureTextBlock_zlWvBa07maU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 8 &#x2013; &lt;span id="xdx_822_z1u0KhmUOMQh"&gt;Elion License Agreement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On May 17, 2022, we amended the third Milestone Event
of Section 6.4 of our License Agreement with Elion Oncology, Inc. changing the third Milestone Event from &#x201c;1&lt;sup&gt;st&lt;/sup&gt; Patient
in Dose Confirmation Study&#x201d; to (a) determination of the maximum tolerated dose (MTD) or (b) determination of the recommended Phase
2 Dose. Prior to this amendment, the third milestone was not considered probable since it was unknown when, or if a dose confirmation
study was going to be conducted. As a result of the modification, we consider it probable that the MTD could be determined in connection
with our current Phase 1B trial for PCS6422. We recorded an expense and related liability of $&lt;span id="xdx_908_ecustom--ExpenseAndRelatedLiability_c20220516__20220517__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zmKftoJb6egj" title="Expense and related liability"&gt;189,000&lt;/span&gt; representing the value of the shares
we anticipate issuing to Elion at the fair value on the date of modification. No other terms or conditions of the License Agreement were
modified.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"/&gt;

</PCSA:ElionLicenseAgreementDisclosureTextBlock>
    <PCSA:ExpenseAndRelatedLiability
      contextRef="From2022-05-162022-05-17_custom_LicenseAgreementMember"
      decimals="0"
      unitRef="USD">189000</PCSA:ExpenseAndRelatedLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-06-30">&lt;p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zalTIWw4lCKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_823_zZvhZaVcLR17"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Obligations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
enter into contracts in the normal course of business with contract research organizations and subcontractors to further develop our
products. The contracts are cancellable, with varying provisions regarding termination. If we terminated a cancellable contract with
a specific vendor, we would only be obligated for products or services that we received as of the effective date of the termination
and any applicable cancellation fees. As of June 30, we are contractually obligated to pay up to approximately $&lt;span id="xdx_908_eus-gaap--PurchaseObligation_iI_pn5n6_c20220630__us-gaap--TypeOfArrangementAxis__custom--AgreementsMember__dei--LegalEntityAxis__custom--ContractResearchOrganizationsMember_zfRC0J7EiMd2" title="Purchase obligation"&gt;5.5&lt;/span&gt; million of
future services under the agreements with the CROs, but our actual contractual obligations will vary depending on the progress and
results of the clinical trials.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2022-06-30_custom_AgreementsMember_custom_ContractResearchOrganizationsMember"
      decimals="-5"
      unitRef="USD">5500000</us-gaap:PurchaseObligation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MK9V6L(XI]$32V@FU%GHE A[MC1)@+.=[WKY<W\>.<[&3Z1Y\5'Q;GS=,36;
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M0UEF:4Q?,];\?:1T+8V&BMR#; !%M,ZD2=*U?:)GWIE1,@Q]C'V=4(,DA&%
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M;(*%-B2JU_O\^I/X%W,L#IS$-[-3;JIO2W8*X,$/.0!IRTZ!IN[LE/<"F__
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M-S;KTM9A@6X5Y>=5:QBAJK7\]2[/C&H!>:W<!R1,:NB#STZM5U:M]!UU6@$
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MIELR.'\8L0G$Z^B%SRBGV_&66#J8=J\-_<R#B44X-7[\NP=RU"[D)'\8<L
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M/*&WWQL='DX' ?@B-<@[K(L6*]N#=40?K0FEI[>FX.*Q_@"\UN2R%;F+[$G
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M>=+,T8J@&RF/(F4V <$H0 ><A,J-JF!T,G?,\":@D4/YZ(.\;."FHV6I\U)
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MBA(:B;D2N:P;(?/WV%,@DZQ!]@/XTAC:B@"_3XF@&8?]R/^1/=]3(2O"6Q_
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M9;%S#J<GX[C?G\"12UHJ?;TSMMNYOE["6Q<01Y-FT5O]R3NJ5%ZL*VW00&6
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MTY-E$L>7<* 8W$K8LE>(S_OI3Z!#8'1";Q9LA?3C.H<M%T@?J$2X>2;4.U7
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ML)UF\.NQG32T75;M@9?&U[[GW'-NZINDYN)1K@$4>BHHDQ-GK50Y=EV9K:'
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M&I-RP]S\1D#9 +._EA)W$YN@^S$EOP%02P,$%     @ $8 +58/BY]3A!@
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M\4?(GL3>8Y*_E46:?LLW?@NN>T8^(A:QI<P15/UY9',613E)C>-[!>W5.?/
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M-5!>WJM;;LAT6]SYN4BE3./BX8;1@/%\!_7Z*DWE;B-/4-\Q/?L/4$L#!!0
M   ( !& "U6GS[,[FP,  )(0   9    >&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;,58;8_:.!#^*U:N.K72[>;];0\B 4GO6G6EU=)>/U3]8)(!HDUBSC:P
M^^_/=D)*((NV>Y'Z!6QGGF<\+TQF&.T)?6!K (X>RZ)B8VW-^>9&UUFZAA*S
M:[*!2CQ9$EIB+K9TI;,-!9PI4%GHEF%X>HGS2HM&ZNR.1B.RY45>P1U%;%N6
MF#Y-H2#[L69JAX/[?+7F\D"/1AN\@CGP+YL[*G9ZRY+E)50L)Q6BL!QK$_,F
M,0T)4!+_Y+!G1VLD35D0\B W'[*Q9L@;00$IEQ18?.U@!D4AF<0]_FU(M5:G
M!!ZO#^SOE?'"F 5F,"/%USSCZ[$6:"B#)=X6_)[L_X;&(%?RI:1@ZA/M:UD_
MU%"Z99R4#5C<H,RK^AL_-HXX @B>?H#5 *Q3@/,,P&X ]DLU. W >:D&MP$H
MT_7:=N6X&',<C2C9(RJE!9M<*.\KM/!77LE$F7,JGN8"QZ.YR+QL6P B2S3G
M)'VXDF[/T(R4(A<95M%,'N4:T-L8.,X+]@Y=H2_S&+U]\VZD<W$+R:6GC<9I
MK=%Z1J.-;DG%UPPE5099#SZ^C/<NX'5A?>L"Z^""J761\..VND:V\0>R#,OJ
MN<_LY7"SSYS_ISUYM?:.,^PV'VS%9S^7#VM,X6IZG@,32G&U E$C.%H\H6.Y
M._RDCB=[3#/T[9.@1!\XE.Q[7W;4^IU^_;(NWK -3F&LB<+'@.Y BW[_S?2,
M/_M",R19/"19,A!9)XA.&T3G$GOTF7!<]/F^AGD*)E\ANTB\4$+;"T?Z[MBM
MYW*!Y]J6W16+>^@".[ \KRN7G,N9IF][,M]W/6:ZK9GN13/OA>,P3=<(5QF*
M82?>>AN5B(=Z]>T6R@70WC2\2/VS:3@D63PD63(062<^7AL?[Q?7$F_(( Y)
M%@])E@Q$U@FBWP;1?UTMJ6'NT8_:"US/<DY*R;F8&9IN>"(6GXL%ON\:QDDE
M.1>S'-<.W/Y"$K0V!A=M_ LJH+A0=622B2XK9YQBV<&^J)1<)/_9+!R2+!Z2
M+!F(K!.AL(U0^(M+23AD$(<DBX<D2P8BZP31-'X,&\;KBDF#Z[0(HM_P'?>D
MG/0(>K[M6R<=3-Q'&'J&?]:;] B&5B!4GY04_6C&*H&NU'#+4$JV%:_;Z_:T
M': G:FP\.9^:-S.SYSR6 [>:Z7[0U]/Z+::KO&*H@*5095S[HO[1>@"N-YQL
MU(2W(%S,BVJY!IP!E0+B^9(0?MA(!>W?$-%_4$L#!!0    ( !& "U7# >/S
MM ,  )T,   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*V7;8_:.!#'
MO\HH=ZIZ4B'/"6PATK)M=7NZO5LMVNN+ZEZ89(!H$YO:#G2E^_!G)R&$DH"0
M]@V)'<_,SW\_S##9,?XBUH@2?N09%5-C+>7FQC1%O,:<B"';(%5?EHSG1*HF
M7YEBPY$DI5&>F8YE!69.4FI$D[+OD4<35L@LI?C(011Y3OCK##.VFQJVL>]X
M2E=KJ3O,:+(A*YRC?-X\<M4R&R])FB,5*:/ <3DU;NV;F1UH@W+$/RGN1.L=
M]%06C+WHQGTR-2Q-A!G&4KL@ZK'%.\PR[4EQ?*^=&DU,;=A^WWO_4DY>369!
M!-ZQ[&N:R/74&!F0X)(4F7QBN]^QGI"O_<4L$^4O[.JQE@%Q(23+:V-%D*>T
M>I(?M1 M ]?I,7!J Z?DK@*5E)^()-&$LQUP/5IYTR_E5$MK!9=2O2ISR=77
M5-G):*Z6.2DR!+:$>UJMLE;K=J&6$)[FS_!W(84D-$GI"MY_0DG23/P& WA"
M(7D:2TQ@+EG\ L\TE0+>*QOU_=L#Y@OD_TY,J2AU+#.NB685D=-#%, #HW(M
MX#--,#FV-]7LFBDZ^RG.G+,._RCH$%SK SB6X\"O8()8$XZB?IR)X#8BNF4$
MMT]$[6@P4YLC@3N6JQ,C:A4Y)W2%:A=+6+Q">]PC>2V[;W>$)_#M3^42[B7F
MHE.R*K[7'5^?W!NQ(3%.#74T!?(M&M&[7^S ^GAF=EXS.^^<]^BO0J^DWB"5
M8!]@AJN44KTA%B0C-,8NY,JI7SK5=\,V\MRQ/W8GYK8#QF]@_"MAB!;PYXU2
M(?@G"+8;N&,[[&8(&H;@+,/7\JAC,B!;Y.KJ@I5:93E(B$18DI3#EF0%PD9Q
MEI -(_S7VGY=P%7<40O8'5IV-VW8T(97*J9.^1)3V:U9>*+9P'&LT:@;8M1
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M*7/UD1_>TV8_H>:+>2ZK7W2H;?'(0G$I%2\:,*R@R%C]3UZ;.)P @,<,\!J
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MV1A&;@PC2@DS%O.4Z[7U%#Z6O* 77E?%J%V%5%GI(V#2FB_.,@I:07_H+W?
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MLC"7:W7XPUQW4,^7C,E=0Q\OZN-D_ ]02P,$%     @ $8 +51%II:^B @
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M6-)V!.,"Z'ZI-6X-]X%^WV9_ 5!+ P04    "  1@ M5$H863#,"  #_!
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MQ05@+.F#5W(F*3.KY"95XM1>*Q\?Q >O<'J']=8.(:>1,K-'WIJ442ZP,Z9
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M_TG6#ZV7?_U7M%V36I7-P9]UOYYG7U!+ 0(4 Q0    ( !& "U4'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ $8 +5:I6EU/M    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ $8 +59E<G",0!@  G"<  !,
M         ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  1
M@ M5;%KGRND%  ##'P  &               @($,"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ $8 +5>\I?J90!@   AL  !@
M         ("!*PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( !& "U5<XK$$PP(   \(   8              " @;$4  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  1@ M5H+\LZR<%  #V%0
M&               @(&J%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ $8 +557)7=.W"0  )DT  !@              ("!!QT  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !& "U5_YFJ:_P8
M %(=   8              " @?0F  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    "  1@ M5:56]O9$"  #7!0  &               @($I
M+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ $8 +5942
M2$=U$@  F2T  !@              ("!\#   'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( !& "U773D#2$ ,  +@&   8
M  " @9M#  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  1
M@ M5I3?U/LL%  !8#0  &0              @('A1@  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !& "U7O >D%9@@  'H3   9
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M970Q-2YX;6Q02P$"% ,4    "  1@ M5)9PPE2P#   "!P  &0
M    @(&#9   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M !& "U6#U5":#1,  ($Q   9              " @>9G  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ $8 +50:5K[ZM @  _P4  !D
M             ("!*GL  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    "  1@ M5N$-)M@$$   3"0  &0              @($.?@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !& "U6NF)+M) ,
M  L'   9              " @4:"  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ $8 +50ZKNMXL P  A@@  !D              ("!
MH84  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  1@ M5
M3"X!I& &  "8-P  &0              @($$B0  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( !& "U7DZ I+B (  'P&   9
M      " @9N/  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ $8 +5?]@O8"6 @  I 8  !D              ("!6I(  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  1@ M5@^+GU.$&   ]/0
M&0              @($GE0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( !& "U6GS[,[FP,  )(0   9              " @3^<  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ $8 +5<,!X_.T
M P  G0P  !D              ("!$:   'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    "  1@ M5<T:WB!81  !/_@  &0
M@('\HP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !&
M"U6D.1*2B ,  ! -   9              " @4FU  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ $8 +50U2# ^# @  ZP4  !D
M         ("!"+D  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    "  1@ M5 .83E<P"  !]"0  &0              @('"NP  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !& "U7K@7$E_@(  %H*
M   9              " @<6^  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ $8 +51%II:^B @  Z@@  !D              ("!^L$
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  1@ M5YZU8
MTU\"  ![!0  &0              @('3Q   >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( !& "U42AA9,,P(  /\$   9
M  " @6G'  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M$8 +50L[[LU5 @  + 4  !D              ("!T\D  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    "  1@ M5N?8R3C,#  !*$P  #0
M            @ %?S   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !& "U67
MBKL<P    !,"   +              "  ;W/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( !& "U5\.(LY? ,  )X8   /              "  :;0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  1@ M5UOKYL7@!   #%@  &@
M        @ %/U   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  1@ M5ZXBZY94!  ""%@  $P              @ '_U0  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     +  L .L+  #%UP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>100</ContextCount>
  <ElementCount>202</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Net Loss per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Elion License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ElionLicenseAgreement</Role>
      <ShortName>Elion License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/IntangibleAssets</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Net Loss per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OperatingLeases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails</Role>
      <ShortName>Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/IntangibleAssetsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of Information About RSU Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails</Role>
      <ShortName>Schedule of Information About RSU Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Stock-based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails</Role>
      <ShortName>Schedule of Net Loss Per Share Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative</Role>
      <ShortName>Net Loss per Share of Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails</Role>
      <ShortName>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Maturities of Lease Liabilities for all Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails</Role>
      <ShortName>Schedule of Maturities of Lease Liabilities for all Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Operating Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>Operating Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OperatingLeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/RelatedPartyTransactions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Elion License Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative</Role>
      <ShortName>Elion License Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/ElionLicenseAgreement</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>pcsa-20220630.xsd</File>
    <File>pcsa-20220630_cal.xml</File>
    <File>pcsa-20220630_def.xml</File>
    <File>pcsa-20220630_lab.xml</File>
    <File>pcsa-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="379">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 100,
   "dts": {
    "calculationLink": {
     "local": [
      "pcsa-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcsa-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pcsa-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcsa-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pcsa-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 323,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 56,
    "http://processapharmaceuticals.com/20220630": 8,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 68
   },
   "keyCustom": 37,
   "keyStandard": 165,
   "memberCustom": 18,
   "memberStandard": 12,
   "nsprefix": "PCSA",
   "nsuri": "http://processapharmaceuticals.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://processapharmaceuticals.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://processapharmaceuticals.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Stock-based Compensation",
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Net Loss per Share of Common Stock",
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock",
     "shortName": "Net Loss per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Operating Leases",
     "role": "http://processapharmaceuticals.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Related Party Transactions",
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:ElionLicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Elion License Agreement",
     "role": "http://processapharmaceuticals.com/role/ElionLicenseAgreement",
     "shortName": "Elion License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:ElionLicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Commitments and Contingencies",
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Intangible Assets (Tables)",
     "role": "http://processapharmaceuticals.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://processapharmaceuticals.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Net Loss per Share of Common Stock (Tables)",
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables",
     "shortName": "Net Loss per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Operating Leases (Tables)",
     "role": "http://processapharmaceuticals.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LiquidityPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherNoncashExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Summary of Intangible Assets (Details)",
     "role": "http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails",
     "shortName": "Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Intangible Assets (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative",
     "shortName": "Intangible Assets (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "shortName": "Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Schedule of Information About RSU Outstanding (Details)",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
     "shortName": "Schedule of Information About RSU Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Stock-based Compensation (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "Stock-based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-06-30_custom_TwoThousandTwentyTwoMember",
      "decimals": "INF",
      "lang": null,
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
     "shortName": "Schedule of Net Loss Per Share Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
     "shortName": "Net Loss per Share of Common Stock (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails",
     "shortName": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Maturities of Lease Liabilities for all Operating Leases (Details)",
     "role": "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails",
     "shortName": "Schedule of Maturities of Lease Liabilities for all Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Operating Leases (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative",
     "shortName": "Operating Leases (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-06-30_custom_CorLystLLCMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Related Party Transactions (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-06-30_custom_CorLystLLCMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "PCSA:ElionLicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-05-162022-05-17_custom_LicenseAgreementMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "PCSA:ExpenseAndRelatedLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Elion License Agreement (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative",
     "shortName": "Elion License Agreement (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "PCSA:ElionLicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-05-162022-05-17_custom_LicenseAgreementMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "PCSA:ExpenseAndRelatedLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30_custom_AgreementsMember_custom_ContractResearchOrganizationsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-30_custom_AgreementsMember_custom_ContractResearchOrganizationsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://processapharmaceuticals.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)",
     "role": "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)",
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Intangible Assets",
     "role": "http://processapharmaceuticals.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 30,
   "tag": {
    "PCSA_AccruedDirectorsFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued directors' fees.",
        "label": "Directors' fees"
       }
      }
     },
     "localname": "AccruedDirectorsFees",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_AgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements [Member]",
        "label": "Agreements [Member]"
       }
      }
     },
     "localname": "AgreementsMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_AposenseLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aposense, Ltd. [Member]",
        "label": "Aposense, Ltd. [Member]"
       }
      }
     },
     "localname": "AposenseLtdMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_AprilOneTwoThousandTwentyTwo2022GrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April 1, 2022 Grant [Member]",
        "label": "April 1, 2022 Grant [Member]"
       }
      }
     },
     "localname": "AprilOneTwoThousandTwentyTwo2022GrantMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_BaseCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Compensation [Member]",
        "label": "Base Compensation [Member]"
       }
      }
     },
     "localname": "BaseCompensationMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_BeneficialOwnershipLimitationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial ownership limitation percentage.",
        "label": "Beneficial ownership limitation percentage"
       }
      }
     },
     "localname": "BeneficialOwnershipLimitationPercentage",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Activities And Organization [Policy Text Block]",
        "label": "Business Activities and Organization"
       }
      }
     },
     "localname": "BusinessActivitiesAndOrganizationPolicyTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ContractResearchOrganizationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Research Organizations [Member]",
        "label": "Contract Research Organizations [Member]"
       }
      }
     },
     "localname": "ContractResearchOrganizationsMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_CorLystLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CorLyst, LLC [Member]",
        "label": "CorLyst, LLC [Member]"
       }
      }
     },
     "localname": "CorLystLLCMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_DailyMaximumCommittedPurchaseObligationsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daily maximum committed purchase obligations, value.",
        "label": "Daily maximum committed purchase obligations, value"
       }
      }
     },
     "localname": "DailyMaximumCommittedPurchaseObligationsValue",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_DirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors [Member]",
        "label": "Directors [Member]"
       }
      }
     },
     "localname": "DirectorsMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_DisclosureElionLicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elion License Agreement"
       }
      }
     },
     "localname": "DisclosureElionLicenseAgreementAbstract",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "PCSA_DisclosureOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "verboseLabel": "Schedule Of Maturities Of Lease Liabilities For All Operating Leases"
       }
      }
     },
     "localname": "DisclosureOperatingLeasesAbstract",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "xbrltype": "stringItemType"
    },
    "PCSA_DueFromTaxAgencies": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from tax agencies.",
        "label": "Due from tax agencies"
       }
      }
     },
     "localname": "DueFromTaxAgencies",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_DueToLicensor": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due to licensor.",
        "label": "Due to licensor"
       }
      }
     },
     "localname": "DueToLicensor",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_ElionLicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elion License Agreement Disclosure [Text Block]",
        "label": "ElionLicenseAgreementDisclosureTextBlock",
        "verboseLabel": "Elion License Agreement"
       }
      }
     },
     "localname": "ElionLicenseAgreementDisclosureTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ElionLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_EquipmentLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Lease [Member]",
        "label": "Equipment Lease [Member]"
       }
      }
     },
     "localname": "EquipmentLeaseMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Distribution Agreement [Member]",
        "label": "Equity Distribution Agreement [Member]"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ExpenseAndRelatedLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense and related liability.",
        "label": "Expense and related liability"
       }
      }
     },
     "localname": "ExpenseAndRelatedLiability",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_FacilityLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Lease [Member]",
        "label": "Facility Lease [Member]"
       }
      }
     },
     "localname": "FacilityLeaseMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness of paycheck protection program loan and related accrued interest.",
        "label": "ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest",
        "negatedLabel": "Forgiveness of PPP loan and related accrued interest"
       }
      }
     },
     "localname": "ForgivenessOfPaycheckProtectionProgramLoanAndRelatedAccruedInterest",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness of payroll protection program loan and related accrued interest.",
        "label": "Forgiveness of PPP loan and related accrued interest"
       }
      }
     },
     "localname": "ForgivenessOfPayrollProtectionProgramLoanAndRelatedAccruedInterest",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_ImpactOfCovidNineteenPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact Of Covid Nineteen [Policy Text Block]",
        "label": "Impact of COVID-19"
       }
      }
     },
     "localname": "ImpactOfCovidNineteenPolicyTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park Capital Fund LLC [Member]",
        "label": "Lincoln Park Capital Fund LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity [Policy Text Block]",
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_MaximumCommitmenttoPurchaseCommonStockValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount committed to purchase.",
        "label": "Commitment to purchase common stock"
       }
      }
     },
     "localname": "MaximumCommitmenttoPurchaseCommonStockValue",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_MaximumNumberOfSharesSoldInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares sold in transaction.",
        "label": "Maximum number of shares issued sold"
       }
      }
     },
     "localname": "MaximumNumberOfSharesSoldInTransaction",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_MaximumNumberOfSharesToBeSoldAtMarketOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares to be sold at the market offering.",
        "label": "Maximum number of shares to be sold at the market offering"
       }
      }
     },
     "localname": "MaximumNumberOfSharesToBeSoldAtMarketOffering",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_MinimumPricePerShareOfEquityCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum price per share of equity compensation.",
        "label": "Minimum price per share of equity compensation"
       }
      }
     },
     "localname": "MinimumPricePerShareOfEquityCompensation",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "PCSA_NonCashAcquisitionOfInprocessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash acquisition of in process research and development.",
        "label": "Non-cash acquisition of in-process research and development"
       }
      }
     },
     "localname": "NonCashAcquisitionOfInprocessResearchAndDevelopment",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_NoncashMilestoneExpenseInConnectionWithLicenseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash milestone expense in connection with license agreement.",
        "label": "Non-cash milestone expense in connection with license agreement"
       }
      }
     },
     "localname": "NoncashMilestoneExpenseInConnectionWithLicenseAgreement",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_NumberOfCommonStockSharesExceedingRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock shares exceeding a regular purchase.",
        "label": "Number of common stock shares exceeding regular purchase"
       }
      }
     },
     "localname": "NumberOfCommonStockSharesExceedingRegularPurchase",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_NumberOfCommonStockSharesinRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock shares in regular purchase.",
        "label": "Number of common stock shares in regular purchase"
       }
      }
     },
     "localname": "NumberOfCommonStockSharesinRegularPurchase",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_OriginalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original [Member]",
        "label": "Original [Member]"
       }
      }
     },
     "localname": "OriginalMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_PercentageOfExchangeCapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of exchange capitalization.",
        "label": "Nasdaq's exchange cap percent"
       }
      }
     },
     "localname": "PercentageOfExchangeCapitalization",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "PCSA_ProceedsFromRentAndOtherCostsReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent and other costs reimbursements received.",
        "label": "Rent and other costs reimbursements received"
       }
      }
     },
     "localname": "ProceedsFromRentAndOtherCostsReimbursements",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement [Member]",
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_ReimbursementFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement fees.",
        "label": "Reimbursement fee"
       }
      }
     },
     "localname": "ReimbursementFees",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operating Leases [Table Text Block]",
        "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesTableTextBlock",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
        "periodEndLabel": "Number of shares, ending balance",
        "periodStartLabel": "Number of shares, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options unvested weighted average grant date fair value.",
        "label": "Weighted-average grant-date fair value per share, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedUnvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options unvested.",
        "label": "Number of shares, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Weighted-average grant-date fair value per share, ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.",
        "label": "Number of shares, vested and unissued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.",
        "label": "Weighted-average grant-date fair value per share, vested and unissued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term1.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBased compensation arrangement by sharebased payment award other than options expected to vest outstanding number.",
        "label": "Number of restricted stock expected to vest, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpectedToVestOutstandingNumber",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award other than options nonvested awards total compensation cost not yet recognized.",
        "label": "Unrecognized share based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_SharesIssuedInConnectionWithPurchaseAgreementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in connection with purchase agreement shares.",
        "label": "Shares issued in connection with the Purchase Agreement with Lincoln Park, shares",
        "verboseLabel": "Number of common stock issued on commitment fees, shares"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithPurchaseAgreementShares",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "PCSA_SharesIssuedInConnectionWithPurchaseAgreementValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued in connection with purchase agreement value.",
        "label": "Shares issued in connection with the Purchase Agreement with Lincoln Park"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithPurchaseAgreementValue",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_StockIssuedDuringPeriodValueNewIssuedInCommitmentFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period values new issue on commitment fees.",
        "label": "Number of common stock issued on commitment fees, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuedInCommitmentFee",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "PCSA_TwoThousandAndNineteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Plan [Member]",
        "label": "2019 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndNineteenPlanMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_TwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2023 [Member]",
        "label": "2023 [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyThreeMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_TwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 [Member]",
        "label": "2022 [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoMember",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "PCSA_UnrecognizedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized share based compensation expense.",
        "label": "Unrecognized restricted stock expense"
       }
      }
     },
     "localname": "UnrecognizedShareBasedCompensationExpense",
     "nsuri": "http://processapharmaceuticals.com/20220630",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r336",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r152",
      "r158",
      "r179",
      "r180",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r315",
      "r316",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r129",
      "r134",
      "r135",
      "r136",
      "r137",
      "r152",
      "r158",
      "r178",
      "r179",
      "r180",
      "r210",
      "r211",
      "r212",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r315",
      "r316",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r129",
      "r134",
      "r135",
      "r136",
      "r137",
      "r152",
      "r158",
      "r178",
      "r179",
      "r180",
      "r210",
      "r211",
      "r212",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r315",
      "r316",
      "r323",
      "r324"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r113",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r19",
      "r283"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r219",
      "r220",
      "r221",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r47",
      "r153",
      "r154",
      "r155",
      "r262"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r47",
      "r118",
      "r123"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible asset",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r9",
      "r55",
      "r99",
      "r102",
      "r108",
      "r115",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r240",
      "r242",
      "r252",
      "r281",
      "r283",
      "r296",
      "r306"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r18",
      "r55",
      "r115",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r240",
      "r242",
      "r252",
      "r281",
      "r283"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r6",
      "r49"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r44",
      "r49",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents \u2013 End of Period",
        "periodStartLabel": "Cash and Cash Equivalents \u2013 Beginning of Period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r44",
      "r253"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Increase (Decrease) in Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants, weighted average exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r298",
      "r310"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r138",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Shares available for future grants"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r60",
      "r61",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11",
      "r283"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $0.0001, 50,000,000 shares authorized: 15,919,317 issued and 15,819,317 outstanding at June 30, 2022, and 15,710,246 issued and outstanding at December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r88",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r47",
      "r56",
      "r230",
      "r235",
      "r236",
      "r237"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred income tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r47",
      "r126"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r27",
      "r244",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r214",
      "r215",
      "r217",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r3",
      "r12",
      "r58",
      "r142",
      "r144",
      "r145",
      "r149",
      "r150",
      "r151",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r19",
      "r58",
      "r142",
      "r144",
      "r145",
      "r149",
      "r150",
      "r151",
      "r277"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r37",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r73",
      "r74",
      "r76",
      "r77",
      "r78",
      "r82",
      "r83",
      "r250",
      "r251",
      "r301",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net Loss per Common Share - Basic and Diluted",
        "verboseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Net Loss per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized share based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Unrecognized stock option expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r31",
      "r32",
      "r33",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r85",
      "r116",
      "r170",
      "r172",
      "r219",
      "r220",
      "r221",
      "r232",
      "r233",
      "r249",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r274",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r7",
      "r122"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future amortization expenses, annual periods thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r122",
      "r294"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Gross intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r122",
      "r293"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/SummaryOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r35",
      "r99",
      "r101",
      "r104",
      "r107",
      "r109",
      "r295",
      "r299",
      "r303",
      "r313"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net Operating Loss Before Income Tax Benefit"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r128",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r57",
      "r71",
      "r72",
      "r98",
      "r226",
      "r234",
      "r238",
      "r314"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Due (from) to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r46",
      "r267"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r117",
      "r120"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net of accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r34",
      "r97",
      "r261",
      "r262",
      "r302"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r40",
      "r96"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Maturities of Lease Liabilities for all Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r55",
      "r103",
      "r115",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r241",
      "r242",
      "r243",
      "r252",
      "r281",
      "r282"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r55",
      "r115",
      "r252",
      "r283",
      "r297",
      "r308"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r55",
      "r115",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r241",
      "r242",
      "r243",
      "r252",
      "r281",
      "r282",
      "r283"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r44",
      "r45",
      "r48"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r28",
      "r29",
      "r33",
      "r36",
      "r48",
      "r55",
      "r63",
      "r65",
      "r66",
      "r67",
      "r68",
      "r71",
      "r72",
      "r75",
      "r99",
      "r101",
      "r104",
      "r107",
      "r109",
      "r115",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r251",
      "r252",
      "r300",
      "r311"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss available to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r99",
      "r101",
      "r104",
      "r107",
      "r109"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating Loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Non-cash lease expense for right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current maturities of operating lease liability",
        "negatedLabel": "Less: current maturities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Non-current operating lease liability",
        "verboseLabel": "Non-current lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets, net of accumulated amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r269",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate for our facility and equipment leases",
        "verboseLabel": "Operating lease borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r268",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Non cash expenditures"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r10",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Net proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r42",
      "r43"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepurchaseOfEquity": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow resulting from the entity's share transaction.",
        "label": "Acquisition of treasury stock"
       }
      }
     },
     "localname": "ProceedsFromRepurchaseOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r127",
      "r283",
      "r304",
      "r309"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Acquisition of in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r172",
      "r283",
      "r307",
      "r320",
      "r321"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r116",
      "r219",
      "r220",
      "r221",
      "r232",
      "r233",
      "r249",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r94",
      "r95",
      "r100",
      "r105",
      "r106",
      "r110",
      "r111",
      "r112",
      "r176",
      "r177",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Net Loss Per Share Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Summary of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r196",
      "r203",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Information About RSU Outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Total",
        "terseLabel": "Stock based compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Weighted average period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Restricted stock units forfeited",
        "negatedLabel": "Number of shares, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Weighted-average grant-date fair value per share, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of shares, awarded",
        "verboseLabel": "Common stock available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted-average grant-date fair value per share, awarded",
        "verboseLabel": "Fair value amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Number of unvested restricted stock award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period, restricted stock units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted-average grant-date fair value per share, shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Warrant cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Maximum equity available for issuance under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of option exercisable during period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Number of options exercisable, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Stock option cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Stock option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Outstanding options for the purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price of stock option outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfInformationAboutRsuOutstandingDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock options exercisable, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock options outstanding, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r26",
      "r31",
      "r32",
      "r33",
      "r60",
      "r61",
      "r62",
      "r64",
      "r70",
      "r72",
      "r85",
      "r116",
      "r170",
      "r172",
      "r219",
      "r220",
      "r221",
      "r232",
      "r233",
      "r249",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r274",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r85",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Issuance of 123,609 shares of common stock in connection with the Purchase Agreement with Lincoln Park"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Shares issued in private placement, net of transaction costs, shares",
        "verboseLabel": "Issuance of common stock shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued in connection with license agreement, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Number of restricted shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r11",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r170",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Shares issued in private placement, net of transaction costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued in connection with license agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r170",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Restricted stock fair value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r11",
      "r172",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r10",
      "r11",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Number of repurchase of common stock, shares",
        "negatedLabel": "Acquisition of treasury stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r10",
      "r11",
      "r170",
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Repurchase of common stock value",
        "negatedLabel": "Acquisition of treasury stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r15",
      "r16",
      "r55",
      "r114",
      "r115",
      "r252",
      "r283"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r54",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r172",
      "r175",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r260",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r260",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r260",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r25",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r25",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury stock shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r25",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock at cost \u2014 100,000 shares at June 30, 2022"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ElionLicenseAgreementDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r86",
      "r87",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r73",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted",
        "verboseLabel": "Weighted average number of common shares-basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r325": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r326": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r327": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r328": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r329": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r330": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r331": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r332": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r333": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r334": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r335": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r336": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r337": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r338": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r339": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r340": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r341": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r342": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r343": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r344": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001493152-22-022063-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-022063-xbrl.zip
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MGX.?*2_?WL5+P4*9P/%$HJ6C/9 2S?$XJSR7";(-*"=A1R9^E%.N 9DJ3O7
M1$G9+ 47B,?$[RA:$+5>*SBB;XV-8 @D6?:(17F$!F"G H/L>-H"\KF>L#!2
M,UU2-Q-CJ4W&,1*GFPXX8'J5K*A+-$NXA&-#PN\(^YTM@#RV.0+^E*-(V.(E
MP+I1)/6$L@@Y+T9.I+Q(UX'4?J1TCJQ#V3)3D2-"FBE?!+BMV3;\'@@0R3FW
M?^U/>#(6K(L\=)%':-%ZRQNM_6VQ0UWKM=9^X"[M-?J F8EC( W *%E5B.EX
M0F"^.5(Q4.@,NW$8+G<657I)UWJ-VI @V&BP.V _]6:2@Y8]H3$DG&JKW;<I
MYU$E]GFN[]^%*N)(@#W%2*[&JCR# >2HJ=24^6S9%HDU1.I\6=ZKF3<3$;=\
M=%6VPBFOR,KT4"*! HQ6D0RXL4A'6@:29Y)F()T6L+4@(4NYIO)L,SZ2(U5S
MFRF5%D!DD)FI5PJM*OT\XI3A,3&+8BD^T</)AJK<P7\C00V1@]%?!"^#."\H
M!D8K,7#OG+@2"O?/INLBHEZ['1+4#&&$C2\1G6N5<"H<7"-(2*X2^WD6E$1$
M;$@^DI$T<U((Z\:EP+2<M71T(76CZ5(%U6NV0%T74TKS+$4\:*MI?%]E@45@
ME>]8)% J$<("3T1* 4=-(.L=]1&8,D6)>!F,>4'D]T'^_I1'N4V21 P1AM"G
M<@J/ZC4Z\W6FO^3J4-\GZ[O+6])SL=$'U=$1"9N8#K+QD<K-UR'<IS#Q16M!
M^CVL9N?UNS V*G<&-GZ%6PH .K0*Y47X^ 71-:!<[8BPRB@Z2"@TJ7VREK8/
MR- D093OYQG1IE+N5ZW6:['2!@_HP!;&M ]+Q=$6V_X*DA 1@-1YJW6!'%L]
M80]!Z'PDR1? =ARL"=<+=41)UP:,"""AD+'MBA2U8LXB>27P94]$;G7P_O<B
M[6[$^_>!O;\\0 U*_GO+Y$7)M$K!91XC$CU SZR(Z@4G.(2U4:2.2PEA[\!F
M'$MCA*7KFGXC!8%"SP()<&2!;8.DR,J:SC7P3=J>8DM\R25PVQ#*$]^>>^QL
MMH<_>'O8C: ),:@,I4_G3'0$X$L!YA05?K%+FPE^117;241;LZV\M2>WY4G6
M@_A8[*>P;:(#JS4IC0?HJ<4BHWV5O(4H1A>0$-+5<[I!8_(ZC['2F+6=35%+
MUI[Z;33!SS@5VK]U4?K## G) V6$/;<%Z>P9?<%.SQ5.F4Q5-!54/1,^+GYK
MR(JC7A&GD9H+/)U-E$NV_ ;WP=4[M$6]]N/JYM-S8]@].NFSX_[)R>5Y]WAP
M^MO[K;TM>WW>[?7*ZP?/8B8#,Z&F>Z\.42LR;(,;OHHBGFH *O_;LB^LM(<7
M#Q]@2K_W0F&5K#0JW2I>?VD/>Z6]E >TBVZ,E#$JAN7=_=2XM7G0//;W7CVA
M*X:])T3^J,"/Y@=WHBX\78(^BKA_Y: S>V;W'R;P[G%GT!YTFKKI@%=>/6@W
M!YWJS/!Q\=3DO/_K5]^5>1M8"UB6( Y)P9(-0UX$K)^I+MMWGHH7-^_YM_*"
MU(VJ;I?E9YKA]KD[*:8?RM?"WZG@WP37C\AS1MQ=V'\$JFX^QE;#06FUW&M?
MZS-PTZK8SK,]1@#P7QH-]D&**#A@Y]C!',+ EQS;<>IXR,Y2>VQRP$ZX-JS1
M*!W4&_Q5HG+36$BO7TDM?DN.86)+_5_5^[?W S?EW:J0OR7X5U77,HS7!.?-
M18]$:'LLN%<QO5R_TO^E[]M-K$6Y+)7%;-)JNA5[#OLQ>E6?7M%W[^S3J_W_
M E!+ P04    "  1@ M5;:K@(YD'  "3,   "@   &5X,S$M,BYH=&WM6]%2
MVS@4?<],_D'+3'=@QB% RSY FIE TFTZ%%C([DP?%5M.M-B6:\E)LU^_YTIV
M8DA*81?:A@D/!-O2U9'NN?<>*:;U?O#QK%VOM=[W.EU\,OII#?J#LUZ[U72?
M>-HL'K=.+KJ?V/7@TUGO[5:H$G/$]O=2PP8R%IJ=BRF[4C%//'?#8]<BD^$6
M.J+KY6/[';.89R.9'#%JNK?5;KV[.!]4K31"'LMH=O0M.[:MEO\(-^Q6^]=D
MJ-/C5I,,8IZ73X/PF!GQQ31X)$>XE<G1V#PEZ-9)N_=E+(?2U&NO]W</6LV3
M]O-.P1>)$=FZ+?S3H\;*G_:N!OUW_=/.H']QOEGYU:C_SK61X>PI8?>]>NT#
MIS[7AB<W(O/8Z5B*D+V3"4]\R2-V$8;2%QE3(;N\NCCM75]WV.7[SM7'SFGO
MSP%<=G;ML?[YZ2Y6-2-\S(RY.5J[I5A3#^[OUFM]-N83P3(QD6(J CA :O8Y
MYQE('LUP/U6982IA[U06HU_CCP=X,U09# F68F 5,)$$L/PA3P1[O>>Q@[V#
M@_5;K#7U\0%\?,(UUA\^C&?L)E'32 0CX3E7%PX.%*PFRC ?!KA,&$]F+$],
ME@NF#3<B1MHCSW/@!S4HND/NXQ:B.Y:&&>7:+35(A"^TYMFL7D.;F-\(2XVY
M48U[ =!@S(CJ,@U"#7R9^7F,9@GZ TJ /#(=2W_,=$Z_%OVG(A.%$9I!+'4D
M>""3$9M*,\8,=2I\BQ!VZ[6"E+Z:H%_ AK/J0JR?@]>4EZ_OXZ5@X;R&+!SM
M@91HCL=9Y;E,D&U .0D[,O&CG'(-R%1QJ@<F2LIF*;A /"9^1]&<J/5:P1%]
M9VP$0R#)LD<LRB,T #L5&&3'TQ:0S_68A9&:ZI*ZF1A);3*.D3C==, !TZMD
M15VB6< E'!L2?D?8;VP!Y+'-$?"G'$;"%B\!U@TCJ<>41<AY,7(BY46Z#J3V
M(Z5S9!W*EIF*'!'23/DBP&W-MN'W0(!(SKF]+_Z8)R/!.LA#5WF$%ONO>6/_
M<%OL4-=Z;?\P<)?V&GW S,0QD 9@E*PJQ'0\(3#?'*D8*'2&W3@,ESOS*KV@
M:[U&;4@0;#38/;"+FQ(UB8SN[1[*Y"FGPD'+KM 8$DZUU>[;E/.H$OL\UP_O
M0A5Q*,">8B178U6>P0!RU$1JRGRV;(O$&B)UOBCOU<R;B8A;/KHJ6^&45V1E
M>BB10 %&JT@&W%BD0RT#R3-),Y!."]A:D)"E7%-YMAD?R9&JN<V42@L@,LC,
MU"N%5I5^'G'*\)B81;$0G^CA9$-5[N"OH:"&R,'H+X*709P7% /#I1AX<$Y<
M"H6'9]-5$5&OW0T):H8PFLB B,ZU2C@5#JX1)"17B?T\"THB(C8D'\I(FADI
MA%7C4F!:SEHZNI"ZU72A@NHU6Z"^%%-*\RQ%/&BK:7Q?98%%8)7O2"10*A'"
M D]$2@%'32#K'?41F#)%B7@9C'E!Y/=!_MZ$1[E-DD0,$8;0IW("C^H5.O/7
M3'_.U;%^2-9WEW>DYWRC#ZJC(Q(V,1UDXT.5FZ]#>$AAXO/6@O1[6,W.JW=A
M;%CN#&S\"K<4 '1L%<J+\/$+HFM N=H189E1=)!0:%+[9"5M'Y&A28(HW\\S
MHDVEW"];K==BI0T>T)$MC&D?EHJC+;;]%20A(@"I\T[K CFV>L(>@M#Y2)+/
M@>TX6&.NY^J(DJX-&!% 0B%CVQ4I:L6,1?)&X,.>B-SIX/WO1=K=B/?O _MP
M<8 :E/SW%LF+DFF5@HL\1B1ZA)Y9$M5S3G (:Z-('9<2PMZ!S3B6Q@A+UQ7]
MA@H"A9X%$N#( ML&29&5-9UKX).T/<66^)Q+X+8AE">^/??8V6P/?_#VL!-!
M$V)0&4J?SIGH","7 LPI*OQ\ES85_(8JMI.(MF9;>6M/;LN3K$?QL=A/8=M$
M!U8K4AH/T%.+>4;[*GD+48PN("&DJ^=T@\;D=1YCI3%K.YNBEJP\]=MH@I]Q
M*K1_ZZ#TAQD2D@?*"'MN"]+9,_J"G9XKG#*9J&@BJ'HF?%1\UY 51[TB3B,U
M$W@Z'2N7;/DM[H.K]VB+>NW'U<WGY\:@<W+68Z>]L[/KR\YI__SWMUM[6_;Z
MLM/MEM>/GL54!F9,3?=>':-69-@&-WP513S5 %3^M65?2VD-KAX_P(2^[X7"
M*EEI5+I5O.32&G1+>RD/:!?=&"IC5 S+NX>I<6OSJ'D<[KUZ1E<,NL^(_$F!
MG\R.[D5=>+H$?1)Q_\9!9_;,[C],X,W3SJ#5;S=UTP&_]?)!J]EO5^>&7U?/
M3<^'OV;U7;FW@36'92GBD,QYLN'(BX#U,]5F^]Y3\8KF W^67I*Z5=GMLOQ,
M,]R^=*?%]&7Y;?@DSSN+4^5B-CN5Z6QB[4?!ZD)FWU_Q?P2V3C["'L1!V=]W
M[X.M3LM-*V_;:WN^ ."_-!H(%A$%1^P26YMC&/B<8Y].'8_916K/4X[8&=>&
M-1JE@[K]OTI4;AIS3?8;R<AOZ31,;+$QJ&X$[FX4;NN^985_9R>P+,<6P;PB
M1&\O>B1"VV/.O8KIQ?J5_B]]WVIB+<IEJ2QFDU;3K=A:;-36D<"M)OU3@?LO
M _IGA'\!4$L#!!0    ( !& "U5;E!3W_P0  *TK   *    97@S,BTQ+FAT
M;>U:VV[C-A!]-^!_8 ULD "^)INBM;4&G-CI>N$F;NRVR",M418;FE1(*HG[
M]9VA),>Y=#=9Y+[R0QR+Y/#,S#D29R#O\_3W4;=<\CX/>GWX)OCQIL/I:-#U
M&NDWC#:R86_OJ']")M.3T>!3)532MDFK&5LRY0MFR"&[(,=J064UO5 E$Z9Y
M6(&%L'3\T'4=LJ!ZSF6;X-1FI>L='!U.UZW40KK@8MG^EATWU_!_6;IMI;LA
M9R;N> TT"'Z.'P=AAUAV:6M4\#E<TGP>V<<$[>UU!Y<1GW%;+NULUUM>8Z_[
MM"[X3%JFWUK@_TF,Y>'RD4/_M^;6,EDN32RU; &1(2HD-F)D/^(L)(-+YB>6
MGS-R%(;<9YI0&61C!UQ2Z7,J5F/C1)N$@@VK2.L7\F=]4M^ODPW#?-MI[>PV
MB]P^6VXG2C"Q+)="I5TZXT3'RH )2*^O%K%8<CDG%]Q&=V:J2H95MRZ1 =,&
M4++@?RD!)L=:^<P82L81U0OJ,YCA4P$ A]*OETN;:&M#!&>)ZNS#]E0N-[3[
MM54E$=-LMH3<:8Q"%=F#TV?,.#8NEN14J@O!@CE#4-2ZX;.$:LBU6!+-8J5A
MJB0'2B\@ +4_5BQ.]R)9&,JE;!5AX%= OB22D1WP=KNYO4W601X[FSE&$B8"
M-G*!XQ!$%S><K=E9PK43C@OM! +( 4AK9Y-N$=AT=6%W,]C*4(':((2@/#0U
MN/0C*N>,]'SG;>O7G8].9"M'N03T"^K,^)!GRC$97+K!%"<)*<=(Q)H9A%+%
M82H$D Z<18G"0 Q03)K5,)=NN006 ^YLXZ8P+1&I*RIFVFUJ;@2S7DCX620\
MC;B!_#A5@)A<CK@!6:!RPT1+;B(@@G%*1]%0W\_H;F%I3HWXSILRBMQE'"9*
M97.K'%3FQ+)^O\@X7"[!\HP*]R%P9AFVG2&)?046@5&PP0PU&X+JI8\C"!TU
MR@5BR';0;,Z-U0"\2BXB!I<TQ#\ \<P8 &0H+AJBE'%V ';=?42%55Q*=2#@
M?H3&T/2<22"S6$.!P10 .Z%SA$!,XD<9@G?"[VEO;S0@^X/1:#+N[0\/?_M4
M:5;<[W&OW\]_/]BS"Q[8"*<V/W3(3&EX/-1\)02-#0#*_ZNX4[<W/7[X!N=(
M>'AVY/&R*JYD9WAOVL_MQ30((%>UF;)6+<!R?3>V:6P>Y,=N\\,3IF+:?T+D
MCPI\;]G^*NHLTSGH/4']TQ0ZWH!X\!T.?'Q<#[QA%OV&::3P^_2<!^1$)7+N
M-8;==?_@S_%34_3^E>2S\J^ M8+E")(BR5A2,.1=P'I-71E7-64]J'M^;I58
MUY[M+BROR</-L8:#%8^QG+@3_M8:_D)<+P6K#V?DKS_D7P);+YE#Z91":;72
M2OSN^W##G6B[;Z%T>Z,5Y],UC6[W"HNF4=$T>M5B>*,:+KI&[[)K]&P$+]I&
M1=OH!VL;K1I&7RBNG5@J3['F*EI&!:R;L!Q%4B0KGA0<>1>P7E-+Y3N:1K=*
MK+?5-+J"CZ? 'AQ*$VGQ9%?TD%X1K**']++'<P#^4ZT&8F$B:),QE"$=,'"6
M8$T$"SOD*';5=YN,J+&D5LL3U!_^E:-*W5B=R7[&8^2WSFG@V%5AL%X(W"P4
MKI_[;I_P;U0"MX]C5V*^0Z+7@RY8Z%:LN+=F^BI^>?[SW'L-B$4>EK5@-C":
M:<1^P/<ZGY' #7S=-GW_%E_3_0]02P,$%     @ $8 +58>Y991$,P$ *U<.
M  P   !F;W)M,3 M<2YH=&WL?6ESVDS6]O=4Y3]H_$RFDBJ1:&%U<N<M#-@A
M\4(,SG)_H834@&PA82VV\:]_3[<D$"#,)H&$>YYG)ABTG#Y]G;5/G_[R_YX&
M&O. 3$LU]'^.^(_<$8-TV5!4O??/D6-W,\6C__?U[9LO?1NN@VMUZY^COFT/
MCS]]>GQ\_/@H?C3,WB>^5"I]>L+7'+D7'3^%7B=P'/_IS\5Y4^ZC@911=<N6
M=!F-;])4_6[Q\_&OXTL[IJ9.78J_\5\B?II[-/RJ3&X(7IS_Y/XX=:D=>FG.
MO=3V+U4M(ROPA9?H<*\8W_"TZ%H>TPPC1'].KL\GE]OAUT\N_62;DFYU#7,@
MV3"'^$FY#"=DA'S@(1D+R5,/@K\_]HR'I<\I9D3>?\[<Y$R/%/_<D:PQQQ4T
MPV[_G? #W"$(_H4FZBY\;/X3_.I?Z%B9GB0-QQ=W):M#+O1^F'HJ?&<:&K)"
MKR:_3%VNV&;&'@V1%4X*_/P)_XSOX3(<GQ'&;)$-1[?-4?A8O1^G7F69]CQ1
M\.7418U*LSR^:F@:,K(L:=B78'IDY-BJ+&G61]D8D)NXO,@=$2E%D@+_,O@_
M7VS5UM#7+Y_<?^'7 ;(E!C\R@^X=]>&?HXJAVTBW,RT8V1$CNW_]<V2C)_N3
M*\R?\'V?O,=^^4\FPYRJ2%..F2:R/S.7T@ =,T_*TV>F7B4?VIQPTKYIOA.J
M9^5R _[!Y#&9S*IWBY4V'GG[A1&W_1&O\=ALV;V+Y_A-;L^);02HA>' _]=T
M8.BH IPR):VN*^CI!QJU.=!L.5$L9,5UGEL*/+<\0+H"_[5/-:G7[L)HT3J/
MX@./JCBFB1^D6L"TOT@R:[I2E6S4=G\^;W)/%RKW?/'SGW_6>44Q\(JJ(3N#
M\3L:R%0-Y12^L]H_UYGO/$9+M<VW/3WI/AR^6N<90KL),$%66V@3L^ ^Q"+?
MK?.<*J:EX3U+G"-INX>7V@W'1.UL\"E#^&:-9Q1@H%=MK*)Y#NZ^_PC?^C1T
M#&7$6/9(0_\<=4&0CQF>&]I,2QT F9?HD;DV!I+.NE^P\ Y3[1*5H:@/_GV*
M:@TU:73,Z(:.R(_JTS&6?61BI4+^4A4%Z43%X#_APDN @:G*KO9XLJ^Q,C\U
MC0$6,ZPH.=XVW,_Y#&@I1H>!P:N0>APJ2$=?)Y+TY=/4*Z)YZY28'7TE<A;+
MBQ8)X='73(87P*[&\M:%<GGT]:?PPAM/34G&=M][%%;"QU4'X9>VI*=R#YQ"
M%5E'4Q25K:MND I5^><(("FH&.+@+)6.&$=7W6M!?L"T6<>ZJH&!,1U@@T^-
M_^H7R/$,_''#-(;(M$<-3=+MLJ[4P(X-\7 OD;T6;?GB_FGC71C,TQ8]WV F
M6\8UT@!^2D,R;9A*#Y[K<(WGLI%35C$& ]7&;+* 9]@A@<AC?;#QV'/:,VD+
MYI,7Q,A):YE(LAQSU+0-^>Z7I#EH+8JRT2/L&EF@XN0^<*J*'I!F$.C7]8;K
MR!TM4&594&4OS&HA^EG=D-!YG3M+:G2R093O*40%Z@/2@::K;D,:0<BB 8TV
M(E?"IYXI#<X-28>!>))=EF5XE5('^L$YL3?D>2DZGL<\D*5S4HI>7_DTU9Z&
M2+?0ICPN[(4P?DP8OXBPZ.WBBAQ;/IG1*ZVZ#O$D O_&H^T$4-I5-Q0<@8]>
M6:U)X#(>"GST D%,4-_0($BPL,MCCT)-$>>:HK9W6WO*@EV@00>9<]2*,5!+
MXK8KQ\;909SDC(S8+!<@UGU-5-RM6Q9HPZIC KVN1T],/GG)B60A\$T&&!XD
M<;=(\/FQX(MK#RTFU,0YKFMD2ZJ.E)IDZO!X:]'0<CL=&@3BY)=P-V.[6<I%
MKW[B&,J*$Y.+WFF&.,S5I^?& C]O,=4X%C#T%]D?O>7<AN"RHJCXD9+6D%3P
MI"K24+4E;1'QT=O6;8A?!>YY;E^F;"-J\WLR99L0.Q5U)="43?NPZPTMAGF(
M>UPK:LQ"]#'%2T.[LON8B,AGJ+A;9V.38:PX(<7H?8N5E.H"JI>;L%+T*G4;
M@M<S824^4<2O O4(,RWKF[#UJ8W>P5G9A*U+K#B5J8[6A*W"W;7#1Y';'W?7
M)Y:/C[O;&U)A[%8*Z_L^(A_#/,0]KM7LD<A'[^23H5VCH6/*?3R(N?&M.9*E
M-DH48G(/(AS$6G9+%&+*0$0XH!7Q)43G@)*% U>QN((#7#1TW5TR^*W:_88W
MMG+/1 @OX&PRKE7T080YR-T,:L7)$O?AG&XC^-E].*=1"7EV'\[I=L#/[C:=
MN)XAG%Z)66M<,>3I8A_7BC*]ERS>8JJ7RW0^>F.^#<'KR71^3QIT"^S'D(6L
MHJ&)9'6IV_K2LJ18C ZXQ,A>&KHL6?T+54.6;>C(6SV=M;?GJHR_'IO;Y5GJ
M4.I+T7'5I[X"U)=EB# M LBK;EWW*J+#RU<VYGP,07UY8)BV^BRYA)^JNJ3+
MH+0JAD7JJ*JJ18KB5U@3"*,XRT5OEZJHBTP3^V.1KK9GN8@=XME*&KF/Y+O=
ME-)D^>C7XX#=6&>A*G+_K>L^E3 VJ:.AN<+)->B-(:PB%6)(L3 5V-KC[44P
M#Z;Z (QN:)*\6(FL0G$V>N4<I'@2#UYUPW)7*PM@+GI'/$@GS#TIN02PD]S\
M6(&4X<X'U9ZKOER#Q?$ND?,;,K2P47" OYQ4XV,B3:S&$(#2<J_ &[*.+;+3
M#A[-D.USQWT3OV4H6U+&WPCS\<E2CKR?\1ZG?XXL=3#4D+O[QWO5],/=UUD&
M(,I[&UQ&-C8<>RP@@WQA:OQ=2OYMB&P&&'\[_EY5\"]=%9D,&0H*W<96J?^8
MWC@P>_/D=9]"W^>];4@<]WDJ+%LR;5R\_W4R'/])D]_F;D-NQ?_7R;@GKU>F
M;O&_GR+ _])CZ6(^3VJCB^ ?IHRW[DY-^^MD .-7>+]$S:04 G":24$DQ<(D
MOW \M4SB_2TV<3!I845HNM@UJ]2RR5)J"VN64\QE?A,N\[OA,G](7%[?0,?*
MY05UQ?,9LGUQ?<)(U,/N=^ '[R<%B'D::JJLVBZMC*+"E6[?B(DW##S#][L1
M!DYY&CK90/6D6D=?@SNKIL;]Y5/H*X+D?0JG;VM+P<5I*1;,^\N)QM>!@1=Y
M\,KP$):[?1TH"!GY*YO[!6L[KV/ZPP?_.A"0,@]KQTQ:O@'C=4A(DEPE;TYV
M.N_454JNJ[0//%!7Z?7J NHJ)<E5VB$"TNLJ[89)-*N4/%=I%RXRS2JEQU7:
M/1ZHJ_1Z=0%UE9+E*L6/@.4[*E['Y"?)"Q!VX/VMMS'E=6 @J5[ /O! O8#7
MJPNH%Y D+V"'"$AOPB16)FW0YNMUR,K>G:9(ZK>"P(F_2HYZ74GVNM(.*.JV
M46VT,7BHW[=WOR^E$$J9XY@:+J_<D^]UR&CB_,W$[LK8J#?BZP!1HOW-M &*
M^IM4&VT,'NIO)L[?3":$UFD ]SK0DRQ/:-/6!K&[T)LVXGL=($JN)Y1"0%%/
MB&JCC<%#/:%D>4+I@5":,V])YO+*S4E?AXPFSM],9M>939O$O@X0)=K?3!N@
MJ+])M='&X*'^9N+\S81!:,$A2M3_V7]),+^33H[4?4FT^[)G/%#OX_7J NH\
M[-UYV \"4I9KVC&3:*HH>:[2+II>TTQ/>ERE?>"!NDJO5Q=05RE)KE*L" A;
MH"-8D!W+-@;MN5,ZW7'[/Y^KNFQH>D,R[SQE>>KHROEYY3 @TQH-T56W;)J2
MWB.C=Z%"SJ=:P)GE0%F%  6IQ^>H)VDUPK# :Y=P?-_YP(2=%3,IYBQF^*+_
M21C#VU4%5=6R3;7C8-L_,YV'C."E@]\KF+PY6P],WO3&O3XA9H1Q,8,@1J,K
MVY9IMR^D)W7@# X?>VG5GJN\'B;R^!J/V7TQ_G-J7O>MHS%Z-ZA>$<1XQ"K8
MS"$J8:*BDSS1B=-!#J(SKA )NS;IS27.^&9Q11%Q6$8JS(<NS FW4%/P+HP_
ME7S\EH>&A8]0/K>5="-V,6#FAI@ B!0V@4@I;B<FF#UI/1JMON%8DJZ4=>52
MU9&-D-[0)'U: 5Z9:D_5#R7;CL=W*0U0 #[+&!&-OAOG\1\E4\%:-T#!-(L/
M-9VW&0PIX X0 (4,/]FITW0Z%KIW</+[8<[].G1XS Q^HA@67!"'2DH=1#%\
M=KSD, 8K7GB[&N*$Y&$ L I\>I!L]0'5@9.F@Q]UK5IW,RB<'?:^7:R$Y?(7
M+%92M"1!7>QHA5(<?\H&5JOQ H9L(^6 :A5F7-C)XG3(6!.@)\2U]02>PKBC
M]07VA0)F_X!)DF'93,/XWG-5-9%L&^:!5,E$BZ-5WHS7QUJJK:&K;EU7U =5
M<20MX"?/,#@!X$V2MIM:GZ"0I9"=<\V"V(MQV8<+;1!"4?AJ41B2L>?65ISQ
M-<U8>)88A>RKA>RN3C&;*,Y<1BCYGR@**0K#%&<NL&JYLN+,Q:TX:52]YZ@Z
M*5L$ NL8K4<8P@B^.(S9_P73K.J]\#6;F;'N6TDD.:>R$FCZ)D*O!S:3T5+@
M;&!=;G35MJZ;-X<!F-6LS/287YVUH4A("!(2KD"V Y!OGTXD"^$=HC!!TN$L
M+<<#KW4H6+()EUC+<-Y3F,< \_+05+4K'87YM?B99Z9T*#LA]X]]0@&&P%1=
M]<H30 5@@0 4,CP74O/XL@"\6!E)L;ZUGH^IYC)>B&,DK0WQ8*7DCG7\;\D\
M> 4]-<9] R1A.G!!L$QA<2#!\&1^<QE.#)]?WY6K&+KE:#:=]\B7@V8YNU^T
MY0+U1W&E7A;VW[:09,K],B@Q]( T8T@BN2<<J1U([K:NR\8 C:/4<T,F(>B<
M'[6,#_LV5 GKR[W"H8H46FF 5CH.6Z302B&TDN=>AYT;3Z&50FCQFT!K1UIK
M@:]UAG1D@ANJ*V5EH.JX21O9$_;ZP+42)_:MN=+F;U%XI0=>*?2Y*+S2 Z\4
M^ET47NF!5_)\K]5V?M#"HCWF.6/=?1'>).E4DE4-J#U'TJ%H$#*4"HS<E&3;
MD;06,@>!O';(B ]_(24XY;@&B42JKV?.PX9\J).^K :]8ICG(\M.?9_1Q5T;
M9T=(_<S5_$P*$.HI+C8;%!:'8B%FCHJD\[L/3W\G'D NP^?'GPJ3QN,RCI)?
MT9DOX2/>MU^ 9V=MOP!/Y"[5_IAGUESA%7&V_46P*[,GZ>HS2=8<R!;]EQ U
MRY;E6-I6=RUE]R&9*T=775#>-*MS,!J0DPK15]4RL@)?.(9K_(?Y/TV_ C]M
MP?.;?<E$UL)7>/PB%VW\#J"OL> ]I.XN1.;QO9?. )F2;82 : T>S-(8]M3
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M:\V;\Q:YY*I1NR:*:&((I91J(GQ4*55%ZZJBG <N\2/S$W=0KH,6JO^J$9S
M%^?^WQAFYU?-&\ .4SZYNFD!%J]_U%K,=;WY(_563"B]%AT5$XSR'HRR'XEG
M?7UUWB00(O%#%:.&8B0A^B4^$!0\9[=>_\A<M;[5K@_*TZ4Z8DMX%'VO]R-S
M7CL#KX0HAUJU?GE&M4-2M,-N(5'R(5'^2!P)YK1<:5U=4SB\=F7!<Y.@Y^;R
MNG96;[9JU[4JTRR?UTCD4OMY4V_]#1[I@?V-FV8-_^AI%HJC5ZE6>'X2U%1K
MIV42[-XT(/IMUB[K5]<!T%" O'9%(TPBEXOZ90T4S&D-]$H@WJ48>95*1/2
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MAS5S^_.EV=C!:/G9!MQ*!_L9X\V9")T7'\]N\D^_^12E'/;5/R?&:FZJ"P]
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MUJL9#3\M)7*Y-L^+[>>SNORM6/RIY#B\>.4,8"0C<LGQ9*J9##.& [,2&I@
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MJ4 >MD#&TXI5+/%LME2B(DE%DHKD!C8R\G:QV:+ EK([J2J*6R##$P;B7,(
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MW4EDR22 R[.$@;-4]$^UZ0QCQ?-?I8[_U-&4E09.IAPUG5+I*MDS6DO8J-?
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MNP/2"CNP'ZPWXH5PQA'" <@NUP,T@OP2<X9P@'+.T2@,W10Z!XT4QFPBW)R
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MH5G/2J@JC%[#.MV\6FL]^<)'*!B-T3,X/9Y!:^'X6;@.(BUB1!0XDAJ:A2/
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MTHQMO=2V<E?6"5TL-0?&Q;8C;+=!-9F$:R@1ISM>5X$O9EL[KZ5-:?S<10A
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M=S>-[1^G=M_YT6KFR[L8DF/I^YEP6PXAMM;(CP[5UG.#WL6""@\!LCJ"I-,
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M@ID5LH^7WCM9 $2[0)??$_J+>'7_9H6=$ R]53*.1+K^9)>N$%JA)IG/C[2
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MD_BF'V;)#$;K:1[E]5IU'M;O]"EQ&ID:*PI;4=CSPRGC**PZEWCFBL)6%+;
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MQ<)M4&"%7B\3K6+\'![ZF'K=FQ3@%,C^-"[[/7C_CF\V[=:?Q@G0*X/UQ$,
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M)4H'@8EY)'[7;(F('%Z!3"C";:.>80%EM4)VO*+8IM^"".C7LDU?=;DG)RW
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M47L$$7M2>7'MM*IN82MDGWN5C$GZ^Z9,PAY7Q?GVM0<D$5!E'WD.@V3@(^\
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M$5=3YUM4QX',PMH$%,3#+>)5D=GA!Y W<"MH@Y.2QENNQYMN];"R B.%'JP
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ML!>7-[/?,+#(8HRIDGDA7],\V54XK_/YP80Y(H+&S"<G6 NU&\-/;.H8U C
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MGNA!CK:"0@((72*&Y,LP5$+&# M5HSV*@YH$_R0PQA*-UBG%3BO;9K7%>Y+
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M/X6_Q8^!8X_>NQ6U]ED.%;6!\^OV Y?R%.BK&&"!$?8@VWI<RA(M'J,)2#7
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M)"IK2-N,-"A9:IW3&-5*E@X(&X  +OLVAOE=;Q1Q[HPQ<G"%$4<TG(FX'#7
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MFH" X(LZ4< P"7MD=7!//3L-_)XH4.4G^9RZ$D0![B)3X.V%CO48$JTR!CE
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MF;C-QXK-L;CEU5RMI):TA1*W1<U;3_/W9[A2=:1Q]BV)U&<YJZ+S5?+7Q2&
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M'\P #"+%#YOW)EJPKN*$/=-S0U\)02E[ 5J\A.IXBD;OQ%/@NQ9.">PC%+&
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M\D_?GSK3*5^%^\ P!RZ?GK#I!Q@4HE@S_$<>?<F_%[A#W7N9QU,5D&D#D[1
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MA$K$-XG0/OK41]U<V24UPYQ11)R(I-'BR* .<<A>M!+LD2@OO7Z"VQ%M5XR
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MSFRG.FQ=C<[/G;N6JUT9OG=SL=WIVOG3TU8I>!I<-+</>MNCJTNW\G3>O3?
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M=IRKP7J]_%C>N:__E\WU_Q]02P,$%     @ $8 +54V=N2B;7@$ P^X! !
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MC+^OR:_-,9GYT\H>Z#[M5+K35I@;UM]-XK//U-/50Y--JB265T+ A)1H7C=
MK@+L*2I*?9PVF,&E,N'94@PG*/X<DSLMVW4#OXC'Q* DJ6Z5;-6OM^:B*;W2
MI=,G.DX7"IE6E:/49./\RD9B\2;% ,"8Z[]L>?G@KCMGJ!H95*#=AL U<+?D
M/AP96 0^UH#WU>4@ @7 6T%H8/UN4]P^!R*^_SIXG!N.!N3X//5AG<RJ(V>'
MC@O]H_X*?75_<D^CR@*HQ]2@DQ:98S*=K<FL?85!_Z?[FVB W*3D"&.[VC&_
MZ@G5#P6,9;3!3CHOB=:W2&PF [=*\G"J;L>;1GQO/?@QN=HF5_LXRT<"1;+9
MJLCO4V_"YR_G.3U^WE+TY>)%K7)OT.=73$[G_M"7/1HC#DOU6F%XB82(LA:U
M5LDSR=%/QGSQZDEJM6YQ"QVCVC1:3$'PK>=#O/R%EO7WW[GWW_[@Y:"(<[I,
M]#U!/-;&-M[YPAW5T)>OE<59G6FCL'J)PF&>K(98C]YNHZU47G=G\IE'S'X
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M7U8V*J[JP$[@B.0Y]4<L 0I/Y.X$_G::CU0&#7P*1@.UFAC7NS7 TX\&5A?
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MCOLUQ.%0=47KW088,09A3<KJ7/]!]85 S5'_.Q35J*_7_'IF=:62X9;=V]K
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M*<??N344#;M+XC&ES]7P54(4_@(\T%&2G;_L^O!J_TX<^&7VXPGB';:#KF[
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MI&S^FW$LO;%TXH%7?,+TAA**]HLCV?=GO'1=>)XN+Z>UE-<>X]P8S0(7;*2
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M^?>Y0U S>0B0PI>:$>MC_-++U-?LO)L\C<I,\/R;$G?4RUB+;,# YBDTXGA
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M\ID_U]+2G>2H^2T40Z6&F^Z5?W6B$-(3;5E,"IX:1L+63CUPM\S'@"WG2"4
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M936.@)&?56-2F7PN'D3DMO0P]MJ46+[:<3P)$(A>I:*B7@)RBSH:R"YJ&.Y
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MLYF^+YZ?MT\Z1$R]JAEEGDK=;AK(85.U$9B<BT(^G(W@N@)DPWI'_[CQ&G"
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MT>5 P#-<E:?P0(8G?[91@<-17DVTH4<IK/P\7\!VK396%H7/L34"N?M\:K6
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M1)65(//R!M53OX%E6S68[):>3)";T#P>N %AN>VW/&;4GS'PQ$69T5>[7Y.
MO9?%(&?2E@@J!='Z$\?MLM,_L\3MQZU]X01;;6CB 0W?P@^6!3A&TVG0"/:>
MY4)YF4,R>T6 .E5JJ-^=&40$6.S- $I4/+P)1-DQ9T6JPF-M/NX7;+UY2!O%
M?>7U.\+'K^HT'CX56T@QWX#],>I(&%;3LTR9.@,//+J;\='U3AT>V-@97,-*
M98ZM'18<NEPJ"+HSKC].]U:A'=1JR*Y>?N5DSZO=33:NS8DA*1/A5\-OEK.&
MHA0L=)5\PQYAFV[R*9O$><7;IHW:\$^ DTOI=QUN>OV[1>B>0!S5I%E5F!](
M#QEQXU+^MPSA[P49%W74;*F226U=7UI=P\":<9P8]TSH;_SD2MFE9A<G]?5U
MZPV#.PDD""U_C+6ESB.0?VRG7S0R07U[5&C@.QX(')G04<_".'*+7JY('A^4
MHX_.",GS2G:-W-#E\,=2V&5@Y2P,5 <R^DK7>%]9P8?G6$@#PX0_Q:C]%J:F
MS?]M<:CGCQWWRP8'Q_"YR7C@AVZN0J0%[GQ&^7]TH?A]A*88&UG84<M?($R\
MSKP-WJO*^6',%W,!YNG*=E"H[2Z&L?7*[,SE-96Y(^=2/:7LB@DGXIT;SJ^?
M\UT@9%ED.MS1&_D3L%%JA@?.'P'[*%MEM#H<#^Q:M/.Z">6OIMPH"[4=4(=4
MDUL.R5(*F@X7YQ!<O=*A+UZPD_E@+MN?7Y)UMC.4M873\'U<',\UQHAIDT_
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MS_U+QE\R_I+QEXR_9/SKR""388 .-"+T+Z'):Y&!]F;9<4\J%1?"<'=,#&\
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M"N[@L#C EL-2-PNJS<[X!V'^-;K) DCO/=WAG=)@B;4@,QV'J@[+Z$N6A=;
MY K(6G0!(92+AK6X^/G/GB[VO4JO?!HLU5]$-"EQZ8(B[D&40BK]]H/V%-*-
M^&QO2:'9E?X">)D4]W,*J:;?&B_YJH#N&[<.M[-ZJICDY.+8,8RMW'.J3R8P
M02O:914UYU#9N"&#,S)86F&'*DY"7N82@9>:8UGLR"D.E**%!PB>^KB-N.+
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MRPFUDD7+J2W,Z MW3$O=5SS@VQTJ?5NG*U.ZA,@7WI5^E_\L]9O\M=3U.=)
MDM,/\ W8M341%^+#3=K>NL]+]*'UHD_3"]SOKPU_7849X8$/M.J[Y>[1I^*2
M]A.(3I:8/8\X"VL\4((' I9CLF@BUY\Q/F4SUEV2M;Y*9RN^DNS2]WS*+F@-
MYX@'?#"71'Y\X1CYV5/A0LK#C91K@E,7[$6JBI%1S,:1O$N!AESYH_76NI0-
M/<#(*WUJ],5&"74R-PF_*Y8*GV&6$TM)R\;LM%]L1_^]*Y=,\TFR[T)X@.8,
MI+JF>.#_8^\]PYKLMG7A*"J(((*@2%5I2E5Z1T2Z=.DE*B ETGL-B((@14!
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M%IJ7.]ER221/^EK3;RJ!=G>FIN1SNF*!?:_S#(8_!XE=<D;"=D*WS18/0K]
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ME$_Q)CZPX6^0.D3\&8!3(<=?9J!B?4IRMM@)=EU=-\7]IF9D8M 9P(O\L@R
MURC2P _',SB];5%#F!PQT'"A\*JV?="E)7]:+#Z_$N!3O%M2KSC7(]6B:RSO
M6J[E$W G>F1@\GZ<KN2\"SG@@%V'DQCT&:*WJQJ#DIS6T L:LS%4\K,.E]#*
ME;4UU57PCO!BM9OZ7.)=!6_D*(;-W9I3#.KR)M;B? Y3H"4\E/BT#+,\B7GQ
M.V$R]-0GPP*7_15_XJP#^')2G?(4V0W6I1A3 SZ$LEM*2-R.R?TJ/6JNS[[M
M>0\UF==9WH\+GZ]N&()52LRQMQZ]>G"=[=85AKO+%R(_:EY>3EE<PBH0HZ@
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M683E,?/4*1M3F],+EG2P?:4S6<>#\$;ONK,1V6> J]91-W3F+@TCJ@2ZRGS
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M#57**'?RPX1_?DY4C=B?]"\#](EKRZ7;@U^THT2*4T4V%[Y-?C4-N:VJJI#
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M32I:S=49YG?P"+^09"?5MB>ZV?JF-/_62D"M)50A:FXT 4'GU PVM-[D@<+
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M8L>4T[@&Q]$9R)KO(MV>3_VOFR"/_6UJDMI8)YBF(X_18!8+WXW-\MQ*=X)
M6>5.3"N,PGMX@\U(A&K?#Z=89_6C7IQ9P94X5C;3A05:#8T.YN D6%Y-A><&
M>G+C#/#C,"6S"*V1LP)/&CE<=>&KY[L7OO@P#"6H- .-)OT*D\08I&9CW5HD
M[8D+>3E'P]#(G-\5=:OXT\?*[)_).)2F'W7. ,2+M"YV"S.$M?;<U^$K@F:^
MBNBZ\4/[H>'D]2# ? DS-R>:%UJK@>\$0XZW/D05UXDV+FWBP4TR0DW3W&>
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M8MZFO$O?;G%@X#'->Q6'FK),9W-NYUP.)?EZ,A"!D P$0L\ \IWCS3"Y :1
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M7VY2*^UT9+RVP7XL"VI9T5#VF8^A'+/G>^&67_ TKDCP03A*?,'Q_>[%L<@
M^A +S93&5+FV,P"@\^I7^Y5:R2<_RO+)-Z+/QV=DQ2(;[/R%$KN?0EH#Z3#F
M]5PZDO$62,JA.U']XBU?V)8ES"+=>LP;UGUQFSR_Z &:N))WT3@YGO9?Q])V
MM)3BD;+,8?J(00Z$[3;O':')UL.!XK%VV>=JLV%L6_$I<6#ZE0=&X^:I9P!!
MGA7<A'7H+8ZX9^WJ%Q3Y@B337*;K=[\?/4TZ_#A,8YKZ2B"'KY9'_#CKV/7S
MUE@?JPETKNY5?Z/@:E*2V"@#?YAL^B&/7[?M''73)&%C6^D):70+]+%#WAG
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MK^":H=O4Q)2JZ.KFD8]&A7]=*-6JP7_1 *HR:LD4?I\PJ?DIK<\W7&=)(2;
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M--.(=RUB!3_1RH@W*:36QKMRSI=/5GP/5TA;\24SEF=*_C(,8NP?:6*0^S^
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MZ%H$L-<U!S\.]X_RO?6X@UB!361'"-S?R'GEQW*%4REML<S-3S^K]#JPV,$
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MY@Z><L/F:&K]/_WTUGLG2,CVEJFA] 'J:=DR4*IK F8+-S;K:/@V>:_VYYB
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M$*']7H0*28@X>+<^61J@FF]$V)"45P<YUZ(7= VVE3(DZ:M0V=E"B69NG 7
MI:$6$TA#BQEPTI5S0WKF^PNE^G#^$RQ@[\I @YNDM[J!A)B[!#>F72BZ7)61
M\:B?<49DN>*6N2@$"R <B;2>*@6AOX\3\3%];6/0'KH]LH\@EW]&+N/G!H9*
MAN<@A'HS72;Y#HS)=)08%K3&J[[Z(&Y8:CUB\ )Z:6,!_Z.]\XIJ<MOV>!3%
M1D=Z"5LZ"()2+$!L""@0I:IT 2DQ"9W0$38@75! 44"*!&F1&FHBTD4Z$DF
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MR'PK86??Y+>CXG%R;B:)GP>ERV<\")&V$''>(\/6OT-;>9FKWJX=3KOU#A]
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M_/\CJ0/& >. << X8/Q[,1K)R%@U6<\Q*S8"@9IR*]7'H^-EW$72Q&,O104
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MQ:!+L,<R)<*5QN6D29@G6)$K+E(;,07NNT?)Y>,B>SXCYN.A%BA0 T5Z^!M
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M#3 W 8?]LA/G]]$//O%.'1&QUIZG? KI-_9R@V\YL[!<WE '1BCT8W X.VU
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MO\9<N=C85KK"" P4ONON@CR2D(IUN&R?T6ZSP-B#\1432(JG6ZV?4Z;,8PY
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MX5]^E;"9@]/:P,ZA4 [6%[VR%PB;"?^Y2G@&C@0\*B/HBX7&IP>;Z7];I5_
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M,2&W*+BG11#M4WBUPO'H5<6O2MUN.F'L'/SE-:+*JNY>XN*=L':'/#H^S>F
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M)YP"5\&51P& 2B:S #E=&!78/$_FU! V0/%6,2G/\*L D>H:JP@ X7)ZO,_
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M+*="KK#/\P'.[+4;VE[,/WN;.'A&<\K^9<2N@+XB)+)]1W)#1FU2PS.>ABH
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M/*_<?(F>ER$D&L, A]VN,[2M42-7#6IKO==E@3,<7+^2\/KZ3!JR%HOUO2
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MT99J>(H,J5RJ=M@ <..!PA&+(&:X-=9Q7-PM6\R@^[11RWHW5)8 M0R*N#0
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MJ2#'AKD)9@T.=9$O;W08ZV%*%WNXQ72QF_NW.&.A;"Q\EM=JS-/5BCOU>4=
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MY.>5XRZ\=(-JMD2>48CWN613Y)OS=]1X;4#?*Q*M;LLL)Q7HX9I0)^2,>%J
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M '#U=]4\^4^TB"(_3<2*:-M3V.3/OPC/96:C;L6_F?AMX)/CSBH\/L@Q*QQ
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MB1X 7,*E2W)1TYAY0I<XXY<J^T[!8)"955Q:)QOP78-EDO?.O@D@I5=OZ*J
MAS5F0@FMA=:.C%R5FXI=[A#?TRTA1Z6=F;!QR(W%THMZIX@=OB$[*@5NDFJ"
M6#FW3@S0974+^^(VCNY4B<-,@BZ-C1YHU\3(4MY9,PI-VFZH+\:GC:27R!)A
M"&_PT^*.)$&D>+-,%OD<IH&SUJ;?XO<NM?GNM/BT%KS 3PA7LM][:O6;]"RB
M:ZD\E5\+Z?T*KJTE:*IF+E)J_824EP8^H1K4]4L(N_9_B9^I4DR=SH($K&;T
M7W<97IVE.&DM?/4 7KV!+/7*YD7"ZLJMU4=*6=46S+91UZ)HM&[*9O]DA:.8
MEMZ;,;'X (JJ+WCACKCQ)]+6G2:':9((V+]$Q7UMM1=W&>&K#"GKVLPB8'%C
M-GXI.*_[/BCM5G:OO2H+/=+"VOPPN"Y.;,##[WDAO%G7"^$7W/>]"FRC\\7M
M6"^]SS:P<7[_,8JIY4D34KGTPS80LU_;!!(#9I8#BP6;54*Q\8]8<6A5EU?G
M3U;10G@.'5;XHL,AA;P(?BNC/!*7)$^3-=NYRMGCR806=$_GQB/R0.)TK:/"
MU#+ T6!F!;04P&U9S#V(N#O BF,YMGEYXCYV6R((#S*X)\&7+;N0,\J$18_M
M56C<B>1EOQPO4IHJ/Q+ETY :.5C]; :IW=IHI_5?A8+Q*N2N>N(L2H(T3BYQ
M]N40KZ,"QR=E$IZ='6IZ9$0>5L_8@96.Z(068FJHTD-,$5%-KYU5W^:Y6(Y>
M8F2)C[J'T]1D7)39X/H0O_U]0YZ*#W$:?)&]]9U^#A95G-35=#NKN7U7?1<U
M'ZZN:O%/(_IM5'\<L:_S:UOT^]*UK>IR/V(@$$?AA;,?RCQB$]6"SDL// *)
MG6=F=SB)?N>]<9E2E_99S\*I!<#BU4ST4BJ>JAC4EL.IT"T)_2K*\MWCIZLU
M#HJ+Y6'Z$(7G%'9!R&@OVRC!ZMD)B(>]*539J.?*J-:&TH-G$5V%A"QL?J37
M=(*P>FH$I3S_5^)0NN,C?F)/W_23KMVD'\AU&H>+XB/U4]C;($N2#3(V3M>&
MU7%SH$OO!HDR.JGFQ"X:.X6Y)2BG)2%<H.*>H!4OCXJ( KVLC$1"53K#%UET
M6_)TK"-KI%$-6'UJ"U>*(1"//'45T0+$$JIBV&&Z6D4%0U.D]2+OD&<UY&_X
MJ,]")NC"ZL;IP'4#4V0YXPD@HX(YP)W$^,8AN$F:</7;2\+ G)/'=H._KMX)
M4;YA.+,@=TFX-ZEHNQ"<4PHLOFY2!6G9QM_5JDYN0EY:]?QF/;<DY+%WLE.7
MB9;$T^&=X;&Q36E@+.1%L,"F!A-(P,]H.R1 Z9 #?L[P>K'#M&;R^:PD :O[
M=/#D^.>.G+_VKOW6SH0H[$V47)&[,L99/67*9V/6JK!Z:#)NZ21,R@C-QUEE
M5ZDQS40Q=BZ"\YYE5W$)2X0]NX-U);R0?AZ!/ZV[25T8PC#Z_0A'\7//]64!
M\E)4:ZYV]B=IP^KO.="ET$=6!EUD"[>_]?>;0)<VV#??\QCHI-QU8#L.I\E-
MAI,<!^K7F*W48'7K),S6.RM\3X6:ZJ(MPL\IL[B0B>_8.]-/E&/)':G.\ZHM
M<_G >50%5@=:XY6.H1M%GGV\4D5!3]=+KWT@"5E&083CB\>$9/E]M#Z+J*D0
MIR4-;/F<R$X/5O]- RV="C7:**W54=SHL_5(58"7GERLTYS%JIT5H6;O4I*
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M8T,D #<02A(%1P8]0DU'4H7:-*!O*QU?!EGDT]7D_](*?7X'I@_TV)21 71
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M->PI16]T_W1&_T7_7/^)_B^6(X_^Y?\#4$L#!!0    ( !& "U5R6W'%QRX
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M0'AS+QXS?'0 ;[;61/PG4,=#P",0Y/=/* S9V90?:6EY6WM-V'^&A%W,IP/
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MG;[@,5F]R%N8"3VXP 79$.7J!U?161Q%>?S^'SA]NBTX&LT(XDB(9C$;J<M
MX"%;:AEW9:T?F]R'T(23T9@UTZD)>!;3F3>7UM+.1]Y_GCCP%-,6I]Z,_EZ.
M32\BX$5RBU-O$R$Z<(C21KXE&;H2+YF,IV=^\G09QB^"XB$_=2D>PL;T^*!.
M14&N634*?FSI!7;NPFBY)?$SIJ(_77Y+V+*P3C,>T;7A.:^IJ.2ORUCN5*,3
M"K)YE-,1,?#ETVX:B"T9;0'X+AS"C2;_+\OS%1/V3E801P$.4876A[BW.6KG
M:] 7T;VIB$UA@&O:.:)R";#B@K+:"OI^V:I 8@GCCLBL^JB0,A-?T!SZ_GA
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M]XF52S_ (4Z7_,O2IU1:6T*?$JBUIGQT+V'6TD41.^I?L--A-;[M3:'WYV8
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MHP3Z"1H_AGC&*10OS&UM]_@T2,)UAX.@XB_LOQ[I:/0W_Q]02P$"% ,4
M"  1@ M50N_%+I4'  #A+P  "@              @ $     97@S,2TQ+FAT
M;5!+ 0(4 Q0    ( !& "U5MJN CF0<  ),P   *              "  ;T'
M  !E>#,Q+3(N:'1M4$L! A0#%     @ $8 +55N4%/?_!   K2L   H
M         ( !?@\  &5X,S(M,2YH=&U02P$"% ,4    "  1@ M5A[EEE$0S
M 0 K5PX #               @ &E%   9F]R;3$P+7$N:'1M4$L! A0#%
M  @ $8 +54V=N2B;7@$ P^X! !               ( !$T@! &9O<FTQ,"UQ
M7S P,2YJ<&=02P$"% ,4    "  1@ M5HKI415P-  #.A0  $0
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M)@, <&-S82TR,#(R,#8S,%]P<F4N>&UL4$L%!@     *  H :P(  .A5 P
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
